Company Code: 688271 Company Abbreviation: United Imaging Healthcare

Summary of Shanghai United Imaging Healthcare Co., Ltd. 2026 Semi-Annual Report

Important Notice

The Board of Directors, directors, and senior management of the Company guarantee that the contents of this semi-annual report are truthful, accurate, and complete, and that there are no false records, misleading statements, or material omissions, and they assume individual and joint legal liability.

Major Risk Warning
The Company has described in detail in this report the relevant risks that may exist. Please refer to "Section III Management Discussion and Analysis, IV. Risk Factors".

All directors of the Company attended the Board of Directors meeting.

This semi-annual report has not been audited.

The person in charge of the Company, Zhang Qiang, the person in charge of accounting work, Wang Jianbao, and the person in charge of the accounting institution (chief accountant), Zhang Hui, declare: guarantee the truthfulness, accuracy, and completeness of the financial reports in the semi-annual report.

Profit distribution plan or capital reserve conversion to share capital plan for the reporting period approved by the Board of Directors resolution
The Company plans to use the total share capital registered on the record date for the implementation of the equity distribution, after deducting the total number of shares in the repurchase special securities account, as the base, and distribute a cash dividend of RMB 1.30 (tax included) per 10 shares. This profit distribution will not include bonus shares and will not use capital reserve to convert to share capital. As of July 31, 2026, the Company's total share capital was 824,157,988 shares, and after deducting the total number of shares in the repurchase special securities account of 6,758,348 shares, based on this base, the total proposed cash dividend is RMB 106,261,953.20 (tax included), accounting for 11.85% of the net profit attributable to shareholders of the listed company in the consolidated statements for the first half of 2026. If the total share capital of the Company or the total number of shares participating in the profit distribution changes before the record date for the implementation of the equity distribution, the Company intends to maintain the same distribution ratio per share and adjust the total distribution amount accordingly.
The above profit distribution plan (proposal) has been authorized by the 2025 Annual General Meeting of Shareholders and approved by the 33rd meeting of the Second Board of Directors.

Whether there are important matters such as special arrangements for corporate governance
□ Applicable√ Not applicable

Risk Statement on Forward-Looking Statements
√ Applicable□ Not applicable
The forward-looking statements regarding the Company's future plans, development strategies, etc., involved in this report do not constitute substantive commitments by the Company to investors. Investors should be aware of investment risks.

Whether there is any situation of non-operational occupation of funds by the controlling shareholder and other related parties
No

Whether there is any situation of providing external guarantees in violation of prescribed decision-making procedures
No

Whether there are more than half of the directors who cannot guarantee the truthfulness, accuracy, and completeness of the semi-annual report disclosed by the Company
No

Other

√ Applicable□ Not applicable
Based on considerations of trade secrets, the Company discloses the projects under research in the form of code names, and the names of some units in the information on other receivables with the top five ending balances aggregated by debtor are disclosed after desensitization.

This document is an English summary of the Chinese version of the 2026 Semi-Annual Report of Shanghai United Imaging Healthcare Co., Ltd. and has been condensed for reference only. In case of any discrepancy, the Chinese version disclosed on the Shanghai Stock Exchange shall prevail.

Table of Contents

Definitions

In this report, unless the context otherwise requires, the following terms have the following meanings:

Definitions of Common Terms		
United Imaging Healthcare, the Company, the Group	refers to	Shanghai United Imaging Healthcare Co., Ltd.
United Imaging Limited	refers to	Shanghai United Imaging Healthcare Technology Co., Ltd., the predecessor of the Company
Wuhan United Imaging	refers to	Wuhan United Imaging Healthcare Technology Co., Ltd., a controlling subsidiary of the Company
Changzhou United Imaging	refers to	United Imaging (Changzhou) Healthcare Technology Co., Ltd., a controlling subsidiary of the Company
Shanghai Xinman	refers to	Shanghai Xinman Crystal Materials Technology Co., Ltd., a controlling subsidiary of the Company
Guizhou United Imaging	refers to	United Imaging (Guizhou) Healthcare Technology Co., Ltd., a controlling subsidiary of the Company
Shenzhen United Imaging	refers to	Shenzhen United Imaging Healthcare Technology Co., Ltd., a controlling subsidiary of the Company
Beijing United Imaging	refers to	Beijing United Imaging Healthcare Technology Co., Ltd., a controlling subsidiary of the Company
Beijing Technology	refers to	Beijing United Imaging Healthcare Technology Development Co., Ltd., a controlling subsidiary of the Company
Shanghai Yixintong	refers to	Shanghai United Imaging Yixintong Technology Co., Ltd., a controlling subsidiary of the Company
Xinjingnan	refers to	Shanghai Xinjingnan Metal Products Co., Ltd., a controlling subsidiary of the Company
Shanghai Zhiyu	refers to	Shanghai United Imaging Zhiyu Technology Co., Ltd., a controlling subsidiary of the Company
United Imaging Zhizao	refers to	Hubei United Imaging Zhizao Technology Co., Ltd., a controlling subsidiary of the Company
Shenzhen United Imaging Data	refers to	Shenzhen United Imaging Healthcare Data Services Co., Ltd., a controlling subsidiary of the Company
United Imaging UK	refers to	United Imaging Healthcare UK Ltd., a controlling subsidiary of the Company
United Imaging	refers	United Imaging Healthcare Hong Kong Limited, a controlling subsidiary of the

Hong Kong	to	Company
United Imaging UAE	refers to	United Imaging Healthcare MENA FZCO, a holding subsidiary of the Company
United Imaging Korea	refers to	United Imaging Healthcare Korea Co., Ltd., a holding subsidiary of the Company
Wuhan Keyi	refers to	Wuhan United Imaging Life Science Instruments Co., Ltd., a holding subsidiary of the Company
Wuhan Liantuo	refers to	Wuhan Liantuo New Materials Co., Ltd., a holding subsidiary of the Company
United Imaging North America	refers to	United Imaging Healthcare North America Inc., a holding subsidiary of the Company
United Imaging Australia & New Zealand	refers to	United Imaging Healthcare (Australia & New Zealand) Pty Ltd, a holding subsidiary of the Company
United Imaging Poland	refers to	UNITED IMAGING HEALTHCARE POLAND SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ, a holding subsidiary of the Company
United Imaging Japan	refers to	United Imaging Healthcare Japan Co., Ltd., a holding subsidiary of the Company
United Imaging Malaysia	refers to	United Imaging Healthcare (Malaysia) Sdn. Bhd., a holding subsidiary of the Company
United Imaging South Africa	refers to	United Imaging Healthcare Southern Africa (PTY) LTD., a holding subsidiary of the Company
United Imaging Morocco	refers to	United Imaging Healthcare North Africa SARLAU, a holding subsidiary of the Company
United Imaging Kazakhstan	refers to	United Imaging Healthcare Kazakhstan Limited Liability Partnership, a holding subsidiary of the Company
United Imaging Singapore	refers to	UNITED IMAGING HEALTHCARE PTE. LTD., a holding subsidiary of the Company
United Imaging Colombia	refers to	UNITED IMAGING HEALTHCARE COLOMBIA S.A.S, a holding subsidiary of the Company
United Imaging Indonesia	refers to	PT UIH Indonesia Solution, a holding subsidiary of the Company
United Imaging Thailand	refers to	United Imaging Healthcare (Thailand) Co., Ltd., a holding subsidiary of the Company
United Imaging Europe	refers to	United Imaging Healthcare Europe B.V., a holding subsidiary of the Company
United Imaging	refers	UNITED IMAGING HEALTHCARE VIETNAM CO., LTD., a holding subsidiary

Vietnam	to	of the Company
United Imaging Spain	refers to	UNITED IMAGING HEALTHCARE ESPAÑA, S.L.U., a holding subsidiary of the Company
United Imaging Italy	refers to	UNITED IMAGING HEALTHCARE ITALY S.R.L., a holding subsidiary of the Company
United Imaging France	refers to	United Imaging Healthcare France SARL, a holding subsidiary of the Company
United Imaging Germany	refers to	United Imaging Healthcare Germany GmbH, a holding subsidiary of the Company
United Imaging Mexico	refers to	UNITED IMAGING HEALTHCARE MEXICO, S. DE R.L. DE C.V., a holding subsidiary of the Company
United Imaging Brazil	refers to	UNITED IMAGING HEALTHCARE DO BRASIL LTDDA, a holding subsidiary of the Company
United Imaging Philippines	refers to	United Imaging Healthcare Philippines, Inc., a holding subsidiary of the Company
United Imaging Turkey	refers to	UNITED IMAGING HEALTHCARE SAĞLIK TEKNOLOJİLERİ LİMİTED ŞİRKETİ, a holding subsidiary of the Company
United Imaging Kenya	refers to	SHANGHAI UNITED IMAGING HEALTHCARE (KENYA) LTD, a holding subsidiary of the Company
UIHT	refers to	UIH Technologies LLC, a holding subsidiary of the Company
UIHS	refers to	United Imaging Healthcare North America LLC, a holding subsidiary of the Company
UIHTM	refers to	UNITED IMAGING HEALTHCARE TECHNOLOGY (MALAYSIA) SDN. BHD, a holding subsidiary of the Company
UIHEU	refers to	United Imaging Healthcare Europe Holding B.V., a holding subsidiary of the Company
UIHGB	refers to	UNITED IMAGING HEALTHCARE GB LIMITED, a holding subsidiary of the Company
Wuhan Medical Engineering Institute	refers to	Wuhan Zhongke Medical Technology Industrial Research Institute Co., Ltd., an associate company
Wuhan Zhongke Polarization	refers to	Wuhan Zhongke Polarized Medical Technology Co., Ltd., an associate company
Lianren Health	refers to	Lianren Health Medical Big Data Technology Co., Ltd., an associate company
APACQ	refers	Shanghai APACQ Particle Equipment Co., Ltd., an associate company

	to	
Jiu Yiyuan	refers to	Sichuan Jiuyiyuan Particle Technology Co., Ltd., an associate company
United Imaging Group	refers to	United Imaging Healthcare Technology Group Co., Ltd., a shareholder of the Company
Shanghai Yingsheng	refers to	Shanghai Yingsheng Investment Partnership (Limited Partnership), a shareholder of the Company
Ningbo Yingju	refers to	Ningbo Meishan Bonded Port Area Yingju Investment Management Partnership (Limited Partnership), the employee stock ownership platform of the Company
Ningbo Yingli	refers to	Ningbo Meishan Bonded Port Area Yingli Investment Management Partnership (Limited Partnership), the employee stock ownership platform of the Company
Ningbo Yingjian	refers to	Ningbo Meishan Bonded Port Area Yingjian Investment Management Partnership (Limited Partnership), the employee stock ownership platform of the Company
Ningbo Yingkang	refers to	Ningbo Meishan Bonded Port Area Yingkang Investment Management Partnership (Limited Partnership), the employee stock ownership platform of the Company
Shanghai Yingdong	refers to	Shanghai Yingdong Enterprise Management Partnership (Limited Partnership), the employee stock ownership platform of the Company
Shanghai Lianhe	refers to	Shanghai Lianhe Investment Co., Ltd., a shareholder of the Company
Zhongke Daofu	refers to	Shanghai Zhongke Daofu Investment Partnership (Limited Partnership), a shareholder of the Company
Shanghai Beiyuan	refers to	Shanghai Beiyuan Investment Partnership (Limited Partnership), a shareholder of the Company
Shanghai Yiduan	refers to	Shanghai Yiduan Investment Co., Ltd., a shareholder of the Company
Shanghai Yingzhi	refers to	Shanghai Yingzhi Investment Partnership (Limited Partnership), a shareholder of the Company
Shanghai Intelligent	refers to	Shanghai United Imaging Intelligent Technology Co., Ltd., an enterprise controlled by the actual controller, formerly known as: Shanghai United Imaging Intelligence Co., Ltd.
Shanghai iHealthcare	refers to	Shanghai United Imaging iHealthcare Investment Management Co., Ltd., an enterprise controlled by the actual controller
Shanghai Microelectronics	refers to	Shanghai United Imaging Microelectronics Technology Co., Ltd., an enterprise controlled by the actual controller
Wuhan Zhirong	refers to	Wuhan United Imaging Surgical Medical Technology Co., Ltd., an enterprise controlled by the actual controller
Shanghai	refers	Shanghai United Imaging MetaHealthcare Technology Co., Ltd., a controlling

Zhiyuan	to	subsidiary of Shanghai Intelligent
Shanghai Research Institute	refers to	Shanghai United Imaging Healthcare Advanced Technology Research Institute Co., Ltd., an enterprise controlled by the actual controller
GE HealthCare	refers to	GE HealthCare, whose core businesses include providing medical technology, pharmaceutical diagnostics, and digital solutions
Siemens Healthineers	refers to	Siemens Healthineers, whose core businesses include imaging diagnostics, clinical diagnosis and treatment, laboratory diagnostics, and supporting service systems for molecular medicine
Philips Healthcare	refers to	Koninklijke Philips, committed to providing solutions in disease prevention, radiological diagnosis and treatment, health management, and monitoring
Elekta	refers to	Elekta was founded in 1972 and is headquartered in Sweden. Its main products include linear accelerators, Gamma Knife, high-field magnetic resonance radiotherapy systems, stereotactic head frame systems, oncology information systems, afterloading brachytherapy units, and source applicators
Varian	refers to	Varian was founded in 1948 and is headquartered in the United States. It is committed to providing radiotherapy, radiosurgery, proton therapy, and brachytherapy equipment and related software for cancer and other diseases. Its main products include linear accelerators, TrueBeam, brachytherapy afterloading units, and source applicators. In 2021, it was acquired by Siemens Healthineers
Mindray Medical	refers to	Shenzhen Mindray Bio-Medical Electronics Co., Ltd., primarily engaged in the R&D, manufacturing, marketing, and services of medical devices. Its main products cover three major areas: patient monitoring & life support, in vitro diagnostics, and medical imaging, among which medical imaging products include ultrasound diagnostic systems, digital X-ray imaging systems, and PACS
Wandong Medical	refers to	Beijing Wandong Medical Technology Co., Ltd., professionally engaged in the R&D, manufacturing, and production of imaging medical devices and imaging diagnostic services. Its products include the DR product line, MR product line, DSA product line, digital gastrointestinal product line, and CT product line, and it also provides medical imaging diagnostic services
Neusoft Medical	refers to	Neusoft Medical Systems Co., Ltd., mainly engaged in the R&D, production, and sales of large medical diagnosis and treatment equipment and related solutions and services. Its product lines cover CT, MR, DSA, XR, US, PET/CT, RT, and in vitro diagnostic (IVD) equipment and reagents
CIC Consulting	refers to	CIC Consulting (Shanghai) Co., Ltd., established in 2013, is an independent third-party professional industry research and analysis institution. Its business areas mainly include strategic consulting, commercial due diligence, and feasibility study

		report services for fundraising and investment
National Health Commission	refers to	National Health Commission of the People's Republic of China
China Securities Regulatory Commission	refers to	China Securities Regulatory Commission
National Development and Reform Commission	refers to	National Development and Reform Commission of the People's Republic of China
FDA	refers to	The process by which the U.S. Food and Drug Administration (FDA) evaluates the safety and effectiveness of food, cosmetics, drugs, biological products, medical devices, and radiological products intended for marketing in the United States in accordance with applicable laws, regulations, standards, and procedures, and then approves them for sale in the market
CE certification	refers to	The EU certification for a product, indicating that the product complies with the requirements of relevant EU directives, and is used to confirm that the product has passed the corresponding conformity assessment procedures and the manufacturer's declaration of conformity, and bears the CE mark. It is a prerequisite for a product to enter the EU market for sale.
NMPA registration	refers to	The process by which the National Medical Products Administration, in accordance with the relevant registration and management systems, reviews and approves drugs, medical devices, and cosmetics intended for marketing in China and grants them permission for sale.
Medical imaging diagnosis	refers to	The use of various medical imaging techniques (such as X-ray, magnetic resonance, gamma rays, etc.) to obtain images of the body's anatomical structures or organ functions, which are used to assist physicians in disease assessment and evaluation of human health status.
Radiotherapy (RT)	refers to	Radiotherapy (Radiation Therapy, RT) refers to a local treatment method for tumors that uses radiation, including alpha, beta, and gamma rays produced by radioactive isotopes, as well as X-rays, electron beams, proton beams, and other particle beams generated by various X-ray treatment machines or accelerators. Currently, mainstream RT products both domestically and internationally include medical linear accelerators, cobalt-based Gamma Knife, and a small number of proton and heavy ion devices.
Life science instruments	refers to	Refers to instruments that provide all necessary equipment for biomedical scientific research, population health management, diagnosis and treatment of various

		diseases, drug development and production, and biological information security and other related fields.
Magnetic resonance imaging (MR or MRI)	refers to	Magnetic Resonance Imaging (MR) applies radiofrequency pulses of a specific frequency to the human body in a static magnetic field, causing the atomic nuclei (mainly hydrogen protons) in the body to be excited and undergo magnetic resonance. After the pulse stops, the nuclei produce MR signals during the relaxation process. Through the reception, spatial encoding, and image reconstruction of the MR signals, the signals are ultimately processed into image information.
X-ray computed tomography (CT)	refers to	X-ray computed tomography (Computed Tomography, CT) refers to a technique that uses a precise X-ray beam together with a high-sensitivity detector to perform cross-sectional scanning around a certain part of the human body. Based on the differences in absorption and transmission rates of radiation by different body tissues, the measured data is processed to generate images.
X-ray imaging (XR)	refers to	X-ray imaging equipment refers to a type of equipment that can emit X-rays that pass through different tissues of the human body, and after image processing, different medical images can be obtained. According to usage characteristics, it is generally divided into General X-ray machines (GXR) and Interventional X-ray machines (IXR). GXR includes conventional DR, mobile DR, mammography systems, and gastrointestinal systems, all of which use radiography for diagnostic examination of diseases; IXR mainly consists of C-arm X-ray machines, primarily used for monitoring X-ray fluoroscopy and radiography during surgical procedures.
Angiography X-ray imaging system (DSA)	refers to	Angiography X-ray imaging system (DSA) is an X-ray imaging device used to provide image guidance for interventional procedures.
Digital medical X-ray imaging (DR)	refers to	Digital Radiography (DR) is a medical radiological imaging device that directly or indirectly converts X-ray photon signals into digital images through digital detectors. It generally consists of an X-ray tube, digital detector, high-voltage generator, image acquisition and processing system, and image output system.
Digital mammography X-ray imaging (Mammo, mammography system)	refers to	Digital mammography X-ray imaging (Mammography, Mammo) is a low-dose X-ray imaging device specifically used for early diagnosis of breast cancer.
C-arm X-ray imaging	refers to	C-arm X-ray imaging is a device mainly used for monitoring mobile X-ray fluoroscopy and radiography during surgical procedures. Based on power, it can be

		classified from small to large into orthopedic C-arms, peripheral interventional C-arms, and digital subtraction angiography X-ray machines (Digital Subtraction Angiography).
PET	refers to	Positron Emission Tomography (PET) is an imaging technique for clinical examination in molecular imaging. It images the distribution of positron-labeled drugs in the human body, reflecting the functional metabolic activity of human organs at the molecular level, thereby achieving the purpose of diagnosis. PET is mainly used for the examination and diagnosis of tumors and functional diseases of the heart and brain.
PET/CT	refers to	Positron Emission Tomography/Computed Tomography (PET/CT) is an imaging device that organically combines two imaging techniques: PET functional metabolic imaging and CT anatomical imaging. The two techniques complement each other's advantages, featuring sensitivity, accuracy, specificity, and precise localization, thereby achieving the purpose of early detection of lesions and diagnosis of diseases.
PET/MR	refers to	PET/MR (Positron Emission Tomography/Magnetic Resonance, PET/MR) is a large-scale functional metabolism and molecular imaging diagnostic device that integrates a positron emission tomography system and a magnetic resonance imaging system into one unit. It has both PET and MR examination functions and is one of the most advanced medical imaging diagnostic devices in the world, applicable to the diagnosis of tumors, neurological diseases, cardiovascular diseases, and other conditions.
Medical linear accelerator	refers to	A medical linear accelerator refers to an acceleration device that uses microwave electromagnetic fields to accelerate electrons with a linear motion trajectory, generating high-energy radiation for external exposure radiotherapy in human medical practice. It is a large medical device widely used in the treatment of various tumors, especially deep-seated tumors.
CT-guided linear accelerator	refers to	A new type of diagnostic and therapeutic device that organically combines CT equipment and a medical linear accelerator. Through same-machine simulation positioning and treatment, it greatly improves the efficiency of tumor radiotherapy.
US	refers to	Ultrasound, i.e., ultrasound diagnostic equipment, is a medical device developed based on the principles of ultrasound. It emits ultrasound pulses into human tissue and forms various types of images by recording and analyzing reflected echoes.
Image post-processing workstation	refers to	a tool that performs post-processing operations on medical images to assist and support the process of image diagnosis or scientific research, providing imaging physicians with an auxiliary tool for disease diagnosis. It can perform various operations including editing images, generating histograms of images, image

		equalization, image smoothing, edge enhancement, adjustment of image grayscale and contrast, positive and negative rotation, reverse color display, pseudo-color drawing and calculation, and grayscale rotation.
PET TOF	refers to	TOF (Time-Of-Flight) refers to the time difference between the arrival of two 511 keV gamma rays at the detector due to the different positions of positron annihilation in a PET scan. This time difference is called the time of flight, and the measurement error of the time of flight is called the time-of-flight resolution.
cps/kBq	refers to	the unit of sensitivity in radioactive instruments, indicating the count of rays emitted by a sample measured by the instrument under a certain level of radiation dose.
Bore	refers to	The bore refers to the diameter of the cylindrical scanning space of the equipment.
Structural imaging	refers to	Structural imaging refers to the technique of conducting anatomical studies using imaging equipment such as CT and MR.
Magnetic field	refers to	the magnetic force space formed by magnets, electric currents, and moving charges.
Magnet	refers to	The magnet is the core component of MR equipment that generates the main magnetic field, maintaining high magnetic field strength and high homogeneity in the target area. It is generally divided into permanent magnets and superconducting magnets. Permanent magnets have relatively weak magnetic field strength, while superconducting magnets operate through superconducting coils, providing stronger magnetic field strength and higher stability, making them the current mainstream technology in the market. All MR products referred to in this document are equipment using superconducting magnets.
RF coil	refers to	The RF coil is one of the core components of MR equipment, responsible for transmitting, receiving, and amplifying MR signals. Since the RF signals collected by MR equipment are very weak and highly susceptible to interference from external noise, the RF receive coil, as the front end of the signal receiving chain, is an important component that determines the signal-to-noise ratio of image quality.
Gradient coil	refers to	The gradient coil is one of the core components of MR equipment, mainly used for spatial localization encoding of MR signals. It also has functions such as generating gradient echo signals, applying diffusion-weighting gradient fields, flow compensation, and velocity encoding of flowing liquids.
RF power amplifier (RFPA)	refers to	Radio Frequency Power Amplifier, which provides amplified RF signals to the RF transmit coil of the magnetic resonance system.
Gradient power	refers	Gradient Power Amplifier, which provides amplified gradient signals to the

amplifier (GPA)	to	gradient coil of the magnetic resonance system.
Spectrometer	refers to	The spectrometer is an important core component and control system of MR equipment, mainly responsible for the timing control of small signals such as RF, gradient, and acquisition in magnetic resonance. The performance of the spectrometer is one of the important criteria for measuring the performance of a magnetic resonance imaging system.
Detector	refers to	The detector is one of the core components of medical imaging equipment. It is a device that converts detected signals into electrical signals that can be recorded, including flat panel detectors used in XR products, detectors used in CT products, and detectors used in PET products.
X-ray tube	refers to	The X-ray tube is one of the core components of medical imaging equipment. The X-ray tube consists of the tube insert, tube housing, heat exchanger, insulating oil, and some auxiliary accessories, and can generate X-rays.
High-voltage generator	refers to	The high-voltage generator is one of the core components of CT and XR equipment. It is a device that provides the high-voltage function for filament heating and electron acceleration in X-ray equipment.
Scintillation crystal	refers to	A scintillation crystal is a transparent crystal that interacts with particles such as X-rays, gamma rays, and charged particles, converting the kinetic energy deposited in the crystal into visible light photons. The scintillation crystals referred to in this document are LYSO (lutetium yttrium orthosilicate) crystals used in PET products.
Silicon photomultiplier tube	refers to	SiPM (Silicon Photomultiplier) is a new type of photodetector device, composed of an array of avalanche diodes operating in Geiger mode. It features high gain, high sensitivity, low bias voltage, insensitivity to magnetic fields, and compact structure.
Accelerator tube	refers to	The accelerator tube is one of the core components of a medical linear accelerator. Electrons injected from the electron gun are accelerated to high energy under the action of a microwave electric field, and finally hit the target to produce high-energy X-rays.
Multi-leaf collimator	refers to	A multi-leaf collimator is a collimator or beam-limiting device composed of individual 'leaves' made of high atomic number materials. Each leaf is independently controlled for movement, synchronously and dynamically adjusting the spatial distribution of the beam to achieve dynamic beam flux modulation, and can be used in radiotherapy equipment.
Reporting period	refers to	January 1, 2026 to June 30, 2026

Section I Company Profile and Key Financial Indicators

I Basic Company Information

Chinese name of the company	上海联影医疗科技股份有限公司
Chinese abbreviation of the company	联影医疗
Foreign name of the company	Shanghai United Imaging Healthcare Co.,Ltd.
Foreign name abbreviation of the company	UIH
Legal representative of the company	张强
Registered address of the company	No. 2258 Chengbei Road, Jiading District, Shanghai
Historical changes to the registered address of the company	Not Applicable
Company Office Address	No. 2258 Chengbei Road, Jiading District, Shanghai
Postal Code of Company Office Address	201807
Company Website	www.united-imaging.com
Email	IR@united-imaging.com

II Contact Person and Contact Information

	Secretary to the Board of Directors	Securities Affairs Representative
Name	TAO CAI	Su Xing
Contact Address	No. 2258 Chengbei Road, Jiading District, Shanghai	No. 2258 Chengbei Road, Jiading District, Shanghai
Telephone	021-67076658	021-67076658
Fax	021-67076659	021-67076659
Email	IR@united-imaging.com	IR@united-imaging.com

III Brief Introduction to Changes in Information Disclosure and Document Storage Locations

Newspaper Names Selected by the Company for Information Disclosure	China Securities Journal (www.cs.com.cn), Shanghai Securities News (www.cnstock.com), Securities Times (www.stcn.com), Securities Daily (www.zqrb.cn)
Website Address Where the Semi-Annual Report is Published	www.sse.com.cn
Location Where the Company's Semi-Annual Report is Stored	Office of the Board of Directors of the Company

IV Overview of the Company's Shares/Depositary Receipts

1. Overview of the Company's Shares

√ Applicable□ Not Applicable

Overview of the Company's Shares				
Share Type	Stock Exchange and Board on Which the Shares Are Listed	Share Abbreviation	Share Code	Share Abbreviation Before Change
A Share	SSE STAR Market	United Imaging Healthcare	688271	Not Applicable

2. Overview of the Company's Depositary Receipts

□ Applicable√ Not Applicable

V Other Relevant Information

√ Applicable□ Not Applicable

Accounting Firm Engaged by the Company (Domestic)	Name	Ernst & Young Hua Ming LLP
	Office Address	Rooms 01-12, 17th Floor, Ernst & Young Tower, Oriental Plaza, No. 1 East Chang'an Avenue, Dongcheng District, Beijing
	Name(s) of Signing Certified Public Accountant(s)	Fei Fan, Fan Qingyuan

VI Key Accounting Data and Financial Indicators of the Company

1. Key Accounting Data

Unit: Yuan Currency: RMB

Key Accounting Data	Current Reporting Period (January-June)	Same Period of the Previous Year	Increase/Decrease (%) Compared to the Same Period of the Previous Year
Operating Revenue	7,051,579,098.09	6,015,901,402.16	17.22
Total Profit	1,033,041,160.87	1,072,972,130.74	-3.72
Net Profit Attributable to Shareholders of the Listed Company	896,995,952.14	998,018,064.12	-10.12

Net Profit Attributable to Shareholders of the Listed Company, Excluding Non-Recurring Gains and Losses	826,729,990.53	965,612,481.04	-14.38
Net Cash Flow from Operating Activities	-242,020,101.49	48,759,799.77	-596.35
	End of Current Reporting Period	End of Previous Year	Increase/Decrease (%) at End of Current Reporting Period vs. End of Previous Year
Net Assets Attributable to Shareholders of the Listed Company	22,027,754,784.54	21,571,867,029.94	2.11
Total Assets	34,435,499,315.37	32,784,579,366.01	5.04

Note: The total profit for the current reporting period was RMB 1,033,041.2 thousand, a decrease of 3.72% compared with the same period of the previous year, mainly due to the impact of exchange gains and losses. In the current reporting period, exchange losses amounted to RMB 118,319.6 thousand, while in the same period of the previous year, exchange gains amounted to RMB 14,606.9 thousand. Excluding the impact of the above factors, the total profit for the current reporting period would have increased by 8.79% compared with the same period of the previous year.

2. Key Financial Indicators

Key Financial Indicators	Current Reporting Period (January-June)	Same Period of the Previous Year	Change from the same period of the previous year (%)
Basic earnings per share (yuan/share)	1.10	1.21	-9.09
Diluted earnings per share (yuan/share)	1.10	1.21	-9.09
Basic earnings per share excluding non-recurring gains and losses (yuan/share)	1.01	1.17	-13.68
Weighted average return on net assets (%)	4.12	4.90	Decrease of 0.78 percentage points
Weighted average return on net assets excluding non-recurring gains and losses (%)	3.79	4.75	Decrease of 0.96 percentage points

R&D investment as a percentage of operating revenue (%)	19.61	18.95	Increase of 0.66 percentage points

Explanation of the Company's key accounting data and financial indicators

√ Applicable□ Not applicable

(I) Operating conditions, financial position, and principal factors affecting operating performance during the reporting period

1. Operating conditions and financial position

In the first half of 2026, the Company achieved total operating revenue of RMB 7,051,579.1 thousand, representing a year-on-year increase of 17.22%; net profit attributable to the parent company's shareholders was RMB 896,996.0 thousand, a year-on-year decrease of 10.12%; net profit attributable to the parent company's shareholders excluding non-recurring gains and losses was RMB 826,730.0 thousand, a year-on-year decrease of 14.38%.

As of the end of June 2026, the Company's total assets were RMB 34,435,499.3 thousand, a year-on-year increase of 5.04%; owners' equity attributable to the parent company was RMB 22,027,754.8 thousand, a year-on-year increase of 2.11%.

2. Principal factors affecting operating performance

During the reporting period, the Company adhered to an innovation-centric product development strategy, continuously launched mid-to-high-end equipment with differentiated competitive advantages, leveraged the synergistic efforts of multiple product lines, and continuously optimized the overall business structure, further enhancing the quality of revenue growth and sustainable development capabilities.

Currently, the demand-driven structure of the domestic market is accelerating its transformation and upgrading. The large-scale equipment renewal policy has entered its third year of normalized implementation. The endogenous momentum for industry growth continues to be consolidated. The market position of the Company's main product lines has been further solidified, high-end advantageous products maintain their leading edge, and the competitiveness of several core products continues to improve. The overseas business continues to maintain a high-speed growth trend. Operating in a dynamic global environment, the Company’s integrated capabilities across technology, products, and supply chains have supported continued expansion across developed markets in Europe, America, and Asia-Pacific, as well as emerging regional markets, effectively hedging against external environmental fluctuations and demonstrating strong operational resilience.

(II) Explanation of the main reasons for changes of 30% or more in the items in the table above

The net cash flow generated from operating activities during the reporting period decreased by 596.35% compared with the same period of the previous year, mainly due to the Company's business

growth, which led to increases in both cash inflows and outflows from various operating activities compared with the same period of the previous year.

VII Differences in accounting data under domestic and overseas accounting standards

□ Applicable√ Not applicable

VIII Non-recurring gains and losses items and amounts

√ Applicable□ Not applicable

Unit: Yuan Currency: RMB

Non-recurring gains and losses items	Amount	Notes (if applicable)
Gains or losses on disposal of non-current assets, including the offset portion of provision for asset impairment	813.00	
Government grants recognized in current profit or loss, excluding those closely related to the Company's normal operating activities, in compliance with national policies, enjoyed according to established standards, and having a continuing impact on the Company's profit or loss	64,590,049.09	
Except for effective hedging activities related to the Company's normal business operations, gains or losses from changes in fair value of financial assets and financial liabilities held by non-financial enterprises, and gains or losses from the disposal of financial assets and financial liabilities	36,298,222.92	
Other non-operating income and expenses other than the above items	-19,114,666.39	
Less: Income tax impact	11,129,166.88	
Impact on minority shareholders' equity (after tax)	379,290.13	
Total	70,265,961.61	

For items not listed in the 'Public Company Information Disclosure Explanatory Announcement No. 1 - Non-recurring Gains and Losses' that the Company recognizes as non-recurring gains and losses items and are significant in amount, and for items listed in the 'Public Company Information Disclosure

Explanatory Announcement No. 1 - Non-recurring Gains and Losses' that the Company defines as recurring gains and losses items, the reasons should be explained

□ Applicable√ Not applicable

IX Companies with equity incentives or employee stock ownership plans may choose to disclose net profit after deducting the impact of share-based payments

□ Applicable√ Not applicable

X Explanation of performance indicators not under corporate accounting standards

□ Applicable√ Not applicable

Section II Management Discussion and Analysis

I Description of the industry and principal business of the Company during the reporting period

(I) Principal business of the Company

United Imaging Healthcare is committed to providing high-performance medical imaging equipment, radiotherapy products, and life science instruments to global customers. The Company is headquartered in Shanghai and has established regional headquarters and R&D centers in the United States, the Netherlands, the United Arab Emirates, Malaysia, Colombia, and other locations. It has production capacity in Shanghai, Changzhou, Wuhan, and Houston, USA, and has established a globalized R&D, production, and service network.

Since its establishment, the Company has continuously invested heavily in R&D, committed to advancing core technologies in the field of large medical equipment such as medical imaging equipment and radiotherapy products. After years of effort, the Company has built a complete product line layout including medical imaging equipment, radiotherapy products, and life science instruments. As of the end of the reporting period, the Company has launched more than 160 products to the market, including Magnetic Resonance Imaging (MR) systems, X-ray Computed Tomography (CT) systems, X-ray Imaging (XR) systems, Molecular Imaging (PET/CT, PET/MR) systems, Ultrasound Diagnostic (US) systems, Medical Linear Accelerator (RT) systems, and life science instruments.

(2) Industry Overview

(1) Development Stage

Global aging, the increase in chronic diseases, and the growth of healthcare expenditures have driven the expansion of the global medical device market, and global public health emergencies have accelerated this market expansion. According to data from CIC Consulting, the global medical device market size had already exceeded USD 480 billion in 2021, and it is expected to reach USD 848 billion by 2030, with a compound annual growth rate of 6.4% from 2021 to 2030, indicating that the global market is expected to maintain steady growth.

Compared with the global medical device market, the Chinese medical device market is developing relatively faster. Due to the level of productivity development, the overall medical device industry in China started relatively late. However, driven by factors such as the enhancement of the country's overall strength, the improvement of national living standards, population aging, and strong government support for the medical field, the Chinese medical device market has grown rapidly. From 2015 to 2020, the size of China's medical device market has grown from RMB 312.55 billion to RMB 778.93 billion, with a compound annual growth rate of approximately 20.0%. In the future, driven by increased market demand, national support for the medical industry, and industrial upgrading brought about by technological development in the medical device industry, the medical device industry is expected to continue maintaining a good momentum of rapid growth. It is projected that by 2030, the medical device market size will reach RMB 2,492.4 billion, with a compound annual growth rate of 11.9% from 2021 to 2030.

According to different functions and uses, medical devices can be divided into categories such as medical imaging equipment, surgical equipment, and in vitro diagnostic equipment. Among these, medical imaging equipment refers to equipment that, for the purpose of diagnosis or treatment guidance, applies various physical signals to the human body, including visible light, X-rays, ultrasound, and strong magnetic fields, records the signal intensity distribution fed back by the human body, forms images, and enables doctors to interpret information on human body structure and lesions from these images. Depending on the purpose, medical imaging equipment can be divided into diagnostic imaging equipment and therapeutic imaging equipment. Diagnostic imaging equipment can be broadly categorized based on the signal type into Magnetic Resonance Imaging (MR) equipment, X-ray Computed Tomography (CT) equipment, X-ray Imaging (XR) equipment, Molecular Imaging (MI) equipment, and Ultrasound (US) equipment, among others; therapeutic imaging equipment can be broadly categorized into Digital Subtraction Angiography (DSA) equipment and stereotactic radiation equipment (e.g., orthopedic C-arms). Medical imaging equipment is the market segment with the highest technical barriers in the medical device industry. With the rapid development of China's economy, the worsening of population aging, the improvement of public health awareness, and the continuous increase in demand for healthcare services, the domestic market demand for high-quality medical imaging has correspondingly grown rapidly. Driven by both market demand and policy dividends, China's medical imaging equipment market will continue to grow. The market size reached RMB 53.70 billion in 2020, and it is expected to approach RMB 110 billion by 2030, with an expected compound annual growth rate of 7.3%.

(2) Basic Characteristics

The high-end medical equipment industry is a high-tech industry characterized by multi-disciplinary intersection, talent intensity, knowledge intensity, and innovation intensity. Compared with the global market, China's medical imaging equipment industry has consistently shown a situation of low industry concentration, small enterprise scale, and low market share of domestic brands in the mid-to-high-end market. In recent years, with the overall improvement in the R&D level of domestic medical equipment, core product technologies have been gradually overcome, and product quality and reputation have risen. Some domestic enterprises have achieved corner overtaking through technological innovation, and the pattern of import monopoly is changing. The domestic medical imaging equipment industry is gradually achieving the goal of keeping pace with international brands.

(3) Main Technical Barriers

The R&D of high-end medical equipment has extremely high technical barriers and belongs to an industry that is multi-disciplinary, knowledge-intensive, and innovation-intensive. The R&D of a single device often involves numerous disciplinary fields such as biomedical engineering, mechanics, algorithms, electronic information, materials science, and medical imaging technology, resulting in high R&D thresholds and long R&D cycles.

The main technical barriers in the field of Magnetic Resonance Imaging include superconducting magnet technology, gradient technology, radio frequency technology, spectrometer design technology, and application technology. The Company possesses the development technology for zero-boil-off magnets

and superconducting magnets at 1.5T, 3.0T, 5.0T, and higher field strengths, and has developed the industry's first 75cm large-bore 3.0T and 5.0T whole-body MR products, as well as the first domestic 3.0T MR and 9.4T animal MR products; it has the capability to develop gradient coils of multiple sizes and high performance, and has mastered the development technology for high-precision, high-power gradient power amplifiers; it possesses the design and manufacturing technology for high-channel RF receive coils suitable for various parts of the human body, and can design and manufacture multi-channel RF transmit coils for the human body at field strengths from 1.5T to 3.0T and above, mastering the development technology for multi-channel, high-power RF amplifiers; it has a self-developed distributed spectrometer system with features such as multi-channel transmission, ultra-high-channel RF parallel data acquisition, nanosecond-level synchronization, and 24/7 component monitoring; it has rich scientific research and clinical application technologies and is an industry leader in AI-empowered innovative applications.

The main technical barriers in the field of X-ray Computed Tomography (CT) include detector technology, X-ray tube and high-voltage generator technology, and reconstruction algorithms. The Company's self-developed Z-Detector has been applied to its CT series products, supporting multiple configurations with the thinnest slice thickness of 0.5mm; it has independently developed bipolar CT tube technology and high-voltage generator technology; it has developed correction and reconstruction algorithms based on CT products, providing excellent CT image quality and enhancing the system's dynamic acquisition capability; it has also developed an AI-based full-model iterative reconstruction algorithm that minimizes dose while ensuring images meet clinical diagnostic requirements.

The main technical barriers in the field of X-ray Imaging (XR) include high-voltage generator technology, image reconstruction and post-processing technology, and automated electromechanical control technology. The Company has developed metal implant identification and graphic noise reduction technology based on deep learning, which can accurately detect the region of metal implants in medical images; it has created a unique full-field scanning trajectory and reconstruction algorithm, expanding the reconstruction field of view of cone beam CT on DSA systems to 431mm; it has mastered the high-voltage generator technology for XR, and this component has already achieved mass production and is used in some products; the self-developed high-voltage generator uses high-frequency inverter technology to reduce product size to meet end-user space requirements, can reduce output ripple to optimize exposure dose and improve image quality, and can increase the switching speed of kV output pulses, thereby reducing the radiation dose received by the subject.

The main technical barriers in the field of Molecular Imaging (MI) include scintillator and detector technology. The Company's detector, through the overall design of a SiPM-based digital detector module and a large axial field of view, achieves high sensitivity that effectively improves image quality and scanning speed while reducing scan dose; the Company's high-resolution detector, combined with high-bandwidth data acquisition and transmission technology, can losslessly record and process data obtained from high-resolution digital detectors. The Company is also one of the few enterprises in the industry capable of designing and manufacturing long-axis PET products.

The main technical barriers in the field of Ultrasound (US) include high-performance transducer technology, ultra-high-frequency ultra-wideband systems, image reconstruction and post-processing technology, and native intelligent agent applications. The Company has the independent R&D and manufacturing capability for high-resolution, high-sensitivity multi-dimensional single-crystal transducers; it has developed a 50MHz ultra-high signal bandwidth system and a series of ultra-high-frequency transducers, enabling ultra-high spatial resolution imaging of superficial skin, musculoskeletal, and other parts; its independently developed OmniFocus global dynamic focusing technology effectively improves imaging resolution and frame rate; it has mastered key imaging technologies such as microvascular imaging and high-frame-rate contrast-enhanced imaging, fully meeting clinical diagnostic requirements; the fully automated workflow realizes the intelligence of the entire ultrasound diagnosis process from transducer activation, scanning and storage of different clips, data analysis, to final report output; the independently developed uTarget intelligent analysis software improves diagnostic accuracy and efficiency; and it possesses rich clinical and scientific application software technology, with outstanding advantages in clinical and scientific applications.

The main technical barriers in the radiotherapy field include accelerator tubes, dynamic multi-leaf collimator technology, and others. The integrated CT imaging system integration technology mastered by the company can integrate the imaging system with the treatment system, achieving a coaxial and same-bed design for CT and medical linear accelerator, making tumors clearer through high-quality diagnostic images and improving the precision of clinical treatment. Meanwhile, the core algorithms of the TPS treatment planning system independently developed by the company include dose calculation algorithms and optimization algorithms, which can improve the speed and accuracy of dose calculation and enhance the work efficiency of clinical medical physicists. The 6MV accelerator tube independently developed by the company outputs a maximum dose rate that reaches the industry-leading level (600MU/min@1m in flat mode, 1400MU/min@1m in flattening filter free mode), and can achieve accurate control of each dose pulse. The dynamic multi-leaf collimator technology independently developed by the company can realize the clinical application of efficient and precise volumetric modulated arc therapy, reducing the radiation dose received by patients' normal tissues through precise dose modulation.

a) Analysis of the company's industry position and its changes

The company's product line covers high-end medical imaging diagnostic products and radiotherapy products, achieving an integrated layout for diagnosis and treatment. The comparison of the company's product line with major participants in domestic and international markets is as follows:

Equipment Type	United Imaging Healthcare	GE Healthcare	Siemens Healthineers	Philips Healthcare	Elekta	Wandong Medical	Neusoft Medical
MR Products							
5.0T and above	▲	▲	▲				
3.0T	▲	▲	▲	▲		▲	▲
1.5T and below	▲	▲	▲	▲		▲	▲
CT Products							
Photon-counting spectral CT	▲	▲	▲				▲
320-slice/640-layer	▲						
256-slice/512-layer		▲	▲				▲
128-slice and below	▲	▲	▲	▲		▲	▲
XR Products							
Large C-arm (DSA)	▲	▲	▲	▲		▲	▲
Mammo	▲	▲	▲			▲	▲
Conventional/Mobile DR	▲	▲	▲	▲		▲	▲
Small/Medium C-arm	▲	▲	▲	▲		▲	▲
MI Products							

Equipment Type	United Imaging Healthcare	GE Healthcare	Siemens Healthineers	Philips Healthcare	Elekta	Wandong Medical	Neusoft Medical
PET/CT							
AFOV>120cm	▲						
AFOV50-120cm	▲	▲	▲				
AFOV<50cm	▲	▲	▲	▲			▲
PET/MR	▲	▲	▲				
Ultrasound Products	▲	▲	▲	▲		▲	▲
RT Products							
Linear Accelerator	▲		▲		▲		▲
Image-Guided Linear Accelerator	▲		▲		▲		▲
Life Science Instruments	▲						

Data source: CIC Consulting, etc.

As shown in the table above, in the field of high-end medical imaging and radiotherapy products, the company's product line coverage is basically consistent with that of international manufacturers such as GE HealthCare, Siemens Healthineers, and Philips Healthcare. In the industry in which the company operates, the mid- and low-end product market has gradually achieved domestic substitution. Although the high-end and ultra-high-end product market is still dominated by imported brands, the company has gained a leading advantage in some fields and continues to expand its market share in competition with international manufacturers. Based on the statistics of the newly added domestic market amount in the first half of 2026, the company's product lines are all ranked at the forefront of the industry.

(III) Main Products and Their Uses

As of the end of the reporting period, the company has launched more than 160 products to the market, including Magnetic Resonance Imaging systems (MR), X-ray Computed Tomography systems (CT), X-ray Imaging systems (XR), Molecular Imaging systems (PET/CT, PET/MR), Color Doppler Ultrasound Diagnostic systems (US), Medical Linear Accelerator systems (RT), and Life Science Instruments.

The company's specific product categories and their uses are as follows:

No.	Category	Product	Product Use
1	Medical Imaging Equipment	Magnetic Resonance Imaging System (MR)	MR has the advantages of no radiation, rich contrast, and high soft tissue resolution. It is widely used in clinical scenarios such as diagnosis of various diseases, physical examination screening, and surgical navigation, and can provide important diagnostic information for research in frontier disciplines such as basic medicine, brain science, and molecular biology.
		CTN (CT)	CT has the characteristics of fast scanning speed and high spatial resolution. It is suitable for medical institutions at all levels and can provide the necessary information for physical examination, diagnosis, and treatment.
		X-ray Imaging System (XR)	XR includes conventional DR, mobile DR, mammography systems, C-arm X-ray machines, DSA, etc., and can be used for screening and diagnosis of various diseases, as well as image guidance for surgical and interventional procedures.
		Molecular Imaging System (MI)	Including PET/CT and PET/MR, etc., it can combine the molecular metabolic activity images of PET scanning with the morphological and functional information of CT or MR scanning; it has broad clinical value in whole-body tissue diagnosis, especially in oncology, cardiovascular, and neurological aspects; it is also of great value in multiple fields such as scientific research and translational medicine.

No.	Category	Product	Product Use
		Ultrasound Diagnostic System (US)	US has the advantages of being safe, non-invasive, radiation-free, real-time, and economical. It is widely used in clinical scenarios such as screening, diagnosis, and follow-up visits for various diseases; at the same time, it is playing an increasingly important role in minimally invasive interventional treatment, intraoperative real-time navigation, and other fields.
2	Radiotherapy Products	Medical Linear Accelerator System (RT)	Radiotherapy is currently an important treatment method for tumors. Among them, the medical linear accelerator has the advantages of wide indications and wide application, and is the mainstream radiotherapy equipment.
3	Life Science Instruments	Animal MR	It can present the tissue structure and functional information of living animals, assist in pathological and pharmacological research of animal models, and provide help for translational medicine.
		Animal PET/CT	It can realize real-time detection of physiological, pathological, and pharmaceutical metabolic processes of various animal models at the dynamic molecular level, assist in drug development, and provide help for translational medicine.

Note: Animal MR and Animal PET/CT are Magnetic Resonance Imaging (MR) and Molecular Imaging (MI) systems applied in the field of animal model imaging. The sales data of life science instruments are combined with medical imaging equipment.

1. Medical Imaging Diagnosis

(1) Magnetic Resonance Imaging System

Magnetic Resonance Imaging (MR) is a device that uses the magnetic resonance signals of atomic nuclei (mainly hydrogen protons) in water molecules in the human body in a strong magnetic field, which are reconstructed to image tissues or organs.

Magnetic Resonance Imaging (MR) is a device that uses the magnetic resonance signals of atomic nuclei (mainly hydrogen protons) in water molecules in the human body in a strong magnetic field, which are reconstructed to image tissues or organs.

The company has the capability to independently design, develop, and manufacture high-field superconducting magnets, high-performance gradient coils, high-density RF coils, multi-channel distributed spectrometers, as well as MR imaging software and advanced image processing applications. The company has launched multiple superconducting MR products such as 1.5T, 3.0T, and 5.0T, which can meet the needs of different market segments from basic clinical diagnosis to high-end scientific research. Many of these products are the first in the industry or the first domestically produced. uMR Jupiter 5T is the industry's first 5.0T MR model for whole-body imaging, enabling ultra-high-field whole-body clinical imaging; uMR Ultra is equipped with the uAIFI.LIVE imaging platform, combined with the latest generation of AI imaging chain, and relies on the synergy of the ultra-high-performance gradient system and the spatiotemporal fusion AI engine to continuously capture high-definition dynamic images of anatomical structures and functional tissue activities, not only ensuring the high definition of each frame but also providing continuous dynamic information, which has great potential for the observation, diagnosis, and research of moving parts of the human body; uMR Max is a new generation 3.0T magnetic resonance system, equipped with a high-performance gradient system, a new online ecosystem platform, and a full-process AI-assisted system, significantly improving examination efficiency and diagnostic consistency; uMR Omega is the industry's first 75cm ultra-large-bore 3.0T MR model, which can better support intraoperative and radiotherapy positioning, and can meet the diagnosis and treatment needs of special groups such as pregnant women and overweight people; uMR 600 is the industry's first silicon carbide magnetic resonance system, equipped with third-generation semiconductor technology silicon carbide (SiC) gradient power amplifier (GPA), combined with the uAIFI platform, which can improve image quality and scanning speed and significantly reduce equipment energy consumption.

The company's main MR products are as follows:

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
1	uMR Jupiter 5T		• The industry's first 5.0T superconducting magnetic resonance system, supporting clinical and scientific research applications for all parts of the body • The first 8-channel volume transmit coil, solving the problem of ultra-high-field RF excitation uniformity and achieving precise whole-body imaging • Equipped with a 3.5MW gradient power amplifier, supporting ultra-high gradient performance of 120mT/m&200T/m/s, helping to explore the frontiers of brain science • Innovative magnet design, requiring only the installation space of a traditional 3.0T magnetic resonance system, greatly improving the accessibility of ultra-high-field systems
2	uMR Ultra		• The world's first LIVE high-definition camera magnetic resonance, a high-performance large-bore 3.0T, ushering in the era of whole-body LIVE camera magnetic resonance • Equipped with the uAIFI.LIVE imaging platform, combined with the latest generation of AI image chain, relying on the synergy of the 100 mT/m @ 200 T/m/s ultra-high-performance gradient system and the spatiotemporal fusion AI engine, it can continuously capture high-definition dynamic images of anatomical structures and functional tissue activities • While ensuring the clarity of single-frame images, it provides stable and continuous dynamic image information, expanding the application boundaries of magnetic resonance in the assessment of motion-related tissues and functions

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
			• Suitable for clinical scenarios such as the nervous system, gastrointestinal tract, pelvic cavity, and joints, providing richer imaging information support for the diagnosis and evaluation of complex diseases and scientific research applications
3	uMR Astra		• Equipped with the next-generation high-density ultra-flexible coil, it achieves precise coverage of all body parts through its high channel count. Its excellent conformity and sensing sensitivity significantly improve the image signal-to-noise ratio, laying a solid foundation for whole-body high-definition imaging while ensuring patient comfort. • Leveraging deep learning acceleration technology, it delivers an ultimate imaging experience of 5 minutes for the head, 8 minutes for the abdomen, and 15 minutes for the heart. While ensuring clinical diagnostic-grade image quality, it helps increase the daily scan volume of a single device by up to 50%, effectively optimizing departmental workflow efficiency and the patient experience. • Deeply integrating AI algorithms with clinical practice, it builds an intelligent management system covering the entire scanning workflow. Through customized solutions for diverse clinical scenarios, it achieves a closed loop from intelligent positioning to precise diagnosis, fully empowering efficient diagnosis and treatment of complex diseases.

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
4	uMR Max		• The revolutionary gradient control system transcends traditional limitations, achieving significant improvements in precise imaging and scanning efficiency. • Relying on the online ecosystem platform, it supports real-time access to a wealth of cutting-edge technologies and diverse clinical solutions. • Full-process AI empowerment enhances the intelligence level of magnetic resonance imaging, significantly improving examination efficiency and diagnostic consistency.
5	uMR Omega		• The industry's first 75cm large-bore 3.0T MR, meeting the diagnostic and treatment needs of pregnant women and overweight patients, and supporting surgical navigation and radiotherapy simulation positioning. • Equipped with a high-homogeneity large-bore superconducting magnet, it achieves the industry's largest 60cm high-definition scanning imaging range. • Equipped with a 3.5MW gradient power amplifier, it meets the clinical needs for high-speed scanning and high-resolution imaging. • "Silent" mode scanning significantly reduces acoustic noise during MR examinations.

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
6	uMR NX		• Ultra-high-performance research-grade 3.0T MR, suitable for high-end research scenarios. • Equipped with a 3.5MW gradient power amplifier, an ultra-high-performance gradient system (single-axis field strength 120mT/m, slew rate 200T/m/s), and a 64-channel ultra-high-density head research coil, suitable for brain science research. • Equipped with a fully digital radio frequency system and uCS imaging technology, it improves scanning speed and image quality.
7	uMR 880		• Whole-body high-performance research-grade 3.0T MR, suitable for research and advanced clinical application scenarios. • Equipped with a 3.5MW gradient power amplifier and a high-performance gradient system (single-axis field strength of 80mT/m, slew rate of 200T/m/s), widely applicable to research and advanced clinical applications across various body parts. • Equipped with ultra-high-density super-flexible coils and a millimeter-wave radar respiratory motion detection system, comprehensively improving image quality and workflow efficiency. • Achieves comprehensive advanced clinical and research applications from neurology to body and cardiac imaging.

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
8	uMR 870		• Whole-body research and clinical 3.0T MR, suitable for scenarios where clinical and research needs are equally emphasized. • Equipped with high-density super-flexible coils and a millimeter-wave radar respiratory motion detection system, comprehensively improving image quality and workflow efficiency. • Whole-body, full-sequence "silent" scanning enhances the patient experience.
9	uMR 780		• The first domestically produced uLight 3.0T MR, suitable for scenarios where clinical and research needs are equally emphasized. • Equipped with uLight imaging technology and a high-performance uLight reconstruction engine, it achieves fast scanning at 0.5 seconds per phase. • Clinical solutions cover static and dynamic application scenarios across all body parts, and are also suitable for clinical scientific research.
10	uMR 680		• Large-bore flagship research-grade 1.5T magnetic resonance imaging system, suitable for scenarios where clinical and research needs are equally emphasized. Single-axis gradient field strength of 45mT/m, gradient slew rate of 200T/m/s. • Equipped with high-definition noise reduction technology, it delivers 3.0T-level high signal-to-noise ratio and higher-resolution images. • Full-sequence ultra-fast silent imaging system, providing an excellent scanning experience and comprehensive clinical and research applications.

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
11	uMR 670 Max		• Large-bore clinical flagship 1.5T magnetic resonance system. • Equipped with the latest generation SuperFlex Coil, supporting 72-channel RF performance, achieving seamless conformity and precise sensing across all body parts. While providing comprehensive clinical support such as radiotherapy simulation positioning, it improves image signal-to-noise ratio and patient comfort. • Relying on the dual engines of ACS and DeepRecon, it achieves leapfrog improvements in image quality and scanning speed. While ensuring clinical diagnostic-grade accuracy, it significantly shortens imaging time for various body parts, helping departments break through daily scan volume bottlenecks and build an efficient ultra-fast imaging system. • All-in-One full-AI intelligent workflow: deeply integrates the intelligent driving system and AI algorithms to create a standardized clinical pathway covering the entire scanning process. Through customized solutions for complex scenarios, it achieves closed-loop management from intelligent positioning to precise image output, fully empowering high-level applications in research and clinical practice.
12	uMR 670		• Large-bore image-fidelity 1.5T MR, suitable for clinical scenarios. • Equipped with high-definition noise reduction technology, it delivers 3.0T-level high signal-to-noise ratio and higher-resolution images. • Equipped with dual millimeter-wave radar remote sensing vital sign detection technology, it acquires physiological signals without contact.

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
			• Full-sequence ultra-fast silent imaging system with an excellent scanning experience.
13	uMR 660		• Image-fidelity 1.5T MR, suitable for clinical scenarios. • Equipped with high-definition noise reduction technology, it delivers higher signal-to-noise ratio and higher-resolution images. • Equipped with a fully digital radio frequency system, achieving high-fidelity, low-noise imaging. • Equipped with uLight imaging technology, effectively improving clinical scanning speed.
14	uMR 630 Max		• High-end advanced 1.5T SiC MRI • Equipped with industry-leading silicon carbide (SiC) power semiconductor technology, achieving exceptional evolution of the radio frequency system and 72 high-channel performance. Through a hardware architecture that excels in both energy efficiency and performance, it provides extremely high signal-to-noise ratio and signal stability while reducing energy consumption, laying a solid technical foundation for ultra-high-definition clinical imaging. • Deeply integrates ACS intelligent light-speed scanning, DeepRecon deep learning reconstruction, and intelligent driving system, building a comprehensive

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
			ultra-fast imaging system covering the entire workflow. Through the deep involvement of AI algorithms in scanning and reconstruction, it significantly shortens single-part imaging time, achieving a simultaneous leap in diagnostic accuracy and departmental operational efficiency. • Relying on powerful gradient performance and computing platform, it enables cardiac imaging under a single breath-hold or even completely free-breathing. Addressing diverse clinical challenges, it provides standardized solutions covering the whole body, helping departments achieve comprehensive advancement in complex disease diagnosis.
15	uMR 600 Max		• 1.5T silicon carbide (SiC) MRI, equipped with ACS intelligent light-speed scanning and DeepRecon deep learning reconstruction technology. Through the collaborative evolution of hardware platform and AI algorithms, it achieves a dual improvement in image signal-to-noise ratio and scanning speed, defining a new height of clinical performance for 1.5T MRI. • Equipped with EasySense zero-restraint respiratory sensing technology, it eliminates the physical constraint of traditional respiratory belts, achieving real-time and precise sensing of the patient's physiological state. While greatly improving examination efficiency and convenience, it effectively suppresses motion artifacts, ensuring the production of highly stable, high-quality diagnostic images in various complex clinical scenarios.

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
			• Adopting the latest generation SuperFlex Coil flexible coil, the high-density channel layout combined with advanced sensing technology not only significantly enhances the detail expression of clinical images, but also provides patients with the ultimate examination comfort.
16	uMR 600		• The industry's first silicon carbide MRI, combined with the new uAIFI platform, achieves both efficiency and energy savings. • Equipped with the pioneering silicon carbide (SiC) gradient power amplifier (GPA) with high electrical energy utilization efficiency, compared with traditional silicon GPA, the device loss of SiC GPA is reduced by more than 60% at the same power level. Combined with a full set of low-carbon and energy-saving solutions, it can save more than 57% of electrical energy. • uCS&DeepRecon Hybrid dual-engine drive system, possessing both image quality and scanning speed, with up to 60% time reduction, supporting exclusive low-carbon sequences and Qscan silent scanning technology.

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
17	uMR 585e		• Fully digital 1.5T MR, suitable for clinical scenarios. • Equipped with industry-leading compressed sensing imaging and AI image reconstruction technology, it can achieve higher resolution and higher signal-to-noise ratio without sacrificing scanning time. • Equipped with a more comprehensive AI positioning workflow: intelligent positioning functions covering multiple common body parts. Reduces manual positioning time for radiologic technologists, improves standardized scanning and image quality control, covering 2D/3D scanning, quantitative analysis, functional and metabolic imaging technologies. • Equipped with high-efficiency radio frequency and integrated high-density phased array coil sets, achieving higher signal transmission efficiency and comprehensive clinical applications.
18	uMR 588		• Fully digital 1.5T MR, suitable for clinical scenarios. • Equipped with fully digital radio frequency transmission technology, achieving high-fidelity, low-noise imaging. • Automated examination workflow, improving usage efficiency. • Equipped with light-speed imaging technology, effectively improving clinical scanning speed.

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
19	uMR 580		• Fully digital 1.5T MR, suitable for clinical scenarios. • Equipped with fully digital radio frequency transmission technology, achieving high-fidelity, low-noise imaging. • Automated examination workflow, improving usage efficiency. • Providing comprehensive clinical solutions.

(2) X-ray Computed Tomography System

The X-ray Computed Tomography (CT) system emits X-rays from the X-ray tube. The X-rays penetrate human tissue and are received by the detector, which converts them into digital signals. After computer processing, cross-sectional or three-dimensional images of the examined area are formed, thereby detecting lesions in human tissues or organs.

The company has mastered the R&D and production capabilities for CT detectors, X-ray tubes, high-voltage generators, high-speed rotating gantries, and advanced image processing applications. The company's CT product line covers clinical economy products and high-end research products, meeting diverse needs such as disease screening, clinical diagnosis, and scientific research. The company has successively launched CT products from 16-slice to 320-slice, including the first domestic photon-counting energy spectrum CT uCT Ultima, which pioneered domestic photon-counting energy spectrum CT for ultra-high-resolution imaging of multiple body parts and precise energy spectrum imaging, suitable for integrated high-end clinical diagnosis and treatment and scientific research scenarios; the world's first dual-wide-body dual-source CT imaging system uCT SiriuX, which for the first time combines wide-body detector and dual-source, two ultra-high-end CT system forms, achieving a breakthrough 8ms industry-leading whole-heart temporal resolution, dual-wide 16cm full-organ volume coverage, and a 470mm ultra-large energy spectrum imaging field of view, achieving comprehensive performance improvement in time, coverage, and accuracy; the new generation ultra-high-end CT uCT Atlas Pro, the first domestic 320-slice ultra-high-end CT product uCT 960+, and the first domestic 80-slice CT product uCT 780. Among them, uCT Atlas Pro, as the latest generation ultra-high-end 320-slice 640-layer CT released by United Imaging Healthcare, is equipped with the new generation AIIR Pro dual-engine supercomputing imaging platform, which not only achieves a revolutionary dual-engine reconstruction algorithm architecture, maintaining the advantages of optical, noise, anatomical, and system models, accurately preserving anatomical and pathological features, while also possessing the advantages of natural and realistic image texture brought by deep learning denoising technology; the innovative CardioBoost cardiac-specific deep learning algorithm technology, carefully developed for

cardiac reconstruction algorithms, uses deep learning technology to significantly enhance image resolution, eliminate artifact interference, while effectively reducing radiation dose and noise, maintaining the natural and realistic image texture, significantly improving the accuracy of cardiac diagnosis; the uCT 960+ is equipped with a self-developed Z-Detector, achieving a 0.25s/rotation gantry rotation speed, with an 82cm large bore, enabling single cardiac cycle cardiac imaging at any heart rate, single-organ perfusion, and fast large-range vascular imaging, while also possessing low-dose imaging and tube voltage switching energy spectrum imaging functions, providing good clinical diagnosis and research value in cardiovascular and cerebrovascular diseases, tumors, emergency, and pediatric examinations. The uCT Orion Plus/Pro/Elite new generation 40-slice practical CT: integrated imaging chain, with self-developed and self-produced detector, X-ray tube, and high-voltage generator, ensuring accurate data and stable system, meeting complex clinical needs such as high-throughput, multi-part combined scanning; the Orion series AI precise quality control: improving quality from scanning standardization and safety, supporting AI recognition of 8 body positions, including one-click positioning, parameter setting, and other functions, avoiding artifacts and safety accidents, ensuring image quality and patient safety, and improving grassroots scanning capabilities; equipped with an AI intelligent clinical application platform: integrating brain hemorrhage AI, lung nodule screening, and other functions, facilitating efficient and precise diagnosis and treatment.

The company's main CT products are as follows:

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
1	uCT Ultima		• The first domestically produced photon-counting spectral CT, leading the industry in achieving ultra-high resolution and precise spectral imaging across multiple body regions, suitable for integrated high-end clinical diagnosis, treatment, and research scenarios. • In ultra-high-resolution imaging, it breaks through the limitations of traditional detector size, reducing the pixel area to 1/9 of the traditional size, enabling visualization of subtle lesion structures, significantly improving spatial resolution, and aiding precise diagnosis. • Major breakthroughs have been achieved in core areas such as overall system design, reconstruction algorithms, and spectral applications, supporting

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
			full-collimation high-resolution imaging, especially suitable for high-definition imaging of large organs such as the heart.
2	uCT SiriuX/ SiriuX Pro		• The world's first entirely new CT system form, subverting traditional architecture, breaking through by combining a wide-body detector with dual-source technology, achieving the industry's highest 8ms whole-heart temporal resolution, 16cm whole-organ volume coverage, and a 470mm ultra-large dual-source spectral imaging field of view. • Filling the gap in traditional clinical dynamic imaging, in cardiac imaging, uCT SiriuX not only clearly presents coronary stenosis and valve motion, achieving single-cardiac-cycle whole-heart dynamic imaging, but also provides a stable and reliable imaging foundation for structural assessment and quantitative measurement through full-phase data acquisition and deep learning motion correction algorithms. • Supports clinical acquisition of whole-body motion imaging from joint movement to organ motion.

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
3	uCT Atlas Pro		• Suitable for integrated high-end clinical and research application scenarios, equipped with the new-generation AIIR Pro dual-engine supercomputing imaging platform, which not only achieves a revolutionary dual-engine reconstruction algorithm architecture, maintaining the advantages of optical, noise, anatomical, and system models to accurately preserve anatomical and pathological features, but also incorporates the advantages of deep learning denoising technology and natural image texture. • The innovative CardioBoost cardiac-specific deep learning algorithm technology, meticulously developed for cardiac reconstruction algorithms, utilizes deep learning technology to significantly enhance image resolution, eliminate artifact interference, while effectively reducing radiation dose and noise, maintaining the natural and realistic image texture, significantly improving the accuracy of cardiac diagnosis. • The new digital intelligent post-processing engine uOmnispace platform brings second-level work efficiency and ultra-realistic rendering technology, providing an excellent imaging experience.

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
4	uCT Atlas Elite		• Suitable for integrated high-end clinical and research application scenarios, as a new generation of ultra-high-end CT, uCT Atlas Elite is equipped with ECG Free deep learning non-ECG scanning, breaking free from ECG constraints, without gating limitations or heart rate restrictions, precisely capturing cardiac rhythm for coronary CTA scans, paving a clear diagnostic path for patients with complex arrhythmias. • Comprehensively innovative CT-AI intelligent agent solutions, covering full-domain neurological emergency second-level recognition, fine analysis of musculoskeletal lesions, and intelligent acceleration of emergency workflows, reshaping clinical solutions with digital intelligence. • Equipped with the uOmnispace digital intelligence engine platform, a new architecture drives research collaboration, multi-modality fusion, and big data integration, allowing clinical exploration to reach new depths. From breakthroughs in cardiac examination to intelligent upgrades in whole-system diagnosis and treatment, to innovations in the research experience, uCT Atlas Elite uses its performance edge to break down diagnostic and therapeutic barriers, leading medical imaging towards a new realm of precision and efficiency.

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
5	uCT 968		• A new generation wide-body CT product suitable for high-end clinical and research scenarios, comprehensively integrating deep learning artificial intelligence technology, providing innovative solutions for CT morphological, functional diagnosis and treatment, and cutting-edge research. • The fifth-generation CT image reconstruction technology - AIIR deep learning full-model iterative algorithm, providing new solutions for low-radiation-dose, ultra-high-resolution imaging across the whole body. • All-in-One cardiac multi-modality imaging technology, integrating coronary morphology, coronary blood flow, and myocardial microcirculation functional assessment, providing comprehensive information for clinical treatment pathway decisions, combined with deep learning head motion artifact removal and AIIR. • The fusion of deep learning full-model iterative algorithms solves the head motion artifact and whole-brain perfusion dose challenges in emergency stroke patients, resulting in lower examination doses, higher image matching accuracy, and significantly improved diagnostic and treatment efficiency.
6	uCT 960+		• The first domestically produced 320-slice ultra-high-end CT product. • A wide-body CT product suitable for high-end clinical and research scenarios.

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
			• Equipped with a self-developed 320-slice wide-body Z-Detector, with a 0.25s/rotation gantry rotation speed, obtaining 640 layers of high-definition images per rotation, improving the success rate of cardiac examination scans. • Improves the speed and imaging quality of cardiac and large-range vascular scans, increasing the success rate of cardiac scans. Possesses the capability for whole-brain, whole-liver, and other large-range whole-organ perfusion and dynamic imaging.
7	uCT 868		• A wide-body CT product suitable for high-end clinical and research scenarios. • Equipped with a 0.25s/rotation gantry rotation speed, 34MHU large heat content X-ray tube, 82cm gantry aperture, and other ultimate hardware. • Equipped with the uSense active sensing platform, which includes various deep learning algorithms for operation, scanning, dose control, image quality, artifact suppression, and more, significantly improving image quality, diagnostic efficiency, and operational consistency.
8	uCT 860		• A wide-body CT product suitable for high-end clinical and research scenarios. • Equipped with a self-developed 160-slice wide-body detector, with a 0.25s/rotation gantry rotation speed, significantly improving the success rate of cardiac scans.

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
			• A 30MHU large heat content X-ray tube meets clinical needs for high-throughput patient examinations.
9	uCT 820		• A CT product suitable for scenarios where clinical and research are equally important. • The ultra-large 82cm gantry aperture provides a more comfortable examination experience for special environments such as high-end physical examinations and emergency departments. • Equipped with a self-developed detector, the system rotation speed can reach 0.25s/rotation, comprehensively improving cardiac scanning capability and success rate.
10	uCT 788		• A CT product suitable for scenarios where clinical and research are equally important. • Equipped with Deep Recon deep learning algorithm, achieving low-dose CT imaging across the whole body; 0.3s/rotation rotation speed combined with adaptive variable speed technology, expanding new scenarios for complex coronary artery examinations; spectral functional imaging provides more quantitative information for clinical diagnosis.

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
11	uCT 780		• The first domestically produced 80-slice CT product • A CT product suitable for scenarios where both clinical and research applications are emphasized • Equipped with a self-developed detector and a 7.5MHU high heat capacity tube, with a system rotation speed of up to 0.3s/revolution, comprehensively improving the success rate of cardiac scanning; it also features a maximum system power of 100kW, suitable for examinations of patients with larger body mass
12	uCT 768		• An industry-leading high-end 160-slice CT, equipped with United Imaging's ultra-high-end CT uSense perception platform, enabling AI empowerment throughout the entire workflow • Suitable for 17cm large-coverage whole brain perfusion weighted imaging, assisting stroke centers in comprehensively evaluating patient conditions • Equipped with ePhase intelligent heart-tracking technology to improve the success rate of coronary artery scanning • Equipped with Tianyan AI technology, providing an intelligent CT scanning experience and improving scanning efficiency

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
13	uCT 760		• A CT product suitable for both clinical and research applications • Equipped with a self-developed detector • Equipped with a 7.5MHU high heat capacity tube, with a system rotation speed of 0.35s/rev and a maximum system power of 80kW, fully meeting clinical applications such as cardiac scanning and angiography
14	uCT Orion Plus/Pro/Elite		• A new-generation 40-slice practical CT with an integrated imaging chain. The detector, tube, and high-voltage generator are all self-developed and self-manufactured, ensuring accurate data acquisition and stable, reliable system performance, while easily meeting complex clinical needs such as high-throughput, multi-region combined scanning, energy spectrum scanning, and multi-phase contrast-enhanced scanning • The Orion series' exclusive AI precision quality control improves the scanning process from two dimensions: scan standardization and scan safety. It supports AI recognition of 8 body positions, and is equipped with one-click AI precise positioning, AI scan parameter setting, AI metal foreign object detection, AI motion detection, AI breathing artifact detection, integrated AI collision warning, AI lead apron wearing recognition, and an AI in-bore detection system, helping to avoid metal artifacts, motion artifacts, and safety accidents, ensuring standardized scanning and safety as well as high-definition image quality, promoting image interoperability and mutual recognition, ensuring patient health

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
			and safety, avoiding medical disputes, and enhancing the scanning capability of primary-level medical imaging examinations • Equipped with a comprehensive AI intelligent clinical application platform, integrating functions such as All-in-One AI cerebral hemorrhage detection, intelligent lung nodule screening, intelligent lung parenchyma analysis, intelligent rib and spine analysis, and intelligent dental analysis, providing intelligent and efficient support for clinical diagnosis, improving diagnostic and treatment efficiency and accuracy

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
15	uCT Orion Eco/Era/Extra		• The new-generation 20-slice CT achieves AI precision quality control based on deep learning technology, supporting AI recognition of 8 body positions, equipped with one-click AI precise positioning, AI scan parameter setting, integrated AI collision warning, AI metal foreign object detection, AI lead apron wearing recognition, and an AI in-bore detection system, effectively avoiding metal artifacts, motion artifacts, and safety accidents, ensuring standardized scanning and safety as well as high-definition image quality • Self-developed and manufactured integrated imaging chain, equipped with a second-generation Z-Detector, a large heat capacity 3.8MHU tube, and a 48kW self-developed high-voltage generator, achieving a comprehensive upgrade of core CT components, precise data acquisition, and stable, reliable system performance; while easily meeting complex clinical needs such as high-throughput, multi-region combined scanning, and multi-phase contrast-enhanced scanning • Equipped with a comprehensive AI-assisted diagnosis platform, integrating functions such as All-in-One AI-assisted cerebral hemorrhage diagnosis, intelligent lung nodule screening, intelligent lung parenchyma analysis, intelligent rib and spine analysis, and intelligent dental analysis, providing intelligent and efficient support for clinical diagnosis, improving diagnostic and treatment efficiency and accuracy

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
16	uCT 550/550+		• Equipped with a self-developed detector • Suitable for a wide range of clinical application scenarios, achieving a 0.55mm acquisition slice thickness, providing clearer and more detailed images for the diagnosis of small lesions and obtaining more diagnostic information • The 5.3MHU tube heat capacity balances scanning speed and image accuracy, meeting the needs of continuous, large-coverage clinical scanning • Utilizing KARL3D iterative noise reduction algorithm, uDose intelligent mA adjustment technology, and 70kV scan mode, low-dose imaging can be achieved
17	uCT 530/530+		• Suitable for a wide range of clinical application scenarios • Equipped with a self-developed detector • Achieves a 0.55mm acquisition slice thickness, making small lesions clearly visible • The 5.3MHU tube heat capacity provides strong continuous X-ray exposure capability and an extended service life, meeting the needs of continuous, large-coverage clinical scanning • Integrating KARL3D iterative reconstruction technology, an intelligent management platform, and other cutting-edge software and hardware, it achieves a triple breakthrough in image accuracy, ultra-low dose, and scanning speed, effectively restoring image details

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
18	uCT 520/528		• Suitable for routine clinical scenarios • Equipped with the self-developed "Z-Detector", it achieves a 0.55mm acquisition slice thickness, providing clearer and more detailed images for the diagnosis of small lesions and obtaining more diagnostic information. It can achieve a 22mm detector coverage width, effectively improving examination speed and reducing respiratory motion artifacts • Equipped with an AI patient positioning navigation system, it enables contactless, precise CT scanning, greatly simplifying the clinical workflow and effectively improving the standardization and normalization of the scanning process • Using KARL3D iterative noise reduction algorithm, uDose intelligent mA adjustment technology, and 70kV scanning mode, low-dose imaging can be achieved
19	uCT 610 Sim		• A brand-new large-bore CT system integrating diagnostic CT scanning, radiotherapy simulation and positioning, and image-guided interventional puncture procedures • 87cm large bore, providing ample patient positioning space and supporting the accommodation of various large-size positioning accessories in radiotherapy scenarios; providing more flexible operating space for interventional image-guided procedures

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
			• 63cm large scan field of view, compared to conventional 70cm bore CT systems, the scan field of view is increased by 26%, presenting more complete anatomical structures for simulation and positioning scans of special patients such as those with large body mass or off-center positioning • Supports preoperative planning, intraoperative scanning (single axial scan, single helical scan, continuous axial scan, and continuous fluoroscopy to meet different interventional puncture application scenarios), postoperative assessment, and provides a complete and professional interventional suite • A comprehensive 4D CT solution that departments can flexibly use across different clinical scenarios, laying a solid foundation for treating moving tumors.
20	uCT 830 Hybrid		• Equipped with an 80-row detector, it can perform scans of the whole body, including multiple areas such as the heart, enabling maximum application across the entire department and all organs. • It features the industry's largest gantry bore of 82cm. The diagnostic-grade large bore offers greater advantages in complex intraoperative scenarios, providing more flexibility in handling surgical situations such as head frames, drapes, and anesthesia breathing circuits. • Equipped with superior core components, including 0.5mm thin-slice scanning capability and a precise flying focal spot liquid metal tube, it ensures that subtle lesions in the lungs and liver cannot escape detection, and minute blood vessels in the distal brain are clearly visible.

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
21	Vehicle-mounted CT		• CT products used in mobile scenarios. • Equipped with a contactless scanning navigation system and a dual-channel body design for medical staff and patients, it avoids cross-infection between medical staff and patients. • Through the CT reinforcement system, stability is enhanced to meet system reliability under long-term and different-distance transportation conditions. • The remote data transmission and processing system ensures the effective and stable operation of the entire system.

(3) X-ray Imaging System

The X-ray imaging system (X-ray, abbreviated as XR) works by emitting X-rays from a tube. The X-rays penetrate human tissue and are received by a detector to generate human images. It has different imaging modes depending on the clinical application, including 2D static imaging, 2D dynamic imaging, and 3D tomosynthesis. XR examinations can be used for screening, diagnosis, and image guidance for surgical and interventional procedures.

Depending on the clinical use, XR products can be categorized into Digital Radiography (DR), Digital Mammography systems (Mammo), Mobile C-arm X-ray imaging systems (Mobile C-arm), and Angiography X-ray imaging systems (DSA). Among these, DR is widely used for routine physical examinations and clinical disease diagnosis, making it the most widely used radiography equipment in clinical applications; Mammo is mainly used for the screening and diagnosis of various breast diseases; Mobile C-arm is mostly used to provide image guidance for surgical procedures; DSA is mostly used for image guidance in various interventional procedures such as cardiac, neurological, and oncological procedures.

Since launching its first XR product in 2016, the company has successively launched the intelligent bionic minimally invasive interventional surgery system uAngio 960, the intelligent bionic aerial robot angiography system uAngio AVIVA, and, equipped with the uAID full-process intelligent radiography platform, empowering clinical practice with industry-leading artificial intelligence technology, the industry's first fully intelligent ceiling-mounted DR system uDR Aurora covering 'positioning - acquisition - processing - diagnosis - quality control', the first domestically produced breast 3D tomosynthesis system uMammo 890i, the first

domestically produced contrast-enhanced mammography system uMammo Vitar, the new generation low-dose large flat panel mobile C-arm uMC Reveal, and the first domestically produced mobile DR product uDR 380i with visual exposure control capability, among other representative products.

The company's main XR products are as follows:

No.	Product Model	Schematic	Product Introduction and Highlights
1	uAngio 960/960X/960 OR		• The intelligent biomimetic minimally invasive interventional surgery system uAngio 960/960X/960 OR, equipped with the industry's first uSpace digital twin spatial system, uses computer vision technology to enhance interventional procedure efficiency, intelligently optimizing equipment motion, image acquisition, and dose control, creating a comprehensive intelligent control experience. • It offers ultra-high flexibility, breaking through motion limitations, and delivers the ultimate whole-department experience with the industry's largest free space, largest angulation, and largest field of view. • Equipped with the proprietary uVera platform, it deeply empowers imaging with digital intelligence, supporting precise diagnosis and treatment in clinical departments such as neurology, cardiology, oncology, and surgery with excellent image quality and superior dose control. • Equipped with the industry's first zero-noise imaging technology, by optimizing the imaging chain platform and combining it with advanced Burst Denoise technology, it increases the signal-to-noise ratio by 4 times while reducing radiation dose by 40-86%.

No.	Product Model	Schematic	Product Introduction and Highlights
			• The system leads the evolution of hybrid operating rooms, comprehensively promoting interdisciplinary integration and clinical exploration and innovation.
2	uAngio AVIVA Elite/Alpha/CX/CE		• The eight-axis aerial robot design, equipped with the industry's first uSpace digital twin spatial system, uses computer vision technology to enhance interventional procedure efficiency, intelligently optimizing equipment motion, image acquisition, and dose control, providing a comprehensive intelligent control experience. • Equipped with the industry's first uLingo intelligent voice system, it supports over 10,000 high-frequency clinical command operations, enabling free dialogue in all scenarios and truly freeing doctors' hands. • The industry-leading 8-axis serial aerial robot unlocks lateral movement to achieve full coverage of any position in the operating room, with extreme flexibility making complex surgeries simple. • Equipped with the proprietary uVera platform, it deeply empowers imaging with digital intelligence, achieving precise diagnosis and treatment in clinical departments such as neurology, cardiology, oncology, and surgery with excellent image quality and superior dose control. • Equipped with the industry's first zero-noise imaging technology, by optimizing the imaging chain platform and combined with advanced Burst

No.	Product Model	Schematic	Product Introduction and Highlights
			Denoise technology, it increases the signal-to-noise ratio by 4 times while reducing radiation dose by 40-86%.
3	uMammo Vitar/Villa/Valent		• The latest generation integrated breast screening, diagnosis, and treatment platform, integrating multiple advanced functions such as CEM contrast-enhanced imaging, dual-angle DBT 3D tomosynthesis, and stereotactic biopsy based on tomosynthesis and contrast-enhanced images. • It can accurately obtain spatial and blood supply information of lesions while providing more comprehensive and precise needle biopsy localization methods.

No.	Product Model	Schematic	Product Introduction and Highlights
			• It enables the continuous completion of screening, diagnosis, and biopsy on the same platform, reducing the need for switching between multiple devices and repeat examinations, effectively shortening the diagnosis and treatment pathway, and reducing dependence on high-resource examinations such as MRI, thereby improving overall workflow efficiency and patient experience while ensuring diagnostic quality.
4	uMammo 890i		• The first domestically produced high-definition low-dose 3D digital Mammo, suitable for medical institutions at all levels. • 3D tomosynthesis can resolve the issue of tissue overlap in traditional 2D imaging, effectively improving the breast cancer detection rate and reducing the false positive recall rate. • The 49.5μm micro-pixel monocrystalline silicon flat panel detector can reduce the radiation dose during examination.
5	uMammo 870i		• A multifunctional mammography platform integrating dual-angle 3D tomosynthesis, intelligent exposure control technology, and intelligent 2D fusion technology, providing high quality and low dose, efficiently meeting different clinical needs and improving diagnostic efficiency.

No.	Product Model	Schematic	Product Introduction and Highlights
6	uMammo 590u		• Economy 2D digital mammography system, rated 5 stars by the US ECRI Patient Safety Organization • Equipped with a large-format breast-specific flat panel detector, meeting imaging requirements for breast soft tissue and micro-lesions • Features an intelligent compression system for the examined area, enabling one-touch rapid intelligent positioning
7	uMC Reveal		• A new-generation low-dose mobile C-arm with a large flat panel, equipped with an industry-leading large-format flat panel detector and the uRADIX full-process dose and image processing platform, delivering high-definition imaging at low doses during surgery • Adopts an innovative lightweight design to reduce trolley pushing resistance and transfer burden; also provides greater intraoperative positioning freedom, delivering an effortless daily operation experience and offering flexible, spacious surgical space for orthopedic, gastroenterology, and urology departments
8	uMC 560i		• Surgical flat panel mobile C-arm, suitable for various surgical procedures • Equipped with a monocrystalline silicon flat panel detector, significantly reducing radiation dose • 2-megapixel imaging chain system, greatly improving image resolution

No.	Product Model	Schematic	Product Introduction and Highlights
9	uDR Aurora		• Equipped with the uAID full-process intelligent radiography platform, empowering clinical practice with industry-leading artificial intelligence technology to achieve full-process intelligent radiography covering "positioning - acquisition - processing - diagnosis - quality control" • Supports innovative features such as intelligent voice guidance, uVision intelligent positioning, automatic FOV and intelligent parameter setting, and uAID intelligent quality control, comprehensively empowering the clinical examination workflow, improving examination efficiency, ensuring image quality, and facilitating accurate diagnosis • Provides specialty-specific clinical solutions for multiple departments, including low-dose pediatric solutions and intelligent orthopedic solutions, supporting fully automatic long bone stitching in standing and lying positions, delivering high-quality panoramic orthopedic images for clinical use and enabling accurate pre- and post-operative assessment of the spine and lower extremity joints
10	uDR 780i Pro /780i		• Enables real-time patient status observation and completion of the examination workflow in an isolation room, suitable for a variety of clinical scenarios • Supports over 200 fully automatic one-click positioning functions with automatic centering and tracking, paired with dual wireless large flat panels for efficient clinical workflow

No.	Product Model	Schematic	Product Introduction and Highlights
			• Supports fully automatic standing and lying stitching advanced applications, assisting in pre-operative examination and post-operative outcome assessment of the spine and lower extremity joints
11	uDR 760i		• Equipped with dual wireless large flat panels, it flexibly and efficiently meets examination needs for large patients, supports built-in charging, and is durable • Enables fully automatic gantry motion with automated positioning functions, improving clinical efficiency
12	uDR 380i Pro /380i		• Equipped with a remote control terminal and remote visualization exposure technology, enabling real-time monitoring, voice guidance, remote parameter adjustment, and remote exposure to improve the success rate of imaging • Features motorized motion assistance and a compact 47cm body design, making it easy to use in confined spaces and at the bedside
13	uDR 330i		• Adapts to extreme environments including high temperature, severe cold, high altitude, high humidity, and high salinity, with waterproof, dustproof, and shockproof features • Portable and easy to use, with convenient transportation

No.	Product Model	Schematic	Product Introduction and Highlights
14	uDR 596i		• Fully automatic floor-standing digital DR • Intelligent one-click positioning function improves clinical efficiency • Equipped with dual wireless large flat panels, meeting examination requirements for large patients • Features fully automatic standing stitching function, assisting clinical practice in achieving accurate pre-operative and post-operative assessment of the spine and lower extremity joints
15	uDR 566i		• Floor-standing digital DR with automatic tracking function, improving clinical efficiency • Equipped with dual wireless large flat panels, meeting examination requirements for large patients
16	uDR 266i		• U-arm DR with wireless high-definition large flat panel • Features intelligent one-click positioning function, improving clinical efficiency • Equipped with a wireless large flat panel, meeting examination requirements for large patients

(4) Molecular Imaging System

Molecular Imaging (MI) systems can display specific molecules at the tissue, cellular, and subcellular levels, reflecting molecular-level changes in living organisms, thereby enabling qualitative and quantitative research of biological behaviors through imaging. Molecular imaging technology can detect abnormalities at the cellular and molecular levels during disease progression, explore the onset, development, and outcome of diseases (such as cancer and Parkinson's syndrome), and evaluate the effects of pharmaceuticals and treatments.

The company is one of the few domestic enterprises to have obtained PET/CT product registration and achieved mass production of complete systems. It has mastered detector development technology, electronics technology, and reconstruction and control technology, enabling high spatial resolution, high time-of-flight (TOF) resolution, high sensitivity, large axial FOV, and whole-body dynamic acquisition, with technology at an industry-leading level. Among these, high spatial resolution provides high clinical image quality, helping clinicians detect early lesions, determine disease staging, formulate treatment plans, and track therapeutic effects; high TOF resolution significantly improves image signal-to-noise ratio and clarity; high sensitivity and large axial FOV effectively enhance image quality and scan speed; and whole-body dynamic acquisition provides strong support for clinical and research applications such as personalized precision diagnosis and treatment and new pharmaceutical development. The company's MI products can be equipped with advanced post-processing applications such as multimodal image fusion, dynamic analysis, oncology, brain analysis, and heart analysis, providing accurate analysis for clinical diagnosis and treatment of oncology, neurological, and cardiac diseases. The company has successively launched a number of industry-leading products, including the industry's first PET/CT product with 4D total-body dynamic scanning capability, uEXPLORER (Total-body PET/CT), the PET/CT product with the industry's highest TOF resolution at the 180ps level, uMI Panorama, the uMI Panvivo equipped with a new generation of fully self-developed detector design, the first domestically produced integrated PET/MR product uPMR 790, the first domestically produced digital TOF PET/CT product uMI 780, and the first domestically produced PET/CT product uMI 510.

The company's main MI products are as follows:

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
1	uEXPLORER (Total-body PET/CT)		• The industry's first 4D panoramic dynamic PET/CT, suitable for cutting-edge scientific research scenarios • Equipped with a 672-ring light-guide detector and 80-slice CT, it can complete total-body high-definition scanning and imaging in just 30 seconds with 1/40 of the dose • It enables real-time total-body dynamic scanning and parametric analysis, supports pharmacokinetic research, and provides support for pathology and drug research • Named one of the "Top 10 Technological Breakthrough Products of the Year" by Physics World magazine in 2018
2	uMI Panorama 28C/Stellar/35C/35S/GS		• Equipped with the industry's first self-developed high-end medical imaging dedicated chip, as the world's first commercial PET/CT to achieve an ultra-high time resolution at the 180ps level, it resets the standard for clinical PET/CT image quality • Equipped with an all-digital PET detector and a large-bore CT with a maximum rotation speed of 0.25s, leading in various performance indicators

3	uMI Panvivo/ Panvivo S/LS/ES/EX/M		• 2.9mm NEMA spatial resolution and effective sensitivity of 181 cps/kBq ensure image clarity and lesion detection capability • AI empowerment across the entire workflow, covering quality control, acquisition, reconstruction, and quantitative analysis, improving operational efficiency and freeing up manpower; equipped with the industry's first multi-nuclide AI iterative reconstruction algorithm, expanding its applicable radiopharmaceutical imaging range and enabling precise diagnosis of multiple diseases
4	uPMR 890		• 32cm longest PET axial FOV, 2.76mm finest crystal size, 1mm highest PET reconstruction resolution, and a new generation of 80mT/m industry-leading MR gradient system • Full-stack AI empowerment, equipped with the industry-leading DPR deep progressive reconstruction PET iterative reconstruction algorithm, DeepRecon MR intelligent deep reconstruction technology, and ACS intelligent MR acceleration technology, achieving simultaneous improvements in scan time, signal-to-noise ratio, and resolution, pushing the limits of PET/MR total-body scanning, and further strengthening and opening up new clinical and research applications • Configured with SuperFlex Coil, using a new type of polymer conductor composite material, ultra-light and ultra-flexible, better conforming to the patient's body, improving patient comfort during scanning, and achieving better image

5	uPMR 790		• The first domestically produced integrated high-performance PET/MR, suitable for clinical and research scenarios • Integrating a 3.0T MR and a 112-ring PET system, equipped with AI scanning and reconstruction algorithms, achieving fast and high-definition scanning • Achieves data streaming fusion of physiological signals, PET, and MR
6	uMI 780		• The first domestically produced digital TOF PET/CT, suitable for clinical and research scenarios • Equipped with a 112-ring digital light-guide detector and 80-slice CT, featuring a large field of view, high resolution, and fast high-definition scanning capabilities • Equipped with a wealth of advanced applications, fully supporting clinical practice and research
7	uMI Vista		• Digital PET/CT, suitable for clinical scenarios • Equipped with an 84-ring light-guide detector and 80-slice CT • Optimized cardiac scanning workflow, supporting clinical cardiac examinations
8	uMI 550		• Digital PET/CT, suitable for clinical scenarios • Equipped with an 84-ring digital light-guide PET detector and 40-slice CT • Equipped with multiple intelligent applications for a more efficient workflow

9	Vehicle-mounted PET/CT		• Digital mobile PET/CT, suitable for clinical scenarios, with high mobility and stability • Equipped with an 84-ring digital light-guide PET detector and 40-slice CT • Equipped with a dedicated mobile workstation, suitable for mobile examinations

(5) Ultrasound Diagnostic System

An ultrasound diagnostic system (Ultrasound, US) is a device that utilizes ultrasound Doppler technology and ultrasound echo principles to simultaneously acquire blood flow motion and tissue motion information, and to achieve imaging of human organs and tissues.

The company has the capability to independently design, develop, and manufacture ultrasound hosts, probes, as well as ultrasound imaging software and advanced applications. The company's US product line comprehensively covers clinical application areas such as general imaging, cardiovascular, and women's health, meeting diverse needs for disease screening, clinical diagnosis, and research. The company has launched ultra-high-end ultrasound products such as the uSONIQUE Genesis G, uSONIQUE Pulse G, and uSONIQUE Venus G, all equipped with the uEDGETEC intelligent ultrasound technology platform. The platform is built on the PureGrid pure matrix detector head, xCompute heterogeneous supercomputing system, DeepFocus imaging algorithm technology, and MindSpace intelligent software architecture as the underlying technology base. Combined with True 1.5D matrix array, uSpaceTime Crystal third-generation ternary piezoelectric single crystal, OmniFocus global dynamic focusing and other technologies, and through intelligent tools such as full-process automated workflow and uTarget automatic analysis, it achieves a comprehensive integration of precise ultrasound imaging, intelligent applications, and an ultimate user experience.

The company's main ultrasound products are as follows:

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
1	uSONIQUE Genesis G/T/P/Q/6/6 PRO		• Ultra-high-end whole-body ultrasound diagnostic system, supporting clinical and research applications for all parts of the body • Supports fully automated abdominal workflow, improving the efficiency and quality of abdominal examinations • Rich advanced functions and auxiliary quantitative analysis tools • Comprehensive research expansion functions
2	uSONIQUE Pulse G/T/P/Q/6		• Ultra-high-end cardiovascular ultrasound diagnostic system, supporting clinical and research applications in cardiovascular medicine • Equipped with professional cardiovascular transducer solutions, providing excellent 2D and 4D cardiovascular image quality • Supports advanced cardiovascular imaging and quantitative functions • Supports fully automated cardiac workflow, improving the efficiency and quality of cardiac examinations
3	uSONIQUE Venus G/T/P/Q/6		• Ultra-high-end obstetric and gynecologic ultrasound diagnostic system, supporting clinical and research applications in maternal, child, and pediatric care • A transducer family covering all scenarios of maternal and child healthcare, while supporting lightweight transducer design to improve user comfort • Supports fully automated obstetric workflow, improving the efficiency and quality of obstetric examinations • Supports 2D and 3D quantitative analysis tools, covering scenarios such as obstetrics, gynecology, and reproduction

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
4	uSONIQUE Nova Pro/G/T/P/Q/R/E/5C/5T; uSONIQUE 4Pro; uSONIQUE Vita Pro/G/T/P; uSONIQUE Grace Pro/G/T/P		• High-performance whole-body ultrasound diagnostic system, supporting clinical applications for all parts of the body • Supports fully automated abdominal, cardiac, and obstetric workflows, improving examination efficiency and quality • Comprehensive advanced imaging functions, promoting the accessibility of quality medical resources • Leading industrial design and human-machine interface
5	uSONIQUE Genesis; uSONIQUE Genesis Pro/Elite/Super/H/S/M/7/ 7C/7T/1P/1S/1E/1		• Ultra-high-end whole-body ultrasound diagnostic system, supporting clinical diagnosis, interventional procedures, and research applications for all parts of the body • Supports fully automated abdominal workflow, improving the efficiency and quality of abdominal examinations • Supports rich advanced functions and auxiliary quantitative analysis tools such as shear wave elastography and fusion navigation • Comprehensive research expansion functions
6	uSONIQUE Venus; uSONIQUE Venus Pro/Elite/Super/H/S/M/7/ 7C/7T		• Ultra-high-end obstetric and gynecologic ultrasound diagnostic system, supporting clinical diagnosis, interventional procedures, and research applications in women, child, and pediatric care • Supports fully automated obstetric workflow, improving the efficiency and quality of obstetric examinations

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
			• Supports rich advanced functions and auxiliary quantitative analysis tools such as shear wave elastography and fusion navigation • Supports 2D and 3D quantitative analysis tools, covering scenarios such as obstetrics, gynecology, and reproduction

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
7	uSONIQUE Genesis; uSONIQUE Genesis Pro/Elite/Super; uSONIQUE Pulse; uSONIQUE Pulse Pro/Elite/Super; uSONIQUE Venus; uSONIQUE Venus Pro/Elite/Super		• Ultra-high-end whole-body ultrasound diagnostic system, supporting clinical diagnosis, interventional procedures, and research applications for all parts of the body • Supports fully automated abdominal, obstetric, and cardiac workflows, improving examination efficiency and quality • Supports rich advanced functions such as shear wave elastography and fusion navigation • Equipped with comprehensive quantitative analysis tools, covering scenarios such as whole-body, cardiovascular, obstetric, gynecologic, and reproductive applications

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
8	uSONIQUE Nova; uSONIQUE Nova Elite; uSONIQUE Vita; uSONIQUE Vita Elite; uSONIQUE Grace; uSONIQUE Grace Elite		• High-performance whole-body ultrasound diagnostic system, supporting clinical applications for all parts of the body • Supports fully automated abdominal, cardiac, and obstetric workflows, improving examination efficiency and quality • Comprehensive advanced imaging functions, promoting the accessibility of quality medical resources • Leading industrial design and human-machine interface

2. Radiation Therapy Products

Radiation Therapy (RT) systems treat tumors using α, β, and γ rays produced by radioactive isotopes, as well as X-rays, electron beams, proton beams, and other particle beams generated by various X-ray therapy machines or accelerators. It is currently an important tumor treatment modality. The most mainstream radiotherapy equipment both domestically and internationally includes medical linear accelerators, cobalt-based Gamma Knife systems, and a small number of proton and heavy ion devices. Among these, medical linear accelerators can be widely applied to the treatment of primary or secondary tumors in multiple parts of the body.

The core components of RT products include the accelerator tube, multi-leaf collimator, power source, modulator, precision control module, and on-board imaging equipment. In the clinical treatment process, the medical linear accelerator system (LINAC), combined with the treatment planning system software (TPS), oncology information management system software (OIS), and radiotherapy simulator (Simulator), jointly completes the radiotherapy process: first, the radiotherapy simulator is used to localize the lesion; based on the localization images, the physician contours regions of interest such as the tumor and organs; then, the treatment planning system software generates a treatment plan based on the treatment plan; finally, the medical linear accelerator system executes the treatment plan; the aforementioned treatment plan and patient-related information are recorded and managed by the oncology information management system.

With the rapid development of precision medicine, precision radiotherapy has become the trend in the development of tumor radiotherapy technology. Precision radiotherapy requires destroying the tumor lesion while ensuring maximum protection of normal human tissues or organs. Therefore, the precise definition and contouring of the tumor target volume and surrounding normal organs is the foundation of precision radiotherapy. The company's pioneering integrated diagnostic-

grade CT-guided accelerator technology integrates diagnostic-grade CT and the accelerator with dual-center coaxial fusion, effectively addressing tumor shape, size, or position changes throughout the entire course of radiotherapy. At the same time, it is equipped with intelligent software, which significantly improves the work efficiency of medical staff while ensuring precision radiotherapy. The company has developed the industry's first integrated CT-guided linear accelerator uRT-linac 506c, the multi-photon multi-electron all-around flagship CT linear accelerator uLinac VisionaryTx, the industry's first integrated ring-gantry CT linear accelerator uLinac HalosTx, the new-generation integrated 6MV single-photon large-bore CT linear accelerator uLinac EternaTx, the first NMPA-approved AI-driven organ and tumor contouring software uIPW, the intelligent radiation therapy planning software uTPS, the radiation therapy record and verify software uRVS, the radiotherapy information management system uOIS, the radiotherapy quality control system uAssureTx, and the radiotherapy remote collaboration platform, among other software and hardware products, building an integrated, independently controllable full-process radiotherapy solution.

The company's main RT products are as follows:

No.	Product Model	Schematic	Product Introduction and Highlights
1	uLinac VisionaryTx		• A multi-photon, multi-electron all-around flagship CT linear accelerator with comprehensive treatment techniques, equipped with the industry's first and only dual-layer equivalent 2.5mm multi-leaf collimator & full-field 40cm×40cm irradiation, enabling sharp "blade" precision stereotactic radiotherapy • Pioneering single-center non-coplanar whole-body intelligent SRS/SBRT stereotactic radiotherapy solution, achieving high-precision irradiation for precise radiotherapy through rapid one-click non-coplanar planning and fully automated workflow implementation • Diagnostic-grade CT imaging enables precise adaptive radiotherapy, pioneering on-demand triggered adaptation to flexibly provide optimal plans based on patient conditions

No.	Product Model	Schematic	Product Introduction and Highlights
			• Equipped with All-In-One radiotherapy, reducing the first radiotherapy waiting time from traditional days to minutes. By combining one-stop radiotherapy with radiotherapy emergencies and SRS/SBRT, optimizing radiotherapy timeliness and improving therapeutic outcomes
2	uLinac HalosTx		• The industry's first integrated CT ring-gantry linear accelerator, equipped with a new-generation 87cm large-bore diagnostic-grade CT image-guided system, providing clinical users with more confident and comprehensive clinical evidence • Through the combination of diagnostic-grade CT hawk-eye imaging, ultra-wide-range in-vivo dose monitoring, and intelligent software, it achieves the industry's first "image-dose dual perception" innovative technology, moving from "not seeing the dose" to "real-time in-vivo dose monitoring," maximizing the protection of patients' precise individualized radiotherapy • Online adaptive radiotherapy and one-stop radiotherapy highly automated applications are fully integrated throughout the workflow, reducing work time,

No.	Product Model	Schematic	Product Introduction and Highlights
			lowering dependence on personnel experience, and achieving a new breakthrough in clinical efficiency and treatment workflow
3	uLinac EternetTx		• New-generation integrated 6MV single-photon large-bore CT linear accelerator • Equipped with an 87cm integrated large-bore diagnostic-grade CT, the industry's fastest 6.5cm/s MLC, and a 6D high-precision treatment couch • Paired with the new dose-guided radiotherapy (DGRT) application, enabling image-guided to dose-guided radiotherapy before treatment, and supporting stereotactic intelligent one-click non-coplanar treatment, online adaptive radiotherapy, and one-stop radiotherapy

No.	Product Model	Schematic	Product Introduction and Highlights
4	uRT-linac 506c		• The industry's first integrated CT-guided linear accelerator • High-resolution CT image guidance, which can be combined with an adaptive radiotherapy planning system to provide customized treatment plans • One-stop full radiotherapy workflow support, multi-function in one machine, integrating rapid workflow design to improve work efficiency • Supports dynamic rotational IMRT uARC technology and fast Monte Carlo algorithm to improve clinical treatment efficiency
5	uRT-linac 306		• Conventional linear accelerator system, suitable for clinical users • Supports automatic contouring, automatic planning, automatic quality control, and 540° ultra-long single-arc treatment mode to improve treatment efficiency
6	Native radiotherapy cloud ecosystem		• Innovatively based on a cloud architecture (B/S architecture), it launches a "five-in-one" United Imaging iHealthcare radiotherapy software solution integrating the AI-driven contouring system uIPW, radiotherapy planning software uTPS, radiotherapy full-process quality control platform uAssureTx, radiotherapy information management system uOIS, and radiotherapy remote collaboration platform, creating a full-chain digital and intelligent radiotherapy solution • Synergizing with the integrated CT linear accelerator system to improve quality and efficiency, rapidly providing individualized and precise treatment

No.	Product Model	Schematic	Product Introduction and Highlights
			plans, and empowering advanced treatment technologies such as adaptive radiotherapy and one-stop radiotherapy • Helping departments achieve intelligent transformation and upgrading, empowering multi-scenario innovation in medical education and research, and helping to build an efficient, flexible, and interconnected native radiotherapy cloud ecosystem

3. Life Science Instruments

Life science instruments include different types of products such as preclinical imaging equipment, optical observation equipment, electron microscopes, and chemical analysis instruments. Among them, preclinical imaging equipment mainly achieves structural and functional imaging through imaging observation of animal models, thereby providing support for basic research in life sciences. Currently, preclinical imaging equipment has been widely used in research on the mechanisms, diagnosis, and treatment methods of major diseases such as brain science, tumors, and cardiovascular diseases.

The company entered the life science instruments field starting with preclinical imaging equipment. To date, it has launched two products: the first domestically produced preclinical ultra-high-field magnetic resonance imaging system uMR 9.4T and the first domestically produced preclinical large-animal whole-body PET/CT imaging system uBioEXPLORER, as follows:

No.	Product Model	Schematic	Product Introduction and Highlights
1	uMR 9.4T		• The first domestically produced 9.4T pre-clinical ultra-high-field MR, suitable for research institutes, universities, pharmaceutical companies, etc. • High-performance gradients, suitable for research on the mechanisms, diagnosis, and treatment methods of major diseases such as brain science, tumors, and cardiovascular diseases in various animal models

			• Equipped with ultra-low-temperature RF probes to improve signal-to-noise ratio and obtain clear image quality; provides a rich sequence application to support users' translational medicine research
2	uBioEXPLORER		• The first domestically developed whole-body PET/CT imaging device for preclinical large animals in China, suitable for research institutes, universities, pharmaceutical companies, etc. • Features a 50 cm axial FOV and 50 cm bore, supporting large animal imaging; ultra-high sensitivity enables low-dose fast scanning. • Equipped with digital light-guide detectors, supports TOF high-definition reconstruction for precise imaging.
3	uMicroEXPLORER PET/CT		• A domestically developed ultra-high-performance whole-body PET/CT imaging device for preclinical small animals, suitable for hospitals, universities, research institutes, pharmaceutical companies, etc. • Features fine crystal dense array cutting and assembly technology and built-in light-guide technology, based on semiconductor silicon photomultiplier tubes (SiPM), and is equipped with the industry's first detector architecture with dual-ended readout, delivering industry-leading ultra-high performance. • Features a 178 mm ultra-long axial FOV and ultra-high sensitivity, supporting single-bed whole-body dynamic imaging of rats, sub-second dynamic reconstruction, and high-throughput simultaneous imaging of 4 mice.

			• Exclusive dual-ended readout technology, combined with digital light-guide detectors, enables full-field image uniformity, ensuring consistent image quality in high-throughput multi-mouse imaging. • High-resolution CMOS flat panel detector CT system, achieving a minimum pixel spatial resolution of 8 μm, comparable to standalone Micro CT.
4	uCT microPCCT Max/Core		• The first domestically developed photon-counting energy spectrum micro-CT imaging system (uCT microPCCT series). • Adopts an innovative technical solution with photon counting detectors and micro-focus X-ray tubes, offering excellent energy discrimination for X-ray photons and near-zero noise data readout, achieving ultra-high-resolution energy spectrum imaging with high signal-to-noise ratio and better beam hardening artifact suppression.

New significant non-main business activities

□ Applicable√ Not applicable

II Discussion and Analysis of Operations

The first half of 2026 was a period when United Imaging Healthcare maintained strategic focus and increased innovation investment, a period when its global layout advanced from breakthroughs in multiple areas to deep cultivation of the system, and a period when the company, against a backdrop of temporarily slowing market demand, demonstrated its comprehensive competitive advantages through continuous market share growth. At the same time, advantageous products continued to consolidate, high-end products accelerated breakthroughs, and innovative products continued to emerge, laying a solid foundation for the release of market demand in the second half of the year and high-quality development throughout the year.

Revenue growth rate reflects the speed of scale expansion, while the source and quality of growth determine the depth of operational quality. During the reporting period, the company's deeper changes were occurring in the latter. The technological leadership of individual devices is being consolidated into value-based operations covering the entire lifecycle of the equipment; domestic market share achieved growth against the trend, and comprehensive competitive advantages continued to strengthen; overseas operations have transitioned from the market entry phase to the deep cultivation phase, with a multi-level synergistic development pattern gradually taking shape. At the critical stage when various product lines are entering commercialization windows, the company has increased R&D investment and global marketing system development, with a phased increase in investment intensity and correspondingly visible results:

In the first half of 2026, the company achieved year-on-year revenue growth across all product lines, and its overall domestic market share increased by 1.7 percentage points against the trend. Against the backdrop of temporarily slowing market demand, the company has continued to consolidate its competitive position in the domestic market by leveraging the synergistic advantages of a full product line, high-end positioning, and clinical value orientation.

The medical imaging business has achieved breakthroughs in multiple areas with an upward structural trend. The magnetic resonance product line remains at the forefront of the industry, with market share for 1.5T and 3.0T continuing to increase, and market share for ultra-high-field magnetic resonance (>3T) maintaining above 70%; as of the end of the reporting period, cumulative orders for ultra-high-field magnetic resonance exceeded 70 units, with over 60 units installed, covering more than 20 provinces and cities nationwide, and achieving the first installations in European and Middle Eastern markets, continuing to lead the ultra-high-field segment. The molecular imaging product line continues to lead, with PET/CT market share increasing by more than 9 percentage points again, ranking first in the Chinese market for eleven consecutive years; PET/MR market share increased by more than 40 percentage points year-on-year. Innovative products such as long-axis PET/CT, ultra-high-resolution brain PET/CT uNeuroEXPLORER, and the uMI Panvivo family are accelerating their entry into the international market,

continuously expanding the application boundaries of precision diagnosis and treatment.

The CT product line is advancing through a coordinated breakthrough across three lines: 'high-end, intelligent, and integrated diagnosis and treatment.' During the reporting period, the company's CT products with 40 or fewer slices, 64-80 slices, and 128-160 slices all ranked first in the Chinese market; ultra-high-end CTs, represented by the world's first dual-wide-body dual-source CT uCT SiriuX and the first domestically developed photon counting energy spectrum CT uCT Ultima, increased market share by nearly 8 percentage points year-on-year, further consolidating the competitive advantage in the ultra-high-end market. The uCT Orion series, equipped with full-process intelligent capabilities, drove a market share increase of more than 9 percentage points for 2cm CT, continuously assisting primary healthcare institutions in improving imaging diagnostic capabilities; CT-Sim market share increased by 15.2 percentage points, leveraging the integrated design of diagnosis and radiotherapy positioning to improve the efficiency of image acquisition, tumor target volume contouring, and radiotherapy planning, providing strong support for precision radiotherapy.

In digital X-ray, the new generation of column products achieved batch breakthroughs in county-level centralized procurement, with uDR Aurora winning orders multiplying, and mobile DR market share increasing by more than 5 percentage points, driving the company's XR product line to regain the top position in the Chinese market.

The integrated diagnosis and treatment layout continues to deepen, with both interventional and radiotherapy treatment businesses advancing simultaneously. The interventional imaging product line maintained steady development, with market share increasing by more than 5 percentage points year-on-year, of which DSA share increased by more than 6 percentage points, entering the top three in the Chinese market for the first time. Radiotherapy equipment became one of the faster-growing segments in the medical device field during the reporting period, and the company's radiotherapy product line has entered the first tier of the domestic industry, forming a competitive landscape alongside major international manufacturers; uRT-linac 506c and uLinac EternaTx successively obtained EU CE MDR certification, driving the radiotherapy business from domestic leadership to a global layout. The coordinated development of interventional and radiotherapy marks the company's upgrade from a leading medical imaging equipment manufacturer to a provider of full-chain solutions for 'diagnosis + treatment.'

At the same time, the company's global layout has achieved new breakthroughs, with high-end products accelerating their entry into overseas markets, and innovative technologies are directly participating in top-tier global competition, with overseas business entering a new stage of simultaneous scale growth and quality improvement. During the reporting period, the company achieved overseas revenue of RMB 1.765 billion, a year-on-year increase of over 50%, with its share of total revenue rising to 25.02%, achieving simultaneous revenue growth, delivery volume expansion, and profitability improvement. As of the end

of the reporting period, the company had delivered over 40,000 units/sets of products, covering more than 17,000 clinical and research institutions in over 100 countries and regions worldwide.

The global access landscape for high-end products continues to expand, with the introduction of flagship products and the formation of project pipelines accelerating. Products such as uMR Jupiter 5T, uCT SiriuX, and uMR Ultra are accelerating their entry into developed markets in Europe, the Americas, and Asia-Pacific, with substantial project pipelines already formed in multiple countries, and some projects are expected to be delivered and installed in the second half of the year. The new generation 3.0T magnetic resonance uMR Astra and 18 uSONIQUE series intelligent ultrasound products obtained US FDA 510(k) clearance; uRT-linac 506c and uTime EternaTx successively obtained EU CE MDR certification. The molecular imaging product line has again achieved key breakthroughs in Europe and the Americas, with flagship products such as the uMI Panorama series and uMI Panvivo series being deployed in markets such as France, Denmark, and the United States, and gradually expanding to key Asia-Pacific markets such as Japan and Australia. In developed Asia-Pacific, Latin America and other regions, the product structure continues to shift upward, achieving full-spectrum coverage from mid-range to ultra-high-end products. In emerging markets, the company's multiple mid-to-high-end and ultra-high-end CT products continue to enter key medical institutions in Africa, Central Asia, the Middle East, Latin America and other regions, and have achieved regional first-unit breakthroughs in some countries; some markets have secured bulk orders, and interventional imaging products have also achieved new regional breakthroughs. Meanwhile, the molecular imaging product line is accelerating the upgrade of local markets from analog equipment to mid-to-high-end digital equipment.

The overseas clinical value of the treatment and interventional businesses is being validated at a faster pace, and the global layout in the radiotherapy field is also accelerating in tandem. The company's integrated CT-linac system has become the core platform for adaptive radiotherapy (ART) at Siloam International Hospitals, Indonesia's largest private hospital group, with an average daily treatment volume of 40 cases, supporting advanced procedures such as respiratory-gated breast treatment, stereotactic radiotherapy, and 4D-CT high-dose lung treatment; in Morocco, the company's equipment is deployed alongside high-end models from leading international manufacturers, and has earned customer recognition and attracted more patients through its treatment coverage capabilities. During the reporting period, the company unveiled its radiotherapy brand for the first time at the annual meeting of the European Society for Radiotherapy and Oncology (ESTRO). Combined with two products receiving CE MDR certification, the global market access and brand influence of the radiotherapy business improved simultaneously, and the company has built a pipeline of key projects targeting equipment upgrade needs of large radiotherapy centers in multiple major countries and regions. In interventional imaging, the company achieved "from zero to one" breakthroughs in multiple markets including Europe and Central Asia, with multiple interventional imaging products successively entering key local medical institutions and securing first-unit or first-batch orders. Some installed projects have received positive customer feedback on image

quality and user experience, laying the foundation for subsequent market expansion and product volume growth. The overseas layout is also accelerating from market access to deeper system cultivation. Leveraging an overseas team of over 900 people and more than 40 global subsidiaries, branches and offices, the company continues to promote the entry of its full medical imaging product line and innovative solutions such as radiotherapy and interventional procedures into overseas high-end clinical and research institutions; focusing on key clinical scenarios such as oncology diagnosis and treatment, cardiovascular and cerebrovascular diseases, precision imaging, and interventional treatment, it deepens clinical collaboration and academic promotion with local medical institutions, experts, and academic organizations. At the same time, the company proactively allocates local registration resources, continuously introduces specialized local talent, and promotes the coordinated linkage of market access, clinical validation, commercial transformation, and after-sales service, steadily enhancing global operational capabilities.
The globalization layout is also accelerating from market access to deeper system cultivation. As of the end of the reporting period, United Imaging Healthcare had a total of over 9,300 employees, maintaining growth for several consecutive years, including an overseas marketing and service team of over 1,900 people and more than 40 global subsidiaries, branches, and offices. The company continues to promote the full medical imaging product line and innovative solutions such as radiotherapy and interventional procedures into overseas high-end clinical and research institutions; focusing on key clinical scenarios including oncology diagnosis and treatment, cardiovascular and cerebrovascular diseases, precision imaging, and interventional treatment, it deepens clinical cooperation and academic promotion with local medical institutions, experts, and academic organizations. At the same time, the company proactively allocates local registration resources, continuously introduces specialized local talent, and promotes the coordinated linkage of market access, clinical validation, commercial transformation, and after-sales service, steadily enhancing global operational capabilities. In addition, as of the disclosure date of this report, the company has had over 70 ultrasound products approved by NMPA, 18 products certified with CE MDR, and 18 products with FDA 510(k) clearance, essentially completing market access in the three major markets of China, the European Union, and the United States, laying a solid foundation for the global expansion of the ultrasound business.

At this stage, United Imaging Healthcare's overseas business has evolved from early single-product exports to a comprehensive solution provider covering market access, clinical validation, channel development, and service support. With the continued accumulation of global installed base, the accelerated introduction of key products, and the continuous strengthening of localization capabilities, the company's international development is transitioning from scale expansion to high-quality growth, building stronger momentum for the continued expansion of the global high-end market.

In the first half of 2026, two aspects of the external environment deserve attention. First, the driving structure of domestic demand is shifting. As the large-scale equipment upgrade policy enters its third year of normalization, its marginal stimulus is leveling off, while the endogenous foundation for industry

growth continues to be consolidated through high-end equipment upgrades, integrated diagnosis and treatment construction, and the expansion of county-level primary healthcare driven by the foundation-strengthening initiative. The former reflects more cyclical characteristics, while the latter represents a structural trend. Demand growth is gradually shifting from phased release to normalized release, indicating that the stability of industry growth is strengthening. At the same time, relevant authorities are promoting a shift in market access from a single focus on price competition to a comprehensive consideration of quality, cost, and innovation, securing more reasonable value returns for leading innovative companies that adhere to original technology. Second, the long-term trend of expanding global demand for medical equipment remains unchanged. Despite disruptions from external factors such as geopolitics and the trade environment, supply certainty, localized marketing, and service capabilities beyond technological leadership have become key variables in global competition.

In response, the company consistently adheres to a dual focus on innovation-driven development and globalization, coordinating and advancing R&D innovation, resilient supply chain construction, and global operational capabilities in an integrated manner to continuously enhance the certainty of global operations.

i. Financial Data and Operating Performance: Steady Growth in Scale Continues, Strategic Investments Build Momentum for Long-Term Development

During the reporting period, the company achieved operating revenue of RMB 7.05 billion, a year-on-year increase of 17.22%; in the second quarter, operating revenue reached RMB 4.14 billion, a year-on-year increase of 17.13%, with steady expansion of operating scale and further enhanced development resilience. Net profit attributable to shareholders of the parent company was RMB 897 million, a year-on-year decrease of 10.12%. The profit side experienced phased pressure, mainly due to the impact of exchange gains and losses, as well as increased investments in global operations system construction, cutting-edge technology R&D, and market capability expansion. Current investments are based on a long-term perspective and focus on the future, serving as the foundation for the company to consolidate its innovation base. They are important support for improving the global layout and enhancing sustainable development capabilities. With the accelerated volume growth of high-end products, the continued expansion of overseas business scale, and further optimization of the revenue structure, the effects of earlier investments are expected to gradually materialize, and operating quality and profitability will be further improved.

The revenue performance deserves particular attention. Against the backdrop of a phased contraction in bidding and tendering in the domestic medical imaging and radiotherapy equipment market in the first half of this year, the company still achieved revenue growth of 17.22%, with the incremental growth mainly coming from the continued volume expansion of overseas business and the counter-trend increase in domestic market share.

Observed by quarter, the business shows a clear trajectory of improving performance quarter by quarter.

In the first quarter of 2026, operating revenue was RMB 2.91 billion, increasing to RMB 4.14 billion in the second quarter, a quarter-on-quarter increase of 42.53%. With the continued progress of order deliveries, the pace of operational delivery has accelerated significantly. Profitability has also recovered in tandem. The gross margin in the second quarter was 47.19%, an increase of 0.03 percentage points quarter-on-quarter; net profit attributable to shareholders of the parent company was RMB 498 million, an increase of 24.88% quarter-on-quarter. The product structure continues to optimize, and the increased proportion of high-end products further supports profitability.

During the reporting period, the company's R&D investment was RMB 1.38 billion, a year-on-year increase of 21.31%, accounting for 19.61% of revenue, an increase of 0.66 percentage points year-on-year; R&D expenses were RMB 1.01 billion, a year-on-year increase of 31.86%; the R&D expense ratio was 14.33%, an increase of 1.59 percentage points year-on-year. The relevant investments mainly focus on next-generation platform technologies, core components, and the industrialization of innovative products. Currently, artificial intelligence is accelerating its deep integration into the physical industry, and medical equipment is also entering an important stage of evolution from intelligence to autonomy. As AI capabilities are gradually integrated into high-end imaging and radiotherapy equipment such as MR, CT, MI, XR, US, and RT, next-generation medical equipment will evolve into new intelligent diagnosis and treatment systems with intelligent perception, assisted decision-making, precise execution, and continuous learning capabilities. In the future, AI-driven full-process intelligent workflows are expected to drive the upgrade of diagnostic and therapeutic equipment from standalone tools to intelligent platforms covering examination, diagnosis, treatment, and follow-up visits, providing physicians with more efficient and precise clinical support, and delivering patients a more convenient and stable diagnostic and therapeutic experience. In the short term, increased R&D investment will have a certain impact on profits; in the long term, it will continue to consolidate the Company's technological leadership and support future product innovation and growth potential.

Corresponding to the continued increase in R&D investment, the Company's overall period expense efficiency has maintained an optimization trend. During the reporting period, selling expenses were RMB 1.05 billion, up 11.41% year-on-year, with a growth rate lower than that of operating revenue; the selling expense ratio was 14.82%, down 0.77 percentage points year-on-year. With the continuous improvement of the global marketing network and the gradual release of economies of scale, the operational efficiency of the sales system has been further enhanced. Administrative expenses were RMB 311 million, up 20.97% year-on-year, and the administrative expense ratio was 4.41%, up slightly by 0.14 percentage points year-on-year, mainly affected by phased investments such as share-based payments and the construction of overseas operating systems, which is consistent with the expansion of the Company's global operations and the need for organizational capability building.

In addition, certain non-operating factors caused fluctuations in current-period profits. Financial expenses

changed from a net gain of RMB 50 million in the same period of the previous year to a net expense of RMB 96 million, mainly due to changes in exchange gains and losses, along with a corresponding increase in interest expenses. With the expansion of overseas business and the diversification of settlement currencies, the impact of exchange rate fluctuations on current-period gains and losses has correspondingly increased. In response, the Company has systematically strengthened foreign exchange risk management by optimizing the settlement currency structure, matching foreign currency assets and liabilities, and prudently utilizing tools such as forward foreign exchange settlement and sales, to enhance its resilience against exchange rate fluctuations and strive to keep the impact of exchange factors on operating results within a reasonable range. Most of the above factors are phased fluctuations or accompany business expansion and do not change the profitability of the main business.

The service business continued its sound growth momentum. During the reporting period, the Company's equipment revenue was RMB 5.85 billion, up 19.66% year-on-year; service revenue was RMB 980 million, up 20.11% year-on-year, accounting for 13.90% of operating revenue, with gross margin maintained above 60%. The significance of the service business lies not only in forming a stable profit contribution, but also in extending equipment delivery from one-time sales to full-lifecycle services covering maintenance, upgrades, and operational support, leveraging the continuously expanding installed base to continuously unlock the value of existing equipment.

As of the end of the reporting period, the Company's cumulative global deliveries exceeded 40,000 units/sets, further enhancing the stability and sustainability of the service business, and accelerating the transformation of the revenue structure from primarily equipment sales to the coordinated development of equipment, services, and ecosystem. In the first half of 2026, the Company continuously densified its service network and enhanced localized support capabilities. As of the end of the reporting period, the Company's service network covered more than 100 countries and regions, with over 1,000 professional engineers. It has established regional service centers in 12 countries and regions globally, over 40 overseas service stations, and nearly 40 global spare parts warehouses, enabling 7×24-hour response and full-lifecycle service support for overseas equipment. A more complete service layout not only improves equipment operation support and customer response efficiency, but also provides strong support for the Company to deepen its presence in key markets, expand high-end customers, and enhance global operational capabilities.

With the expansion of installed capacity and the increase in service touchpoints, the Company has continuously accumulated product application experience and service practices across different countries, different tiers of medical institutions, and different clinical scenarios, and has integrated clinical feedback into product R&D, technological iteration, and service improvement in a timely manner. R&D innovation, product application, clinical feedback, and service support are interconnected, driving innovative achievements to reach clinical practice faster, continuously optimizing product performance, and steadily

improving service quality, further forming a positive cycle oriented toward clinical benefit.

All that is beneficial must move with the times. During the reporting period, the Company achieved steady revenue growth, continued to increase R&D and globalization investments, and further optimized its operating structure. At a critical stage of technological iteration and global market expansion, the Company has increased its forward-looking layout for future capability building, which also reflects management's strategic determination to continuously invest in long-term, globally comprehensive competitiveness. With the scaled delivery of high-end products, the gradual maturity of the overseas operating system, and the sustained growth of the service business, the technological advantages, market advantages, and operational capabilities formed by early-stage investments are expected to accelerate their transformation into future growth momentum, driving the Company toward higher-quality and more sustainable development.

ii. Domestic and International Market Expansion: Gaining Share in the Domestic Market Against the Trend, and Deepening and Broadening the Overseas Market

Where growth comes from and whether it can be sustained are important dimensions for observing the Company's operating quality. During the reporting period, although the growth paths of United Imaging Healthcare in domestic and international markets had different focuses, they all pointed in the same direction: a more solid foundation for growth, more stable growth momentum, and more diversified development drivers.

In the domestic market, strategic new products in the ultra-high-end and high-end segments accelerated their volume ramp-up, and the product structure continued to upgrade toward the high end; repeat purchases from leading hospital customers steadily increased, the synergy effect across multiple product lines further emerged, and single-equipment sales are accelerating the shift toward full-lifecycle value management for customers. In the international market, the Company adheres to the coordinated advancement of global layout and localized operations, achieving breakthroughs in multiple regions and product lines, with the breadth and depth of market expansion continuously improving. At the same time, with the continuous expansion of the global installed base, service revenue from maintenance and upgrades has grown steadily, revenue sources have become more diversified, and operational resilience has been further enhanced.

The volume ramp-up of high-end products enhances value contribution, deep customer cultivation consolidates the growth foundation, global expansion opens development space, and service operations strengthen long-term resilience. United Imaging Healthcare's growth is showing a distinctive feature of continuous scale expansion with simultaneous quality improvement.

1. Domestic Market:

During the reporting period, United Imaging Healthcare's China business maintained steady growth, with China market revenue of RMB 5.29 billion, up 8.49% year-on-year. As centralized procurement projects in multiple provinces have gradually entered the execution phase, the demand backlogged in the first half due to procedural delays will be gradually realized. With the steady advancement of the procurement pace, it is expected to become a window for concentrated demand release in the future, providing strong support for achieving the annual operating targets.

By sub-category, traditional mature products experienced some market performance fluctuations due to phased factors such as procurement pace; high-end products such as molecular imaging and radiotherapy maintained sound growth momentum, with market demand continuing to be released. With the continuous improvement of precision diagnosis and treatment needs and the ongoing expansion of clinical application scenarios, related products are gradually evolving from supplementary configurations to routine configurations, further opening market space. It is worth noting that the phased adjustments in mature categories reflect more of a change in demand pace rather than a weakening of demand itself. Long-term drivers such as medical equipment renewal, upgrading of clinical diagnosis and treatment needs, and deepening application of domestic high-end equipment have not changed. Some demand has been deferred in phases and will be gradually released in the future. The development mainline under the industry's precise diagnosis and treatment needs has not changed.

Total volume fluctuates, but the structure is being optimized; the pace is adjusted, but the trend remains unchanged. Industry demand is shifting toward high-end, precise, and intelligent directions. For United Imaging Healthcare, short-term fluctuations in market pace are not the determining factor; continuously building long-term competitive advantages is the fundamental driver of growth. More importantly, it is essential to align with the direction of industrial upgrading, maintain strategic focus, enhance the competitiveness of high-end products, improve comprehensive solution capabilities, and win new development space amid the demand shift. The first source of incremental growth is the trend toward high-end and intelligent products, which stems from the continuous clinical demand for higher performance, and the demand base is shifting from top-tier research institutions to regional medical centers and county-level medical institutions. The continuously enhanced competitiveness of the product matrix provides a more solid internal support for the Company's growth.

In the first half of 2026, the market position of the Company's major product lines was further consolidated, high-end advantageous products maintained their leadership, and the competitiveness of multiple core products continued to improve. New products represented by uMI Panvivo, uLinac EternaTx, and uDR Aurora are accelerating market adoption, with related revenue growing over 100% year-on-year, driving the overall product matrix to break through upward.

As of the end of the reporting period, the company has cumulatively received approval for more than 160

NMPA products, of which 8 have been approved as innovative medical devices by the National Medical Products Administration (NMPA). A batch of new products, including uAngio AVIVA CS, uCT SiriuX Pro, uMR Jupiter EX, uCT SiriuX, and uLinac ChallengerTx, are expected to accelerate market introduction in the second half of the year, working in synergy with the existing product matrix to further unleash the comprehensive advantages formed by original technology, full-stack layout, and a platform-based R&D system. The company's growth momentum is increasingly coming from systematic improvements in the product matrix, rather than phased breakthroughs in a single product or a single market. Meanwhile, the layout of the ultrasound product line is also accelerating. Following the approval and official release of the first batch of 3 uSONIQUE series products in November 2025, the company has successively obtained 3 more ultrasound product registration certificates since 2026, including 1 Class II certificate and 2 Class III certificates, further expanding the application scope of products to scenarios such as intraoperative and navigation. With the continuous completion of high-end configurations and product gradients, the company is accelerating the construction of a complete ultrasound product system covering multi-level and differentiated clinical needs. By product line, the rapid volume growth of mid-to-high-end and flagship products, along with the precise implementation of multi-level solutions, is driving simultaneous improvements in market position and operational quality across all segments.

During the reporting period, the company's MR business achieved revenue of RMB 2.29 billion, a year-over-year increase of 16.15%, accounting for 39.08% of equipment revenue. In the first half of the year, the trend toward high-end MR systems further deepened, with the demand share of 3.0T products continuing to rise, becoming an important driver of industry growth, while procurement demand from private medical institutions also accelerated. Relying on a complete field strength layout and continuous technological innovation, the company's MR business maintained steady growth, with 1.5T, 3.0T, and ultra-high-field products working in synergy, further consolidating its competitive advantages in the core market.

In the mainstream market, 1.5T MR continued its growth trend; in the 3.0T product line, the company accelerated market expansion through innovative products such as uMR Ultra and uMR Astra, driving an increase of nearly 1.5 percentage points in 3.0T market share. Among them, uMR Ultra revenue grew more than 100% year-over-year, with smooth market introduction since its launch, further strengthening the company's leading position in the high-end 3.0T market. In the ultra-high-field segment, the company continued to maintain the top market share, with cumulative orders for uMR Jupiter 5T exceeding 70 units, covering more than 20 provinces and cities nationwide; during the reporting period, revenue from the 5T product line grew more than 50% year-over-year, with a 100%-win rate, and the efficiency of converting orders into revenue continued to improve. It has now successfully entered more than 60 high-level clinical and research institutions both domestically and internationally, providing strong support for cutting-edge medical research and precise diagnosis and treatment of major diseases.

Technological innovation continues to lead, and growth momentum continues to accumulate. Looking ahead to the second half of the year, the company will focus on the coordinated development of the 3.0T, 1.5T, and 5.0T product lines, further improving the layout of high-end, mainstream, and economy products, and continuously consolidating its advantages in the core MR market. In the 3.0T segment, the company will stabilize its base with mainstay products, accelerate the commercial transformation of new products such as uMR Ultra and uMR Astra, and strengthen clinical research value and full-process intelligent capabilities through clinical research collaborations, the LIVE dynamic acquisition platform, and the uVision intelligent application system. In addition, a new generation of ultra-high-gradient 3.0T MR platform is also expected to be approved within the year, providing new technical tools for neuroscience, myocardial microstructure, and cellular-scale research with higher gradient performance, stronger RF capabilities, and multi-nuclear metabolic imaging capabilities such as sodium, phosphorus, and deuterium. In the 1.5T segment, the company will further improve the product gradient, leveraging the silicon carbide platform, intelligent reconstruction, and full-process AI capabilities to balance high performance and low energy consumption, while enhancing adaptability to primary-level and private markets and promoting large-scale expansion. In the 5.0T segment, the company will maintain its high-end positioning, continuously strengthening value delivery around overall system performance, X-nuclei imaging, and scientific research applications, and accelerating coverage of key regions and high-level medical research institutions. Through product portfolio optimization, breakthroughs in key markets, and channel synergy, the company will promote the coordinated growth of MR systems across all field strengths, continuously improving the market share and growth quality of the MR business.

During the reporting period, the company's CT business achieved revenue of RMB 1.65 billion, a year-over-year increase of 8.96%, accounting for 28.22% of equipment revenue. Affected by the pace of procurement and project implementation, the domestic CT market volume declined slightly year-over-year, but the upgrading of clinical needs continues to drive the market toward high-end, functional, and precise evolution. Relying on a complete product matrix and continuous independent innovation, the company's CT business maintained steady growth, with further enhanced competitive advantages in high-end and ultra-high-end products and continued consolidation of its market position.

In the high-end and ultra-high-end market, innovative products represented by the first domestic photon-counting energy spectrum CT uCT Ultima and the world's first dual-wide-body dual-source CT uCT SiriuX are accelerating market introduction, with the market share of photon-counting and dual-wide-body CT increasing by nearly 8 percentage points year-over-year, of which uCT SiriuX won a cumulative 9 orders in the first half of the year. In the 128-slice to 160-slice CT market, the company ranked first in China; in the 256-slice and above market, the company ranked second, with ultra-high-end CT represented by uCT ATLAS Astound/Pro achieving revenue growth of nearly 50% year-over-year, further improving the product gradient of mainstream and high-end products. CT simulation positioning products also achieved relatively fast growth, with market share increasing by more than 15 percentage points year-

over-year, injecting new momentum into the development of the theranostics business.

In the primary-level market, with the continuous advancement of projects such as county-level medical communities and the Strong Foundation Project, the company, centered on the uCT Orion series products, relies on deep learning AI quality control, intelligent perception, and precise diagnosis platforms to provide intelligent assisted analysis capabilities covering scenarios such as cerebral hemorrhage, lung nodules, lung parenchyma, spine, and bone, focusing on addressing the actual needs of primary-level medical institutions in terms of scan quality control, diagnosis of common diseases, and total cost of ownership. At the same time, the company continues to promote independent R&D and large-scale production of core components, further enhancing product reliability and cost competitiveness. During the reporting period, the company's market share in the 40-slice and below CT market increased by more than 9 percentage points year-over-year, and the company ranked first in the Chinese market in the 40-slice and below, 64-80-slice, and 128-160-slice CT segments, with continuously strengthening competitiveness in the primary-level market.

Innovative technologies are accelerating the transition from R&D breakthroughs to clinical applications, with the pace of market cultivation and transformation of high-end products accelerating simultaneously. During the reporting period, the company focused on the two cutting-edge technology platforms of dual-wide-body and photon-counting, continuously improving the transformation path of "benchmark installation - clinical validation - consensus formation - large-scale promotion."

During the reporting period, the company has jointly carried out 12 professional promotion activities with high-level clinical institutions, established more than 20 clinical demonstration sites, and continuously enhanced the clinical recognition and industry influence of high-end CT. Based on the dual-wide-body platform, the company will further promote the R&D and clinical application of free ultra-high-definition dual-wide-body CT, promoting the deep integration of static, dynamic, and energy spectrum imaging capabilities. At the same time, it will carry out multi-center clinical research with leading medical institutions, accumulate high-quality clinical evidence, promote the formation of expert consensus and application standards, and accelerate the application and promotion of innovative technologies in high-end clinical scenarios such as complex cardiovascular diseases and critical care.

In terms of photon-counting CT, United Imaging Healthcare continued to advance the clinical application and commercialization of its uCT Ultima platform in the first half of 2026. The system has been formally installed and put into clinical use, becoming the first domestically produced photon-counting spectral CT to enter commercial clinical application in China. This marks an important milestone for domestic ultra-high-end CT equipment in moving from R&D to clinical implementation. Looking ahead to the second half of the year, the company will continue to promote clinical validation, product optimization, and the development of application standards, accelerate the transformation of cutting-edge imaging technologies

into broader clinical use, and further consolidate its technological and market advantages in the CT field.

At the same time, the company continues to promote regionalized and differentiated market strategies. During the reporting period, the Company achieved positive breakthroughs in multiple key regions and strategic projects. Market shares in major product tiers, including 16cm, 8cm, 4cm, and 2cm, all increased. High-end, mid-range, and economy products developed in synergy, continuously strengthening market coverage breadth and regional penetration depth. Leveraging the synergistic advantages of product innovation, clinical benefit, localized marketing, and service systems, the Company has established a market expansion pathway characterized by "innovation-driven, clinically led, regionally focused, and nationally replicated" growth. Going forward, the Company will further translate its competitive advantages in high-end products into market advantages, continuously accumulating new momentum for long-term growth in the CT business.

In the first half of 2026, the Company's molecular imaging business generated revenue of RMB 1.06 billion, representing a year-over-year increase of 26.37% and accounting for 18.16% of equipment revenue, up 0.96 percentage points year-over-year. During the reporting period, demand for precision medicine accelerated, with continued development in early screening for major diseases, precision diagnosis, and integrated nuclide-based diagnosis and treatment (theranostics), driving a year-over-year increase of nearly 50% in the domestic molecular imaging market volume. Relying on a coordinated product portfolio of long-axis PET/CT, short-axis PET/CT, and PET/MR systems, the Company's molecular imaging business maintained rapid growth, further consolidating its market leadership.

By product category, the PET/CT business continued to maintain its leading position, with domestic market share increasing by more than 9 percentage points year-over-year to exceed 60%, ranking first in the domestic market for the eleventh consecutive year. The PET/MR business achieved significant breakthroughs, with market share increasing by more than 40 percentage points year-over-year, returning to the top position in the domestic market. The coordinated development of long-axis, short-axis, and multi-modality products has extended the Company's competitive advantages in molecular imaging from leadership in a single product to leadership across a complete product portfolio.

From whole-body imaging to brain science research, and from clinical diagnosis and treatment to life science exploration, the Company is accelerating the construction of a molecular imaging innovation ecosystem covering multiple tiers and scenarios. The uMI Panvivo family enhances adaptability to medical institutions of different levels and clinical scenarios through various axial FOV configurations and mobile solutions; the uMI Panorama family continues to expand the boundaries of precision imaging by leveraging detector platform and system design advantages. Among them, the uMI Panorama GS features an ultra-long 148cm axial FOV design, providing robust support for ultra-low-dose scans, dynamic imaging, and whole-body quantitative analysis. The ultra-high-resolution brain PET/CT

uNeuroEXPLORER and the next-generation PET/MR uPMR Zenith are advancing in parallel, expanding applications in frontier areas such as brain science, precision oncology diagnosis and treatment, new drug development, and theranostics. With continuous improvements in system sensitivity and imaging efficiency, some examination times have been reduced from tens of minutes to minutes or even seconds, accelerating the clinical adoption of innovative applications such as ultra-low-dose and fast scanning.

Meanwhile, the deep integration of artificial intelligence with nuclear medicine is further expanding the clinical benefit and service boundaries of molecular imaging. The Company is enhancing intelligent capabilities across consultation, imaging, reporting, quality control, treatment, and research, integrating AI-assisted diagnosis, intelligent reporting, and workflow quality control into the nuclear medicine workflow to improve the standardization of diagnosis and treatment in primary and county-level medical institutions. At the same time, the Company continues to develop platforms such as multi-modality small animal imaging, extending molecular imaging capabilities from clinical examinations to interventional procedures, research translation, and life science instruments, gradually forming a business structure where equipment, software, intelligent applications, and research platforms develop in synergy.

Facing real-world medical scenarios, the Company is accelerating the upgrade of molecular imaging from imaging equipment to integrated diagnosis, treatment, and research platforms. Focusing on key areas including liver cancer, prostate cancer, lung cancer, nasopharyngeal carcinoma, neurological diseases, and pediatric diseases, the Company is collaborating with high-level medical and research institutions to advance the development of disease-specific intelligent agents, promoting the deep integration of imaging information, clinical knowledge, and treatment decisions. On this basis, the Company is actively exploring cutting-edge technology directions such as interventional nuclear medicine, brain-computer interfaces, proton and heavy ion therapy, and boron neutron capture therapy, promoting the synergistic development of molecular imaging with precision radiotherapy, radionuclide therapy, and neuroscience research, opening new space for theranostics and the translation of research achievements.

Looking ahead, the Company will continue to improve its "three-in-one" product portfolio of long-axis PET/CT, medium-long-axis and short-axis PET/CT, and PET/MR systems. For long-axis PET/CT, the Company will accelerate the promotion of products such as uEXPLORER and uMI Panorama GS at world-class medical and research institutions, continuously expanding dynamic imaging, whole-body quantification, and cutting-edge research applications. For mid-long-axis and short-axis PET/CT, the Company will leverage high performance, high reliability, and total cost of ownership advantages to accelerate coverage of regional medical centers, county-level, and primary medical institutions. For PET/MR, the Company will leverage next-generation products to continuously optimize clinical workflow and routine diagnostic adaptability, accelerating the transition from research applications to routine clinical use. In terms of internationalization, the Company will further deepen global academic exchanges and clinical collaborations, actively participate in the construction of the global molecular imaging

innovation ecosystem through original technologies and high-end products, and accelerate the translation and application of China's original achievements in broader markets and clinical scenarios.

The second source of incremental growth is the theranostics business. The significance of radiotherapy and interventional procedures extends beyond the revenue contribution of a single product line; they expand the Company's competitive unit from a single device to a complete clinical pathway encompassing diagnosis, interventional procedures, and treatment.

During the reporting period, the Company's radiotherapy business generated revenue of RMB 397 million, a year-over-year increase of 63.97%, accounting for 6.78% of equipment revenue, an increase of 1.83 percentage points year-over-year, with both revenue scale and business proportion improving simultaneously. New product market introduction achieved significant results, with revenue from circular accelerators represented by uLinac HalosTx increasing by more than 150% year-over-year; uLinac EternaTx has achieved nearly 10 installations since its approval and launch, with revenue increasing by more than 100% year-over-year. The coordinated volume growth of ring-type and C-arm systems has become an important pillar supporting the rapid growth of the Company's radiotherapy business.

From benchmark breakthroughs to multi-unit repeat purchases, customer recognition is continuously translating into scale growth. Radiotherapy equipment has high clinical adoption barriers. After installation, it is often accompanied by departmental workflow restructuring, personnel training, and ongoing service, resulting in strong customer stickiness and significant lifecycle value. As of the end of the reporting period, the Company's repeat purchase rate among leading hospitals reached 30%, with 14 high-level clinical and research institutions achieving repeat purchases, totaling 38 units, of which 7 customers purchased 3 or more units. Repeat purchases are expanding from single-unit additions to multi-device, multi-scenario coordinated configurations, indicating that the Company's product reliability, clinical benefit, and service capabilities have received sustained recognition, laying the foundation for deeper value extraction from existing customers and long-term business growth.

The product portfolio is being rapidly improved, further enhancing the synergy across the entire radiotherapy workflow. Focusing on core processes such as simulation and localization, target volume contouring, treatment planning, quality control, and precision treatment, United Imaging Healthcare has formed an integrated radiotherapy solution with coordinated software and hardware: the uLinac ring-based and C-arm systems constitute a differentiated product portfolio; software products such as uOIS and uTPS continue to enter high-level medical institutions; the intelligent contouring system uIPW further improves target volume contouring efficiency and workflow standardization; and the CT-Sim product is accelerating commercial deployment, with its market share in China increasing by more than 15 percentage points year-over-year during the reporting period.

During the reporting period, online adaptive radiotherapy accelerated its transition from technological breakthroughs to routine clinical application. The Company is conducting multi-disease clinical validation in collaboration with high-level medical institutions, continuously accumulating application experience in online adaptive radiotherapy, All-in-One radiotherapy, and imaging-dose coordinated sensing. Centered on the uLinac HalosTx, the Company is gradually establishing a new product introduction mechanism that integrates high-specification installation, clinical validation, expert exchange, demonstration and promotion, and regional translation, while advancing the implementation of related demonstration projects and application guidelines. Guided by real-world medical scenarios, United Imaging is focused on addressing clinical issues such as image quality, workflow efficiency, and online decision-making, advancing advanced radiotherapy technologies from "being achievable" to "stable, reliable, and standardized application."

Furthermore, extending from equipment supply to department construction solutions, the Company's radiotherapy business model is further deepening. During the reporting period, the Company aligned with radiotherapy reimbursement policies and changes in clinical benefit, focusing on high-value procedures such as online adaptive radiotherapy and stereotactic body radiotherapy, strengthening the synergy between policy orientation, product capabilities, customer benefits, and project implementation, thereby improving the clinical translation efficiency of innovative technologies. For mature radiotherapy centers and newly established radiotherapy departments, the Company has developed standardized solutions such as Smart Radiotherapy Centers and high-standard new radiotherapy departments, expanding from single equipment configuration to holistic solutions covering department planning, product portfolio, clinical workflow, and operational development, and advancing the business upgrade from equipment sales to solution delivery.

Talent development and user ecosystem building are advancing in parallel. During the reporting period, the Company continued to conduct the "Elite Training Camp" focused on disease-specific scenarios and advanced technologies, strengthening training in clinical applications, standardized operations, and advanced techniques; leveraging the "Qingyun Plan," the Company promoted the integration of radiotherapy teaching software, training courses, and practical resources into university teaching systems. To date, collaborations have been completed with 4 medical schools, with multiple additional partner universities planned for the second half of the year, embedding radiotherapy workflows, clinical standards, and product ecosystem into talent development at an early stage. By connecting universities, hospitals, and the industry, the Company is progressively building a long-term ecosystem that links talent development, clinical application, and technology promotion, building momentum for industry capability building and sustainable business growth.

In February 2026, the integrated image-guided radiotherapy system uRT-linac 506c obtained EU CE MDR certification, marking a significant step forward for the Company's high-end radiotherapy products in

international registration and quality systems. With continued improvements in overseas product market access, clinical validation, and localization capabilities, the Company's radiotherapy business is accelerating its transition from domestic market leadership to global expansion, further opening long-term growth space.

Looking ahead, the Company will continue to prioritize both product innovation and clinical benefit, market expansion and capability building, solidifying installation reputation through high-quality delivery, enhancing solution capabilities through department co-construction, and cultivating long-term demand through talent development and regional collaboration. As the scale effects of high-end products are gradually realized, prefecture-level markets expand rapidly, and international market access continues to convert, the Company's radiotherapy business is expected to advance from single-unit breakthroughs to portfolio expansion, deep customer engagement, and global collaborative development, forming a new landscape of synchronized growth in scale and quality.

In the first half of 2026, the Company's XR business generated revenue of RMB 455 million, representing a year-over-year increase of 40.50%, accounting for 7.77% of equipment revenue, up 1.15 percentage points year-over-year, and its domestic market share returned to the top position in the industry. Among these, the interventional imaging business accelerated its breakthrough, with DSA product revenue growing 98.73% year-over-year, domestic market share exceeding 10%, up more than 6 percentage points year-over-year, and market ranking entering the top three in the industry, becoming a key growth driver for the XR business.

From product introduction to scale breakthrough, the interventional imaging business has achieved leapfrog development. Since the uAngio AVIVA product received approval in 2024, the uAngio AVIVA series became the first domestic DSA product to exceed 100 annual orders in 2025, and successfully ranked among the top three in domestic market share in the first half of 2026. As of the end of the reporting period, the Company's DSA cumulative users exceeded 180, covering more than 30 top 100 hospitals in China, with over 60 installations; tertiary hospital users accounted for more than 70%, of which Class A tertiary hospitals accounted for more than 60%, and the customer repurchase rate approached 30%. The continued adoption by high-level hospitals, multi-unit configurations, and deep repurchases further validate product performance, clinical value, and service capabilities, indicating that the Company's interventional imaging business is transitioning from benchmark breakthroughs to scaled expansion.

Original technologies are rapidly translating into clinical value and international recognition. As the first and only domestic system with NMPA, CE, and FDA triple certification, the uAngio AVIVA series has been rated by the international authoritative organization ECRI as a global four-star system with "Excellent" ratings across performance, safety, workflow, and compatibility. Its zero-noise technology has been confirmed by authoritative research to significantly reduce radiation dose during interventional procedures, with related findings published in the internationally renowned journal "Circulation"; in

addition, a multi-center clinical trial involving nineteen top hospitals was initiated during the reporting period, covering all types of interventional procedures across the body, providing systematic evidence-based support for the clinical value of high-end interventional imaging.

The clinical demonstration network continues to expand, with benchmark effects accelerating transmission to regional markets. As of the end of the reporting period, the Company had established 36 national and provincial clinical demonstration centers across 20 provinces, with 9 provinces simultaneously deploying cardiac interventional and interventional radiology demonstration centers. Leveraging high-level hospitals for clinical validation, academic exchange, physician training, and standardization, the Company is progressively forming a market expansion pathway of "benchmark installation - clinical validation - demonstration and promotion - regional replication," extending product influence from central cities to prefecture-level medical institutions and laying the foundation for future market share growth.

Meanwhile, the Company's DSA product portfolio is rapidly expanding from single equipment to comprehensive scenario-based solutions. To address the needs of hybrid operating room construction, the Company will further improve its All-in-One interventional solutions covering multiple surgical procedures, departments, and clinical scenarios, strengthening the synergy between interventional imaging and operating room tables, ultrasound, navigation, and other diagnostic and therapeutic equipment. In the high-end market, the Company will build differentiated advantages through original technology, system performance, and clinical solutions; in the mid-to-high-end market, it will emphasize clinical value, configuration adaptability, and full lifecycle services; in the mid-to-low-end market, it will enhance product competitiveness through platform-based R&D, self-developed core components, and flexible software configuration, forming a complete product portfolio covering medical institutions at different levels. In the future, for specialized surgical and hybrid procedure scenarios, the Company will further improve ceiling-mounted interventional products and multi-modality collaborative solutions, replicating existing technical capabilities to a broader range of operating room and primary care application scenarios, and extending the interventional imaging product line from fixed equipment to multi-form, multi-scenario coverage.

In the digital radiography field, driven by the batch breakthrough of the new-generation column products in county-level centralized procurement and the exponential growth in uDR Aurora order wins during the reporting period, United Imaging Healthcare's market share in China returned to the top position in the industry, with fixed DR ranking first; mobile DR market share increased 5 percentage points year-over-year to second; and mammography products ranked second. The structural opportunity in the mammography segment is particularly clear: three-dimensional mammography systems now account for 70% of market volume, and the Company's new-generation product uMammo Vitar will continue to meet clinical needs with a combination of advanced features including contrast-enhanced imaging, stereotactic

puncture, and tomosynthesis-guided puncture. In the second half of this year, the Company will introduce a new micro-dose technology platform to drive the industry's redefinition of low-dose standards, with a focus on accelerating application promotion in radiation-sensitive scenarios such as maternal and child health, pediatrics, and health screening.

The third source of incremental growth is the cultivation of new growth engines. The Company has established ultrasound as the third growth curve following radiotherapy and interventional imaging:
In the first half of 2026, United Imaging Healthcare's ultrasound business completed its high-end market entry, with the third growth curve beginning to take shape. As the final piece of the Company's comprehensive imaging portfolio, since the approval of the natively intelligent uSONIQUE series in November 2025, the Company has adhered to a high-profile market strategy: during the reporting period, initial users covered six provinces/municipalities, with customer types including top-tier clinical institutions, establishing a complete scenario sample for subsequent scaled replication. Most critically, the Company adheres to product value and clinical value as its core, continuously enhancing market awareness through benchmark applications and consolidating its high-end market positioning.

From an industry development perspective, the ultrasound market is rapidly evolving toward high-end and intelligent directions, with market competition gradually shifting from price-driven to comprehensive competition in technical strength, product performance, and service capabilities. During the reporting period, high-end whole-body and cardiovascular ultrasound expanded against the trend, with their share of total value exceeding 50%, becoming a high-certainty incremental track. Combined with the support of diagnosis-related group payment reform for high-technology-value projects, the upgrading of linear array detector head technical standards, and the replacement space created by the still-low domestic adoption rate in tertiary hospitals, manufacturers with native intelligent architecture and self-developed core component advantages are presented with a window of opportunity.

During the reporting period, the Company's ultrasound products underwent clinical validation and real-world application at multiple high-level medical institutions, with continuous optimization around product performance, clinical workflows, and application needs, and related academic research and application scenario development progressed steadily. Meanwhile, the Company continuously improves its market promotion and clinical application support system through multi-level training, clinical exchange, and channel empowerment. With the accelerated introduction of whole-body application products and the continuous improvement of specialized products in cardiovascular, obstetrics and gynecology, and other fields, the company's ultrasound product matrix and clinical coverage have been further expanded.
In the future, leveraging the demonstration applications of high-level medical institutions, the company will continue to deepen industry-university-research-medicine collaboration, accelerate the accumulation of clinical evidence and the translation of innovative achievements, and continuously enhance product recognition and market coverage capabilities. As the product portfolio is gradually improved and

application scenarios continue to expand, the company will drive its ultrasound business from product introduction toward systematic development, accumulating long-term momentum for large-scale business expansion.

By hospital tier, during the reporting period, the company's market penetration across medical institutions at all levels continued to increase. Its advantages in the high-end hospital market were further consolidated, and coverage in the primary care market continued to deepen, achieving an extension from top-tier hospitals to a broader range of medical institutions. Against the backdrop of the national push to expand and decentralize quality medical resources and strengthen county-level medical capacity, the company has leveraged its complete intelligent product portfolio and comprehensive solution capabilities to continuously enhance its competitive advantages in the primary care market, laying a more solid foundation for future market expansion and demand release.

During the reporting period, in the tertiary and secondary hospital markets, the company's market share increased by more than 6 percentage points year-over-year, ranking second in the industry; in the primary care market at the county level and below, the company's market share increased by 14 percentage points year-over-year and retained the top position. The leadership in the primary care market is particularly critical. It is highly aligned with the national direction of strengthening primary care capabilities and provides the company with a first-mover advantage in capturing subsequent county-level expansion demand.

From the demand side, the development of the primary care system is nurturing long-cycle opportunities. The State Council's "Implementation Plan for the Medical and Health Infrastructure Strengthening Project" focuses on strengthening the primary level, consolidating the foundation, and ensuring basic services. Its twelve key tasks cover system improvement, service optimization, disease control and traditional Chinese medicine, and resource guarantee, establishing a long-term framework for county-level medical capacity building. What deserves more attention is the shift in the connotation of construction: the Strong Foundation Project is transitioning from new construction and expansion to the renovation of existing facilities and equipment quality improvement, with funding primarily directed toward informatization and artificial intelligence development, regional hierarchical diagnosis and treatment and resource-sharing platforms, as well as the development of service capabilities such as emergency and critical care, oncology centers, and whole-course disease management.

The above shift is highly aligned with United Imaging Healthcare's expertise in intelligent imaging, digital intelligence platforms, and full-lifecycle services, and is also mutually corroborated by the company's established market share advantages in the primary care market. To capture the market opportunities arising from the enhancement of county-level medical capabilities, the company continues to advance its expansion in the county-level market. Leveraging its complete product portfolio, intelligent capabilities,

and comprehensive service capabilities, it is exploring integrated solutions for county-level medical communities, creating model projects for county-level medical community construction in multiple regions, and helping primary care institutions improve their diagnostic and treatment capabilities through the synergistic integration of equipment, data, artificial intelligence, and clinical application capabilities. In the future, competition in the county-level market will shift from single equipment procurement to systematic capability building, and companies with capabilities in overall planning, delivery implementation, and continuous operations will gain greater development space.
In the second half of the year, the company's operational focus in the domestic market can be summarized into three main lines: consolidating the fundamental business, strengthening the growth curve, and improving organizational efficiency.

Consolidating the fundamental business focuses on achieving connectivity in both horizontal and vertical dimensions. Horizontally, the company will continue to deepen integrated cooperation with high-level hospitals and hospital clusters affiliated with medical universities, upgrading single-point equipment supply into long-term relationships covering clinical practice, research, and talent development; vertically, it will increase investment in county-level medical communities and private medical groups, leveraging intelligent, cost-effective product portfolios and systematic service capabilities to capture the structural demand for primary care expansion and equipment upgrading. The high-end and primary care markets are not a zero-sum game, but rather an extension of the same technology platform across different market tiers.
Strengthening the growth business focuses on translating technological advantages into market position. Radiotherapy and interventional procedures, as the second growth curve, focus on accelerating penetration into prefecture-level city markets, leveraging the clinical demonstration of benchmark institutions to drive regional adoption, and converting established brand momentum into replicable market share; ultrasound, as the third growth curve, uses top-tier hospitals as a breakthrough point, establishing product differentiation through research collaborations and differentiated AI capabilities, while simultaneously building a high-end brand reputation and marketing system. At the same time, the company will strengthen forward-looking assessment and coordinated management of bidding and centralized procurement to enhance its responsiveness to the demand rhythm of multi-tier markets.

Improving organizational efficiency focuses on staying close to clinical practice and team building. The company will drive sales and clinical application teams deeper into diagnostic and treatment scenarios, enabling product value to be validated and propagated in real clinical workflows; and through systematic practical training and internal talent development mechanisms, it will enhance the professional capabilities and execution efficiency of the marketing team. In terms of services, the company will deepen full-lifecycle management around the installed base, increase service contract coverage, expand service and upgrade solutions for out-of-warranty equipment, and drive the transformation of services from delivery support to proactive value creation.

As growth sources become increasingly diversified, business resilience continues to strengthen, and the growth logic of the company's China business is shifting from single-product-driven to multi-dimensional capability-driven. Continued breakthroughs in high-end products, deep management of core customers, continuous expansion of the primary care market, accelerated penetration of intelligent integrated solutions, and continuously improving service capabilities together constitute a more diversified and resilient source of growth. As long-term trends such as medical equipment renewal, high-end equipment upgrades, and the enhancement of medical service capabilities continue to advance, the company will continue to adhere to technological innovation and high-quality development, deepen product portfolio and customer coverage, and continuously enhance the stability and sustainability of growth.

2. Overseas Markets: Rooted Locally, Reaching Globally

During the reporting period, the company's overseas revenue reached RMB 1.77 billion, a year-over-year increase of 54.46%, and its share of total revenue increased by 6.03 percentage points to 25.02%; in addition, overseas deliveries increased by more than 55% year-over-year, with revenue growth and delivery volume growth remaining in sync. Alongside scale expansion, the profitability quality of the overseas business also improved, primarily benefiting from the increased share of high-end product revenue and the continuous optimization of localized delivery efficiency.

More noteworthy than the growth rate is the continued refinement of regional market strategies. In North America, the company has focused on addressing the clinical needs of customers at different levels, while further improving service responsiveness and localized operational capabilities. In Europe, it has continued to deepen operations through a more comprehensive product portfolio and service network. In Asia-Pacific and emerging markets, the company has steadily expanded market access and customer support capabilities. Overall, the overseas business is entering a new phase of development, moving from individual market breakthroughs toward more systematic and sustainable growth.

The quality and structure of orders are core leading indicators for assessing the growth potential of the overseas business. During the reporting period, the company's overseas new orders maintained strong growth momentum and became increasingly concentrated in high-end and innovative product lines; high-value orders were secured consecutively in strategically important markets such as North America, Europe, India, and Latin America, significantly optimizing the business structure. In tandem with its growing global brand influence, the company has simultaneously deepened overseas channel empowerment and global delivery system development, comprehensively improving the efficiency of converting "orders into revenue." Orders are the leading indicator of revenue, and the continuous accumulation of high-quality orders has laid a solid foundation for the company's revenue certainty in the full year and beyond.

By region, North America is the region where the company's overseas presence began earliest and has the most complete business system, and it is also a key market for testing the competitiveness of high-end

products, localized operational capabilities, and global delivery standards. During the reporting period, the company generated revenue of RMB 421 million in the United States, accounting for 5.98% of total operating revenue. With the continued advancement of high-end product introduction, key customer breakthroughs, service business growth, and operational system development, the business structure and profitability quality in North America have been continuously optimized. As of the end of the reporting period, the company had delivered more than 850 units/sets cumulatively in North America. The business is transitioning from market access and benchmark breakthroughs to deeper customer cultivation and systematic operations.

The introduction of high-end products and breakthroughs with strategic customers are advancing in parallel. Several flagship products, including the long-axis PET/CT uMI Panorama GS, the high-definition dynamic MR uMR Ultra, and the uMI Panorama series, have been deployed or have formed key project pipelines at leading clinical and research institutions in the region. Among them, uMR Ultra has achieved important project implementation in North America, further expanding the international clinical applications of the company's high-end 3.0T MR products. Meanwhile, the company has entered the customer systems of multiple Integrated Delivery Networks (IDNs) and obtained framework cooperation qualifications, opening space for subsequent equipment procurement, multi-product line collaborative sales, and long-term service cooperation. The North American business is gradually extending from single-unit equipment sales to group customer coverage, product portfolio expansion, and long-term account management.

Around this stage-by-stage goal, the company continues to optimize its sales organization and resource allocation. On the one hand, it focuses on large medical groups, core strategic customers, and key projects, strengthening high-value customer coverage and the capability to tackle major projects; on the other hand, it promotes product teams moving closer to the front line, improves multi-level project tracking and closed-loop management mechanisms, and dynamically optimizes regional divisions and sales force deployment. Driven by breakthroughs with benchmark customers, the company has further increased resource investment in entering mainstream medical markets, promoting the coordinated implementation of high-end products, clinical benefit, and localized service capabilities, and extending from demonstration at key institutions to scaled commercial expansion. The foundation of localization on the operational side has also been consolidated. As of the end of the reporting period, the North American regional team exceeded 350 people. With the accelerated integration of marketing, supply chain, and customer service data, project response, delivery efficiency, and operational quality in the region have continued to improve. During the reporting period, the company's North American service revenue grew by more than 30% year-over-year, and the synergy between equipment sales, clinical applications, and full lifecycle services continued to emerge, further optimizing the regional revenue structure.

Product access capabilities have continued to improve. As of the end of the reporting period, the company

had a cumulative total of 78 products certified through FDA 510(k), with 20 new products added during the reporting period. The new-generation 3.0T MR uMR Astra entered the U.S. market, and 18 uSONIQUE series intelligent ultrasound products received FDA 510(k) clearance, further improving the overseas ultrasound product portfolio. In addition, according to the FDA's publicly released list of AI-enabled medical devices, the company has more than 35 AI medical devices on the list, ranking among the top in the industry.

The value of the North American market lies not only in current revenue contribution, but also in its comprehensive test of product performance, clinical benefit, compliance systems, and localized operational capabilities. Achieving sustained installations, benchmark customer breakthroughs, and multi-product line implementation in a mature market with full competition and strict standards demonstrates that the company's high-end medical equipment has established a systematic foundation for global competition, and has also accumulated replicable product, customer, and operational experience for expansion into other overseas regions. Looking ahead to the next stage, the company will continue to focus on high-end product introduction, IDN customer expansion, strategic account management, and localized service capability building to drive coordinated efficiency improvements across marketing, products, delivery, and services. With the gradual conversion of key projects, the continuous enrichment of the product matrix, and the ongoing improvement of the digital operations system, the North American business is expected to move from benchmark breakthroughs to scale expansion and quality improvement, providing more solid support for the company's globalization.

In the first half of 2026, the European region achieved revenue of RMB 266 million, a year-over-year increase of 49.37%. During the reporting period, the introduction and implementation of the company's high-end flagship products in the European market continued to accelerate: multiple innovative products, including long-axis PET/CT, digital PET/CT, ultra-high-field MR, dual-wide-bore dual-source CT, and ultra-large-bore MR, achieved first orders, deliveries, or key project breakthroughs in core Western European markets and Central and Eastern European regions, with application scenarios covering high-end clinical diagnosis and treatment and cutting-edge scientific research platforms.

While flagship products accelerate their entry into Europe's top clinical and research institutions, the company continues to promote in-depth regional market expansion, with mature and emerging markets working in tandem. Several key markets in Southern Europe achieved project breakthroughs in the public healthcare system, further enhancing the market coverage and competitive position of molecular imaging and high-end CT products; multiple countries in Central and Eastern Europe also achieved first orders or new installations in high-end and ultra-high-end CT, MR, and other product lines, with a continuously growing pipeline of high-end projects. Leveraging key project demonstrations, deepened clinical cooperation, and improved localized operational capabilities, the company is accelerating the expansion of market space for multi-product line collaborative development. The European business is gradually

transitioning from early market access and single-point breakthroughs to a deep cultivation stage characterized by high-end product introduction, clinical value validation, and systematic operations.

The theranostics product line achieved key breakthroughs in the European market. During the reporting period, the company's radiotherapy brand made its debut at the European Society for Radiotherapy and Oncology (ESTRO) annual meeting, and officially launched its smart radiotherapy ecosystem for the European market, showcasing a full-process solution integrating multi-modality simulation positioning, precision contouring, automated planning, rapid quality control, and precise treatment, further strengthening the company's clinical value proposition in the integrated diagnosis, interventional procedure, and treatment field. During the same period, two radiotherapy products, uRT-linac 506c and uLinac EternaTx, successively obtained EU CE MDR certification, marking that the company's radiotherapy products have met the strict access requirements of the European market in terms of safety, clinical evidence, and full-lifecycle quality management. Among them, the uRT-linac 506c, with its integrated design of diagnostic-grade high-definition CT and linear accelerator, as well as native CT-based online adaptive radiotherapy capabilities, can support more efficient and precise radiotherapy workflows. After obtaining certification, the company has achieved initial order breakthroughs in several key European markets. As of the end of the reporting period, multiple key projects targeting equipment upgrades and clinical capability enhancement needs of large radiotherapy centers are progressing steadily, laying a solid foundation for order conversion in the second half of the year and beyond.

At the same time, the interventional imaging product uAngio AVIVA is also being promoted in multiple markets in Western and Central and Eastern Europe. The accelerated introduction of radiotherapy and interventional products is driving the company's product offerings in Europe to extend from medical imaging diagnosis to a full-chain solution of "diagnosis-interventional procedure-treatment," and the customer cooperation model is also deepening from single-unit procurement to systematic configuration and long-term clinical collaboration.

The continuous accumulation of the installed base is also driving the European service business into a value release phase. As of the end of the reporting period, the company's cumulative delivery volume in the European region exceeded 780 units/sets, covering the full product lines of CT, MR, MI, and XR; during the reporting period, European service revenue grew by more than 80% year-over-year. High-end customers in Europe and the U.S. and mature medical markets have good service payment habits and a high recognition of the value of full-lifecycle maintenance. The service contract coverage rate is steadily increasing, with renewals and new contracts jointly building revenue growth, and the business model of "installed base driving services, services driving stickiness" has been strongly validated in the European and U.S. markets. Underpinning the above progress is the steady formation of localized organizational capabilities. As of the end of the reporting period, the company's European team exceeded 160 people, with more than half at senior or above levels, and a localized team that understands local markets, industry

rules, and can provide rooted services has taken shape. During the reporting period, the company deepened its local talent strategy, continuously optimized its employment structure, and simultaneously enhanced cohesion and stability. At the same time, the company is actively exploring a channel model that combines direct sales and agency sales, with a more balanced marketing network layout, laying a solid organizational foundation for the deep cultivation of the European market. From the batch implementation of flagship products to the breakthrough of theranostics, from the accelerated release of service value to the establishment of local organizations, the company's layout in the European market has expanded from point to surface and from shallow to deep, forming a favorable pattern of coordinated progress across products, services, and ecosystems. Looking ahead, with the continuous expansion of the installed base and the increasingly close cooperation network, Europe is expected to grow into a core growth pole with both scale and quality in the company's globalization landscape.

During the reporting period, the Asia-Pacific and emerging markets have become the fastest-growing and most incremental segments of the company's overseas business. In the first half of 2026, the company's Asia-Pacific region achieved revenue of RMB 1.01 billion, a year-over-year increase of 148.54%, accounting for 57.15% of overseas revenue; the emerging markets region achieved revenue of RMB 68 million. The company is replicating the high-end product portfolio, localized operational experience, and clinical cooperation models validated in mature markets to more countries and regions in a tiered manner, with overseas growth gradually shifting from being driven by a few benchmark projects to coordinated volume expansion across multiple countries and product lines.

During the reporting period, developed markets in Asia-Pacific achieved a leap from point to area, with markets such as Australia/New Zealand, Japan, and Singapore continuing to contribute high-quality incremental growth. The Company's cooperation with leading local medical groups continued to deepen, with multiple high-end molecular imaging and magnetic resonance products accelerating their entry into key medical institutions; a top-tier clinical institution in Singapore once again introduced the Company's flagship equipment, PET/CT installations in Australia continued to increase, and positive progress was made in deepening the high-end PET/CT market in Japan. Meanwhile, high-end projects in Southeast Asia, South Asia, and other markets continued to advance steadily. Products such as ultra-high-field magnetic resonance, long-axis PET/CT, high-end magnetic resonance, PET/MR, and radiotherapy have been successively deployed or achieved breakthroughs in key projects. Regional business is accelerating its shift from coverage by mid-range products to demonstration of high-end products and coordinated development of multiple product lines.

The regional depth and localized operational capabilities in emerging markets have also improved simultaneously. In the Middle East, Africa, and Latin America, breakthroughs continued in products such as high-end CT, molecular imaging, and interventional imaging, with key projects in multiple countries progressing steadily. In Latin America, the Company further improved its channel network combining

direct sales and distribution, promoting the localization of delivery, service, and customer management capabilities. New categories such as radiotherapy, interventional procedures, and ultrasound also accelerated their global expansion, generating orders, installations, or project reserves in Africa, Southeast Asia, Central Asia, South Asia, and Latin America, thereby extending the Company's overseas supply from medical imaging equipment to a full-chain solution covering "diagnosis-intervention-treatment." With the continuous upward shift in product structure and the continuous improvement of regional operational systems, the Company's growth foundation and long-term development space in Asia-Pacific and emerging markets have been further expanded.

Alongside equipment sales, the globalization of service capabilities is also expanding. As of the end of the reporting period, the Company's cumulative global deliveries exceeded 40,000 units/sets, with a service network covering more than 100 countries and regions, over 1,000 professional engineers, regional service centers established in 12 countries and regions worldwide, overseas service stations increased to 44, and global spare parts warehouses reaching 39, providing 7×24-hour real-time response and full lifecycle service support for more than 4,500 units/sets of equipment overseas. During the reporting period, the Company's overseas service revenue increased by more than 60% year-on-year. Relying on the continuously expanding overseas installation base, the service business is rapidly shifting from a supporting role in equipment delivery to value management covering the entire lifecycle, gradually becoming an important support for the sustained growth of overseas business.

High-quality overseas growth is a long-term and systematic undertaking. In the face of external factors such as geopolitical tensions, tariff changes, and long cross-border project cycles, the Company continues to improve its diversified regional layout, strengthen localized marketing, delivery, and service capabilities, and enhance operational resilience through global resource coordination.

iii. R&D Innovation and Resilient Supply Chain Construction: Innovation Capabilities Continue to Accumulate, Supply System Accelerates Upgrade

The core of technological innovation lies not only in sustained investment, but also in transforming innovation capabilities into sustainable product competitiveness and commercialization capabilities. For United Imaging Healthcare, the innovation capability, platform-based and systematic capabilities of the R&D system are important foundations for supporting technological breakthroughs and large-scale product implementation.

The uIPD integrated product development system is precisely the capability fulcrum for rapid innovation. Leveraging a unified architecture, unified interfaces, and modular design, the Company continuously iterates its product portfolio, including magnetic resonance (1.5T to 5T), CT (mainstream to photon counting), and molecular imaging (short-axis to long-axis), on a shared technology base. During the reporting period, the uIPD system continued to empower the development of multiple products and key

technologies, accelerating the industrialization of innovation outcomes. As of the end of the reporting period, R&D personnel accounted for over 40% of the Company's workforce, forming a talent pipeline with high technology, high quality, and high potential. At the same time, the existence of a platform-based system amplifies the marginal efficiency of R&D investment: the same underlying technology can be reused across the product portfolio, thereby reducing the development cost amortized per model. As a result, R&D is no longer just a current expense for the Company, but a long-term asset that can be amortized and reused.

Currently, competition in high-end medical equipment is evolving from a competition of single product performance to a comprehensive competition in original technology, clinical value, integrated solutions, and industry standards. As medical imaging enters a stage of high-quality development, industry competition is evolving from single-point technological breakthroughs to systematic competition in original technology, clinical value, and standard systems. Continuous breakthroughs in key core technologies, extensive validation of clinical applications, and the continuous improvement of industry standards are becoming important supports for reshaping the competitive landscape of the industry and building long-term competitive advantages. This is also an important logic for understanding the long-term value of the Company's sustained innovation investment.

In the first half of 2026, the Company adhered to original technological innovation as a guide, continuously increased R&D investment, and commercialization in frontier fields, achieved breakthroughs in core components and key technologies such as photon-counting spectral CT, and continuously consolidated the independent technological foundation for high-end medical imaging equipment. These related accumulations will accelerate the transformation into all-modality product innovation and clinical application, promote the continuous upgrade of medical imaging capabilities, and provide strong support for the Company to expand product boundaries and enhance long-term competitiveness in response to more complex clinical needs.

In addition, the support for innovation competition is also the accumulation of AI and platform capabilities. The Company embeds artificial intelligence into all equipment lines from the product definition stage, forming digital and intelligent technology platforms such as uAIFI magnetic resonance brain-like, uExcel molecular imaging, uSense CT active sensing, uVera interventional intelligent bionics, and uEDGETEC ultrasound super sensing, achieving comprehensive innovation from hardware, software, and applications to workflow, with the number of AI-enabled devices approved by the FDA ranking among the top in the industry. The platform-based approach enables AI capabilities to be migrated and reused across the product portfolio, transforming single-point algorithm advantages into system-wide advantages. Furthermore, the positioning of AI is evolving from a tool for image recognition and feature annotation to an intelligent decision support system; when equipment, data, algorithms, and clinical pathways are connected, AI will become the hub connecting pre-diagnosis prediction, intra-diagnosis decision-making,

and post-diagnosis management. The Company's value creation thus expands from selling a device to providing an intelligent system that runs through the entire diagnosis and treatment process. Along this direction, the form of medical equipment itself is also evolving: from a tool that passively executes instructions to an intelligent terminal capable of perceiving the environment, understanding needs, making autonomous decisions, and coordinating collaboration. The relationship between equipment and people is thereby reset, no longer requiring people to adapt to the equipment, but rather the equipment actively adapting to and serving clinical practice.

At the same time, the digital and integrated construction of the supply chain system is also an important foundation for the Company to enhance its large-scale delivery capabilities, and is an extension of United Imaging Healthcare's technological innovation.

In the first half of 2026, a more profound change occurred at the intersection of artificial intelligence and organizational operation. United Imaging Healthcare positions artificial intelligence as a foundational capability that runs through all departments and processes, rather than a technical label attached to a single product line. Around this positioning, the Company systematically promotes the large-scale application of artificial intelligence in internal operations, with its impact reflected in three aspects:

First, in terms of working methods, human-machine collaboration is becoming the mainstream form, with business processes being reshaped accordingly, and organizational structures and collaboration mechanisms evolving in tandem; second, in terms of resource allocation, the investment approach is shifting from the accumulation of human resources to the synergy of knowledge assets and intelligent tools, with AI capabilities becoming an important component of departmental human efficiency; third, in terms of talent structure, the value of composite talents skilled in using intelligent tools is becoming prominent, and the Company promotes the aggregation of individual efficiency improvements into an overall organizational efficiency leap through systematic training and tool popularization. As a result, the dividends of technological innovation are not only reflected in the product end, but also continuously accumulated as the Company's operational efficiency and organizational resilience.

The above positioning has been implemented in the operational management and supply chain systems. On the planning side, leveraging multi-dimensional data such as historical orders, regional business climate, and project progress, the accuracy of demand forecasting and production scheduling has continued to improve, correspondingly shortening the response cycle from order to delivery. On the procurement side, tiered supplier management and risk early warning for key materials have become more proactive, enabling earlier identification and faster response to supply fluctuations. On the manufacturing side, intelligent image recognition has been applied to quality inspection at key processes, extending quality control from sampling inspection to full-scope monitoring. On the inventory and delivery side, the Company dynamically adjusts its inventory structure based on business development stages and

implements intelligent optimization of the global spare parts network and transportation scheduling, driving simultaneous improvements in the efficiency of operational assets and operational quality. As a result, operations management has shifted from relying on experience-based judgment to continuous calibration driven by data and algorithms.

As technological innovation continues to evolve, a resilient supply chain system has become a critical capability affecting the long-term development of high-end medical equipment companies. In the face of globalized operations and a complex external environment, during the reporting period, United Imaging Healthcare continuously enhanced the stability, synergy, and responsiveness of its supply chain at three levels, providing a solid foundation for the large-scale expansion of its business. First, core components are independently controlled, with all core components of the full range of high-end medical imaging and radiotherapy products adhering to independent R&D, with a self-developed and self-manufactured ratio exceeding 90%, and multiple technologies filling domestic gaps in technology and processes, with performance parameters reaching world-class levels. Second, the Phase II base in Shanghai will be put into operation as planned, and the Phase II bases in Changzhou and Wuhan will reach full production capacity, significantly expanding the production capacity of core components such as X-ray tubes, magnets, MI crystals, RT, and DSA. The Company’s North American headquarters in Houston, USA has completed its planned capacity expansion, enhancing local delivery, service response, and supply chain support across the region, strengthening operational resilience and stability across the globe. Third, the company continues to advance the construction of MOM, ERP, MES, and other systems, promoting the full-chain integration of R&D, planning, procurement, manufacturing, and quality management. The resilience of the supply chain also extends to the depth of the industry. As of the end of the reporting period, the company has supported the collaborative development of upstream and downstream partners through technology enablement and ecosystem co-building, cultivating a broad base of high-quality domestic suppliers. A number of ecosystem partners have also achieved further development through capital market access. The value of a leading company lies not only in the stability of its own supply chain, but also in helping the broader industry chain strengthen resilience, efficiency, and long-term innovation capabilities.

The core of cost control lies not in short-term procurement price negotiations, but in continuously driving cost reduction through core technological breakthroughs and engineering innovation. During the reporting period, the company not only continuously strengthened supplier tiered management, dynamic assessment, and key material assurance mechanisms to enhance supply chain security and operational efficiency; more importantly, by focusing on independent R&D of core components, product design optimization, and material and process innovation, the company has moved cost improvement forward to the R&D and manufacturing stages, forming a more sustainable cost competitiveness while ensuring supply resilience.
First, the common platform-based R&D architecture provides a systematic foundation for cost optimization. The company promotes unified architecture, unified interfaces, and modular design from the

product definition stage, facilitating the collaborative evolution of product lines such as MR, CT, molecular imaging, and radiotherapy on a shared technology platform. Underlying technologies and key modules can be reused across models, which not only improves the efficiency of R&D investment and shortens product iteration cycles, but also drives component standardization, large-scale procurement, and flexible scheduling in the supply chain. R&D reuse and supply chain resilience are not independent of each other, but rather manifestations of the same system capability in different operational aspects.

Second, technology-driven cost reduction and product capability enhancement go hand in hand. The company continuously improves the total lifecycle cost of products through design optimization, material substitution, process innovation, and engineering innovation; once these results are solidified in the platform and product portfolio, they can repeatedly release value with product iterations. Each improvement in core component capabilities and each breakthrough in manufacturing processes not only helps optimize the cost structure, but also further consolidates technological barriers. As of the end of the reporting period, the company had applied for a total of 10,643 patents and obtained 5,547 patents; among them, a total of 8,770 invention patent applications were filed, accounting for 82.40% of the total patent applications, and a total of 4,301 invention patents were obtained, accounting for 77.54% of the total patents obtained. The continuous accumulation of high-quality intellectual property provides solid support for core technological breakthroughs, product platform iterations, and the enhancement of cost competitiveness.

iv. Sustainable Development: Anchoring Long-Term Value through High-Level Governance

Since its establishment, the concept of sustainable development has been deeply integrated into the entire process of United Imaging Healthcare's R&D innovation, production operations, and global operations. The company has continuously improved its management systems and promoted related practices in key areas such as product quality and safety, supply chain management, talent development, business ethics, information security, and green operations. During the reporting period, with the expansion of business scale and the deepening of global layout, the company further enhanced its fundamental capabilities in technological innovation, compliant operations, and operational resilience, providing support for long-term stable development.

In the first half of 2026, the company further increased R&D investment, focusing on core components, key technologies, and underlying platforms, and promoting the transformation of related results into product innovation and clinical applications. As of the end of the reporting period, the company had over 9,300 employees, including 3,748 R&D personnel, an increase of 357 compared to the same period last year, with R&D personnel accounting for 40.12%. The company has always maintained a high proportion of R&D personnel, continuously consolidating its R&D capabilities in medical imaging, radiotherapy, interventional imaging, and related intelligent technology fields. As of the end of the reporting period, the company had applied for a total of 10,643 patents and obtained a total of 5,547 patents; among them, a

total of 8,770 invention patent applications were applied, accounting for 82.40% of the total patent applications, and a total of 4,301 invention patents were obtained, accounting for 77.54% of the total patents obtained. The continuous accumulation of intellectual property provides support for core technology R&D, product platform iterations, and engineering applications.

While pursuing technological breakthroughs, United Imaging Healthcare continuously improves its full lifecycle quality management system covering R&D, procurement, production, delivery, and after-sales service, and conducts quality management in accordance with the regulations and standards of major global markets. As of the end of the reporting period, the company's quality management system certification covered all production bases, with 77 products obtaining EU CE certification and 78 products obtaining US FDA 510(k) clearance. In the first half of 2026, the company underwent 18 external audits, with a 100% pass rate, no major non-conformities, and maintained a 100% validity rate of its quality management system certification certificates. United Imaging Healthcare also updated 200 quality and safety-related management documents, further optimizing institutional processes and execution standards. In terms of product verification and quality control, the company continuously improves R&D verification, reliability testing, production process control, and post-market surveillance mechanisms, strengthening the management of product safety, effectiveness, and traceability. On the basis of meeting external regulatory, registration, and certification standards, United Imaging Healthcare has established an internal product quality and safety management system covering the entire process of R&D, verification, production, and post-market management.

On the R&D side, the company takes the uIPD R&D quality management system as the core, setting strict stage review points in the integrated product development process, with the R&D Quality Assurance (R&D QA) team participating throughout the entire process of requirements analysis, design input and output, design verification, design validation, design transfer, and design changes; at the same time, a product risk management mechanism is established in accordance with ISO 14971, implementing risk identification, analysis, evaluation, and control throughout the entire product lifecycle, and ensuring the stability and control of key processes, production environments, and operational procedures through production process control specifications and standard operating procedures that are stricter than regulatory requirements.

On the testing side, the company follows more than 100 internal design and testing guidelines, including the "Product Development Process," "Verification Procedure," "Design Validation Procedure," "Product Risk Management," "Product Cybersecurity Management Process," "AI System Lifecycle Process," "Product Usability Engineering Management," as well as "Reliability Testing Specification Guide," "Packaging Reliability Testing Specification," "HALT Test Specification," "Environmental Climate Test Specification," "EMC Test Specification," "ESS Test Specification," "Environmental Mechanical Test Specification," and "Component Accelerated Life Test Specification," and is equipped with professional

testing facilities and a dedicated testing team, forming verification and testing capabilities covering components, systems, and complete machines.

In the first half of 2026, United Imaging Healthcare cumulatively executed 6,964,936 tests of various types, covering 1,259 components, 354 systems, and 53,199 test cases, maintaining 100% test case coverage; the testing scope covered major product lines including CT, MR, molecular imaging, digital X-ray, radiotherapy, and ultrasound, as well as key core components and software systems, spanning multiple dimensions such as functionality, performance, safety, electromagnetic compatibility, environmental adaptability, and reliability.

Among these, the company cumulatively conducted 6,755,645 component and system reliability tests, covering 2,141 reliability test cases, encompassing test scenarios such as high and low temperature environments, mechanical durability, vibration and shock, storage and transportation, accelerated life, and fatigue life. The company embeds reliability management throughout the entire process of product development and engineering translation, continuously outputs reliability technical reports for key materials, modules, components, and complete systems, and feeds test results back into design optimization and process improvement, forming a closed-loop quality cycle of "testing-discovery-improvement-verification," providing assurance for product safety, stable operation, and clinical application.

Meanwhile, to meet the product registration and safety access requirements of different countries and regions, United Imaging Healthcare continues to conduct product testing and certification in accordance with domestic and international standards such as GB 9706.1 and its series standards, and the IEC 60601 series standards. As of the end of the reporting period, the Company has obtained third-party test reports for all its marketed products, including MR, CT, XR, PET/CT, PET/MR, RT, software post-processing applications, and ultrasound, with the testing coverage further expanded to the ultrasound product line. Relying on continuously improved internal laboratory capabilities, a global regulatory registration system, and product testing mechanisms, the Company continuously enhances its quality and compliance assurance capabilities for products entering the international market. In addition, during the reporting period, the Company conducted environmental compliance tests on 24,549 homogeneous materials to ensure products comply with relevant environmental regulations; quality and safety-related training cumulatively reached 313,915 person-times, with a cumulative training duration of 94,422.07 hours, achieving 100% coverage of quality and safety training for all employees.

In terms of supply chain management, United Imaging Healthcare continues to strengthen supplier tiered management, dynamic evaluation, and key material assurance mechanisms to enhance supply chain stability and risk response capabilities. The Company incorporates requirements for quality, environment, occupational health and safety, and business ethics into the entire process of supplier admission, auditing,

and continuous improvement, and implements differentiated management based on supplier risk levels. As of the end of the reporting period, the proportion of tier 1, tier 2, and tier 3 suppliers that have obtained third-party system certification was 97.3%. In the first half of 2026, United Imaging Healthcare continued to conduct training on supplier quality, environmental regulations, and carbon management, promoting supply chain partners to enhance their quality and compliance management capabilities.

In terms of talent development, United Imaging Healthcare continues to improve its human resources management system, strengthening talent recruitment, development, evaluation, succession, and incentives in areas such as technology R&D, global marketing, localized operations, and key functions. In the first half of 2026, the Company completed the assessment of 133 high-potential talents and provided specialized training and practical opportunities for 203 high-potential management reserve talents; as of the end of the reporting period, the Company's key position reserve rate reached 90.6%. United Imaging Healthcare continuously strengthens organizational capabilities by improving management training, professional talent development, and cross-regional talent allocation mechanisms, providing talent assurance for business expansion and global operations. At the same time, United Imaging Healthcare places emphasis on the development and cultivation of leadership capabilities for all employees, extending leadership development from the management level to all employees and advancing the construction of a leadership development system for all employees. In the future, the Company will leverage AI empowerment to develop multiple general-purpose online leadership courses applicable to all employees, aiming to achieve 100% leadership training coverage for all employees.

Meanwhile, United Imaging Healthcare continues to improve its compensation and long-term incentive arrangements, promoting the sharing of results between employees and the Company's long-term development. As of the end of the reporting period, the Company's employee equity incentive plans had cumulatively granted 88.0272 million shares, covering more than 6,980 person-times; in the first half of 2026, restricted shares were newly granted to more than 1,500 employees domestically and internationally. The Company also continues to improve employee communication, occupational health, safety assurance, and welfare systems, striving to create an equal, inclusive, and safe working environment, and supporting employees in achieving career growth across different positions and development stages.

In terms of corporate governance, United Imaging Healthcare continues to improve the operating mechanisms of the Board of Directors and its special committees, strengthening oversight of strategy, risk, environment and social responsibility, and business ethics. In the first half of 2026, the Company held 5 board meetings and 1 shareholders' meeting, and all directors attended the aforementioned meetings, with no absences or instances of entrusting other directors to attend board meetings or shareholders' meetings. At the same time, all directors conducted comprehensive investigations and understanding of the matters under review, fully utilized their professional knowledge and practical experience to provide reasonable suggestions to the Company, exercised their powers objectively and independently, actively promoted the

objectivity and standardization of board decisions, and effectively safeguarded the legitimate interests of the Company and all shareholders.

As a globally leading medical technology company, United Imaging Healthcare regards business ethics and compliance management as the cornerstone of its corporate operations, ensuring the highest standards of business ethics are upheld in all business activities through the establishment of a rigorous compliance system. During the reporting period, the Company released this year's business ethics and compliance training course to all employees, publishing both Chinese and English versions of the video training materials on its internal learning platform, requiring all employees to complete the training, achieving a 100% training coverage rate, with cumulative participation exceeding 12,000 person-times. At the same time, the course remains open for subsequent new employees to continue participating in the training, ensuring that all employees can fully understand the Company's business ethics standards and compliance systems and policies. Meanwhile, the Company continues to conduct training on anti-corruption, anti-bribery, conflict of interest, bidding compliance, and responsible marketing for key positions, achieving 100% coverage of all marketing, procurement, and other relevant personnel, and strengthening risk identification and closed-loop management in key areas through mechanisms such as routine audits, special audits, unannounced inspections, and corrective action tracking.

In terms of information security, United Imaging Healthcare continues to improve its data security and personal information protection management system to safeguard the information rights and interests of customers, partners, employees, and other stakeholders. As of the end of the reporting period, the Company has obtained system certifications including ISO 27001 for information security management, ISO 27701 for privacy information management, and ISO 27017 for cloud services information security management, and continues to enhance its cybersecurity, data management, and privacy protection capabilities in global operations, providing assurance for digital business and global development.

In terms of green operations, United Imaging Healthcare, guided by the goal of "reducing Scope 1 and Scope 2 carbon emission intensity per unit revenue by 50% by 2035 compared to 2023," continues to promote the application of clean energy, energy efficiency improvement, green product innovation, supply chain collaborative carbon reduction, and transportation optimization. In the first half of 2026, production bases in Shanghai, Wuhan, and other locations collectively purchased over 7 million kWh of green electricity; at the same time, the Company continues to improve energy efficiency through measures such as replacing equipment with high-efficiency alternatives, establishing energy consumption monitoring systems, and analyzing energy efficiency in production processes.

United Imaging Healthcare continues to integrate ecological design, material environmental compliance, and product lifecycle environmental management into its R&D, production, and delivery processes, and promotes collaborative carbon reduction across the value chain through measures such as green

procurement management and supplier carbon capability building. The Company's ongoing practices in the environmental, social, and governance fields have been recognized by external institutions, maintaining an MSCI ESG AA rating, achieving the highest AAA rating in the CSI ESG rating, and ranking in the top 10% of the industry in the S&P Global Corporate Sustainability Assessment.

Halfway through the journey, momentum is building toward new heights! Looking ahead, United Imaging Healthcare will continue to cultivate innovation frontiers with original technologies, safeguard product safety with a global quality system, ensure stable delivery with a resilient supply chain and localized service network, and consolidate the foundation for long-term development with green operations and responsible governance, continuously promoting the deep integration of intelligent medical equipment and clinical needs, making innovative healthcare accessible to a broader population, and contributing to the efficiency, equity, and sustainable development of global healthcare systems.

Analysis and Outlook on Changes in Non-GAAP Financial Indicators
□ Applicable√ Not Applicable

Major changes in the Company's operations during the reporting period, as well as matters that occurred during the reporting period that have had a significant impact on the Company's operations and are expected to have a significant impact in the future
□ Applicable√Not Applicable

III Analysis of Core Competitiveness during the Reporting Period

i.Analysis of Core Competitiveness

√Applicable□Not Applicable
The Company is a leading medical technology enterprise in China and one of the few globally that has mastered the core technologies of high-end medical imaging diagnostic products, radiotherapy products, and life science instruments, with full life-cycle product management capabilities from R&D, production, and sales to after-sales maintenance.
1. Comprehensive Product Portfolio and Leading Product Performance
(1) Comprehensive Product Coverage
The Company has formed a rich product line centered on high-end medical imaging equipment, covering diagnostic products such as MR, CT, XR, PET/CT, PET/MR, and US, radiotherapy products such as conventional RT and CT-guided RT, and life science instruments such as animal MR and animal PET/CT, which can meet the needs from preclinical research to diagnosis and treatment. The Company's equipment is equipped with self-developed medical image processing software and advanced applications, which can realize the organic combination of research, diagnosis, and treatment plans, providing an All-in-One solution for precision diagnosis and treatment.

(2) Advanced Product Performance

Many of the products developed by the Company have created industry or domestic "firsts", including the industry's first PET/CT product with 4D whole-body dynamic imaging function, uEXPLORER (Total-body PET/CT), which was named one of the "Top 10 Technology Breakthroughs of the Year" by Physics World in 2018; the industry's first ultra-high-field whole-body imaging MR uMR Jupiter 5T, which broke the previous limit of ultra-high-field MR to only perform neurological scans, achieving ultra-high-field whole-body clinical imaging for the first time, and demonstrating its unique advantages in the heart, brain, and abdomen, enabling better understanding, differentiation, and diagnosis of diseases; the industry's first high-definition "camera" MR equipment, uMR Ultra, equipped with the uAIFI.LIVE imaging platform, combined with an AI imaging chain, and leveraging the synergistic advantages of an ultra-high-performance gradient system and a spatiotemporal fusion AI engine, can continuously capture high-definition dynamic images of anatomical structures and functional tissue activities, holding great potential for the observation, diagnosis, and research of moving parts of the human body; the industry's first intelligent bionic minimally invasive interventional surgery system, uAngio 960, which is also the first DSA system in China with a multi-degree-of-freedom robot as the gantry structure, meeting the needs of high-precision, complex surgical scenarios in multiple disciplines such as pan-vascular, orthopedics, thoracic surgery, and gastrointestinal surgery; the first domestic photon-counting spectral CT, uCT Ultima, which is the first to achieve ultra-high-resolution imaging and precise spectral imaging of multiple body parts with a domestic photon-counting spectral CT, suitable for integrated high-end clinical diagnosis and treatment and scientific research scenarios; the world's first dual-wide detector dual-source CT imaging system, uCT SiriuX, which for the first time combines wide detector and dual-source, two ultra-high-end CT system forms, achieving a breakthrough 8ms industry-leading whole-heart temporal resolution, dual-wide 16cm whole-organ volume coverage, and a 470mm ultra-large spectral imaging field of view, achieving comprehensive performance improvements in temporal resolution, coverage, and accuracy; and the industry's first diagnostic-level CT-guided integrated radiotherapy accelerator, uRT-linac, an integrated CT linear accelerator, among other products.

2. Strong Comprehensive R&D Capabilities

(1) Vertical R&D System

The Company has built a vertical innovation system that runs through technology, products, and software, conducting core technology R&D around the core components of each product line, laying a solid foundation for achieving independent control of core technologies and building barriers to product competitiveness. The Company's self-developed ratio ranks among the top in the industry, and the main core components of each product line are self-developed and self-produced.

(2) Platform-based R&D Model

The Company has built a common software and common hardware R&D platform, providing a foundation for technology reference and exchange, product integration and iteration through a cross-product-line platform-based R&D model. At the R&D level, the common underlying architecture provides innovation convenience for developing multi-modality products; at the project level, shared software and hardware

designs can improve R&D efficiency and accelerate product iteration; at the product level, unified systems combined with unified industrial design and interface design ensure high consistency in brand image and user experience across the Company's different product lines, which helps to enhance brand influence and promote the continued promotion of products.

(3) Forward-looking Innovation Strategy

The Company guides its innovation direction with forward-looking research and market trends. On the one hand, the Company has established future laboratories in Shanghai and Houston, USA, actively laying out forward-looking research, exploring and grasping new opportunities for industry transformation and development, and providing technical reserves for the Company's R&D and innovation; on the other hand, each product business unit is closely connected to the market, continuously promoting technological innovation and iterative upgrades of all product lines through rapid feedback on market demands.

(4) Global R&D Talent Reserve

Talent is the foundation of the Company's continuous R&D and innovation. Through self-development and external introduction, the Company has built a globally-minded R&D team led by a number of top scientists and personnel with extensive industry management and R&D experience. As of the end of the reporting period, the Company had a total of 3,748 R&D personnel, accounting for 40.12% of the total number of employees.

3. Complete Intellectual Property Portfolio

The intellectual property system is the core support for technological innovation and an important guarantee for the sustainable development and globalization of an enterprise. The Company has established a comprehensive database and intellectual property management platform to achieve platform-based management of the entire life cycle of intangible assets. The Company's intellectual property system covers patents, trademarks, copyrights, and technical secrets. As of the end of the reporting period, the Company's total number of intellectual property applications, mainly patents, exceeded 12,800, of which invention patent applications accounted for more than 80% of all patent applications. The Company has cumulatively obtained more than 7,000 intellectual property authorizations, of which more than 4,300 are invention patent authorizations. At the same time, the Company strictly protects its technical secrets in accordance with the "Information Security Management Measures" and the "Trade Secret Management System" and other systems, striving to build a comprehensive intellectual property portfolio system to protect the Company's technological innovation achievements from different perspectives.

(1) Forward-looking Portfolio Strategy

Since its establishment, the Company has always regarded the patent portfolio strategy as an important means of strengthening its own competitiveness, continuously building patent barriers based on its own technology path, industry frontier technologies, and market expansion directions. The Company's patent mining mechanism runs through the entire life cycle of technology R&D, and patent applications broadly cover all product lines. At the same time, during the R&D process, the Company plans in advance for technologies that may be implemented in the future and protects them with patents to seize the first opportunity, ensuring that the Company obtains more basic patents and higher portfolio efficiency.

In terms of trademarks, the Company carried out trademark portfolio planning in conjunction with product launch plans at the early stage of its establishment, leveraging the advantages of the Madrid System for global trademark portfolio, laying the foundation for overseas market expansion.

The Company has formed a set of intellectual property portfolio that is both offensive and defensive, based on its own technology path, industry frontier trends, and market expansion directions.

(2) Systematic System Establishment

The Company has established a comprehensive and systematic intellectual property management system based on its own development strategy, covering the acquisition, maintenance, and utilization control of intellectual property. At the risk control level, it can support intellectual property risk identification and legal dispute handling; at the document and regulation level, the Company has established control procedures including intellectual property documents and laws and regulations; and at the information security level, the Company has implemented strict confidentiality management for intellectual property information resources.

4. Multi-dimensional Marketing Network

The Company combines direct sales and distribution models to build a diversified and multi-dimensional marketing system covering domestic and overseas markets, including top research institutes, universities, Class III Grade A hospitals, and primary care institutions. The Company actively implements the national hierarchical diagnosis and treatment strategy, penetrating the primary healthcare market through a rich product portfolio, and promoting the sinking of medical resources by combining innovative equipment with technologies such as the Internet. In overseas markets, as of June 30, 2026, the Company has established sales networks in multiple countries and regions around the world, including the United States, the United Kingdom, Singapore, Japan, South Korea, Australia, New Zealand, South Africa, Morocco, Malaysia, and Colombia, and its products have successfully entered more than 100 countries and regions, including the United States, Japan, South Korea, New Zealand, and Italy.

5. Comprehensive After-sales Service

The company is customer experience-centric and has built a comprehensive customer service system that addresses routine after-sales needs, emergency response needs, and feedback needs. The company has established an after-sales team that emphasizes attention to detail and continuous improvement, providing customers with comprehensive services covering training, installation, repair, upgrade, and maintenance. In addition, the company places great emphasis on continuous communication with customers and obtaining feedback to facilitate product optimization and upgrades by the R&D team.

6. Integrated Innovation of Industry, Academia, Research, and Medicine

The company is gradually transitioning from the single dimension of empowering clinical practice with products and technologies to building a comprehensive, technology-supported, deeply integrated innovation system of industry, academia, research, and medicine. The company has opened up the entire chain of "basic research - clinical application - translational medicine - industrial transformation," using clinical needs and major medical challenges to drive product definition, performance optimization, application expansion, and clinical demonstration, forming a closed-loop management from innovation to

commercial transformation, and continuously expanding innovation leadership and commercial competitiveness.

ii. Events that occurred during the reporting period that had a serious impact on the company's core competitiveness, impact analysis, and response measures

□ Applicable√ Not applicable

iii. Core Technology and R&D Progress

1. Core technologies and their advanced nature, as well as changes during the reporting period

After years of R&D accumulation, the company has mastered the following core technologies:

(1) Core Technologies of Magnetic Resonance Imaging System (MR)

No.	Category	Core Technology	Technological Advancement	Technology Source	Main Application	Applied Products
1	Core Hardware Design and Production Technology	Superconducting Magnet Design and Production Technology	1. The company is one of the few enterprises that have mastered the core technology of 5.0T and above high-field human superconducting magnets 2. Possesses industry-leading magnet uniformity indicators 3. First to achieve a 75cm ultra-large patient bore 3.0T superconducting magnet 4. Has mature zero liquid helium boil-off magnet technology 5. Has mastered low liquid helium and helium-free magnet development technology	Independent R&D	Superconducting magnet design and manufacturing	MR, PET/MR
2		High-Performance Gradient Coil Design and Production Technology	1. Gradient amplitude covers 33mT/m to 300mT/m, and gradient slew rate covers 125T/m/s to 220T/m/s, at the industry-leading level	Independent R&D	Gradient coil design and manufacturing	MR, PET/MR

No.	Category	Core Technology	Technological Advancement	Technology Source	Main Application	Applied Products
			2. Uses vacuum potting technology and advanced material formulations, with high mechanical performance and operational reliability			
3		All-Digital Megawatt-Class Gradient Power Amplifier (GPA) Technology	1. The industry's first third-generation semiconductor SiC gradient amplifier (GPA) technology and its industrialization 2. Gradient power amplifier power covers 0.5 MW to 3.5 MW power levels, reaching the industry-leading level 3. All-digital control technology improves gradient magnetic field fidelity and stability	Independent R&D	Gradient power amplifier design and manufacturing	MR, PET/MR
4		All-Digital RF Power Amplifier (RFPA) Technology	1. Uses all-solid-state power amplification and high-density, highly integrated structural optimization technology to reduce size and cost 2. Uses all-digital non-linearity compensation technology to improve signal fidelity and stability	Independent R&D	RF power amplifier design and manufacturing	MR, PET/MR
5		High-Field Multi-Channel RF Transmission Technology	Has mastered multi-channel independent control technology, which can improve the uniformity of the RF transmission magnetic field, at the industry-leading level	Independent R&D	RF transmission coil design and manufacturing	MR, PET/MR

No.	Category	Core Technology	Technological Advancement	Technology Source	Main Application	Applied Products
6		RF Receive Coil Design and Production Technology	1. High-channel dedicated receive coils can cover all parts of the body, at the industry-leading level 2. Has mastered low-noise preamplifier and new coil technologies	Independent R&D	RF receive coil design and manufacturing	MR, PET/MR
7		Distributed Spectrometer and Optical Fiber Digital Transmission Technology	High number of receive channels and signal stability reach the industry-leading level	Independent R&D	MR spectrometer design and manufacturing	MR
8	Core Software Applications and Algorithm Technology	MR Fast Imaging Technology	1. The industry's first dynamic imaging technology LIVE platform, enabling a breakthrough in MR imaging from "photography" to "videography" 2. The industry's first uCS (LightSpeed) imaging technology platform, achieving 0.5-second/phase fast dynamic high-definition imaging 3. The intelligent uCS imaging technology platform integrates the advantages of artificial intelligence and uCS imaging technology, enabling hundred-second-level imaging of all parts of the body	Independent R&D	MR imaging sequence and clinical application development	MR, PET/MR

No.	Category	Core Technology	Technological Advancement	Technology Source	Main Application	Applied Products
9		MR Automated Scanning Technology	1. Full-process intelligent empowerment, achieving intelligent scanning of various parts including the head, heart, spine, and abdomen 2. Equipped with intelligent functions such as one-key table in, convenient multi-protocol planning, automated post-processing, early warning of critical component failure, and sleep/wake-up.	Independent R&D	Implementation of intelligent MR scanning workflow	MR, PET/MR
10		Advanced MR applications and post-processing technologies	1. Possesses industry-first advanced application technologies in MR, including complex-domain diffusion reconstruction, multi-echo advanced susceptibility weighted imaging, and 3D high-definition MATRIX technology. 2. Possesses multiple quantitative imaging technologies, including liver fat quantification FACT technology and dynamic contrast-enhanced DCE technology. 3. Possesses multiple advanced post-processing applications, including deep learning-based fully automatic cardiac chamber segmentation	Independent R&D	Development of advanced MR applications and post-processing products	MR, PET/MR

No.	Category	Core Technology	Technological Advancement	Technology Source	Main Application	Applied Products
			software and quantitative analysis software for dynamic contrast-enhanced liver scanning.			

(2) Core technologies of X-ray computed tomography (CT) systems

No.	Category	Core Technology	Technological Advancement	Technology Source	Primary Application	Product Application
1	Key component design and manufacturing technologies	Detector	The "Z-Detector" can significantly reduce electronic noise, lower radiation dose while improving image resolution, with performance at the industry-leading level.	Independent R&D	CT detector manufacturing and processing	CT
2		X-ray tube	Features high power capability, high heat content, and long lifespan, improving image resolution through flying focal spot technology.	Independent R&D	CT tube design and manufacturing	CT
3		High-voltage generator	1. Reduces the size and weight of the high-voltage generator through fully digitally controlled high-frequency inversion, high-voltage transformer boosting technology, and high-frequency rectification technology, while improving the switching speed of kV output pulses. 2. Possesses high-speed grid control technology and flying focal spot technology.	Independent R&D	CT high-voltage generator design and manufacturing	CT

No.	Category	Core Technology	Technological Advancement	Technology Source	Primary Application	Product Application
4	Full-chain low-dose technology	Precise organ dose modulation technology	Uses artificial intelligence technology to perform precise dose modulation for different examination subjects and body parts.	Independent R&D	Used to achieve low-dose scanning and reduce patient dose.	CT
5		Deep learning noise reduction reconstruction technology	By reducing noise, it can lower radiation dose while improving the imaging capability of small lesions.	Independent R&D	Reduces dose, improves lesion detection capability, and assists physicians in diagnosis.	CT
6		Iterative noise reduction technology	Effectively reduces image noise and improves signal-to-noise ratio, achieving reduced radiation dose while improving image quality.	Independent R&D	Reduces dose and improves lesion detection capability.	CT
7	Efficient automated scanning technology	"Tianyan" platform technology	Automatically identifies patient body parts via camera and intelligently matches them with scanning protocols, optimizing the CT scanning workflow.	Independent R&D	Used to assist in CT scan preparation and improve scanning workflow efficiency.	CT
8		Easylogic automated prediction technology	Uses algorithms to improve image reconstruction speed and accelerate the scanning workflow.	Independent R&D	Improves scanning workflow efficiency.	CT
9		ePhase automated phase recommendation	By automatically selecting the best reconstruction phase from different cardiac cycles, it reduces the operator's manual judgment and selection steps, improving coronary artery image quality and physician processing efficiency.	Independent R&D	Improves image quality and work efficiency.	CT

No.	Category	Core Technology	Technological Advancement	Technology Source	Primary Application	Product Application
10		Cardio Capture coronary artery tracking technology	Corrects motion artifacts in coronary arteries on cardiac CT images, reducing diagnostic difficulties caused by pulsation artifacts and significantly improving the success rate of cardiac scanning.	Independent R&D	Improves image quality and work efficiency.	CT
11	Post-processing technology	Automated post-processing technology	Comprehensive CT image analysis applications, including efficient automated cardio-cerebrovascular vessel segmentation and dynamic analysis, tissue segmentation, and report generation functions. Provides functional assessment results based on structural assessment.	Independent R&D	Precise post-processing, improving post-processing accuracy and efficiency, and assisting diagnosis.	CT

(3) Core technologies of X-ray imaging systems (XR)

No.	Category	Core technology	Technological Advancement	Technology Source	Primary Applications	Products Utilized
1	Image Reconstruction and Post-Processing Technology	Full Field of View Cone Beam CT Reconstruction Technology	Based on a proprietary full field of view scanning trajectory and reconstruction algorithm, the reconstruction field of view of cone beam CT has been expanded to	Independent Development	Increase the reconstruction field of view size of cone beam CT	DSA

No.	Category	Core technology	Technological Advancement	Technology Source	Primary Applications	Products Utilized
			431mm, achieving full field of view coverage of the abdomen.			
2		Image Reconstruction Technology in Breast Tomosynthesis Systems	Combining the imaging characteristics of tomosynthesis systems, it suppresses artifacts caused by data undersampling, thereby improving resolution in different directions.	Independent Development	Improve image resolution	Mammography System
3		Multi-Scale Image Enhancement and Equalization Technology in Static DR Imaging	Based on human visual recognition patterns, the image is decomposed into nonlinear multi-scale components, and enhancement and noise reduction are achieved for specific features.	Independent Development	Highlight lesion locations	DR
4		Real-Time Multi-Scale Image Processing Technology in Dynamic Fluoroscopy	During real-time dynamic processes, based on human visual recognition patterns, multi-scale dynamic range equalization and multi-level detail enhancement are performed on ROI anatomical structures.	Independent Development	Improve real-time performance and image clarity of dynamic imaging	Mobile C-arm

No.	Category	Core technology	Technological Advancement	Technology Source	Primary Applications	Products Utilized
5	Low-Dose Imaging Technology	Automatic Exposure Parameter Adjustment Technology in X-ray Fluoroscopy Equipment	Using the target image brightness as a feedback parameter, it ensures consistent image quality across different anatomical regions during real-time imaging while reducing radiation dose.	Independent Development	Reduce radiation dose	DSA, Mobile C-arm
6		Radiation-Free Positioning Technology Based on Optical Encoding Positioning	Integrating the motion behavior of mobile X-ray equipment with the image acquisition process, it achieves radiation-free positioning, avoids additional trial exposures, and improves surgical efficiency, leading the industry.	Independent Development	Improve positioning accuracy and reduce trial exposures	DSA, Mobile C-arm
7		Zero-Noise Imaging Technology	Through Burst-Denoise technology, noise levels are reduced in real time, thereby lowering radiation dose, leading the industry.	Independent Development	Reduce radiation dose and improve signal-to-noise ratio	DSA
8	Automated Electromechanical Control Technology	Multi-Degree-of-Freedom Electromechanical	Based on kinematic modeling and dexterous point-based planning technology, it achieves precise motion and automatic path planning	Independent Development	Gantry motion control and obstacle avoidance	DSA

No.	Category	Core technology	Technological Advancement	Technology Source	Primary Applications	Products Utilized
		System Control Technology	for equipment with high degrees of freedom.			
9		Medical Equipment Speed Control and Motor Dynamic Output Adjustment Technology	Based on angle sensors and automatic motion control technology, it enables real-time adjustment of motor energy requirements at different angles, achieves electric speed control based on the trolley tilt angle, and improves the user experience for operators.	Independent Development	Improve the operating experience of motorized motion	DR
10		Mobile X-ray Machine Assisted Positioning System and Technology	Using spatial position automatic detection technology, it achieves automatic planning and memory functions for spatial positions.	Independent Development	Assisted positioning during movement	Mobile C-arm
11		X-ray Machine Motion Trajectory Planning Technology	Using artificial potential field technology to achieve motion trajectory planning for moving components	Independent Development	Motion obstacle avoidance	DR
12		Remote Monitoring and Exposure Control Technology Based on	Based on wireless communication technology and video surveillance, it achieves remote monitoring and exposure control functions, reducing	Independent Development	Remote video monitoring and remote exposure control	DR

No.	Category	Core technology	Technological Advancement	Technology Source	Primary Applications	Products Utilized
		Wireless Communication Technology	radiation dose to clinical medical staff.			
13	Core Component Technology	High-Voltage Generator Technology	High-frequency power electronic switch parallel technology is used to increase output power, and high-frequency inverter technology is used to reduce component size and output ripple, improve the switching speed of kV output pulses, and reduce ineffective radiation dose.	Independent Development	As the electrical control device of the X-ray tube, it provides the high voltage, tube current, filament current, and rotating anode drive required to generate X-rays.	DSA, DR, Mammography System

(4) Core Technologies of Molecular Imaging (MI) Systems

No.	Category	Core Technology	Technological Advancement	Technology Source	Primary Applications	Products Utilized
1	PET Detector Technology	Digital Light-Guide PET Detector Design	A new digital modular PET detector based on SiPM and LYSO crystals, with built-in light guide design, achieving industry-leading sensitivity and spatial resolution	Independent research and development	PET detector design and manufacturing	PET/CT PET/MR
2		Crystal growth and assembly technology	Manufacturing methods and processes for large-size, high-luminescence-efficiency scintillation crystals, providing	Independently developed	PET detector crystal material	PET/CT PET/MR

No.	Category	Core Technology	Technological Advancement	Technology Source	Primary Applications	Products Utilized
			support for high-performance detectors and reaching an industry-leading level		manufacturing and processing	
3		High-precision PET detector calibration technology	Efficiently extracting detector status information to improve PET detector signal processing accuracy, thereby enhancing image quality, reaching an industry-leading level	Independently developed	Maintaining PET system stability	PET/CTPET/MR
4		PET detector temperature control technology	Low-cost, high-efficiency cooling design, improving the temperature uniformity and stability of the PET detector system, reaching an industry-leading level	Independently developed	Maintaining PET system stability	PET/MR
5	Electronics technology	Coincidence processing technology capable of discriminating continuous events	Improving coincidence efficiency and system count rate characteristics, reaching an industry-leading level	Independently developed	High count rate coincidence processing	PET/CT PET/MR
6		Cross-unit coincidence technology	Achieving ultra-high sensitivity in long-axis PET systems, reaching an industry-leading level	Independently developed	Coincidence processing for long-axis PET systems	PET/CT
7		Load balancing technology for parallel acquisition	Real-time balancing of multiple loads during parallel acquisition, significantly enhancing the data acquisition	Independently developed	High-speed PET data acquisition	PET/CT

No.	Category	Core Technology	Technological Advancement	Technology Source	Primary Applications	Products Utilized
			and processing capabilities of long-axis systems, reaching an industry-leading level			
8	Reconstruction and image processing technology	Parallel image reconstruction method	GPU-accelerated efficient parallel reconstruction algorithms can effectively improve computational speed, enhance quantitative accuracy through comprehensive physical corrections, and output high-quality images, reaching an industry-leading level	Independently developed	PET image reconstruction	PET/CTPET/MR
9		Regularized iterative reconstruction algorithm	Incorporating noise control into iterative reconstruction, improving quantitative accuracy while suppressing image noise, enhancing lesion detectability, reaching an industry-leading level	Independently developed	Improving lesion detectability	PET/CTPET/MR
10		Artificial intelligence reconstruction algorithm	Reducing image noise, improving image quality, and shortening scan time, reaching an industry-leading level	Independently developed	Reducing image noise and enabling low-dose fast scanning	PET/CT PET/MR
11		Artificial intelligence attenuation correction technology	Precise segmentation of whole-body tissues, for the first time including body skeletal tissue information, significantly improving image quality and quantitative accuracy, reaching an industry-leading level	Independently developed	Attenuation correction during image reconstruction	PET/MR

No.	Category	Core Technology	Technological Advancement	Technology Source	Primary Applications	Products Utilized
12		Motion artifact elimination technology	Based on data-driven methods, reducing PET image artifacts caused by respiratory motion and head motion, improving image quality, reaching an industry-leading level	Independently developed	Reducing motion artifacts and improving image quality	PET/CT
13		Tumor analysis	Comprehensive support for PERCIST and RECIST standards, supporting multi-time-point comparative analysis, one-click analysis completion, reaching an industry-leading level	Independently developed	Rapid and accurate diagnosis of tumor diseases	PET/CTPET/MR
14		Parametric imaging and analysis technology	Providing quantitative analysis of pharmaceutical metabolism based on multiple models, obtaining pharmacokinetic information, reaching an industry-leading level	Independently developed	Improving diagnostic accuracy	PET/CT

(5) Core technologies of ultrasound diagnostic system (US)

Serial number	Category	Core technology	Technological advancement	Technology source	Main application	Products applied to
1	Key component design and	Transducer interface control board	Supporting high-element-count transducers and full interchangeability of all transducer interfaces	Independently developed	Ultrasound system design and manufacturing	US

Serial number	Category	Core technology	Technological advancement	Technology source	Main application	Products applied to
2	manufacturing technology	Front-end system	Equipped with 256 high channels and a wide aperture to enhance penetration and signal-to-noise ratio; 50MHz ultra-wide bandwidth ensures high-frequency signal integrity; high-precision transmit and focus delay control significantly improves spatial resolution	Self-developed	Ultrasound system design and manufacturing	US
3		Back-end system	Up to 52TFlops computing power, flexible configuration, leveraging the advantages of each computing unit to meet the computing demands of ultrasound systems for advanced imaging and software applications	Self-developed	Ultrasound system design and manufacturing	US
4		Power supply system	Multiple programmable high-voltage power supplies, digital and analog circuit power supplies, improving system signal-to-noise ratio through fine control of the power supply system	Self-developed	Ultrasound system design and manufacturing	US
5		Third-generation ternary single-crystal probe	The industry's first mass-produced third-generation ternary single-crystal probe, with better voltage withstand and acoustic emission capabilities than traditional materials, as well as less depolarization and better thermal stability	Self-developed	Probe design and manufacturing	US
6		Multi-dimensional matrix probe	Through dynamic focusing, simultaneously reduces slice thickness in both near and far fields, significantly	Self-developed	Probe design and manufacturing	US

Serial number	Category	Core technology	Technological advancement	Technology source	Main application	Products applied to
			improving spatial resolution and frame rate in both near and far fields			
7		Active heat dissipation	The industry's first to apply active heat dissipation technology on a large scale to ultrasound probes; using proprietary active heat dissipation technology, significantly improving heat dissipation efficiency and imaging mode performance	Self-developed	Probe design and manufacturing	US
8	Core imaging algorithms and post-processing technology	Full-field dynamic focusing	Adopts a pixel-by-pixel beamforming algorithm to achieve precise delay calculation and phase correction; completes beamforming calculations in real time based on a heterogeneous supercomputing system, ensuring uniform high resolution across the entire field of view	Self-developed	Ultrasound imaging and post-processing	US
9		Ultra-sensitive blood flow	Effectively suppresses tissue motion artifacts through joint time-frequency computation, significantly improving signal-to-noise ratio; maintains imaging stability through real-time motion artifact suppression; adopts a data-driven hemodynamic model and enhances blood flow morphology through computational fluid dynamics simulation	Self-developed	Ultrasound imaging and post-processing	US

Serial number	Category	Core technology	Technological advancement	Technology source	Main application	Products applied to
10	Software technology	Microservice software architecture	With elastic, scalable, and maintainable features, effectively addresses complex data processing and intelligent demands; loosely coupled services are easier to integrate across systems Through service isolation and fault-tolerant design, ensures the continuity of clinical diagnosis and treatment workflows	Self-developed	Intelligent ultrasound software architecture	US
11		Fully automated workflow	Applicable to multi-scenario, full-process real-time automated workflows, including automatic probe activation, automatic clip recognition and storage, automatic clip measurement and quality assessment, etc.; effectively improves diagnostic efficiency and has high accuracy	Self-developed	Intelligent workflow implementation	US

(6) Core technologies of radiotherapy system (RT)

No.	Category	Core Technology	Technological advancement	Technology source	Main application	Product used in
1	Electrovacuum technology	High dose rate same-source dual-	Simultaneously outputs high dose rate therapy beam and ultra-low energy imaging beam; the therapy beam in FFF mode achieves a	Self-developed	Improving radiotherapy treatment efficiency and precision	CT-guided linear accelerator,

No.	Category	Core Technology	Technological advancement	Technology source	Main application	Product used in
		beam accelerator tube technology	maximum output of over 1400MU/min, greatly improving treatment execution efficiency; the low-energy imaging beam can output electron beams below 1.5MV, significantly reducing the imaging dose required for image guidance			linear accelerator
2	Electronics control technology	Precision dose control system	Through fully digital real-time control system, dynamic trajectory planning algorithm, dose closed-loop algorithm, etc., the minimum control dose following accuracy can reach below 0.1MU, and long-term stability can reach below 1%; the dual-channel dose system is fully independently designed to avoid failure risks	Self-developed	Precision dose control	CT-guided linear accelerator, linear accelerator
3	Precision mechanics and control technology	Dynamic multi-leaf collimator system	Key IMRT technology, enabling precise conformal therapy, with repeated positioning accuracy of less than 0.5mm and minimum leaf width of 5mm; supports real-time dynamic control and dynamic rotational IMRT, covering the entire field range	Self-developed	Precise conformal therapy	CT-guided linear accelerator, linear accelerator

No.	Category	Core Technology	Technological advancement	Technology source	Main application	Product used in
4	Image integration technology	Integrated CT image integration technology	Accurate pre-treatment registration enables easy and precise detection of changes in the target volume and surrounding tissues and organs; during treatment, imaging information is used to monitor the dose distribution of the patient's treatment and adjust the treatment plan, enabling personalized adaptive precision radiotherapy. The entire radiotherapy workflow can be completed in a single treatment room, enabling a fast all-in-one treatment process	Independently developed	Radiotherapy simulation positioning and contouring, pre-treatment image-guided positioning correction, individualized adaptive radiotherapy, online treatment plan modification	CT-guided linear accelerator
5	Precision mechanics and control technology	High-precision treatment couch and automatic deformation compensation technology	Through special dimensional design, graded motion, CT imaging combined with laser displacement transducers and other technologies, a treatment couch with the industry's longest motion range, highest stiffness, and smallest error is achieved	Independently developed	Tumor patient immobilization and positioning	CT-guided linear accelerator
6	Physics algorithm technology	Monte Carlo dose calculation algorithm	While ensuring calculation accuracy, routine plan calculation is completed in less than 1 minute, comparable to the time of conventional clinical application algorithms	Independently developed	Treatment plan design	CT-guided linear accelerator,

No.	Category	Core Technology	Technological advancement	Technology source	Main application	Product used in
						linear accelerator
7	Physics algorithm technology	Treatment plan optimization calculation algorithm	Through advanced functions such as direct optimization and fast move down gradient, multiple plan support and rapid plan creation are achieved, while also supporting automatic planning and online adaptive radiotherapy	Independently developed	Treatment plan design	CT-guided linear accelerator, linear accelerator

(7) General software and hardware core technologies

No.	Category	Core Technology	Technological advancement	Technology Source	Primary Application	Products Applied to
1	Software technology	Medical image post-processing technology developed based on server multi-concurrency technology	1. Developed based on server multi-concurrency technology, offering strong deployment flexibility and providing solutions with different IT costs for small to large medical institutions. 2. Can be used as a post-processing tool within or across departments in hospitals, and supports application scenarios such as remote use across hospital campuses.	Independently developed	Medical image post-processing	Full line of medical imaging equipment

No.	Category	Core Technology	Technological advancement	Technology Source	Primary Application	Products Applied to
			3. Can be integrated with existing hospital information systems such as PACS/RIS.			
2		Cross-modality software workflow technology	1. Clinical needs are emphasized during development, with product development and iterative upgrades aimed at improving clinical efficiency 2. Interaction consistency is achieved across different product lines within the company, improving user efficiency and reducing end-customer learning costs 3. Facilitates the expansion from single products to converged products 4. Preprocessing is performed based on data characteristics, and users can see the preprocessing results immediately upon opening the data, improving patient throughput.	Independently developed	User interaction workflow	Full line of medical imaging equipment, radiotherapy equipment
3		3D medical image visualization engine technology	1. Visualization is deeply integrated with equipment data acquisition, reconstruction, and image preprocessing to achieve optimized display of vascular details near bone, enabling	Independently developed	Image visualization effect optimization	Full line of medical imaging equipment, radiotherapy equipment, imaging cloud

No.	Category	Core Technology	Technological advancement	Technology Source	Primary Application	Products Applied to
			ultra-high-resolution sub-pixel precision visualization of small lesions. 2. Hyper Realistic Rendering (HRR) technology presents finer tissue surface and internal details with ultra-realistic rendering, providing stronger depth and spatial perception, thereby achieving results closer to real tissue texture, vascular course, and spatial relationships of lesions. 3. Full-body support for real rendering of CT and MR images of the head, abdomen, shoulder, hip, breast, foot, and all other body parts, providing corresponding tissue color tables for tissues with different grayscale values and giving different tissues the optimal color presentation and rendering effect. 4. Zero-waiting second-level real-time rendering allows users to view rendering preview effects in real time during interaction and complete detail iteration after interaction stops.			

No.	Category	Core Technology	Technological advancement	Technology Source	Primary Application	Products Applied to
4		Medical image segmentation and registration technology	1. Precise segmentation of complex structures such as organs, blood vessels, and bones, as well as lesion regions, in multi-modality images 2. Supports motion correction and registration fusion of data from different modalities and different phases	Independently developed	Post-processing application image segmentation	Full line of medical imaging equipment, radiotherapy equipment, imaging cloud
5	Hardware technology	Hardware circuit design technology in complex electromagnetic environments	1. From conventional 1.5T to 9.4T strong magnetic field strength environments, the hardware magnetic field compatibility design capability for electronic components is at a leading domestic level 2. The first domestic manufacturer to achieve a 39*4Gps high-speed data acquisition system at a rotation speed of 0.25s 3. To address the strong radiation interference during radiotherapy, aerospace-grade single-event upset mitigation technology is introduced into the RT system, effectively reducing single-event upset effects and improving the reliability of the equipment control system and product service life	Independently developed	Hardware design related to system control, data acquisition, and data reconstruction systems	PET/CT, PET/MR, MR, CT, RT

No.	Category	Core Technology	Technological advancement	Technology Source	Primary Application	Products Applied to
6		ECG gating extraction technology under strong gradient fields	1. The first ECG gating technology in China to support 5.0T MR applications 2. Capable of detecting ECG signals up to 300bpm, suitable not only for human scanning but also for animal ECG detection in scientific research applications 3. The independently developed technical solution adopts high-performance hardware circuits and intelligent adaptive filtering algorithms. The product can suppress gradient fields above 300 mT/m/s, significantly improving image quality	Independent development	MR physiological signal gating equipment	MR, PET/MR
7		Multi-modality equipment registration and balancing technology	1. Achieves six-degree-of-freedom full-directional registration, with cumulative registration error less than the minimum resolution of each modality 2. Supports precise registration of up to 9 modality devices within 0.5 mm over a length of 3 m, ensuring image fusion accuracy 3. High-speed rotational balancing technology achieves an unbalanced mass of the CT rotating	Independent development	Multi-modality equipment registration and CT gantry dynamic balancing	PET/CT, CT, RT

No.	Category	Core Technology	Technological advancement	Technology Source	Primary Application	Products Applied to
			body of less than 0.02% of the total weight, with maximum vibration in the CT scan field of view of less than 0.1 mm, supporting the highest rotation speed among mainstream high-end CT products in the industry			
8		High-load, high-precision motion control technology	1. Adaptable to special patient needs, achieving a leading indicator among mainstream industry products with a 300 kg load, 55 mm/s motion speed, and motion repeatability accuracy of 0.1 mm 2. The CT server rack can achieve a rotation speed of 0.25 s/revolution, with angular control accuracy of 0.1 degrees under a rotational inertia of 500 kg·m²	Independent development	Precision motion control	All product lines
9		High-precision cooling and temperature control technology	1. Precise thermal simulation and precise temperature control technologies are adopted to achieve temperature control accuracy for core components 2. Through high-precision cooling and temperature control technology, the company has mastered temperature control analysis at the	Independent development	System cooling and temperature control	MR, PET/CT, PET/MR, CT-guided linear accelerator, linear accelerator

No.	Category	Core Technology	Technological advancement	Technology Source	Primary Application	Products Applied to
			system, core component, circuit board, and chip levels, achieving overall system temperature control			

National Science and Technology Award winning status

√ Applicable□ Not applicable

Award name	Award year	Project name	Award level
National Science and Technology Progress Award	2020	Independent development and industrialization of high-field magnetic resonance medical imaging equipment	First prize

2. R&D achievements obtained during the reporting period

As of the end of the reporting period, the company has filed a cumulative total of 12,874 intellectual property applications and obtained 7,017. During the reporting period, the company filed 582 new intellectual property applications and obtained 568, including 259 invention patent applications and 338 invention patent grants. In addition to the invention patent grants already applied for and obtained, the company also owns multiple non-patented technologies, which also constitute an important part of the company's technological competitiveness and play a significant role in the company's business operations.

List of intellectual property obtained during the reporting period

	New additions in this period		Cumulative quantity	
	Number of applications	Number obtained	Number of applications	Number obtained

Invention patents	259	338	8,770	4,301
Utility model patents	49	47	1,450	957
Design patents	3	20	423	289
Software copyrights	15	12	363	357
Others	256	151	1,868	1,113
Total	582	568	12,874	7,017

Note 1: Where the "cumulative quantity" is greater than the sum of the previous year's "cumulative quantity" and "new in this year," this is due to patent transfers and European patents from previous years taking effect during the reporting period; where the "cumulative quantity" is less than the sum of the previous year's "cumulative quantity" and "new in this year," this is due to the expiration of intellectual property from previous years.

Note 2: Others include "copyright of works" and "trademarks."

3. R&D investment table

Unit: RMB

	Current period	Same period of the previous year	Change (%)
Expensed R&D investment	1,010,648,325.79	766,458,924.01	31.86
Capitalized R&D investment	372,292,241.25	373,572,154.42	-0.34
Total R&D investment	1,382,940,567.04	1,140,031,078.43	21.31
Total R&D investment as a percentage of operating revenue (%)	19.61	18.95	Increase of 0.66 percentage points
Proportion of capitalized R&D investment (%)	26.92	32.77	Decrease of 5.85 percentage points

Reasons for significant changes in total R&D investment compared to the previous year

□ Applicable√ Not applicable

Explanation of significant changes in the proportion of capitalized R&D investment and their reasonableness

√ Applicable□ Not applicable

During this reporting period, the number of R&D projects reaching the capitalization point decreased.

4. Ongoing R&D projects

√ Applicable□ Not applicable

Unit: Ten thousand yuan

No.	Project name	Expected total investment scale	Investment amount for this period	Cumulative investment amount	Progress or phased results	Target to be achieved	Technical level	Specific application prospects
1	MR R&D Project 1	10,400.00	289.91	6,769.47	Registration certificate obtained	Obtain registration certificate	Industry leading	Applicable to clinical scenarios
2	MR R&D Project 2	20,000.00	3,714.58	12,330.00	Partially obtained registration certificates	Obtain registration certificate	Industry leading	Applicable to clinical and scientific research scenarios
3	MR R&D Project 3	28,000.00	4,362.63	24,239.48	Partially obtained registration certificates	Obtain registration certificate	Industry leading	Applicable to clinical scenarios
4	MR R&D Project 4	45,000.00	10,188.29	34,700.53	Partially obtained registration certificates	Obtain registration certificate	Industry leading	Applicable to clinical and scientific research scenarios
5	MR R&D Project 5	25,000.00	2,511.08	14,814.93	Registration certificate obtained	Obtain registration certificate	Industry leading	Applicable to clinical scenarios
6	MR R&D Project 6	10,000.00	485.87	6,398.60	Registration certificate obtained	Obtain registration certificate	Industry leading	Applicable to clinical and scientific research scenarios
7	MR R&D Project 7	7,000.00	158.34	4,026.95	In progress	Obtain registration certificate	Industry leading	Applicable to clinical and scientific research

								scenarios
8	MR R&D Project 8	7,400.00	1,021.19	6,335.22	Registration certificate obtained	Obtain registration certificate	Industry leading	Applicable to clinical and scientific research scenarios
9	CT R&D Project 1	4,600.00	373.54	3,568.22	In Progress	Obtain Registration Certificate	Industry Leading	Applicable to Clinical Scenarios
10	CT R&D Project 2	25,000.00	893.93	9,863.07	Registration Certificate Obtained	Obtain Registration Certificate	Industry Leading	Applicable to Clinical and Research Scenarios
11	CT R&D Project 3	4,000.00	68.23	3,756.56	Registration Certificate Obtained	Obtain Registration Certificate	Industry Leading	Applicable to Clinical and Research Scenarios
12	CT R&D Project 5	14,000.00	2,409.53	10,469.92	Partially Obtained Registration Certificate	Obtain Registration Certificate	Industry Leading	Applicable to Clinical and Research Scenarios
13	CT R&D Project 6	4,800.00	1,331.45	3,434.96	Registration Certificate Obtained	Obtain Registration Certificate	Industry Leading	Applicable to Clinical Scenarios
14	CT R&D Project 7	15,000.00	279.80	12,305.89	Registration Certificate Obtained	Obtain Registration Certificate	Industry Leading	Applicable to Clinical and Research Scenarios
15	CT R&D Project 8	35,000.00	4,662.48	26,066.79	Partially Obtained Registration Certificate	Obtain Registration Certificate	Industry Leading	Applicable to Clinical and Research Scenarios
16	CT R&D Project 9	12,000.00	2,475.26	9,433.58	Registration Certificate Obtained	Obtain Registration Certificate	Industry Leading	Applicable to Clinical Scenarios
17	CT R&D Project 10	6,800.00	1,312.48	5,167.13	In Progress	Obtain Registration Certificate	Industry	Applicable to Clinical

							Leading	and Research Scenarios
18	CT R&D Project 11	10,000.00	2,865.12	6,907.31	In Progress	Obtain Registration Certificate	Industry Leading	Applicable to Clinical and Research Scenarios
19	RT R&D Project 1	10,000.00	1,287.25	2,685.75	In Progress	Obtain Registration Certificate	Industry Leading	Applicable to Clinical Scenarios
20	RT R&D Project 2	50,000.00	6,649.81	39,172.16	Registration Certificate Obtained	Obtain Registration Certificate	Industry Leading	Applicable to Clinical Scenarios
21	RT R&D Project 3	18,800.00	1,473.14	11,506.48	Partially obtained registration certificate	Obtained registration certificate	Industry leading	Suitable for clinical scenarios
22	RT R&D Project 4	16,000.00	2,723.95	11,860.94	Partially obtained registration certificate	Obtained registration certificate	Industry leading	Suitable for clinical scenarios
23	Software R&D Project 1	45,000.00	5,140.83	38,452.61	Partially obtained registration certificate	Obtained registration certificate	Industry leading	Suitable for clinical scenarios
24	Software R&D Project 2	23,000.00	1,120.57	10,753.50	Partially obtained registration certificate	Obtained registration certificate	Industry leading	Suitable for clinical scenarios
25	Software R&D Project 3	13,600.00	1,180.54	9,183.68	Registration certificate obtained	Support mass production of imaging products and new product development	Industry leading	Suitable for clinical scenarios
26	XR R&D Project 1	20,000.00	2,125.69	14,046.88	Registration certificate obtained	Obtained registration certificate	Industry leading	Suitable for clinical scenarios

27	XR R&D Project 2	43,000.00	5,008.27	31,279.98	Registration certificate obtained	Obtained registration certificate	Industry leading	Suitable for clinical scenarios
28	XR R&D Project 3	8,000.00	1,338.96	6,629.16	Registration certificate obtained	Obtained registration certificate	Industry leading	Suitable for clinical scenarios
29	MI R&D Project 1	5,000.00	376.22	2,306.47	Registration certificate obtained	Obtained registration certificate	Industry leading	Suitable for clinical and research scenarios
30	MI R&D Project 2	11,000.00	1,571.14	9,261.02	Registration certificate obtained	Obtained registration certificate	Industry leading	Suitable for clinical and research scenarios
31	MI R&D Project 3	13,500.00	338.52	6,260.45	Registration certificate obtained	Obtained registration certificate	Industry leading	Suitable for clinical scenarios
32	MI R&D Project 4	16,800.00	2,422.65	15,074.35	Partially obtained registration certificate	Obtained registration certificate	Industry leading	Suitable for clinical scenarios
33	MI R&D Project 5	3,000.00	241.59	506.16	In progress	Obtained registration certificate	Industry leading	Suitable for clinical and research scenarios
34	MI R&D Project 6	5,800.00	1,504.49	4,113.16	Partially obtained registration certificate	Obtained registration certificate	Industry leading	Suitable for clinical and research scenarios
35	MI R&D Project VII	13,000.00	2,674.12	10,437.95	In progress	Obtained registration certificate	Industry leading	Suitable for clinical scenarios
36	MI R&D Project VIII	2,100.00	279.77	1,795.64	Partially obtained registration certificate	Obtained registration certificate	Industry leading	Suitable for clinical scenarios

37	Component R&D Project I	15,000.00	2,527.26	10,525.59	Partially obtained registration certificate	Obtained registration certificate	Industry leading	Applied to equipment components
38	Component R&D Project II	2,300.00	301.28	1,903.23	Registration certificate obtained	Obtained registration certificate	Industry leading	Applied to equipment components
39	Component R&D Project III	5,800.00	621.76	3,772.64	In progress	Obtained registration certificate	Industry leading	Applied to equipment components
40	Component R&D Project IV	11,000.00	1,056.09	6,309.79	In progress	Obtained registration certificate	Industry leading	Applied to equipment components
41	Component R&D Project V	4,000.00	558.74	1,742.12	In progress	Obtained registration certificate	Industry leading	Applied to equipment components
42	Ultrasound R&D Project I	54,000.00	8,435.23	37,524.51	Partially obtained registration certificate	Obtained registration certificate	Industry leading	Suitable for clinical scenarios
43	Ultrasound R&D Project II	10,000.00	689.09	4,383.31	In progress	Obtained registration certificate	Industry leading	Suitable for clinical scenarios
44	Ultrasound R&D Project III	9,500.00	1,908.85	7,392.85	In progress	Obtained registration certificate	Industry leading	Suitable for clinical scenarios
45	Ultrasound R&D Project IV	6,000.00	477.00	2,023.74	In progress	Obtained registration certificate	Industry leading	Applied to equipment components
46	Life Science Instrument Project I	3,600.00	449.68	3,172.15	Mass production and market launch completed	Research promotion and mass production launch	Internationally leading	Suitable for research scenarios
47	Life Science Instrument Project II	5,000.00	261.36	2,556.05	In progress	Research promotion and mass production launch	Industry-leading	Applicable to scientific research scenarios
48	Life Science Instrument Project III	12,000.00	602.13	7,300.92	In progress	Scientific promotion and mass-market launch	Industry-leading	Applicable to scientific research scenarios

49	Next-generation product pre-research project	23,000.00	4,859.25	15,568.54	In progress	Obtain next-generation product and technology planning	Industry-leading	Applicable to clinical scenarios
Total	/	762,800.00	99,608.94	530,090.39	/	/	/	/

Note: The estimated total investment scale of the Company's projects under research is adjusted based on factors such as the actual R&D progress of the project and the overall planning of the Company's projects under research; the statistical period for cumulative investment amounts is January 1, 2022 to June 30, 2026.

5. R&D Personnel Information

Unit: Ten Thousand Yuan Currency: RMB

Basic Information		
	Current Period	Same Period of Previous Year
Number of R&D personnel (persons)	3,748	3,391
Proportion of R&D personnel to total employees (%)	40.12	40.27
Total R&D personnel compensation	90,872.97	85,341.17
Average R&D personnel compensation	24.25	25.17

Education Level		
Educational Background Composition	Number (persons)	Proportion (%)
Doctoral degree	424	11.31
Master's degree	2,482	66.22
Bachelor's degree	760	20.28
Associate degree	82	2.19
Total	3,748	100
Age Structure		
Age Range	Number (persons)	Proportion (%)
Under 30 years old (excluding 30)	1,227	32.74
30-40 years old (including 30, excluding 40)	2,031	54.19
40-50 years old (including 40, excluding 50)	446	11.90
50-60 years old (including 50, excluding 60)	40	1.07
60 years old and above	4	0.11
Total	3,748	100

6. Other Notes

□ Applicable√ Not Applicable

IV Risk Factors

√ Applicable□ Not Applicable

i.Risks of International Operations and Business Expansion

The Company places great importance on the expansion and sales of high-end medical imaging diagnostic and radiotherapy products in overseas markets and has achieved sales in countries and regions such as the United States, Japan, Europe, Africa, and Southeast Asia.

However, different overseas markets and regions typically have different regulatory policies and regulations for medical devices, international situations are uncertain, and there are also differences in the intensity of regulation regarding intellectual property protection, unfair competition, consumer protection, and other aspects. As the scale of overseas business further expands, the overseas legal environment the Company faces will become more complex and changeable. If the Company fails to promptly respond to changes in the overseas market environment and policy environment, it will have an adverse impact on the Company's overseas business expansion and operations. Details are as follows:

1. Policy and approval risks: In recent years, the international landscape has been volatile, with frequent uncertainties and instabilities. The international trade environment has become increasingly complex, trade frictions and disputes are recurring, and geopolitical factors may adversely affect the economy and trade of certain countries or regions. Some countries have long maintained strong approval barriers for the licensing of high-end medical device operations and sales. The time cycle for completing product registration is relatively long, and market access is difficult. Different overseas markets and regions typically have different regulatory policies and laws for medical devices. Political and economic situations are uncertain, and there are also differences in the intensity of regulation regarding intellectual property protection, unfair competition, and consumer protection.

2. Market competition risks: Companies such as GE Healthcare, Siemens Healthineers, and Philips Healthcare have dominated many fields of medical equipment for years, holding significant advantages in academic research, clinical evidence, customer awareness, global supply chain integration, product technology development, overseas after-sales service, and brand influence. In the face of international market competition, if the Company cannot maintain and continuously strengthen its competitive advantages and core competitiveness, the market share and prices of the Company's products may decline due to intensified market competition.

3. Overseas sales channel expansion risks: In the overall overseas strategic layout, the Company will promote overseas business development targeting specific markets, focusing on overseas product registration, team and network building, production bases, and supply chain layout. As of the end of the reporting period, the Company has established overseas teams through 25 overseas subsidiaries. However, the overseas sales channels have been established for a relatively short period. If the Company fails to effectively integrate overseas sales teams and local distributor channels, resulting in the Company's products failing to quickly open up overseas markets, it may adversely affect the Company's overseas market share and business development.

In response to the above risks, the Company will comprehensively strengthen the management and layout of global R&D, production, sales, services, and supply chains, make scientific decisions, and promote the

implementation of the Company's various strategic plans and business layouts in a reasonable and orderly manner. Through effective marketing activities and industry-university-research-medicine collaborations, the Company will further enhance its brand influence and awareness in the international market.

ii.Market competition risks

According to the CIC research report, the market size of medical imaging equipment in China exceeded RMB 50 billion in 2020, with a compound annual growth rate of 12.4% from 2015 to 2020. Although building a "Healthy China" has been elevated to a national strategy, and factors such as the rapid expansion of China's big health market, the construction of national medical centers, the construction of national regional medical centers, the "Thousand Counties Project" to improve the comprehensive capabilities of county-level hospitals, and the issuance of the "Catalogue for the Administration of Permits for the Allocation of Large Medical Equipment (2023)" have all promoted the potential demand for medical imaging equipment, the Company still faces a relatively intense market competition environment.

On the one hand, China's high-end medical imaging equipment market has historically been monopolized by foreign companies such as GE Medical, Siemens Medical, and Philips Medical. In the high-end PET/CT, MR, and CT product markets, imported brands once held more than 90% of the market share. However, after more than a decade of development in domestic medical imaging equipment technology, the trend of import substitution by domestic brands has become increasingly evident, and the market share of imported brands has shown a declining trend. Nevertheless, imported manufacturers still hold a leading market position by leveraging their brand advantages, channel advantages, and technological advantages built over many years.

In response to the above risks, the Company will continuously strengthen its core technology research and development and investment in next-generation products, and promptly assess market trends and demands. Guided by cost management, product quality management, and service quality management, the Company will focus on the full lifecycle quality requirements of its products. The Company will build up talent reserves, technology reserves, product reserves, and customer expansion globally, deepen its international strategic layout, and enhance its competitiveness in the global market.

iii.Financial risks

1. Tax policy change risks: The Company and some of its subsidiaries are legally recognized as High and New Technology Enterprises and may enjoy the preferential corporate income tax policy for High and New Technology Enterprises when meeting all conditions for enjoying such tax incentives. In the future, if the above tax incentive policies change or the Company fails to meet the conditions for tax incentives and is unable to continue enjoying the relevant preferential policies, the Company's tax burden will increase, which may have a certain impact on the Company's business operations. The Company will continue to monitor the trends of tax policies, consolidate, and strengthen its R&D capabilities, continuously increase R&D investment, and solidify its qualification as a High and New Enterprise.

2. Exchange rate fluctuation risks: The Company's overseas business is growing rapidly. The Company prices and settles transactions with some overseas customers and suppliers in foreign currencies such as

USD and EUR. Affected by factors such as changes in the international situation and environment, the difficulty of exchange rate risk management may increase in the future. Exchange rate fluctuations directly affect the amount of the Company's exchange gains and losses, which may have a certain impact on the Company's business operations. The Company attaches great importance to exchange rate risk management, adopting both short-term and medium-to-long-term measures and reasonably using financial and operational methods to address exchange rate fluctuation risks.

V Principal operating conditions during the reporting period

Please refer to "Section III Management Discussion and Analysis" of this report.

VI Analysis of principal operations

i.Analysis table of changes in financial statement related items

Unit: RMB Currency: RMB

Item	Current period	Prior year same period	Change ratio (%)
Operating revenue	7,051,579,098.09	6,015,901,402.16	17.22
Operating costs	3,724,610,123.40	3,132,664,301.76	18.90
Selling expenses	1,045,327,479.93	938,304,878.27	11.41
Administrative expenses	311,122,220.11	257,182,484.27	20.97
Financial expenses	96,397,998.40	-49,616,563.05	Not applicable
R&D expenses	1,010,648,325.79	766,458,924.01	31.86
Net cash flows from operating activities	-242,020,101.49	48,759,799.77	-596.35
Net cash flows from investing activities	1,251,483,543.99	483,100,691.14	159.05
Net cash flows from financing activities	259,835,654.59	-521,753,297.02	Not applicable

Explanation for changes in operating revenue: Mainly due to the company's stable operations during the reporting period, resulting in steady revenue growth.

Explanation for changes in operating costs: Mainly due to business growth during the reporting period, operating costs increased correspondingly.

Explanation for changes in selling expenses: Mainly due to the company's increased investment in overseas marketing system development and sales during the reporting period.

Explanation for changes in administrative expenses: Mainly due to increased depreciation and share-based payment expenses during the reporting period.

Explanation for changes in financial expenses: Mainly due to increased exchange losses caused by exchange rate fluctuations during the reporting period.

Explanation for changes in research and development expenses: Mainly due to the company's increased investment in R&D during the reporting period.
Explanation for changes in net cash flows from operating activities: Mainly due to business growth during the reporting period, with cash receipts and payments from various operating activities increasing compared to the same period last year.
Explanation for changes in net cash flows from investing activities: Mainly due to the company's purchase and redemption of wealth management products during the reporting period.
Explanation for changes in net cash flows from financing activities: Mainly due to increased borrowings from financial institutions during the reporting period.

ii. Detailed explanation of significant changes in the company's business type, profit structure, or profit sources during the current period

□ Applicable√ Not applicable

iii. Explanation of significant profit changes caused by non-core business

□ Applicable√ Not applicable

iv. Analysis of assets and liabilities

√ Applicable□ Not applicable

1. Asset and liability status

Unit: Yuan

Item name	Current period-end balance	Proportion of current period-end balance to total assets (%)	Prior year-end balance	Proportion of prior year-end balance to total assets (%)	Change ratio of current period-end balance compared to prior year-end (%)	Explanation
Monetary funds	7,232,226,619.15	21.00	5,502,937,108.96	16.79	31.42	Mainly due to increased sales and redemption of wealth management products during the reporting period
Trading financial assets	1,717,054,366.96	4.99	4,926,542,409.75	15.03	-65.15	Mainly due to changes in the balance of wealth management products purchased and redeemed by the company during the

						reporting period
Notes receivable	163,116,314.71	0.47	91,603,965.94	0.28	78.07	Mainly due to an increase in unmatured notes during the reporting period
Accounts receivable	5,866,601,509.12	17.04	5,590,248,672.01	17.05	4.94	Mainly due to the company's stable operations and steady revenue growth during the reporting period
Prepayments	357,725,329.92	1.04	264,137,851.08	0.81	35.43	Mainly due to increased advance payments for raw material purchases
Other receivables	222,600,328.99	0.65	160,381,814.73	0.49	38.79	Mainly due to an increase in tax refunds receivable and supplier deposits
Other current assets	441,425,746.00	1.28	243,037,673.10	0.74	81.63	Mainly due to an increase in input

						VAT to be deducted
Short-term borrowings	1,524,607,874.56	4.43	944,721,233.21	2.88	61.38	Mainly due to new borrowings taken by the company based on funding needs
Notes payable	659,285,502.57	1.91	420,141,402.99	1.28	56.92	Mainly due to an increase in unmatured notes during the reporting period
Accounts payable	3,248,099,946.18	9.43	2,349,170,643.63	7.17	38.27	Primarily due to the increase in unsettled payments during the reporting period.
Employee compensation payable	447,230,093.91	1.30	806,276,577.83	2.46	-44.53	Primarily due to the distribution of year-end bonuses during the reporting period.
Treasury stock	733,148,424.63	2.13	449,839,312.68	1.37	62.98	Primarily due to the company's share repurchase during the reporting period.
Other	-136,641,451.86	-0.40	-52,269,467.74	-0.16	Not applicable	Primarily due to the

comprehensive income						translation differences of foreign currency financial statements caused by exchange rate fluctuations during the reporting period.
Minority interest	-6,753,341.45	-0.02	-10,486,424.01	-0.03	Not applicable	Primarily due to the combined effect of capital contributions from minority shareholders of joint ventures and continued losses during the reporting period.

Other notes: None

2. Overseas assets

√ Applicable□ Not applicable

(1) Asset scale

Of which: overseas assets 6,373,340,377.12 (Unit: Yuan Currency: RMB), accounting for 18.51% of total assets.

(2) Notes on the relatively high proportion of overseas assets

□ Applicable√ Not applicable

Other notes

None

3. Restrictions on major assets as of the end of the reporting period

√ Applicable□ Not applicable

Unit: Yuan

Item	Carrying amount at period end	Reason for restriction
Monetary funds	51,810,854.83	Deposits and others
Other non-current assets	11,523,047.22	Deposits
Total	63,333,902.05	/

4. Other notes

□ Applicable√ Not applicable

v.Investment analysis

1. Overall analysis of external equity investments

√ Applicable□ Not applicable

Unit: Yuan Currency: RMB

Investment amount for the reporting period (Yuan)	Investment amount for the same period of the previous year (Yuan)	Change rate
-	98,487,200.00	-100%

(1) Significant equity investments

□ Applicable√ Not applicable

(2) Significant non-equity investments

√ Applicable□ Not applicable

No.	Project name	Implementing	Estimated total investment (including	Project progress	Source of funds
1	Next-generation R&D product project	United	RMB 6.168 billion	72.32%	Raised funds and self-
2	High-end medical imaging equipment	United	RMB 3.126 billion	82.80%	Raised funds

(3) Financial assets measured at fair value

√ Applicable□ Not applicable

Unit: Yuan Currency: RMB

Asset category	Beginning balance	Changes in fair value gains/losses for the current period	Cumulative changes in fair value recognized in equity	Impairment recognized in the current period	Purchase amount in the current period	Sale/redemption amount in the current period	Other changes	Ending balance
Trading financial assets	4,926,542,409.75	-7,013,914.79			18,705,383,500.00	21,907,857,628.00		1,717,054,366.96
Other non-current financial assets	130,880,900.00							130,880,900.00
Total	5,057,423,309.75	-7,013,914.79			18,705,383,500.00	21,907,857,628.00		1,847,935,266.96

Securities investment

□Applicable√Not applicable

Derivative investment

□Applicable√Not applicable

(4) Private equity fund investment

□Applicable√Not applicable

Other notes: None

vi. Disposal of major assets and equity

□Applicable√Not applicable

vii. Analysis of major holding and participating companies

√Applicable□Not applicable

Information on major subsidiaries and participating companies with an impact of 10% or more on the Company's net profit

□Applicable√Not applicable

Acquisition and disposal of subsidiaries during the reporting period

□Applicable√Not applicable

Other notes

□Applicable√Not applicable

viii. Structured entities controlled by the Company

□Applicable√Not applicable

ix. Other disclosure matters

□Applicable√Not applicable

Section III Corporate governance, environment and society

I Changes in directors, senior management and key technical personnel

□Applicable√Not applicable

Description of changes in directors, senior management and key technical personnel

□Applicable√Not applicable

Description of the determination of key technical personnel

√Applicable□Not applicable

The Company comprehensively considered factors such as the specific job responsibilities of R&D personnel, educational background and professional expertise, their roles and contributions in past and current core technology development, and overall performance, and determined 10 key technical personnel.

No.	Name	Position
1	Zhang Qiang	Chairman, Co-Chief Executive Officer
2	HONGDI LI	Senior Vice President, Chief Technology Officer
3	QUN CHEN	Key Technical Personnel
4	Huang Xiangyu	Key Technical Personnel
5	YANFENG DU	President of the Computed Tomography Business Unit
6	Li Guobin	President of the Magnetic Resonance Business Unit
7	Xiang Jun	President of the X-ray Business Unit
8	Wang Chao	President of the Molecular Imaging Business Unit
9	An Shaohui	Vice President of the Molecular Imaging Business Unit
11	Hu Wei	Vice President of the Transformation Office

II Profit distribution or capital reserve conversion to share capital proposal

Proposed interim profit distribution plan and capital reserve conversion to share capital plan

Whether to distribute or convert	Yes
Bonus shares per 10 shares (shares)	0
Cash dividend per 10 shares (RMB) (tax inclusive)	1.30
Capital reserve conversion per 10 shares (shares)	0
Description of the profit distribution or capital reserve conversion to increase shares proposal	
The Company plans to distribute a cash dividend of RMB 1.30 per 10 shares (tax inclusive) based on the total share capital registered on the record date for equity distribution, less the total number of shares in the repurchase special securities account. No bonus shares will be distributed and no capital reserve will be converted to share capital in this profit distribution. As of July 31, 2026, the Company's total	

share capital was 824,157,988 shares. After deducting 6,758,348 shares held in the repurchase special securities account, the total cash dividend to be distributed is calculated to be RMB 106,261,953.20 (tax inclusive), accounting for 11.85% of the net profit attributable to shareholders of the listed company in the consolidated financial statements for the first half of 2026. If the company's total share capital or the total number of shares participating in profit distribution changes before the record date for implementing the profit distribution, the company intends to maintain the per-share distribution ratio unchanged and adjust the total distribution amount accordingly.

The above profit distribution plan (proposal) has been authorized by the company's 2025 Annual General Meeting of Shareholders and approved at the 33rd meeting of the Second Board of Directors.

III Status and impact of the company's equity incentive plans, employee stock ownership plans, or other employee incentive measures

i.Where relevant equity incentive matters have been disclosed in interim announcements and there has been no progress or change in subsequent implementation

√ Applicable□ Not applicable

Overview of matters	Query index
On May 29, 2026, the Company held the 31st meeting of the Second Board of Directors, at which proposals including the "Proposal on the Company's <2026 Restricted Stock Incentive Plan (Draft)> and Its Summary" were reviewed and approved.	See the announcement published on the Shanghai Stock Exchange website (www.sse.com.cn) on June 1, 2026
On June 22, 2026, the Company held its 2025 Annual General Meeting, at which proposals including the "Proposal on the Company's <2026 Restricted Stock Incentive Plan (Draft)> and Its Summary" and the "Proposal on the Company's <Implementation and Assessment Measures for the 2026 Restricted Stock Incentive Plan>" were reviewed and approved.	See the announcement published on the Shanghai Stock Exchange website (www.sse.com.cn) on June 23, 2026
On June 22, 2026, the Company held the 32nd meeting of the Second Board of Directors, at which proposals including the "Proposal on the Initial Grant of Restricted Stock to Incentive Recipients under the Company's 2026 Restricted Stock Incentive Plan" were reviewed and approved.	See the announcement published on the Shanghai Stock Exchange website (www.sse.com.cn) on June 24, 2026

ii. Incentive matters not disclosed in interim announcements or with subsequent progress

Equity incentive details

□ Applicable√ Not applicable

Other explanations

□ Applicable√ Not applicable

Employee stock ownership plan details

□ Applicable√ Not applicable

Other incentive measures

□ Applicable√ Not applicable

IV Environmental information of listed companies included in the list of enterprises required to disclose environmental information in accordance with the law and their major subsidiaries

□ Applicable√ Not applicable

Other explanations

□ Applicable√ Not applicable

V Specific work on consolidating and expanding the achievements of poverty alleviation and rural revitalization

□ Applicable√ Not applicable

VI Carbon emission management

As a globally leading medical technology company, United Imaging Healthcare has incorporated carbon management into its overall corporate strategy system. The Company believes that, during the phase of rapid growth in global business, setting forward-looking emission reduction targets and establishing supporting verifiable implementation mechanisms is not only a reflection of corporate social responsibility, but also an internal driving force for improving operational efficiency, ensuring supply chain stability, and supporting long-term sustainable development.

The Company has established a carbon governance architecture from the Board of Directors to the executive level: the Board has established a Strategy and Social Responsibility Committee under it, responsible for top-level strategic oversight; senior management personnel are clearly designated to lead the specific implementation of carbon emission management, and the ESG Working Committee, composed of key departments, is responsible for breaking down the strategic goals of carbon emission reduction and carbon neutrality into specific action plans, forming a governance system with clear responsibilities and efficient linkage from strategic decision-making to operational execution. Under this architecture, the Company continues to advance emission reduction actions along five major pathways: energy efficiency improvement, renewable energy application, technological improvement, supply chain

decarbonization, and transportation optimization, while continuously improving the coverage of carbon targets and the management mechanism for emission reduction effectiveness, steadily advancing the realization of the "net zero emissions for operations and supply chain" goal.

i. Emission reduction targets and progress

1. Setting of emission reduction targets

United Imaging Healthcare has formulated practical, feasible, and traceable medium-term greenhouse gas emission reduction targets based on its operational realities and business development, forming a tiered target system linking medium-term and long-term goals:

- **Medium-term target:** Using 2023 as the base year, achieve a 50% reduction in carbon emission intensity per unit of revenue by 2035, covering Scope 1 (direct emissions) and Scope 2 (energy indirect emissions);
- **Long-term net zero target:** Achieve net zero emissions across the entire value chain by 2050, fully covering Scope 1, Scope 2, and Scope 3.

To ensure the accuracy, completeness, and scientific management of greenhouse gas emission data, the Company adopts the "operational control approach" as the core principle for defining organizational boundaries, in accordance with standards such as the *Greenhouse Gas Protocol* (GHG Protocol). Based on this principle, the Company's greenhouse gas emission reduction targets and carbon inventory scope have covered major operating entities within the organizational scope and entities of financial significance. In light of the Company's global business layout and actual operating conditions, the operating entities and financially significant entities included in core emission reduction management include the parent company United Imaging Healthcare's Shanghai headquarters Phase I campus, as well as core subsidiaries Wuhan United Imaging, Changzhou United Imaging, Shanghai Xinman, United Imaging Poland, and United Imaging Healthcare America. The above entities cover the Company's major production bases, R&D centers, and core operating sites, and their Scope 1 and Scope 2 greenhouse gas emissions account for more than 98% of the Company's total Scope 1 and Scope 2 emissions. With respect to the emission categories covered by the emission reduction targets, the Company's long-term net zero target has achieved full coverage of Scope 1, Scope 2, and Scope 3, with the emissions covered by the targets accounting for 100% of the Company's total greenhouse gas emissions.

As for the offices established by the Company in other countries or regions around the world, the greenhouse gas emissions generated by their daily operations are extremely low, accounting for less than 2% of the Company's total emissions, and thus have a limited impact on the overall carbon inventory results and emission reduction target management. Based on the "materiality" principle of carbon accounting, and in order to concentrate resources on refined management of core emission sources, the Company has not yet included these offices in its core carbon management scope.

In terms of dynamic assessment and update mechanisms, the Company reviews and updates the coverage of emission reduction targets annually in light of business development, changes in organizational boundaries, and shifts in emission structure, continuously and dynamically assessing the emission status

of global operating entities, and optimizing organizational boundaries in a timely manner based on business development and regulatory requirements, gradually incorporating newly added significant operating entities and Scope 3 emissions into target management, thereby enhancing the completeness and transparency of the carbon management system.

2. Progress on carbon emission reduction targets

Using 2023 as the base year, United Imaging Healthcare has formulated a clear tiered pathway for reducing carbon emission intensity: with a medium-term target of reducing carbon emission intensity per unit of revenue by 50% compared to the base year by 2035, driving continuous and verifiable intensity reductions in its own operations (Scope 1 and Scope 2) carbon emissions. As of the end of 2025, the company's carbon emission intensity per unit revenue has decreased from 6.65 tCO_2e/million RMB revenue in the base year to 5.06 tCO_2e/million RMB revenue, a cumulative decrease of 24%, with the mid-term target nearly halfway completed. During the same period, total carbon emissions from its own operations were 69,958.32 tons CO_2e, rebounding compared to 2024, mainly due to revenue scale expansion and the commissioning of new production capacity. However, the intensity indicator has continued to show a steady downward trend, reflecting the company's effectiveness in decoupling business growth from carbon emission intensity.

Indicator	2023 (Base Year)	2024	2025
Total carbon emissions from own operations (Scope 1 + Scope 2) (tCO_2e)	75,875.97	54,443.92	69,958.32
Carbon emission intensity per unit revenue (tCO_2e/million RMB revenue)	6.65	5.29	5.06
Reduction from base year	-	19%	24%
Progress Notes	Target base year	Intensity indicator decreased significantly year-on-year	Mid-term target completion rate: 48%

ii. Carbon Reduction Pathways

To achieve the above goals, the company has systematically deployed five major carbon reduction pathways, clarifying the responsible departments and annual action plans for each pathway:

1. Energy Efficiency Improvement: Carry out energy-saving technological renovations, improve energy efficiency management, establish an ISO 50001 energy management system, implement monthly energy usage monitoring and annual energy management plans, continuously improving energy efficiency and reducing energy consumption.

2. Renewable Energy Investment: Actively invest in renewable energy projects, including rooftop photovoltaic systems for new factories, and cooperate with power suppliers and third-party electricity retail companies to increase the proportion of renewable electricity procurement, while exploring other renewable energy technologies such as wind power and hydropower.

3. Technological Improvement: Optimize production facilities and equipment through the establishment of smart energy systems to further enhance energy management, while focusing on waste management, promoting the circular economy, and prioritizing the use of low-GWP refrigerants to reduce environmental impact.

4. Supply Chain Decarbonization: Given the significant proportion of purchased goods, especially aluminum alloys and steel, in overall carbon emissions, the company cooperates with suppliers to explore low-carbon production technologies and prioritizes suppliers using sustainable low-carbon materials.

5. Transportation Optimization: Optimize transportation modes, prioritize low-emission modes such as rail and sea freight, improve transportation efficiency, reduce carbon emissions during transportation, and implement inter-regional logistics plans to reduce emissions from global transportation.

iii. Emission Reduction Actions

The company continues to advance emission reduction efforts across the five major pathways and regularly tracks progress against targets. As of the first half of 2026, the company's emission reduction targets have not been adjusted or postponed. The company continues to promote multiple emission reduction measures, focusing on clean energy application, energy management improvement, operational energy efficiency optimization, and collaborative carbon reduction across the value chain, to support the orderly achievement of carbon reduction targets. In the first half of 2026, the company mainly carried out the following emission reduction initiatives:

1. Promoting Clean Energy Applications

By continuously expanding photovoltaic power generation, green electricity procurement, and other clean energy applications, the company is continuously increasing the share of clean energy usage, reducing fossil energy consumption and greenhouse gas emissions during operations.

(1) Clean Energy Management Mechanism and Target Setting: The company has integrated clean energy usage into its energy management system and institutionalized clean energy management requirements, forming five implementation management mechanisms: First, an energy management responsibility system, with designated energy management personnel responsible for monthly statistics on electricity consumption, green electricity share, and carbon emission data; Second, a clean energy procurement management system, signing one-year long-term green electricity agreements; Third, equipment and facility operation and maintenance management, establishing routine inspection and maintenance mechanisms for photovoltaic, ground-source heat pump, and energy storage systems; Fourth, a carbon reduction ledger system, with green electricity emission reductions calculated and archived monthly; Fifth, continuously promoting energy-saving and clean transformation of high energy-consuming systems. In terms of target setting, the company has defined specific targets for clean energy

applications: gradually reducing the proportion of purchased grid electricity from thermal power, increasing the share of green electricity consumption by approximately 5% annually; and gradually increasing the coverage of self-generated distributed photovoltaic systems across factory sites, achieving full coverage of rooftop PV installations on buildings.

(2) Expansion and Application of Clean Energy Structure: The company continues to promote diversified clean energy applications, gradually building a multi-energy complementary system centered on photovoltaic and purchased green electricity, supplemented by ground-source heat pumps, solar energy, and air-source heat pumps for heating: 1. Advancing the construction and commissioning of a photovoltaic project with an installed capacity of 5,175.14 kW; 2. Promoting the commissioning of air-source and solar hot water heating, and continuously optimizing the operation of ground-source heat pump systems; 3. Continuously increasing the proportion of green electricity procurement, ultimately achieving 100% green electricity coverage. These initiatives will ultimately form a low-carbon energy system of 'self-generated PV for self-use + purchased green electricity supply + ground-source heat pump/solar/air-source heat pump heating for all dormitories', continuously reducing dependence on traditional fossil energy and carbon emissions, and meeting the requirements of dual-carbon assessment and green production.

(3) Progress on Self-Owned Clean Energy Projects: During the reporting period, the company steadily advanced the layout of clean energy projects at various production bases, continuously expanding the scale of self-owned clean energy installations. The Phase II PV project at the Shanghai campus is under construction and is expected to be connected to the grid and commissioned by the end of the year. The project has an installed capacity of 5,175.14 kW and is expected to generate over 5,000,000 kWh of renewable electricity annually, equivalent to reducing carbon emissions by 3,048,000 kg of CO_2. The living building at the Wuhan base uses a solar hot water system, which can save 20,000 kWh of electricity per year and reduce CO_2 emissions by 12,192 kg per year.

(4) Green Electricity Procurement and Application Results: While advancing the construction of its own clean energy projects, the company continues to expand the scale of green electricity procurement and increase the proportion of clean energy usage. In the first half of 2026, green electricity procurement and carbon reduction are as follows:

Production Base	Green Electricity Procurement in H1 2026	Green Electricity Share	Carbon Reduction (kg CO_2)	Annual Green Electricity Procurement Plan and Estimated Carbon Reduction
Shanghai	Procured 5,650,660 kWh of green electricity	27.86%	3,444,642	Planned procurement of 15,274,162 kWh, accounting for 33.34%, with an estimated carbon reduction of 9,311,129 kg

Production Base	Green Electricity Procurement in H1 2026	Green Electricity Share	Carbon Reduction (kg CO_2)	Annual Green Electricity Procurement Plan and Estimated Carbon Reduction
Wuhan	Procuring 360,000 kWh of green electricity monthly since January 2026	20.15%	1,316,735	Planned procurement of 4,320,000 kWh, with an estimated carbon reduction of 2,633,471 kg
United States	Purchased 1,157,760 kWh of electricity, of which over 50% was green electricity and the remainder was natural gas energy	Over 50%	—	—

2. Energy Consumption Management and Operational Efficiency Improvement

By continuously improving the energy management system, advancing energy-saving technology upgrades, and strengthening energy consumption monitoring and analysis, the Company has continuously enhanced energy utilization efficiency and operational efficiency while steadily reducing energy consumption during operations.

(1) Energy Consumption Management System: The Company strictly adheres to national standards for energy conservation, energy consumption metering, and accounting, establishing and improving internal systems for comprehensive energy consumption management, statistical accounting, metering operation and maintenance, and supervision and assessment, with clearly defined management responsibilities, statistical scopes, and reporting procedures, ensuring standardized and institutionalized energy consumption management.

(2) Energy Consumption Monitoring System and Platform Development: The Company has established a four-tier energy consumption monitoring system covering overall, zonal, system, and key equipment levels, with full coverage of energy consumption segments including water, electricity, cooling/heating, and clean energy. Measuring instruments are calibrated on a regular basis to ensure data compliance and traceability. The Company is actively advancing the construction of a smart energy management platform for its parks, which is expected to be put into use by the end of 2026. The platform will feature real-time data collection, visual monitoring, energy efficiency analysis, anomaly alerts, green electricity carbon accounting, and automatic ledger generation. Through automatic data collection by smart meters and platform verification and analysis, the Company has established a routine workflow of daily monitoring and monthly analysis, while also establishing a closed-loop energy consumption management mechanism covering the entire process of "real-time monitoring—anomaly alert—investigation and rectification—effectiveness verification—long-term optimization," effectively

ensuring the authenticity and accuracy of energy consumption data and continuously improving the level of refined energy management.

(3) Data Statistics, Accounting, and Cross-Departmental Collaboration: The Company continuously optimizes and improves its energy consumption statistics and accounting system, strictly follows national energy consumption and carbon emission accounting standards, and unifies energy conversion methods, data statistical scopes, and ledger management specifications, forming a standardized accounting process to ensure compliance and consistency of energy consumption and carbon emission data. The Company has established a sound cross-departmental data collection and reporting mechanism, with clearly defined data reporting responsibilities for each department and a multi-level review and verification system; leveraging the smart energy consumption platform, it enables cross-verification of meter-collected data, financial payment data, and production operating data, ensuring the completeness, accuracy, and traceability of energy consumption data in all aspects.

(4) Energy Audit Arrangements: The Company conducts routine internal energy consumption self-inspections to verify the authenticity and validity of data; at the same time, it has made overall plans for energy audit work, and will complete a comprehensive internal energy audit within 2026, followed by commissioning third-party external special audits at an appropriate time to further verify data accuracy and accounting compliance, explore energy-saving potential, and consolidate the foundation for refined energy management.

(5) Energy-Saving Renovation Projects and Quantitative Results: The Company continues to regard energy efficiency improvement as an important path to green operations, continuously improving energy utilization efficiency through equipment upgrades, system optimization, and process improvements. In the first half of 2026, the main energy-saving renovation projects and their results are as follows:

Production Base	Energy-Saving Renovation Project	Implementation Time	Expected Annual Electricity Savings	Expected Annual Carbon Reduction (kg CO_2)
Shanghai	Replaced three old air compressors with first-class energy efficiency air compressors	May 2026	104,000 kWh	55,182
Changzhou	Replaced original third-class energy efficiency air compressors with first-class energy efficiency units (Model: SRCLEO SCR220WEOM2-7)	April 2026	192,000 kWh	101,875

(6) Exploring Emission Reduction Potential in Production Processes: In the first half of 2026, the Company conducted extreme high-temperature scenario analyses for major equipment and key processes in MR (161 items) and CT (63 items) production, identifying potential operational risks that extreme weather may cause while further identifying opportunities for energy optimization and energy-saving potential in production processes, providing a basis for subsequent energy-saving renovation projects.

3. Value Chain Collaborative Carbon Reduction

United Imaging Healthcare continues to advance value chain carbon management, committingted to systematically improving the efficiency of carbon reduction across the value chain and gradually building a green management system covering the entire product lifecycle. In the first half of 2026, the Company conducted special carbon management training for 3 metal suppliers and 1 PCBA supplier, effectively enhancing the carbon management awareness and compliance capabilities of supply chain partners; at the same time, by collecting product carbon footprint data for aluminum alloy materials, it further improved the Scope 3 indirect emission accounting system and enhanced the accuracy of overall carbon inventory.

VII Human Capital Development

Guided by the mission of "Creating Different, for Health for All," United Imaging Healthcare has always upheld the core values of "customer-centric, innovation-driven, and people-oriented," regarding employees as the core driving force for the Company's sustainable development. The Company respects and protects employee rights, is committed to creating an equal, inclusive, and diverse working environment, and supports employees in continuously breaking through themselves and achieving their career goals and personal value on the United Imaging platform by providing diverse training and career development pathways and establishing smooth communication mechanisms; it also provides employees with comprehensive benefits and health and safety protection, fostering a happy and harmonious workplace atmosphere.

i.Talent Management and Development Strategy

1. Human Capital Governance Structure and Compliance Foundation

United Imaging Group has always regarded human capital as an important driving force for "high-quality, sustainable development" and has established a comprehensive human capital management structure. The Company has established a Compensation and Assessment Committee under the Board of Directors, responsible for reviewing the compensation and performance plans for directors and senior executives; the United Imaging Group Human Resources Committee regularly reports key human capital indicators such as talent density and key position succession rates to the Board of Directors; the headquarters Human Resources Center is responsible for coordinating global organization, key talent, and compensation and benefits design, with human resources functions embedded locally in each region and subsidiary, forming a three-tier governance of "headquarters direction—regional adaptation—business closed loop," ensuring that human capital policies and strategic goals are implemented in alignment.

With the continuous expansion of overseas business, the Company continuously improves and complies with the laws and regulations of the locations where it operates. Domestically, the Company strictly complies with the *Labor Law of the People's Republic of China*, the *Labor Contract Law of the People's*

Republic of China, the *Employment Promotion Law of the People's Republic of China*, the *Law of the People's Republic of China on the Protection of Women's Rights and Interests*, and other relevant laws and regulations; internationally, the Company pays special attention to the labor laws and regulations and personal privacy protection requirements of the countries where it operates (such as the *EU General Data Protection Regulation* (GDPR) and other relevant laws in other regions), and fully respects local cultural customs and employment practices. On this basis, the Company has formulated multiple core systems, including the *Recruitment Management System*, the *Overseas Assignment Policy*, and the *Employee Leave Management Regulations*, covering the entire process of recruitment, assignment, compensation, leave, and promotion, ensuring that the human resources management system is legal and compliant, transparent in process, and dynamically optimized.

2. Talent Planning and Human Capital Analysis Mechanism

United Imaging Group prepares an annual human resources budget and an overall plan for the following year each year based on the overall strategic direction, annual business plan, organizational capability status, and key talent profiles, covering annual staffing needs by function and level, employment types (regular employees, interns, part-time employees, outsourced personnel, and retired rehired personnel), key position investments, and human capital costs, ensuring the systematic, forward-looking, and flexible allocation of human resources during strategy execution. The overall plan is implemented after approval by the Company's Executive Management Committee (EMC).

In terms of human capital analysis, the Company conducts monthly human resources data analysis, with core indicators covering total talent, staffing match rate, talent acquisition (social recruitment, campus recruitment) progress, and talent retention rate, with the analysis scope covering R&D, marketing, operations, and functional areas. The analysis results are directly applied to the preparation of dynamic adjustments, optimization of recruitment strategies, filling critical position talent gaps, and internal talent mobility arrangements, providing scientific and reasonable support for the precise allocation of human capital.

3. Building a Diverse Talent Pool

United Imaging Healthcare continuously improves its talent reserve system characterized by "strategy-oriented, diversified coverage," and is committed to building a diversified, internationalized, and professional talent pool. Through innovative recruitment strategies, the company broadly attracts global talent, providing solid support for diversified business expansion and globalization, including but not limited to the following key areas:

- Talent pool for core R&D positions: Focusing on the core technology R&D needs of medical imaging equipment (such as MR, CT, PET/CT, RT, XR, etc.), the company attracts compound technical experts with product market insight, systems engineering capabilities, project management, product management, and interdisciplinary backgrounds to accelerate technology iteration and product innovation, serving as the core support for the company's "technology leadership strategy."

- International talent pool: Focuses on attracting marketing and business development talent with a global perspective, cross-cultural communication skills, and localization operational experience, to support the company's global business layout and localized implementation in overseas markets.
- Management reserve talent pool: Focuses on reserve talent for critical positions with leadership potential and management capabilities, building an organizational leadership pipeline through systematic development, ensuring management resilience during rapid expansion and business transformation.
- Professional functional talent pool: Covers key functional areas such as manufacturing, supply chain management, quality control, digital tool application, human resources, and financial support, aiming for "professionalism, refinement, and efficiency" to ensure the smooth operation of R&D results transformation, international market implementation, and organizational management.

ii.Skills and Knowledge Development Training

United Imaging Healthcare places high importance on talent development and has established a panoramic development system covering core modules such as leadership development, professional development, international talent cultivation, and new employee training. Through the "U-Change" leadership model and the "International Talent Capability Model," the company systematically enhances the strategic leadership and global adaptability of managers and reserve talent, driving a leapfrog improvement in the leadership, professionalism, competence, and global perspective of all employees.

1. Career Development Paths and Internal Mobility

Based on the job grading system and qualification management mechanism, the company encourages employees to plan their personal career development, achieving a virtuous cycle of capability enhancement and value creation; it encourages multi-directional internal talent mobility, formulates and implements employee transfer policies, and builds a "zigzag" career development path, ensuring employees can apply for internal transfer opportunities based on their personal interests and career plans.

United Imaging Healthcare's career development plan includes three stages: First, defining career development paths. Through annual talent reviews, the company comprehensively assesses employee performance and potential, and, considering employee aspirations, clarifies the direction of their next-stage development. Based on position competency standards and development goals, supervisors evaluate employees' strengths and areas for development through daily behavioral observation. Second, formulating development plans. Through supervisor-subordinate discussions, the company aligns the manager's perspective with the employee's personal perspective on career development paths and areas for development, reaching a consensus on development goals. This approach balances organizational development needs with individual development aspirations, and employees formulate specific learning and development actions accordingly, with supervisors providing corresponding development opportunities and resources. Third, implementing and reviewing development plans. Supervisors and subordinates regularly review the implementation progress and evaluate development outcomes, making necessary iterative updates to development actions.

2. Tiered Leadership Development

United Imaging Healthcare emphasizes the development of leadership capabilities among all employees, extending leadership development from the management level to all employees, aiming to achieve 100% leadership training coverage for all staff.

On the one hand, the company is advancing the development of a leadership training system for all employees. The company will leverage AI-enabled approaches to develop multiple general-purpose leadership online courses for all employees, aiming to achieve 100% leadership training coverage. The leadership curriculum is closely designed around the "U-Change" model, comprehensively and systematically building the manager's role and consolidating foundational management capabilities, from *Role Awareness for Managers* to *Human Resource Management for Managers* and *Financial Management for Managers*. Furthermore, through management skills courses such as *Task Planning and Execution*, *Coaching and Mentoring*, and *High-Quality Decision Making*, employees are equipped with problem-solving skills applicable to various business scenarios. At the same time, with the support of AI technology, the company rapidly develops foundational cognitive courses such as *Growth Mindset* and *Creating Extraordinary Results*, aiming to extend leadership competency development from the management level to all employees, thereby strengthening the talent foundation for sustained innovation and high-quality organizational development.

On the other hand, the company adheres to the core philosophy of "talent-driven innovation" and has established and continuously implements the "U-Change Leadership Development System." This system is centered on strategic communication. By introducing internationally recognized assessment tools such as Hogan, it scientifically and accurately identifies the development needs of managers. It covers three levels of management: the strategic leadership level (L1), the strategic promotion level (L2), and the strategic execution level (L3). Through a tiered development mechanism, it forms a dynamic talent development mechanism of "developing one group, training another, and promoting another," creating a positive closed loop of "strategy decoding - talent empowerment - efficiency improvement."

- L1—Leaders: Aimed at shaping senior leaders with strategic vision, overall coordination, and industry transformation capabilities, the company conducts annual strategic calibration workshops and global healthcare innovation seminars to promote deep consensus among the executive team on business strategy, resource allocation, and cultural communication. Through continuous Top team and culture discussion workshops, the company co-creates a "strategy-organization-culture" three-axis linkage mechanism, positioning strategic decision-making efficiency at a leading level in the global healthcare industry according to BCG's organizational advantage survey results.
- L2—Drivers: Focuses on enhancing the strategic promotion and organizational effectiveness of middle managers. Through the implementation of the "7-2-1" blended development model (70% business scenario practice + 20% benchmarking learning + 10% course input), the company emphasizes strengthening middle managers' ability to translate clinical needs and collaborate across systems. As of the first half of 2026, 86% of L2 managers have been covered, with an

average training duration of 14 hours per person, effectively improving the efficiency of cross-departmental collaboration processes.

- L3—Practitioners: Focuses on enhancing the strategic implementation and team management capabilities of frontline managers. Through a mechanism of "standardized management tools + scenario-based assessment," the company accelerates the role transition of new managers from business experts to effective managers. As of the first half of 2026, 89% of L3 frontline managers have completed team management training, with an average of 12 hours of training per person, and the time to full competency has been shortened to 90 days.

In addition, the company has launched the "Elite Club" online live streaming course series, which, in the form of "night school," helps managers continuously improve their capabilities in five key areas: strategy, globalization, innovation, operations, organization, and talent. From August 2023 to June 2026, a total of 50 sessions have been held, achieving 100% training coverage for all managers.

3. High-Potential Identification and Succession Planning

To proactively plan for key strategic areas, the company implements the "Climber Program," establishing a high-potential talent identification and development system tailored to the healthcare industry, balancing potential exploration and capability development. During the reporting period, the company employed a dual-dimensional screening approach using Hogan assessments and innovation potential evaluations, completing a review of 133 high-potential talents. Through a combination of strategic project experience and executive mentorship, the company systematically cultivated core talent covering emerging fields such as high-end medical device manufacturing and medical AI. As of the end of the reporting period, the company's critical position reserve rate had reached 90.6%.

In terms of succession pipeline management, United Imaging Healthcare has established a comprehensive succession pipeline management system that integrates talent assessment, recruitment, training, and internal mobility, continuously building a reserve talent pool with a reasonable structure and sufficient supply. The company adheres to a strategy of dynamic management and prioritizing internal promotion, regularly assessing talent development status based on business development needs. In 2026, the company identified over 932 management reserve talents covering levels L1 to L3; through the implementation of succession plans, more than 228 reserve talents were promoted during the year, accounting for 30.6% of the total reserve talent, with an internal management supply rate of 96.0%. To address gaps in the succession pipeline, the company reviews high-potential talent across departments and organizations through mechanisms such as nominations, collective discussions, and decision calibration, thereby achieving effective internal talent mobility management.

In terms of succession pipeline development, the Company provides customized development plans for successors, including leadership training, Individual Development Plans (IDP), and challenging projects and practical opportunities. In the first half of 2026, the Company implemented a high-potential reserve talent development program, providing over 24 hours of specialized training to 203 high-potential management reserve talents at L2 to L3 levels. The curriculum covers core content such as *Unlocking Leadership Potential*, *Coaching-Based Mentoring*, *Task Planning and Execution*, *High-Quality Decision-*

Making, *Cross-Functional Collaboration*, and *Building High-Performing Teams*. Meanwhile, an IDP is developed for each reserve talent, offering targeted practical and learning opportunities such as participation in strategic transformation projects, helping them clarify their career direction and build core competencies while addressing new challenges.

Looking ahead, United Imaging Healthcare will continue to deepen leadership development, high-potential selection, and succession pipeline building, further expand the coverage of development programs, and enhance the precision and effectiveness of training. By continuously optimizing the closed loop of "selecting, using, developing, and retaining" talent, the Company will support its globalization strategy and sustainable, innovative development.

iii. Regular Performance Evaluation and Feedback

United Imaging Healthcare regards performance management as a key mechanism connecting corporate strategy, organizational capability building, and employee growth and development. Adhering to the performance management philosophy of "driving value creation, empowering continuous improvement of organizational capabilities, and stimulating employee motivation," and based on the Company's *Performance Management Measures*, the Company has established a PDCA closed-loop management system covering performance goal setting, performance feedback and coaching, performance evaluation, and application of results for all employees, creating a positive cycle of value creation, value evaluation, and value distribution. In 2025, the score for the "Performance Management" dimension in the Company's organizational survey increased for the third consecutive year, reaching 4.21 points; the company-wide employee engagement survey showed that the score for the "Performance Evaluation" dimension reached 85%, significantly higher than the average level in the Chinese market.

1. Performance Goal Setting - Unlocking Individual Potential. Employee performance goals are managed in a closed loop through the Company's internal digital talent management platform, supporting the entire performance management process and ensuring standardized procedures and traceable management records. When setting employee performance goals at the beginning of each year, the Company, on the one hand, precisely allocates core organizational goals to each level to ensure that employee goals are closely aligned with the organization's strategic direction; on the other hand, managers tailor individual goals for each employee based on their job responsibilities and career development stage. Employee performance goals include both "work results" and "work behaviors," focusing not only on performance output but also on behavioral aspects such as collaboration and dedication. Goal setting follows the SMART principles and the requirements of the Balanced Scorecard, ensuring that goals are specific, measurable, achievable, relevant, and time-bound. The Company implements dynamic goal management, tracking and reviewing employees' goal achievement on a quarterly basis and providing corrective coaching. During strategic reviews, if the external environment or key tasks change, the Company will adjust employee goals accordingly.

2. Performance Feedback and Coaching - Strengthening Communication Support. The Company integrates performance coaching into employees' daily work and career development. In addition to the annual formal performance feedback interviews, the Company has established an open and continuous

feedback mechanism. Managers regularly provide timely feedback on employee performance and support their capability improvement through work reviews, daily communication, project summaries, and periodic reviews. Communication methods include face-to-face meetings, online meetings, and various channels such as internal systems and email notifications. To ensure that managers effectively master performance feedback skills, the Company requires every newly promoted manager to complete mandatory training on performance feedback interview techniques, and the Human Resources department provides supporting materials such as the *Performance Feedback Interview Operation Manual*. Each year, HRBPs provide coaching to all managers on performance goal setting and feedback, achieving 100% training coverage. The training includes course learning and role-playing, transitioning from professional knowledge to practical scenario simulations.

3. Performance Evaluation - Value-Driven, Fair, and Objective. The Company adheres to the principles of value orientation and comprehensive objectivity in performance evaluation, comprehensively considering factors such as performance, business strategy, environmental changes, company values, and contribution. Employees are evaluated from two dimensions: work results and behavioral performance. The performance evaluation cycle is set from December each year to January of the following year, covering all employees. The evaluation process includes employee self-assessment, manager evaluation, Talent Organization Committee (TOC) resolution, publication and application of performance results, and performance appeals, ensuring that performance results are aligned with employees' value contributions. After the evaluation is completed, the Company provides feedback on performance results to employees through the internal talent management platform, fully safeguarding employees' right to know; managers are required to conduct formal communication and feedback interviews with employees regarding performance results, objectively evaluate employees' strengths and areas for improvement, and jointly formulate goals and personal development plans for the next cycle.

4. Application of Performance Results - Supporting Development and Motivation. Performance results are applied to employee incentive scenarios such as salary adjustments, year-end bonuses, promotions, and non-material incentives. The Company uses performance evaluation results as an important basis for value distribution. For employees whose performance falls short of job requirements, the Company provides targeted coaching and resource support through Performance Improvement Plans (PIP), including capability training, work guidance, and periodic feedback, helping employees continuously improve their capabilities and achieve sustained growth.

iv. Development of Employee Communication and Grievance Mechanisms

1. Multiple Grievance Channels

United Imaging Healthcare has always regarded employee voices as a valuable asset for the Company's development. We have established smooth and privacy-protective employee grievance and reporting mechanisms, and issued the *Whistleblower Protection Policy*[1] and *Internal Investigation Policy*,

[1] *Whistleblower Protection Policy*: https://global.united-imaging.com/-/media/uih/pdf/investor/20240823/whistleblower-protection-policy_en.pdf

clarifying channels for employee feedback and complaint handling procedures, effectively safeguarding employees' legitimate rights and interests while fully protecting the security of personal information. The Company categorizes grievance channels into two main types based on the different types of employee grievances:

- Grievances related to work matters (such as performance, compensation, and compliance management) can be submitted through dedicated encrypted channels, including the Compliance Hotline email (UIH_Compliance@united-imaging.com) and the Employee Voice feedback email (Ourvoice@united-imaging.com);
- Grievances related to personal rights and interests (such as career development and welfare benefits) can be submitted through internal secure platforms such as uTalk, the United Imaging community, and the online service desk.

All the aforementioned grievance channels are open to all employees worldwide, 24/7, covering all employment categories including regular employees, interns, part-time employees, outsourced employees, and retired rehired personnel, ensuring that employees' concerns and suggestions are heard by the Company regardless of when and where they are. The Company encourages employees to promptly file grievances or reports regarding human resources-related incidents such as child labor, forced labor, human trafficking, harassment, and discrimination, and commits to responding within 24 hours and achieving 100% closed-loop resolution. In addition, the Company's employee union is democratically elected by employees. Union representatives engage in equal, regular, and binding consultations with management on matters of vital interest to employees, such as labor compensation, working hours, rest and leave, insurance and benefits, occupational safety and health, and vocational training, forming a collective consultation mechanism that is actionable, traceable, and reviewable.

2. Personal Information Security Protection

To alleviate employees' concerns about speaking up, the Company has embedded personal information security protection measures throughout the entire grievance process. In terms of channel design, all channels support both anonymous and real-name feedback, allowing employees to choose freely. For anonymous grievances, the system does not record any personally identifiable information (such as IP addresses, device information, etc.), eliminating the risk of identity disclosure at the source. During the handling process, the Company establishes strict information access boundaries, conducts investigations and communications in a confidential manner, desensitizes or encrypts all data involving employee privacy, and prohibits any retaliatory actions against complainants, whistleblowers, or individuals involved in the investigation. The union also strictly adheres to information confidentiality obligations to ensure the security of employees' personal data.

(1) Grievance Handling Process for Work-Related Matters

- Submitting an appeal: Employees submit appeals through designated dedicated channels, and all appeal information is only accessible to authorized personnel;
- Preliminary review: Conducted by designated authorized personnel, with information circulated only within a limited scope; all documents related to the appeal content are marked as

"Confidential" and are prohibited from being forwarded or sent externally through insecure channels such as personal email or instant messaging tools;

- In-depth investigation: The investigation is conducted under the principle of minimum necessary knowledge, disclosing only necessary information to personnel who genuinely need to know, and interview records conceal the identity information of relevant individuals; all documents, recordings, and transcripts generated during the investigation are kept by designated personnel and stored in locked physical filing cabinets or password-protected independent electronic folders, and access without authorization is prohibited;
- Decision-making: Decisions are made based on de-identified investigation information, protecting the privacy of the parties involved throughout the process, and are accessible only to specific decision-makers within the minimum necessary scope;
- Result feedback: The processing result is communicated to the complainant, avoiding disclosure of investigation process details or the privacy of other individuals; the feedback content must be reviewed by the compliance department to ensure it does not contain any information that could identify third parties; if the complainant is not satisfied, a secondary review procedure may be initiated;
- Result archiving: All appeal and processing records are archived after de-identification, with access controlled by permissions; archived files are stored in a separate confidential records room or a password-protected dedicated electronic directory, and any access requires approval and registration.

(2) Appeal handling process for personal rights

- Timely response: Relevant departments such as Human Resources and Legal & Compliance contact the employee within 24 hours through secure means, prioritizing the use of the Company's internal secure communication system over personal contact methods to ensure a controllable communication chain;
- Information verification: Understand the content and validity of the appeal while protecting the privacy of relevant parties, and supplement verification of related information; supporting materials obtained during verification (such as attendance records, compensation data, etc.) are used only for this appeal and are promptly destroyed or archived encrypted upon completion in accordance with data retention policies;
- Investigation: Conducted jointly by relevant departments and HRBP (Human Resources Business Partner) under confidential conditions; investigation meetings are held in separate meeting rooms, with meeting records kept by designated personnel, and photography, recording, or external sharing of screenshots is prohibited;
- Result feedback: The processing result is communicated to the employee, and relevant records are archived after privacy processing; feedback emails or notifications do not contain any investigation details or information about other involved parties, presenting only conclusive content.

In the first half of 2026, through the above public channels, the Company received a total of 10 complaints, all of which were accepted and handled in strict compliance with the above privacy protection standards. No employee personal information leakage incident occurred as a result of appeal handling. In the future, the Company will continue to improve relevant mechanisms, further expand secure and convenient anonymous channels, and upgrade information protection technologies and management standards to ensure that every genuine voice and constructive suggestion can be heard and adopted in an environment with full privacy protection.

v.Employee satisfaction survey

United Imaging Healthcare values employees' work experience and regards it as an important component of organizational capability building and sustainable development strategy. The Company conducts comprehensive, multi-dimensional company-wide surveys annually to continuously understand employee needs, optimize employee experience, enhance employee satisfaction, and drive organizational effectiveness and employee value realization.

In terms of organizational health surveys, since 2022, the Company has engaged an external third-party institution, BCG, to conduct systematic and comprehensive organizational surveys covering 6 major directions and 12 key dimensions, including strategy, organization, talent, and innovation, while continuously improving organizational management mechanisms. After four years of strategic advancement and systematic governance, the questionnaire response rate and valid response volume have continued to improve, and the Company's overall score has steadily increased from 3.80 in 2022 to 4.14 in 2025. The 2025 survey results show that all 12 dimensions improved compared to the previous year, with 9 dimensions entering the top 25th percentile of the global healthcare enterprise database, indicating a significant enhancement in the Company's organizational health and sustainable development capabilities.

In terms of closed-loop survey management, the Company uses a systematic process of "survey—feedback—action—evaluation" to continuously identify organizational management issues, guide responsible departments in developing targeted improvement plans, and incorporate improvement outcomes into performance appraisals to ensure the implementation of every optimization measure. The Company continuously optimizes in the following five key dimensions:

- Strategic transformation dimension: Clearly translate the strategic vision into concrete actions understood by all employees, ensuring alignment between employee work and Company goals;
- Leadership dimension: Implement targeted talent development programs, providing innovative and developmental opportunities so that employees experience both personal growth and value contribution within the organization;
- Key capabilities dimension: Identify and develop important organizational and employee capabilities, helping employees fully align with role requirements and support their personal career development;
- Talent dimension: Systematically plan talent needs, open internal and external talent acquisition channels, and foster a fair and diverse development environment;

- Mission dimension: Fully communicate and implement the Company's mission, vision, and values, enabling employees to clearly perceive and strongly identify with them.

In terms of company-wide satisfaction surveys, the Company engages a professional third-party institution to conduct an annual anonymous satisfaction survey covering all employees domestically and internationally, focusing on three dimensions—culture and atmosphere, organizational support, and total rewards—encompassing 22 key drivers, systematically collecting employees' work experiences and genuine feedback to identify key drivers and potential areas for improvement. To increase employee participation and response rates, the Company ensures employees fully understand the significance and operating mechanism of the survey upgrade through company-wide communication and targeted outreach, and follows up on employees' completion progress through internal communication platforms, email, and other means. The results of the company-wide anonymous survey conducted with the support of the third-party institution show a response rate of 72% and an employee satisfaction rate of 92%. Among these, the top five dimensions in terms of employee recognition are: Top-1 Customer Orientation, Top-2 Diversity and Inclusion, Top-3 Work Environment, Top-4 Work Partners, and Top-5 Sense of Achievement, reflecting high recognition of the Company's customer-oriented culture, inclusive atmosphere, and employee belonging.

After the survey results are generated, the Company collaborates with external institutions to conduct a comprehensive analysis of the data and provides feedback and communication to managers at various levels, sharing survey results, key insights, and priority improvement areas. In-depth discussions are held on topics of concern to employees across the three dimensions—culture atmosphere (e.g., teamwork, values implementation), organizational support (e.g., resource support, work coordination mechanisms, internal communication), and performance (e.g., compensation and incentives, career development paths, benefits, work-life balance)—and special optimization plans are developed based on business realities, with continuous tracking of implementation outcomes. Through the closed-loop management mechanism of "survey-analysis-feedback-action-evaluation," the Company continuously enhances its employee experience management capabilities, enabling employees to feel that their opinions are heard, their needs are addressed, and their suggestions are implemented, fostering a positive cycle of mutual growth between employees and the organization.

vi.Compensation and incentive system development

United Imaging Healthcare consistently adheres to a talent-centric strategic philosophy, closely integrating compensation and incentives with organizational development and business strategy. The Company strictly complies with the laws and regulations of the countries and regions where it operates, including the *Labor Law*, the *Employment Rights Act*, and the *Pay Transparency Directive*, paying employees' compensation and contributing to corresponding social insurance; it conducts external compensation benchmarking and internal compensation diagnostics annually to optimize the compensation framework and ensure the market competitiveness of employee compensation.

1. Performance-linked variable compensation

United Imaging Healthcare has established a compensation incentive mechanism closely linked to performance, covering all employees. Employee compensation consists of fixed compensation, variable bonuses, and long-term incentives, applicable to various job categories including management, sales, production, functional, new graduates, expatriates, and piece-rate workers, ensuring that employees at all levels and in all categories can receive corresponding incentives through performance contributions.

In terms of scope, the Company's variable compensation is not limited to management or sales positions; non-management and non-sales employees are equally eligible for performance-based variable compensation. In terms of assessment dimensions, the Company adopts a multi-dimensional performance evaluation system that comprehensively considers organizational performance, individual performance, production performance, and other dimensions, ensuring that assessment results are objective, fair, and quantifiable. In terms of linkage methods, performance results are directly converted into actual compensation returns through diversified bonus mechanisms, including annual regular performance bonuses, marketing performance assessment bonuses, marketing war zone bonuses and commissions, and other special bonuses.

In terms of long-term incentives, United Imaging Healthcare aligns the interests of core talent with the Company's long-term development through mechanisms such as the retention plan, setting staged vesting cycles based on performance and position value to guide key position employees to focus on long-term value creation.

In the first half of 2026, United Imaging Healthcare completed the calculation and distribution of variable bonuses for different job sequences and the allocation of long-term incentives through standardized processes. Among these, warzone bonuses achieved cross-functional calculation and distribution, reflecting the scalability of the compensation system in complex organizational scenarios; the service period, performance, and allowance benchmarking calculation and payment for expatriate employees were completed simultaneously, and retention plan bonuses due were also vested on time, ensuring the accuracy and timeliness of compensation incentives.

2. Employee Equity Plans

The Company has launched diversified employee equity incentive plans at different development stages, including the Employee Stock Ownership Plan (ESOP), the Second Type Restricted Stock Incentive Plan, and the Employee Strategic Placement Share Plan, covering employees at different levels and in different countries, ensuring that every eligible employee can share in the growth and success of United Imaging Healthcare. As of the first half of 2026, the Company's employee equity incentive plans have granted a cumulative total of 88.0272 million shares, covering more than 6,980 participants.

- Employee Stock Ownership Plan (ESOP): Converted pre-IPO virtual shares into actual shares, granting a total of 62.0559 million shares, covering more than 800 employees with outstanding performance. Through transparent vesting rules and flexible reduction mechanisms, employees' sense of responsibility and belonging as shareholders of the Company is strengthened;

- Second Type Restricted Stock Plan: To further expand the scope and increase the intensity of incentives, the Company specially designed the second type restricted stock plan for core employees with outstanding performance globally, with a total of 5,403 participants and a total grant of 16.1231 million shares; in the first half of 2026, an additional 4.5012 million shares were granted to more than 1,500 employees domestically and internationally. This plan is linked to the Company's operating results, and the vesting of equity is related to the Company's market performance, motivating employees to contribute to enhancing the Company's market value;
- Employee Strategic Placement Share Plan: To reward employees for their work achievements, the Company launched the Employee Strategic Placement Share Plan before the IPO, with a total of 754 people subscribing for 9,848,191 shares, with subscription funds reaching RMB 1.133 billion, reflecting employees' confidence in the Company's development.

vii.Non-Compensation Benefits

United Imaging Healthcare has built the U-Care non-compensation benefits system, covering four major aspects: "Health Care," "Career Companionship," "Recognition and Commendation," and "Communication and Connection," covering all employees, including regular employees, contract workers, interns, part-time employees, and outsourced personnel. The Company tailors and updates benefits strategies for employees and their families every year, fully considering the personalized needs of employees in different regions and positions as well as industry best practices, and making every effort to ensure the competitiveness and advancement of employees' non-compensation benefits. At the same time, the Company strictly complies with the *Law of the People's Republic of China on the Protection of Women's Rights and Interests*, and does not treat female employees differently in career development based on age, pregnancy, childbirth, or other reasons, eliminating any form of gender discrimination in the workplace.

1. Health Care

- Health Protection: Provides supplementary medical insurance and physical examinations for all employees, with insurance coverage including personal accidents, outpatient and emergency hospitalization medical care, and critical illnesses; for employees traveling abroad on business, the Company provides comprehensive overseas travel insurance, ensuring that every employee enjoys comprehensive medical protection both domestically and internationally;
- Health Promotion: Provides employees with free gym access, encourages the development of various clubs such as badminton, table tennis, and football, and organizes activities such as basketball and badminton competitions; regularly carries out activities such as Traditional Chinese Medicine consultations, dental check-ups, and eye disease prevention, such as the "Wo Jia Xing Lin" Traditional Chinese Medicine micro market activity and joint hospital Traditional Chinese Medicine experience services, bringing health care initiatives into practice;
- Dining Care: Provides meal subsidies for all employees to ensure the quality of their meals, and has specially set up dedicated dining tables for pregnant female employees; the cafeteria regularly

organizes various food festival activities, and the labor union carries out summer "cooling" activities;

- Family Care: Provides discounted commercial insurance covering outpatient/emergency treatment and critical illnesses for more than 600 employees' family members, and additionally gifts the 'Beautiful Journey' transportation accident travel insurance; employees' family members can also enjoy discounted physical examination packages, summer camps for employees' children, and assistance with school enrollment for employees' children;
- Female Employee Care: Implements rigid protections such as prenatal check-up leave, maternity leave, nursing leave, and parental leave, and sets up nursing rooms for female employees, priority seats for pregnant women, and customized gifts for International Women's Day, providing comprehensive protection for all female employees;
- Parenting Benefits: The Company actively promotes family support policies, providing all employees with additional paid parenting-related leave beyond the statutory standards. All employed fathers are entitled to no less than 10 days of fully paid paternity leave; for employees with children under the age of three, each parent can enjoy a cumulative total of no less than 5 days of fully paid parental leave per year. In the first half of 2026, more than 540 people have enjoyed parental and paternity leave, with a cumulative total of 2,680 days of leave, of which male employees accounted for 78%, reflecting the culture of shared responsibility between the enterprise and the family;
- Housing Security: On the basis of paying housing provident fund in full in accordance with the law, the Company has additionally established a supplementary housing provident fund system, enhancing employees' housing affordability through more competitive contribution support; at the same time, it links with local affordable housing resources, coordinating talent rental housing, doctoral-exclusive youth apartments, and other housing options, providing low-cost transitional rental options for young employees and high-level scientific research talent.

2. Career Companionship

- Onboarding Care: Provides comprehensive onboarding care at the organizational, departmental, and individual levels for new employees, helping them quickly integrate into the Company's culture and understand the Company's business and work processes;
- Anniversary Commemoration: Provides employees who have completed service anniversaries with welfare annual leave, paid sick leave, and other leave based on their length of service, and enhances employees' sense of belonging through anniversary celebration activities, electronic badges, and greeting cards;
- Birthday Congratulations: Provides employees with birthday gifts and other benefits, with an investment of approximately RMB 800,000 in the first half of 2026;
- Marriage Congratulations: Provides employees with marriage gifts and other benefits, wishing employees a happy married life;

- Childbirth Congratulations: Provides childbirth gifts to new parents in the workforce, supporting employees' family life;
- Festival Celebrations: Provides exclusive gifts for traditional festivals such as International Women's Day, Dragon Boat Festival, and Mid-Autumn Festival, enhancing the sense of belonging and cohesion.

3. Recognition and Commendation

- Company Awards: Establishes various public non-material incentive awards such as Quarterly Star, High-End Product Breakthrough, and Marketing Victory Report, encouraging employees to continuously create value;
- Honorary Titles: Selects honorary titles such as Special Contribution, Excellent Team, Outstanding Employee, and United Imaging Craftsman. In 2025, a total of more than 20 company-level excellent teams, more than 80 outstanding employees, more than 50 department-level excellent teams, and more than 300 outstanding employees were selected, with a total annual recognition investment exceeding RMB 5 million.

4. Communication and Connection

- Executive Communication: Organizes one-on-one communication between executives and employees, allowing employees to directly provide feedback and suggestions to the company's management, enhancing employees' sense of participation while helping management better understand employee needs;
- United Imaging Anniversary: Organizes celebration activities for all employees at important moments such as the company's anniversary, inspiring employees' pride and sense of ownership by reviewing the company's development history.

Through the systematic and comprehensive U-Care non-compensation benefits system, United Imaging Healthcare not only enhances employees' happiness, sense of belonging, and satisfaction, but also strengthens the organization's attractiveness and competitiveness. In the future, the Company will continue to optimize its benefits strategies and practices, incorporating employee feedback and industry best practices to ensure that non-compensation benefits remain at the forefront of innovation, advancement, and sustainability.

VIII Product Safety and Quality Management

United Imaging Healthcare has always regarded product safety and quality management as the core strategy for sustainable corporate development, making quality strategy an important component of its core competitiveness. The Company has established a "zero defect" quality management objective and built a full lifecycle quality management system covering product R&D, manufacturing, supplier quality, and after-sales service, achieving globalized and integrated operations.

The Company continuously improves its domestic and international certification systems for product safety and quality, expands testing capabilities and coverage, and strengthens professional training capabilities for internal staff and partners. At the same time, it actively promotes the coordinated

development of supplier certification and training, incorporates responsible marketing management, compliance audits, and regular audits into the full-chain management process, and establishes risk mitigation and emergency response mechanisms for sudden situations such as supply interruptions, ensuring that upstream and downstream supply chain parties jointly adhere to strict quality and compliance standards.

i. Product Safety and Quality Management Certification

1. Quality Management Organizational Structure and Responsibilities

The Company has established the Quality and Compliance Management Committee as the highest decision-making and supervisory body for quality management, responsible for coordinating product quality matters and ensuring that all products meet industry regulations and regulatory standards. The Quality Management Department, as the core execution department, leads the establishment, implementation, and continuous improvement of the quality management system and coordinates full-process quality control. Each production base has dedicated Product Quality Assurance (PQA) and Quality Control (QC) teams responsible for specific quality planning, inspection, and release activities across product lines and production processes.

In the field of R&D quality, the Company fully deepens the implementation of the United Imaging Product Development system (uIPD), scientifically coordinates the five major sub-modules of "requirements management, product and technology portfolio management, technology development, integrated product development, and lifecycle management," and builds a full-chain closed-loop R&D matrix, embedding quality and safety concepts throughout the entire product lifecycle. The R&D Quality Assurance team (R&D QA) is responsible for overseeing quality reviews, risk management, design verification, and design validation at each stage of product development, ensuring product safety and effectiveness are controlled from the source.

2. Product Safety Quality Certification and Management Process

The Company has established four production bases globally—the Shanghai headquarters production base, Wuhan production base, Changzhou East China production base, and Houston, USA production base—all of which uniformly implement the United Imaging Healthcare quality management system standards. As of the end of the reporting period, United Imaging Healthcare's quality management system certification has achieved 100% coverage across all production bases, and all products on the market have passed core system certifications. The specific certification status is as follows:

- ISO 13485 Medical Device Quality Management System Certification: Covered by all production bases, ensuring that the entire medical device production process complies with international regulatory requirements;
- ISO 9001 Quality Management System Certification: Obtained by the Shanghai and Wuhan production bases, covering a broader scope of quality management dimensions;
- MDSAP Medical Device Single Audit Program Certification: The Company has obtained MDSAP certification, which allows the audit to simultaneously satisfy the quality management

system audit requirements of five regulatory agencies: the US FDA, Health Canada, Japan's MHLW, Brazil's ANVISA, and Australia's TGA, significantly improving global market access efficiency.

- Product-level safety certifications: Multiple core products have obtained US NRTL (Nationally Recognized Testing Laboratory) safety certifications, covering major product lines such as CT, MR, and PET/CT; all products have successively obtained EU CE certification (MDR regulation). As of the first half of 2026, the Company has obtained EU CE certification for 77 products and US FDA 510(k) clearance for 78 products.

United Imaging Healthcare's quality management workflow follows the PDCA cycle model, standardizing operations at each stage through the *Quality Manual* and supporting procedure documents. From R&D design input, supplier qualification, incoming material inspection, production process control, and finished product inspection to post-market surveillance, a complete quality control chain is formed. Product release is subject to strict review by the quality department, ensuring that every device shipped from the factory meets regulatory and standard requirements.

3. Internal Product Safety and Quality Standard System

The Company has established and adopted internal product safety and quality standards that are stricter than external standards, conducting routine internal certifications and assessments of its own operations, production bases, and full product lines. Based on meeting international standards such as ISO 13485 and ISO 9001, the internal standards incorporate stricter process control requirements and product reliability indicators, taking into account the characteristics of the medical device industry and the Company's "zero defect" quality objective.

(1) Internal Product Safety Management System. First, the uRDM R&D quality management system, as the core of internal R&D quality control, integrates product development processes with strict stage review checkpoints. Each stage must pass quality review before proceeding to the next. The R&D Quality Assurance team (R&D QA) participates throughout the entire process, including requirements analysis, design input, design output, design verification, design validation, design transfer, and design change. Second, the risk management system: the Company has established the *Product Risk Management* procedure, following the ISO 14971 standard, to identify, analyze, evaluate, and control risks throughout the entire product lifecycle, keeping residual risks within acceptable limits. Third, production process control standards: the Company has developed internal process control specifications that are stricter than regulatory requirements, including key process parameter control and environmental management, and has detailed them into every operational step through SOPs (Standard Operating Procedures).

(2) Standard Development and Implementation Procedures. The Company uses the *Quality Manual* as the top-level document, supported by a three-tier document system consisting of procedure documents, work instructions, and record forms. As of the end of the reporting period, a total of 200 quality and safety-related management documents were updated in 2026, continuously optimizing institutional processes. Standard development follows three principles: compliance (comprehensively covering medical device regulatory requirements in major markets such as China, the United States, and the European Union), advancement (benchmarking against the quality levels of top international medical device companies and

introducing management methods such as Six Sigma and Lean Production), and executability (ensuring standards are practical and implementable based on the actual conditions of each production base). At the implementation level, the Company ensures standard implementation through mechanisms such as company-wide quality training, process audits, and performance assessments.

(3) Internal Certification Assessment Results. The Company organizes multiple rounds of internal system audits each year to comprehensively evaluate the operation of the quality management systems at each production base and product line. Internal audit results show that the systems at all bases continue to operate effectively.

4. Regular Audit Monitoring Mechanism and Certification Validity Management

The Company has established a multi-level, comprehensive audit monitoring system to continuously ensure the effective operation of the quality management system and product testing processes. In terms of internal audits, the Company regularly organizes internal audits of the quality management system, covering all departments and production bases, to verify the effectiveness of system operations. In terms of management reviews, top management regularly reviews the suitability, adequacy, and effectiveness of the quality policy, quality objectives, and quality management system. In terms of external audits, the Company accepts supervisory audits, unannounced inspections, and annual surveillance audits from regulatory authorities and third-party certification bodies. In terms of daily monitoring, the Company uses digital and intelligent quality control platforms to monitor and analyze production processes and product testing data in real time.

Regarding certification validity review and renewal, the Company has established a comprehensive periodic review mechanism. ISO 13485 certification, ISO 9001 certification, and MDSAP certification are each valid for 3 years, with an annual surveillance audit by the certification body and a recertification audit in the third year. The Company has established a certificate validity ledger and initiates recertification preparations 6 months in advance to ensure timely renewal.

In the first half of 2026, the external audits accepted by the Company covered various types, including NMPA (China National Medical Products Administration) product registration system assessments, EU MDR CE certification, Brazil INMETRO certification, US and Canada NRTL certification, ISO 13485 quality management system audits, ISO 9001 quality management system audits, and Kazakhstan product registration certification system assessments. Internal audits covered key processes such as R&D, production, procurement, distribution, and after-sales service. The specific details are as follows:

Audit Category	Indicator	First Half of 2026
External Audits	Number of External Audits Accepted	18 times
External Audit	External audit pass rate	100%
External Audit	Major nonconformity	0 items
Internal Audit	Number of internal system audits and special audits	8 games

Audit Category	Indicator	First Half of 2026
Internal Audit	Number of auditor participations	64 person-times
Internal Audit	Timely completion rate of rectification for minor non-conformities	100%
Certification Status	Holding a valid quality management system certification certificate	100%

Currently, all quality management system certification certificates held by the company are in valid status; all external audits accepted in the first half of the year were passed smoothly with no major non-conformities; the internal audit system operates consistently, stably, and under control. In the future, the company will continue to benchmark against the highest international standards, deepen the "zero-defect" quality culture, and upgrade quality management capabilities through digital and intelligent means.

ii. Product Testing Capability

United Imaging Healthcare strictly controls the product quality and safety testing process, conducting work in accordance with over a hundred product design and testing guidelines, including the *Product Development Process*, *Verification Procedure*, *Design Validation Procedure*, *Product Risk Management*, *Product Cybersecurity Management Process*, *AI System Lifecycle Process*, *Product Usability Engineering Management*, *Reliability Testing Specification Guide*, *Packaging Reliability Testing Specification*, *Signal Integrity Testing Specification*, *HALT Test Specification*, *Environmental Climate Testing Specification*, *EMC Testing Specification*, *ESS Testing Specification*, *Environmental Mechanical Testing Specification*, *Component Accelerated Life Testing Specification* and *Cable Procurement Design Verification Guide*, to ensure the authenticity, accuracy, completeness, and traceability of test results. The company is equipped with testing equipment and facilities that meet product testing requirements, as well as a dedicated testing team. As of the end of the reporting period, each product line has professional and comprehensive testing capabilities.

1. Internal Laboratory Construction and Accreditation

The company has established a professional laboratory to test and verify the reliability and stability of products under varying environmental conditions. The laboratory is equipped with advanced testing equipment and can perform a variety of tests including environmental, vibration, shock, and durability testing. It follows strict testing standards to ensure that product quality and reliability are comprehensively evaluated and guaranteed at all stages from design to manufacturing.

In terms of laboratory qualifications and international recognition, the safety and electromagnetic compatibility laboratories for the full range of United Imaging products in Shanghai are customer testing facilities (CTF-1) recognized by TÜV SÜD and TÜV Rheinland, as well as customer testing facilities (CTF-2) recognized by SGS; United Imaging in Wuhan is a customer testing facility (CTF-1) recognized by TÜV SÜD, TÜV Rheinland, and SGS. The above laboratory undergoes annual audits by TÜV SÜD,

TÜV Rheinland, and SGS, with qualifications covering all product-line-related IEC safety and electromagnetic compatibility standards, meeting all conditions for on-site witnessed testing of products.

2. Design Verification and Clinical Evaluation Testing

United Imaging Healthcare conducts design validation and clinical evaluation testing for its products, engaging clinical medical experts to assess and continuously optimize the interactivity, image quality, and workflow of the products, ensuring that product functions are specialized, refined, and intelligent. During the design validation phase, the company requires that prototypes meet the standard of initial production units or equivalent items, with both test execution rate and pass rate required to reach 100%. Issues or defects discovered during design validation must be resolved before passing.

During product development and before launch, the company also requires external customer evaluations covering customer experience, workflow, interface interaction, and other aspects. The evaluation targets include complete systems, product software, or a specific function or application within the product, to supplement customer input on product requirements. For products that adopt brand-new technology, the company selects medical institutions qualified for clinical trials in accordance with the regulatory requirements of the *Medical Device Clinical Trial Quality Management Standards* to conduct trial use or verification of the product under normal use conditions, in order to evaluate whether it meets the expected safety and effectiveness.

In 2026, to meet the product registration and safety access requirements in multiple regions, the company obtained third-party test reports for all marketed products across MR, CT, XR, PET/CT, PET/MR, RT, software post-processing applications, and US, in accordance with domestic and international standards such as GB 9706.1 and its series standards, and the IEC 60601 series standards. The coverage of the test reports was further expanded compared to the previous year to include the ultrasound product line.

3. Product Reliability Testing

The company embeds product reliability management into the entire product development lifecycle. Based on the *Reliability Activity Guide*, it summarizes the implementation of reliability activities at each project stage, covering reliability planning, determination and decomposition of reliability indicators, reliability design and analysis, and reliability test planning and execution. It outputs a series of complete reliability technical reports on key raw materials, modules, components, and complete machines, and feeds test results back into the design optimization process, forming a closed loop of "testing, discovery, improvement, and verification."

In the first half of 2026, United Imaging Healthcare executed a total of 6,964,936 tests across various categories, covering 1,259 components, 354 systems, and 53,199 test cases, maintaining 100% test case coverage. The testing scope covered major product lines including CT, MR, molecular imaging, digital X-ray, radiotherapy, and ultrasound, as well as key core components and software systems, encompassing multiple dimensions such as functionality, performance, safety, electromagnetic compatibility, environmental adaptability, and reliability.

Among them, a cumulative total of 6,755,645 component and system reliability tests have been conducted, covering 2,141 reliability test cases, including test scenarios such as high and low temperature

environments, mechanical durability, vibration and shock, storage and transportation, accelerated life, and fatigue life. The company embeds reliability management throughout the entire process of product development and engineering transformation, continuously outputs reliability technical reports on key materials, modules, components, and complete machines, and feeds test results back into design optimization and process improvement, forming a "test-discovery-improvement-verification" quality closed loop, providing assurance for the safe and stable operation of products and their clinical application.

4. Production Testing and Quality Control Process

The company has established a comprehensive production quality management system, covering core process documents such as the *Design Transfer Procedure*, *Process Development Procedure*, *Production Control Procedure*, *Incoming Material Inspection Control Procedure*, *In-Process and Final Quality Control Procedure*, *Nonconforming Product Control Procedure*, *Measuring Instrument Management Procedure*, *Equipment Management Procedure*, *and Environmental Control Procedure*, ensuring that design outputs are accurately transformed into production specifications and achieving full-process quality control from raw material management, process development, and production manufacturing to finished product inspection.

In terms of raw material control, the company has established and implemented a risk assessment system based on the trinity of material importance, supplier capability, and material quality, closely integrating the assessment results with tiered management of incoming material inspection to implement quality control from the source. In process development and validation, the company systematically conducts FMEA analysis to comprehensively identify potential failure modes, quantitatively assess risk levels, and formulate targeted prevention and control measures; key process characteristics are managed throughout the entire process, and quality issues are prevented through measures such as improving process flows and enhancing quality control. In terms of production process control, the company has built a multi-dimensional whole-process monitoring system based on the 5M1E management framework (Man, Machine, Material, Method, Environment, Measurement), including personnel qualification management, environmental monitoring, equipment maintenance, and product sampling inspections, to ensure that the production process is stable and under control.

5. Final Product Testing and Inspection

In the final product testing and inspection stage, the company strictly adheres to the medical device quality management system and relevant regulatory requirements, implementing 100% testing and inspection on all products to ensure their safety, effectiveness, and regulatory compliance. Testing and inspection cover multiple categories including protective earth resistance, withstand voltage, noise, system functions, and images, totaling more than 19,949 items, comprehensively covering the product's functional performance, electrical safety, and other key technical indicators. The company has established a long-term data retention and traceability mechanism, retaining testing and inspection records for 30 years to ensure traceable management of products throughout their entire lifecycle. Meanwhile, to safeguard the occupational health and safety of testing and inspection personnel, the company identifies job-specific protection requirements and provides necessary protective equipment and training to prevent injuries.

6. Environmental Protection and Product Environmental Regulation Testing

The company strictly follows the system document *Product Environmental Regulation Requirements* at all stages including product initiation, R&D, incoming materials, production, and market launch, ensuring that every material in all products continuously complies with environmental regulations throughout the entire lifecycle. Based on the alert notifications from the European Union's Rapid Alert System for non-food consumer products (RAPEX), and considering the different materials used in the company's products, the company not only tests the compliance of hazardous substances in materials at the incoming end but also commissions third-party laboratories to test the content of hazardous substances in materials, ensuring that testing covers all products. In the first half of 2026, the company tested a total of 24,549 homogeneous materials to ensure products meet system and regulatory standards in terms of environmental protection.

iii. Employee Product Quality and Safety Training

United Imaging Healthcare has established the *Training Control Procedure* as the top-level system, supported by a series of documents such as the *Training Management System* and *Lecturer and Course Management System*, in accordance with regulatory standards including ISO 9001:2015, ISO 13485:2016, China's Good Manufacturing Practice for Medical Devices (2025 No. 107), US 21 CFR 820 (QMSR), Japan's QMS, Brazil's GMP, Korea's Medical Device Regulations and Digital Medical Device Regulations and Korea's GMP, EU Directive 93/42/EEC (MDD), EU Regulation 2017/745 (MDR), Canada's SOR/98-282 CMDR, and Australia's TG(MD)R, thereby building a layered, categorized, and comprehensive product quality and safety training management mechanism.

- **Training objectives:** To firmly establish the "zero defect" quality philosophy and implement quality and safety responsibilities throughout the entire lifecycle of medical devices; to ensure all personnel master job-applicable regulations, quality system documents, product safety risks, and standard operating procedures; to ensure all personnel on duty possess quality capabilities matching their positions, reducing quality risks across the entire chain of design, procurement, production, delivery, and after-sales service, and continuously ensuring the safety and effectiveness of medical device products.
- **Training coverage:** Product quality and safety training covers all relevant personnel, including regular employees, probationary employees, new hires, transferred employees, part-time employees, labor dispatch and outsourced personnel, interns, and temporary workers. Among them, outsourced personnel and interns must complete quality and safety access training and pass the assessment before starting work; those who fail the assessment are not allowed to enter the work area or carry out related work independently.
- **Training frequency:** New employees, interns, and outsourced personnel complete mandatory access training in the first phase of onboarding, and continue to participate in department-level job quality deepening training after starting work; regular employees and part-time personnel undergo annual continuous quality retraining, with special immediate training organized when regulations are updated, system versions are revised, or major quality events occur; transferred personnel undergo pre-job quality and safety training for the new position

and can only perform their duties after passing the assessment; routine quality culture learning relies on the Feishu platform subscription account (QM Broadcast Station), quality journals, and quality-themed activities, carried out continuously throughout the year.

- **Training methods:** The company adopts a diversified model combining online and offline, theory and practice: online, it relies on the E-learning platform, self-paced learning on the Zhiyuan Academy courses, micro-course push, and online quizzes; offline, it conducts centralized lectures, case discussions, quality risk scenario simulations, on-site practical training, and special sharing sessions by internal lecturers; in terms of cultural carriers, it continuously pushes regulatory interpretations, quality cases, and standard key points through the Feishu platform subscription account and the *Quality Journal*, and carries out annual Quality Month themed activities and quality improvement proposal exchanges; in terms of external empowerment, it invites industry experts or participates in special training on regulations and standards organized by external professional institutions, continuously increasing investment in internal and external training resources.
- **Training assessment and effectiveness tracking:** The company has established a closed-loop mechanism of "training-assessment-record keeping." For access-type quality and safety qualification-related training, regarding special quality and safety positions required by regulations (such as forklift operation, welding, etc.), employees are organized to participate in the assessment for position qualification certificates; for key quality and safety position qualification-related training, each person should form a quality and safety training file, and after evaluation by relevant personnel, they can only start work after passing the evaluation; for general position qualification training, the effectiveness of training is evaluated through various methods such as online quizzes, after-class questionnaires, on-site practical assessments, performance indicator tracking, on-site observation, and work outcome reviews. The company simultaneously improves its training statistics capabilities, regularly counting the number of personnel covered by training, the total number of training sessions, the total training hours, and the number of participants, and dynamically monitoring the progress of training objectives.

In the first half of 2026, the company implemented differentiated quality and safety training in layers for different personnel categories, covering new employees, existing employees, interns, outsourced and part-time personnel, with training formats including access training, online E-learning, online Zhiyuan Academy, special topic training on systems, quality culture activities, and regular promotion through the *Quality Journal*.

- **Quality and safety access training for new employees, interns, and outsourced personnel:** Training topics cover the company's quality policy and "zero defects" quality objectives, fundamentals of medical device regulations, basic requirements of ISO 13485, product safety red lines, basic quality standards for positions, quality risk awareness, nonconforming product management, and confidentiality and traceability requirements; the training format combines offline classroom lectures, online compulsory courses, and basic

assessments, covering new employees hired in the first half of 2026, interns at various bases, and newly added outsourced operations personnel. The company strictly implements the principle of "training first, then working," with a 100% participation rate in access training and a 100% pass rate, helping new employees establish a basic quality bottom-line awareness and reducing quality operation risks in the early stage of onboarding.

- **Ongoing E-learning and Zhiyuan Academy online quality training for existing employees:** Training topics cover interpretation of updates to quality management system documents, product lifecycle risk management, post-market surveillance (PMS) management requirements, design changes and design control, supplier quality control, review of typical quality adverse cases, and updates to domestic and international regulations (new regulations related to NMPA, FDA, and MDR); the training format is self-paced learning on the online platform combined with timed online quizzes, covering all existing employees in R&D, production, quality, procurement, global services, supply chain, and functional management. This format fully utilizes fragmented learning time, breaks geographical limitations, and simultaneously covers personnel in Shanghai, Wuhan, Changzhou, and overseas bases, achieving rapid dissemination of regulatory and system change requirements to all employees.
- **Special policies, systems, and in-depth special training for key positions:** Training topics cover uIPD R&D quality processes, key points of GRA R&D stage quality reviews, production process control and cleanroom management, finished product inspection and release specifications, medical device adverse event reporting procedures, internal auditor capability improvement, MDSAP audit key points, and CAPA implementation specifications for rectifying nonconformities found in internal audits; the training format is offline special lectures by internal lecturers, group case discussions, and problem exchanges, covering key positions such as R&D engineers, process engineers, production team leaders, QC and PQA, procurement engineers, after-sales technical leaders, and system internal auditors. This training strengthens the professional quality capabilities of key position personnel, enhances the consistency of system implementation, and supports all bases in successfully passing various external supervision audits in the first half of the year.
- **Routine carriers of quality culture:** The company publishes the *Quality Journal* monthly, including regulatory news, quality case warnings, answers to common system questions, and excellent quality improvement cases, and organizes online quality knowledge quizzes and quality improvement proposal sharing salons, covering all employees, interns, and outsourced personnel. The above measures create a company-wide quality culture atmosphere, continuously strengthen routine quality awareness, and encourage employees to proactively identify job-related quality risks and propose quality improvement suggestions.

As of the first half of 2026, the company's quality and safety-related training has been conducted for a total of 326,394 person-times, with a total training duration of 106,948.07 hours; the coverage rate of quality and safety training for all employees reached 100%; the overall completion rate of annual

compulsory quality courses for existing employees remained high; and the comprehensive assessment pass rate for various quality training remained at a high level. Through the implementation of layered training, employees' ability to identify quality risks has been continuously improved.

iv. Supply Chain Management

In the global supply chain system, supplier management and auditing are core links in ensuring product quality, safety, and compliance. United Imaging Healthcare integrates quality, environmental, and social responsibility requirements throughout the entire supplier management process, including supplier admission, performance evaluation, regular audits, and continuous improvement, through a rigorous supplier management program. Leveraging systematic supplier certification, audit, and training mechanisms, the company strengthens supply chain resilience and promotes green procurement and responsible supply chain development.

1. Supplier Certification and Tiered Review System

In accordance with the *Supplier Management Procedure* and the *Supplier Audit Procedure*, all new Tier 1, Tier 2, and Tier 3 suppliers must undergo evaluation, audit, or qualification confirmation before being included in the Approved Supplier List. In July 2026, the Company updated the *Supplier Audit Procedure*, adding a standalone EHS module to supplier system audits and refining risk management-related checklists, further strengthening the screening of suppliers that better meet ESG requirements during supplier admission audits. The evaluation criteria cover multiple aspects, including technical support, commercial support, quality data, environmental hazardous substance control, and employee occupational health. Supplier audits or qualification confirmations primarily verify the supplier's quality system and third-party system certifications. As of the end of the reporting period, 97.3% of the Company's Tier 1, Tier 2, and Tier 3 suppliers had obtained third-party system certifications.

The Company has established differentiated evaluation and audit frequency arrangements for suppliers at different tiers: Tier 1 and Tier 2 suppliers undergo an annual business evaluation and a system audit every two years, with audit content covering quality system audits (including the EHS module), product audits, etc. Suppliers are required to rectify issues identified during audits to ensure the continued conformity of their quality and environmental systems. Tier 3 suppliers undergo an evaluation every two years, along with a comprehensive review and archiving of qualification certificates such as agency qualifications and quality system certifications, to ensure all certificates remain valid. For suppliers that do not meet requirements, the Company drives them to implement corrective actions and, when necessary, implements an elimination mechanism.

2. Supplier ESG Assessment and Risk-Based Tiered Management

The Company embeds ESG requirements into the full lifecycle management of suppliers. At the admission stage, suppliers that do not meet social responsibility requirements such as environmental protection and labor protection are not approved for inclusion in the Approved Supplier List. Assessment dimensions cover technical capability, delivery capability, quality performance, environmental management, occupational health and safety, and business ethics (such as anti-bribery and prohibition of child labor or forced labor). Based on evaluation and audit results, the Company classifies suppliers into risk tiers and

implements differentiated evaluation, audit, and management measures to strengthen supply chain resilience, risk control capability, and sustainable development capability.

In terms of green procurement control, the Company explicitly sets environmental requirements in the quality agreements and contract orders for all purchased products, emphasizing that materials used by suppliers must meet green environmental standards and comply with regulatory requirements. The Company has established a GPM (Green Product Management) platform, using an information system to comprehensively monitor and manage the environmental indicators of purchased materials. The Company actively guides suppliers to implement energy conservation and emission reduction measures in their production and operations, and encourages suppliers to adopt clean energy sources such as solar and wind power. In 2026, the Company established a dedicated ESG team within the procurement department, using environmental compliance requirements such as RoHS and REACH as entry points to drive suppliers from "passive response" to "proactive commitment," building a sustainable green supply chain system through signing compliance declarations and incorporating them into annual audits.

In terms of audit data management, the Company systematically integrates and regularly updates supplier evaluation, audit, and rectification data to achieve full-chain traceability management. Audit methods cover questionnaires, third-party audits, and on-site audits, with audit frequency flexibly adjusted based on business development, while continuously tracking supplier improvement effectiveness.

In the first half of 2026, the Company continuously monitored through annual evaluations and audits whether suppliers continued to meet requirements in terms of technology, delivery, quality, and social and environmental responsibility. Based on the annual evaluation and audit data completed in 2026, all suppliers of the Company met the requirements, and the supply chain remained stable and controllable overall. Details are as follows:

Indicator	H1 2026 Status
Number of new suppliers evaluated and audited	11 suppliers, all passed evaluation and audit
Number of approved suppliers with planned annual audits	97 suppliers
Number of audits actually completed in H1	50 suppliers, all passed with no major abnormalities
Number of suppliers with annual evaluations (completed in March 2026)	333 suppliers (based on 2025 quality, cost, technical process, and delivery performance)
Excellent suppliers with evaluation scores above 90	11 suppliers
Suppliers failing evaluation and placed on the elimination plan	3 suppliers (2 eliminated, 1 in the process of business transfer)
Proportion of Tier 1, Tier 2, and Tier 3 suppliers with third-party system certification	97.3%

3. Supplier Quality Standards Training

United Imaging Healthcare places emphasis on supplier capability building, incorporating supplier training into the supplier management system as a key measure to drive overall supply chain quality improvement and sustainable development. In accordance with the *Supplier Training Policy*, the Company plans and implements annual routine training covering all suppliers each year, and conducts flexible special training through online knowledge sharing, WeChat official account promotions, quality meetings, procurement technical exchange sessions, and special training programs, achieving training coverage for all suppliers.

In terms of training content, supplier training focuses on quality system standards and requirements, United Imaging Healthcare quality standards, applicable quality and environmental regulations, as well as ESG-related management requirements such as labor, safety, environment, and carbon emissions. In terms of assessment, after the annual training, the Company conducts examinations for supplier quality representatives, with exam content covering quality requirements and related compliance requirements. Those who pass the exam will receive JQE (Joint Quality Engineer) certification, continuously promoting suppliers to enhance their quality and compliance management capabilities. The supplier training activities in the first half of 2026 are as follows:

Training Format	H1 2026 Implementation Status
Annual routine training coverage	All Tier 1, Tier 2, and Tier 3 suppliers
Special inspections and coaching	Joint R&D teams conducted special inspections and coaching for 46 suppliers to enhance their management capabilities for sub-tier suppliers and key materials
Key supplier quality meetings	Over 344 sessions in total, with training exceeding 541 hours
Online GPM environmental regulation training	16 training sessions conducted for 147 suppliers

In addition, the Company plans to hold a Supplier Quality Conference in September 2026. On the one hand, it will share and exchange excellent experiences, inviting suppliers with outstanding performance in quality management or social responsibility management to share their experiences, and United Imaging Healthcare manufacturing process experts will share process development and process control experience. On the other hand, special training will be conducted on topics such as quality, standards, regulations, environmental hazardous substance management, and carbon emission management.

4. Supply Chain Collaborative Development and Industry Initiative Participation

United Imaging Healthcare actively monitors the development of industry supply chain associations and related industry initiatives and cooperative organizations, and continuously evaluates the feasibility of

participating in industry initiatives and cooperative organizations related to supply chain and contractor risk assessment (such as RMI). Going forward, the Company will develop action plans for participating in such cooperative organizations based on business realities and supply chain risk management needs. By systematically analyzing and learning from industry best practices and advanced management experience, the Company will continuously optimize upstream and downstream collaboration models and strengthen supply chain synergies.

5. Risk mitigation management for product inventory stability, reliability, and safety

United Imaging Healthcare has built a multi-tiered risk mitigation system covering production, supply, warehousing, logistics, and technological innovation, centered on production continuity, reliability, inventory stability, and safety. All measures have been implemented and are being continuously optimized.

(1) Backup production bases and multi-site capacity layout: The Company leverages its global production bases in Shanghai, Changzhou, Wuhan, Houston (USA), and other locations to achieve distributed multi-site capacity and product layout. The Jiading Phase II Intelligent Manufacturing Base, currently under construction, is expected to commence operations in early 2027. Meanwhile, other overseas regional production bases are also being planned, further enhancing capacity flexibility and supply diversification.

(2) Self-reliance and dual sourcing of key components: The Company adheres to the principle of self-development and self-manufacturing of core components, having achieved self-reliance and control over core components across its entire product line and completed domestic substitution for multiple key components, advancing the localization of key components such as FPGAs, power semiconductors, analog chips, slip rings, and scintillators. Simultaneously, by establishing long-term, stable strategic partnerships with multiple global suppliers, leveraging centralized procurement advantages, and strengthening tiered supplier management and dynamic assessment mechanisms, the Company ensures diversified supply and rapid switching capabilities for key raw materials and components.

(3) Safety inventory and spare parts allocation: The Company has established a tiered material management plan, implementing corresponding inventory management strategies for different material tiers. A global service network has been established, and safety stock and replenishment plans are developed based on installed base and forecasted installations in each global region. The Company's headquarters central warehouse maintains sufficient spare parts, and spare parts at storage centers can be flexibly allocated.

(4) Logistics assurance: The Company's innovative cold magnet sea freight model now covers nearly 100 countries and regions globally, significantly reducing equipment installation costs while ensuring delivery stability and minimizing the consumption of scarce resources.

(5) Risk avoidance at the technology source: The Company is developing helium-free superconducting magnetic resonance systems and technology to achieve zero helium boil-off, thereby avoiding supply risks for strategic materials such as liquid helium at the technology source. Leveraging a service network covering over 100 countries and regions globally and a localization strategy, the Company has formed a comprehensive, dynamic supply chain security assurance system.

(6) Emergency response mechanism for contingencies: In response to emergencies such as natural disasters, public health events, and supply chain disruptions, the Company issued the *Procurement Risk Management Guide* at the end of 2025. This guide systematically defines material procurement supply risks, covering supplier control, supply situation assessment, contingency plans, and the full lifecycle risk management and response measures from supplier admission, evaluation, cooperation, performance, to exit. In response to the impact on semiconductor delivery caused by the explosive growth in demand for artificial intelligence, the Company promptly established an emergency response team and formulated a response plan based on this guide. Through risk identification and multiple targeted measures, the Company effectively mitigated supply interruption risks, fully validating the effectiveness of the emergency mechanism.

v. Responsible Marketing Management

1. Responsible Sales and Marketing Policy

In the global medical device industry, responsible marketing practices are not only a core requirement for compliant corporate operations but also an important measure to protect patient rights and maintain market credibility. The Company has formulated the *Responsible Sales and Marketing Policy*[2] and published it on its official website to ensure that the marketing activities of the Company and its subsidiaries and branches worldwide remain legal, compliant, honest, and upright. This policy applies to the Company and its subsidiaries and branches. Third-party organizations such as distributors and service providers that represent the Company or participate in activities related to the Company's business (collectively, "Third Parties") must also comply. All marketing personnel, including but not limited to directors, senior management, full-time employees, dispatched workers, part-time employees, temporary workers, and consultants, must also strictly adhere to it.

(1) Basic principles. The Company requires that all marketing activities be legal, proper, honest, and truthful, and comply with local laws, regulations, industry standards, and regulatory requirements, including medical device regulatory laws, the Anti-Unfair Competition Law, the Advertising Law, and the Anti-Monopoly Law. It also ensures compliance with laws and regulations on data security, cybersecurity, and personal information protection in marketing activities, safeguarding the business secrets and information security of partners and customers. The Company adheres to high ethical standards and strictly prohibits any form of corruption and bribery in marketing activities. It strictly complies with the generally accepted principles of fair competition in the business community. Marketing activities must not contain any content that violates public order and good customs in relevant countries and cultures, nor may they abuse customer trust or exploit the vulnerability of patients lacking experience. All marketing content must be truthful and accurate and must not mislead customers or patients in any way.

(2) Promotion and publicity requirements. The Company requires strict compliance with laws and regulations on medical device promotion and advertising, ensuring that all promotional content clearly,

[2] *Responsible Sales and Marketing Policy*：https://global.united-imaging.com/-/media/uih/pdf/investor/20240823/responsible-sales-and-marketing-policy_en.pdf

accurately, objectively, and truthfully describes the functions, quality, intended uses, and other information of products and services, and remains consistent with the latest valid scientific research, trial data, and clinical practice. The content of marketing materials must be consistent with product registration certificates or filing materials and must not include or imply functions that the equipment does not possess or performance parameters that cannot be achieved. For products or functions that have not obtained marketing authorization or registration, their safety and effectiveness must not be promoted, and their authorization or registration status must be indicated in marketing materials. If promotional materials involve scientific research results, statistical data, survey findings, abstracts, data, or quotations, they must be truthful, accurate, and complete, with sources and validity periods indicated.

(3) Review and control of promotional materials. The Company has established and continuously improves a strict review mechanism for promotional materials and a control process for marketing documents, ensuring that the preparation, review, release, and archiving of all external promotional materials comply with the *Marketing Document Control Process*. All promotional materials must be reviewed and approved by relevant departments before official release. The Legal and Compliance Department has compiled the *Promotion Compliance Self-Checklist* as a compliance promotion guide, including common promotional compliance review opinions, for relevant business departments to reference and study when creating promotional materials.

The Company has also formulated a series of compliance policies and documents, including the *Code of Business Conduct*, *Anti-Bribery and Anti-Corruption Policy*[3], *Supplier Code of Conduct*, and *Distributor Code of Conduct*, which clearly define the business conduct standards for all employees, marketing personnel, and relevant partners in sales, promotion, supply chain management, and other activities. To ensure that distributors and suppliers are familiar with and understand the Company's compliance policies, the Company requires distributors to sign and comply with the *Distributor Code of Conduct* and requires suppliers to sign and comply with the *Supplier Code of Conduct*.

2. Responsible Marketing Training

The *Responsible Sales and Marketing Policy* specifies the requirements for responsible marketing training, promoting the Company's continuous development of responsible marketing education and training for employees. This ensures that responsible marketing awareness is conveyed to all marketing staff, key employees in external communication roles, and third-party personnel, ensuring that the information conveyed by employees and received by customers accurately reflects the characteristics of the Company's products and services.

The Company conducts responsible sales and marketing policy training for all employees annually. During the reporting period, the Company delivered business ethics and compliance training covering all employees, as well as compliance training for all marketing personnel, to communicate and emphasize the compliance requirements on business ethics, promotion, and publicity highlighted in the *Responsible Sales*

[3] *Anti-Bribery and Anti-Corruption Policy*：https://global.united-imaging.com/-/media/uih/pdf/investor/20240823/anti-bribery-and-anti-corruption-policy_en.pdf

and Marketing Policy. Training participants included managers, regular employees, interns, part-time staff, and outsourced personnel. At the same time, the Company requires all marketing personnel to sign a compliance confirmation letter, further clarifying the compliance requirements and responsible marketing awareness for employees in their roles, ensuring the full implementation of the *Responsible Sales and Marketing Policy*.

3. Responsible Marketing Audit

United Imaging Health has established an independent and efficient audit and supervision system. The internal audit team consists of dedicated personnel with extensive industry experience and professional competence. Organizationally independent from management, the team reports directly to the Audit Committee, ensuring the independence and impartiality of audit work. In accordance with the Company's risk management strategy, the internal audit department develops a systematic audit plan annually, defining audit objectives, scope, methodology, and responsibilities. Marketing compliance audits are included in the annual key audit items, and comprehensive compliance audits of the marketing activities of United Imaging Health and its distributors are conducted regularly.

The audit work focuses on the effectiveness of risk management and control systems, compliance with laws, regulations, and internal systems, the authenticity and completeness of information disclosure, and the protection of customer privacy data. It continuously upholds the principle of responsible marketing to prevent the risk of misleading or false publicity. Through an audit model combining "routine + key + special" audits, the Company identifies potential risks and opportunities for management improvement in business processes, driving continuous optimization of the internal control system. To unify audit standards and enhance oversight effectiveness, United Imaging Healthcare has issued the *Internal Audit Practice Guide - Responsible Marketing Audit* and established a market activity spot-check mechanism, providing clear and actionable operational guidance and evaluation criteria for all functional units.

To fully implement the responsible sales and marketing policy, the internal audit department includes all aspects of marketing activities within the scope of audit oversight, covering the authenticity and reasonableness of marketing expenses, compliance of conferences and academic promotion activities, accuracy and completeness of product information disclosure, declaration and management of conflicts of interest, compliance of distributor cooperation, and the standardization of after-sales spare parts management. Through a combination of annual risk assessments, sample audits, and marketing complaint investigations, the Company continuously monitors the implementation of the responsible sales and marketing policy by business personnel and third-party business partners.

In terms of audit frequency and coverage, the Company conducts a dedicated responsible marketing audit on a regular basis each year and has established a three-year full coverage plan to ensure that the audit scope covers all domestic and overseas employees and management, wholly-owned subsidiaries and their subordinate branches at all levels, and core third-party business partners (distributors, suppliers, and service providers, etc.) without any gaps. Through the systematic operation of the above mechanisms, the internal audit department effectively identifies and promptly corrects compliance

deviations in marketing activities, ensuring the legality, compliance, and information transparency of the Company's marketing practices.

During the reporting period, the internal audit department established a dual-track supervision mechanism of "spot checks + regular audits" to comprehensively strengthen the responsible marketing oversight system. Among these, market activity spot-checks serve as a key regulatory measure, adhering to the principle of "no prior notice, random sampling" to ensure the authenticity and objectivity of inspection results, with a focus on special inspections of key issues such as the authenticity and reasonableness of marketing expenses, compliance of conference and academic promotion activities, and compliance with anti-fraud, anti-bribery, and anti-corruption regulations. The internal audit department scientifically formulates spot-check plans based on the annual market activity plan and activity application forms, maintaining a reasonable sampling frequency to achieve dynamic monitoring of various marketing and promotion activities. The audit scope covers the entire process of promotion activities of all operating units, distributor conduct standards and cooperation compliance, the implementation of responsible marketing training for employees, and the implementation of customer privacy protection, among other core aspects.

For issues identified during inspections, the internal audit department has established a full-process closed-loop management mechanism: issuing formal audit reports in a timely manner and providing corrective action requirements to business departments; establishing a corrective action tracking ledger, clarifying responsible persons and completion deadlines, and implementing corrective action verification management; reporting audit results at quarterly marketing meetings and publicly disclosing typical issues; compiling a list of issues and communicating regularly with functional departments such as finance and legal to promote systematic root cause governance.

In the future, the internal audit department will continue to deepen the risk supervision and audit mechanism: in terms of regulatory breadth, further expand the coverage of spot checks to overseas regions; in terms of regulatory depth, strengthen data-driven risk warning capabilities to achieve a breakthrough improvement in regulatory effectiveness, providing solid support for the Company's compliant operations and sustainable growth.

IX Corporate Governance

United Imaging Healthcare continues to strengthen its corporate governance level, is committed to enhancing the Company's management capabilities, pays close attention to key factors such as diversity, independence, equality, and inclusiveness in the Company's sustainable development, improves the executive compensation management mechanism, and strengthens performance constraints related to sustainable development responsibilities. The Company has identified key matters related to business ethics, improved the construction of its business ethics management system, extensively carried out training and capacity building, and established a comprehensive business ethics audit and supervision mechanism to comprehensively promote the implementation of corporate governance measures and enhance their quality and effectiveness.

i.Protection of Shareholders' Rights

United Imaging Healthcare always adheres to improving its corporate governance system, strengthening the protection of shareholders' rights, and promoting the fairness, transparency, and efficiency of the governance structure. Voting rights are the core right of shareholders to participate in the Company's operation and management. To protect the interests of all shareholders, especially minority shareholders, the Company continuously improves mechanisms such as cumulative voting, separate vote counting, solicitation of voting rights, and online voting, and implements these mechanisms in the voting on proposals such as director elections and compensation plans to enhance the level of governance.

According to Article 87 of the *Articles of Association of United Imaging Healthcare*, the Company implements a cumulative voting system when electing directors. This system applies to the competitive election of directors, and the number of votes determines the qualification of candidates for election. The *Company Law* clearly stipulates that the cumulative voting system means that when the shareholders' meeting elects directors, each share has the same number of voting rights as the number of directors to be elected, and the voting rights held by shareholders can be used in a concentrated manner. The implementation of the cumulative voting system helps to enhance the voting influence of minority shareholders in director elections. Compared with the traditional simple majority voting system, the cumulative voting system gives shareholders greater voting flexibility, allowing them to freely allocate their voting rights according to their own interests, effectively reducing the disadvantage of minority shareholders in director elections, enhancing their actual influence on corporate governance, and avoiding insufficient representation caused by dispersed shareholding.

To ensure the fairness and transparency of director elections, the Company strictly complies with the requirements of the *Company Law* and other laws and regulations, fully discloses the resumes and basic information of candidates, and ensures that shareholders can make voting decisions. In addition, the Company strictly implements the cumulative voting system and separate vote counting mechanism. For major matters involving the rights and interests of minority shareholders (such as director compensation proposals), the voting results of minority shareholders are separately disclosed to enhance their decision-making influence and ensure the fairness of the voting process.

United Imaging Healthcare attaches great importance to the reasonableness and transparency of director compensation and reviews relevant compensation plans at the annual shareholders' meeting each year to ensure that compensation policies are in line with shareholders' interests. Article 83 of the *Articles of Association of United Imaging Healthcare* stipulates that when the Company deliberates on major matters involving the interests of minority investors (such as director compensation), it implements a separate vote counting mechanism for minority investors, and the vote counting results must be disclosed separately, thereby enhancing the decision-making influence of minority shareholders and ensuring that their rights and interests are fully protected.

During the reporting period, the Company held its 2025 annual shareholders' meeting on June 22, 2026, and approved the *Proposal on the 2026 Director Compensation of the Company*. The proposal was subject

to separate vote counting for minority investors, further reflecting the Company's respect for and protection of the rights and interests of minority shareholders.

The Company is always committed to enhancing shareholder participation and decision-making transparency, continuously optimizing various mechanisms to ensure the fairness and openness of the governance structure. In the future, the Company will further improve various procedures around shareholder voting rights, strengthen the fairness of director elections, optimize the compensation governance system, and benchmark against international advanced governance standards to enhance the Company's governance level and market recognition.

ii.Board Diversity

The Board of Directors of United Imaging Healthcare consists of 9 directors, including 3 executive directors, 1 employee director, and 5 non-executive directors (including 3 independent directors).

In the first half of 2026, the Company held 5 board meetings and 1 shareholders' meeting. All directors attended the aforementioned meetings, and there were no absences or instances of entrusting other directors to attend board meetings or shareholders' meetings. At the same time, all directors conducted comprehensive investigations and understanding of the matters under review, fully utilized their professional knowledge and practical experience to provide reasonable suggestions to the Company, exercised their duties objectively and independently, actively promoted the objectivity and standardization of board decisions, and effectively safeguarded the legitimate interests of the Company and all shareholders.

To further improve the corporate governance structure and strengthen the role of independent directors in the corporate governance system, the Company strictly complies with the relevant provisions of the *Company Law* and the *Articles of Association*, and in accordance with regulatory requirements such as the *Measures for the Administration of Independent Directors of Listed Companies* and the *Self-Regulatory Guidelines for Listed Companies on the Science and Technology Innovation Board of the Shanghai Stock Exchange No. 1 - Standardized Operations*, has established an Audit Committee, a Nomination Committee, a Compensation and Assessment Committee, and a Strategy and Social Responsibility Committee under the Board of Directors. Each committee is responsible for supervision and review in specific areas and performs decision-making duties within the scope of its authorization. Among them, the Audit Committee and the Compensation and Assessment Committee are composed of 3 independent directors to ensure the independence, fairness, and professionalism of supervision and decision-making. In the first half of 2026, the Compensation and Assessment Committee of the Board of Directors held 3 meetings, the Audit Committee held 1 meeting, and the Strategy and Social Responsibility Committee held 2 meetings.

United Imaging Healthcare deeply recognizes that board diversity and professionalism are crucial to the company's sustainable development and sound governance. The company continuously promotes the construction of a diverse and inclusive board in terms of gender, age, cultural background, and professional experience, leveraging its multi-dimensional perspectives and rich experience to enhance the comprehensiveness of complex decision-making and strategic formulation. The company's board members have diverse nationalities and cultural backgrounds, with professional expertise spanning

multiple disciplines including biomedical engineering, physics, law, and financial management, and possess career experience from leading global enterprises and academic institutions. This diverse and professional background enables the board to ensure that company policies comply with international standards and best practices, while more effectively supervising and guiding management, thereby improving the quality and transparency of governance. The company also places great emphasis on promoting gender diversity. There are already multiple female executives in the management team, fully practicing gender-diverse management.

The company also attaches great importance to the professional composition and independence of the Audit Committee to ensure its effective performance in financial supervision, compliance management, and risk control. The Audit Committee of the company's board consists of 2 independent directors and 1 non-executive director. The three members have backgrounds as a financial expert, an industry expert, and a legal expert respectively. All members possess professional knowledge and experience in financial management, audit supervision, legal compliance, and the pharmaceutical and biotechnology industry, forming multi-dimensional professional support to ensure the robust operation of the Audit Committee in core functions such as financial reporting quality, internal control, legal compliance, and risk management. Among them, Mr. Wang Shaofei, the financial and risk management expert and Chief Independent Director, serves as the Chairman of the Audit Committee. He has a solid professional background in accounting and financial management, as well as profound theoretical knowledge and practical experience in financial supervision, accounting standards, corporate financial management, and capital market operations. Mr. Shen Siyu, an industry expert and member of the Audit Committee, has over ten years of experience in pharmaceutical and biomedical industry management and investment. He is familiar with the investment and financing operations, financial governance, and capital market regulatory requirements of the healthcare industry, and can provide professional support for the company's financial supervision, internal control, and risk management in light of industry characteristics. Mr. Sheng Leiming, a legal and risk management expert, also serves as a member of the Audit Committee. He has a strong legal professional background and has long focused on corporate governance, securities legal compliance, and risk management.

The company also attaches great importance to building the diversified capabilities of directors and actively encourages board members to participate in various professional skill enhancement and compliance training programs, covering national policies, securities market laws and regulations, operational mechanisms, company systems, as well as environmental and social responsibility-related topics (such as climate change). Through these training programs, the compliance awareness and performance capabilities of board members have been effectively enhanced. In the first half of 2026, the company continued to organize board members to participate in special training and learning exchanges covering multiple areas, including capital market regulatory dynamics, corporate governance and compliance requirements, sustainable development and ESG rating trends, climate change and environmental policies, and industry development and technological frontiers. The training formats include special lectures, external study programs, and industry exchange meetings, helping board members

stay abreast of regulatory policies and the latest industry developments in a timely manner, and continuously enhancing their governance decision-making capabilities and ESG professionalism.

iii.Director Independence

United Imaging Healthcare attaches great importance to director independence and is committed to safeguarding and continuously improving the quality of decision-making and the effectiveness of supervision. To fully leverage the positive role of independent directors in corporate governance, the company continuously improves the working mechanism for independent directors, promotes the establishment of a Chief Independent Director to organize, coordinate, and lead independent directors in fully performing their functions of participating in decision-making, exercising checks and balances, and providing professional consultation, effectively regulating the conduct of independent directors, safeguarding the overall interests of the listed company, and protecting the legitimate rights and interests of shareholders. As of the first half of 2026, the number of independent directors on the board is 3, accounting for one-third of the total number of directors.

During the reporting period, independent directors prudently judged matters such as related-party transactions of the company. The implementation of this system has further strengthened the independence and supervisory functions of independent directors, ensured the fairness and scientificity of board decisions, and effectively safeguarded the legitimate rights and interests of shareholders.

In addition to exercising the powers of an independent director, the Chief Independent Director is also required to perform the following duties:

- Convene and preside over special meetings of independent directors;
- Solicit suggestions from all independent directors regarding matters under board review and meeting agendas, and communicate with the Board Secretary and other senior management personnel of the company;
- Provide recommendations to the conveners of the board's special committees regarding the preparation of agendas for the special committees;
- Organize research on systems related to independent directors and propose revision recommendations, and convene independent directors to work on-site at the company.

For details, please refer to the *Working System for Independent Directors* disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn).

During the reporting period, all independent directors of the company, upholding an attitude of responsibility toward the company and all shareholders, strictly complied with the requirements of various laws and regulations, faithfully and diligently performed their duties as independent directors, participated in the decision-making of major company matters, expressed opinions and exercised voting rights independently and impartially, fully leveraged the supervisory role and independence of independent directors, and made due efforts to safeguard the overall interests of the company and the rights and interests of all shareholders.

iv.Compensation Management

1. Compensation Linked to Sustainable Development

The company deeply recognizes the intrinsic connection between corporate success and social responsibility and sustainable development. As an industry leader, the company is not only committed to commercial excellence but also actively seeks effective ways to address social and environmental issues through innovation and professional services. The company's ESG strategy is a core force driving long-term sustainable development, profoundly influencing the company's decision-making and daily operational practices.

To ensure that the company's leadership team remains highly aligned with the company's sustainable development vision and strategic goals, the company has specifically elevated the importance of sustainable development in its compensation policies. The company has formally incorporated sustainable development goals into the individual performance assessment system for members of the Executive Management Committee. Specifically, 5% of the assessment weight for members of the Executive Management Committee is directly linked to "improvement in ESG rating performance," with assessment indicators covering sustainable development dimensions such as ESG rating results, product safety and quality performance, employee development, carbon footprint management, and the implementation of emission reduction commitments. This not only strengthens the company's commitment to ESG performance but also incentivizes the company to continuously optimize and improve in the ESG field, thereby ensuring the creation and maintenance of long-term value for all stakeholders. Through this incentive mechanism, the company expects to promote positive changes in key areas such as environment, society, and governance, achieving a harmonious coexistence of corporate value and social value.

2. Compensation Say-on-Pay Policy

The company attaches high importance to shareholders' say in the compensation matters of senior management and executive directors, and has established institutionalized shareholder voting arrangements through the company's articles of association and internal governance systems. According to the *Articles of Association of United Imaging Healthcar* and the *Working Rules of the Board Compensation and Assessment Committee*, the director compensation plan is formulated by the Board Compensation and Assessment Committee, reviewed by the board of directors, and then submitted to the shareholders' meeting for review and voting, with an annual regular voting mechanism; for director compensation proposals involving the interests of small and medium-sized investors, the company implements separate vote counting for small and medium-sized investors and separately discloses the voting results.

In terms of scope, the say-on-pay policy applies to the compensation plans of all directors (including executive directors) of the company; the compensation plans of senior management are reviewed by the Compensation and Assessment Committee and then reported to the board of directors for approval, and are disclosed in periodic reports, subject to shareholder supervision. In terms of implementation process, the company follows the complete chain of "formulation by the Compensation and Assessment Committee

- review by the board of directors - voting by the shareholders' meeting - disclosure in periodic reports," ensuring that the compensation decision-making process is legal, compliant, open, and transparent.

In terms of shareholder communication, the company continuously listens to shareholders' and investors' opinions and suggestions on corporate governance and executive compensation arrangements through various channels such as performance briefings, the SSE e-interaction platform, investor conference calls, and on-site and online research receptions, providing shareholders with opportunities to consult and provide feedback on executive compensation plans. In the future, the company will further enrich the forms of shareholder communication, strengthen shareholder participation in compensation governance, continue to benchmark against advanced domestic and international governance practices, and improve the standardization and transparency of the say-on-pay mechanism.

During the reporting period, the company's 2025 annual shareholders' meeting reviewed the *Proposal on the Compensation of Directors for 2026*, and the voting result was: 469,092,689 shares in favor, accounting for 99.7225% of the total voting shares held by shareholders attending the meeting; among which, the voting by small and medium-sized investors was 106,377,479 shares in favor, accounting for 98.7880%.

3. Incentive Clawback Mechanism and Bonus Recovery

To strengthen the alignment between compensation incentives and the Company's long-term sound operations, and to prevent risks associated with short-termism and misconduct, United Imaging Healthcare has embedded corresponding clawback and recovery arrangements into its existing compensation and incentive system. At the equity incentive level, the Company's equity incentive plan explicitly stipulates that if an incentive recipient engages in conduct that seriously damages the Company's interests or reputation, such as violating laws or regulations, breaching professional ethics, disclosing Company confidential information, dereliction of duty or malfeasance, or if the Company's financial reports are issued with an adverse audit opinion or a disclaimer of opinion, or the Company restates previously disclosed financial reports, the Company has the right to terminate the recipient's participation rights, void unvested equity, and recover granted equity and related gains in accordance with applicable regulations. At the performance bonus level, the *Company's Performance Management Measures* and related bonus management regulations stipulate that the Company has the right to adjust, deduct, or recover bonuses already paid out due to distorted performance data, business violations, or circumstances subsequently discovered to be non-compliant with payment conditions.

Regarding responsible parties and execution mechanisms, the Board's Remuneration and Appraisal Committee is responsible for reviewing and supervising the implementation of compensation clawback-related policies; the Audit Department is responsible for identifying triggering events through routine and special audits and proposing handling recommendations; the Human Resources Department and Finance Department are responsible for specific calculation and execution; matters involving directors and senior management are reviewed and decided by the Board of Directors. Triggering events mainly include material errors in financial reports or retrospective restatements, material compliance violations or business ethics violations, major safety or quality incidents, and material distortion of performance results.

The execution process follows a closed-loop management of "event identification - investigation and verification - committee review - board resolution - execution of recovery - disclosure of results."

In terms of statistics and reporting, the Company maintains a ledger for the triggering reasons, involved parties, recovered amounts, and execution results of compensation clawbacks, which is periodically reviewed by the Remuneration and Appraisal Committee and reported to the Board of Directors. During the reporting period, no circumstances requiring the initiation of compensation clawback occurred.

The Company has included the formulation and online disclosure of a dedicated *Senior Management Compensation Clawback Management Policy* in its next-stage governance improvement plan, intending to further clarify the scope of covered groups (executive directors and senior management), the specific scope and proportion of compensation subject to clawback within the compensation structure, the look-back period, as well as triggering conditions, execution procedures, and handling measures, and will simultaneously publish Chinese and English versions to continuously enhance the standardization and international comparability of compensation governance.

4. Director Remuneration for the First Half of 2026

Unit: RMB ten thousand

Name	Allowance	Paid Remuneration	Employer Contributions to Various Social Insurance and Housing Funds, etc.	Total Pre-tax
Zhang Qiang	-	157.50	11.08	168.58
GUOSHENG TAN	-	131.20	1.58	132.78
JUN BAO	-	128.63	1.58	130.20
TAO CAI	-	94.50	1.58	96.08
Bao Chen	-	-	-	-
Shen Siyu	-	-	-	-
Sheng Leiming	10	-	-	10
Wang Shaofei	10	-	-	10
JIA HONG GAO	10	-	-	10

Note: Any discrepancies in the above figures are due to rounding.

v.Business Ethics

As a globally leading medical technology company, United Imaging regards business ethics and compliance management as the cornerstone of its operations, and ensures the highest standards of business ethics are practiced in all business activities through a robust compliance system.

1. Business Ethics Management

(1) Business Ethics Supervision and Management System and Performance of Duties

United Imaging's business ethics compliance system is directly managed by the Board of Directors, with the Strategy and Social Responsibility Committee and the Audit Committee under the Board ensuring the effective implementation of high standards in business ethics. The Legal & Compliance Department, Financial Control Department, Internal Audit, and various specialized committees are responsible for the specific execution and implementation of this system. The system covers multiple key areas, including anti-bribery and anti-corruption (ABAC), conflict of interest management, code of business conduct, information security and privacy protection, data compliance, responsible marketing, antitrust, anti-unfair competition, data security, export controls, and economic sanctions. The scope of the Company's business ethics compliance system covers all employees and its global business partners.

Board Strategy and Social Responsibility Committee: According to the *Working Rules of the United Imaging Strategy and Social Responsibility Committee*, the Board's Strategy and Social Responsibility Committee undertakes important management responsibilities in business ethics. The Committee is responsible for setting the Company's long-term goals in the field of business ethics and ensuring that these goals are fully reflected in the Company's daily operations and strategic planning. The Committee regularly monitors the implementation of the Company's policies on anti-corruption and anti-fraud, ensuring that all business conduct complies with the Company's ethical standards. At the same time, the Committee is also responsible for assessing business ethics risks, proposing improvement recommendations, and promoting the Company's continuous progress in areas such as social responsibility and environmental protection. In the first half of 2026, the Strategy and Social Responsibility Committee played a key role in the strategic planning and execution of business ethics. The Committee ensures the implementation of the Company's business ethics goals in daily operations and long-term strategy by setting and monitoring them; it also regularly reviews the Company's measures in anti-corruption and anti-fraud to ensure their effective implementation, and assesses and responds to potential business ethics risks.

Board Audit Committee: In accordance with the *United Imaging Healthcare Audit Committee Working Rules*, the Board Audit Committee is primarily responsible for supervising and reviewing the Company's financial information and its disclosure, ensuring the truthfulness, accuracy, and completeness of financial reports, and preventing any conduct that may damage the Company's business ethics. The Audit Committee regularly evaluates the effectiveness of the Company's internal audit procedures and the independence of external audit institutions, ensuring that audit reports can objectively and fairly reflect the Company's financial condition. Through oversight of internal controls and external audits, the Audit Committee ensures that the Company consistently adheres to high standards of business ethics in all its business activities.

During the reporting period, the Board Audit Committee regularly conducted rigorous reviews of the Company's financial reports and the financial information contained in periodic reports, ensuring the truthfulness, accuracy, and completeness of information disclosure, avoiding financial fraud or misconduct that could affect the Company's business ethics, and effectively safeguarding the transparency and compliance of the Company's financial information. In addition, the Audit Committee also supervises and evaluates the work of the Company's internal audit department, ensuring the effectiveness and independence of its procedures; simultaneously, it reviews the independence and professionalism of external audit institutions, ensuring that their reports objectively and fairly reflect the Company's financial condition and operating results.

In the first half of 2026, the Audit Committee regularly listened to work reports from the Audit Department, reviewed proposals related to business ethics matters, and supervised the independence and effectiveness of internal audit work, ensuring compliance with Board requirements. During the year, the Company conducted routine audits in key areas according to the audit rotation plan, and implemented special audits and anti-corruption system health assessments based on business risks. At the specific execution level, the review focused on the compliance of business collaborations with healthcare professionals, and unannounced spot checks were conducted on market conferences and events to ensure compliance with regulatory and Company policy requirements, effectively preventing corruption risks. Meanwhile, the Company conducted follow-up reviews of high-risk areas identified in previous audits and continued to advance the three-year full coverage plan, ensuring that business ethics audits cover all operating entities globally. In the issue confirmation phase, a "two-way communication" mechanism was adopted, combining verification of written materials with on-site interviews to ensure that audit findings are fully validated; when the final audit report is issued, responsible departments are simultaneously required to formulate actionable rectification plans, and the Audit Department continuously tracks the rectification progress to achieve closed-loop handling of issues.

(2) Business Ethics System

During the reporting period, the Company continued to improve its business ethics system, having reviewed and publicly disclosed the *Anti-Bribery and Anti-Corruption Policy* on its website. This policy applies to all employees of United Imaging Healthcare, clearly stipulates that the Board of Directors provides guidance and management on anti-bribery and anti-corruption related matters, identifies applicable anti-corruption and anti-bribery laws in China and other parts of the world where the Company operates, including but not limited to the *Anti-Unfair Competition Law of the People's Republic of China* (AUCL), the *U.S. Foreign Corrupt Practices Act* (FCPA), and the *UK Bribery Act* (UKBA), improves the principles of integrity, transparency, lawfulness, and accountability, as well as the definition and scope of bribery and corruption, and specifically regulates the anti-bribery and anti-corruption compliance requirements for United Imaging Healthcare employees, customers, suppliers, distributors, and other relevant parties. At the same time, the policy specifically specifies the scope, frequency, topics, and other requirements for anti-bribery and anti-corruption training for United Imaging Healthcare employees and business partners: for all employees, United Imaging Healthcare will provide anti-bribery and anti-

corruption training upon onboarding, and subsequently once a year; for employees in key positions, the Company will conduct multi-topic training on a regular and ad-hoc basis each year. For business partners, the Company requires distributors in each region to participate in at least one United Imaging Healthcare compliance training session per year and to commit to anti-bribery and anti-corruption compliance by signing necessary documents. Furthermore, this policy clearly stipulates the reporting channels for anti-bribery and anti-corruption matters and the provisions for handling disciplinary violations.

(3) Reporting Management System

The Company persists in optimizing its complaint and reporting investigation mechanism, and combined with routine internal supervision and inspection, continuously conducts systematic evaluation and oversight of the completeness and effectiveness of the internal control system. At the same time, the Company focuses on the accuracy and completeness of financial information, ensuring the truthfulness and reliability of financial reports.

The Company is committed to continuously improving the reporting management system, promoting the active participation of all employees in supervising and reporting misconduct, and building a more open and transparent compliance supervision platform. The Company takes received reports and leads seriously, initiating investigations promptly to ensure that the handling of violations and related personnel is compliant and reasonable. The Company has publicly disclosed the Chinese and English versions of the *Whistleblower Protection Policy* on its website, clarifying the requirements for whistleblower protection, strictly prohibiting any form of retaliation, and striving to create a safe and reliable reporting environment. The Company has publicly disclosed reporting channels such as the reporting email and hotline through internal systems and emails, so that whistleblowers can effectively report issues. The Company encourages whistleblowers to provide valid contact information whenever possible when providing information, so that the Company can better understand, verify, and investigate the relevant circumstances; at the same time, the Company also respects and protects the right of whistleblowers to remain anonymous for their own safety considerations. The specific reporting channels are: reporting email UIH_Compliance@united-imaging.com, reporting hotline 021-67076619.

(4) Three Lines of Defense Control Procedures

To ensure the comprehensiveness and effectiveness of the business ethics compliance system, United Imaging Healthcare has established three lines of defense control procedures, ensuring that business departments, the Compliance Office, and the Audit Department collaborate with each other to implement internal risk management and supervision, strengthen internal management and risk prevention, and safeguard the rights and interests of the Company and all stakeholders.

First Line of Defense: Business Departments. Each business department is the first line of defense for business ethics compliance management, primarily responsible for identifying and controlling compliance risks in daily business operations. United Imaging Healthcare's business departments include, but are not limited to, the Sales and Marketing Department, Procurement Department, Supply Chain Management Department, R&D Department, and Customer Service Department. These departments bear direct compliance management responsibilities within their respective business areas, ensuring that all

employees understand and strictly adhere to the Company's business ethics compliance policies and other relevant compliance requirements. Each business department must establish clear operating procedures and internal control mechanisms in high-risk areas such as contract management, procurement processes, product development, supply chain management, and customer interactions; department heads must regularly organize self-inspections, identify and report potential compliance risks, and take necessary preventive measures based on assessment results, including adjusting processes, strengthening training, or introducing new control measures, to ensure the legality and transparency of business activities.

Second Line of Defense: Legal & Compliance Department, Financial Control Department, and Various Business Compliance Committees. The Legal & Compliance Department and the Finance Control Department serve as the Company's second line of defense, bearing the important responsibility of formulating, implementing, and supervising the execution of business ethics compliance policies across the Company. The Legal & Compliance Department is primarily responsible for formulating and updating compliance policies, ensuring that the Company complies with laws and regulations in all business activities, identifying and preventing potential legal risks through close cooperation with other business departments, providing compliance guidance, and supervising and correcting conduct that may violate laws and regulations; the Legal & Compliance Department is also responsible for conducting regular compliance training for all employees. The responsibilities of the Finance Control Department include strict supervision and management of the Company's financial processes, particularly in high-risk areas such as contract management, procurement, sales, and capital flows, ensuring that all financial operations comply with laws, regulations, and Company policies; the Finance Control Department also regularly audits and assesses the financial activities of each business department, identifies and addresses potential compliance risks, and proposes improvement suggestions and preventive measures based on audit results. In addition to the Legal & Compliance Department and the Finance Control Department, United Imaging Healthcare has also established multiple specialized business compliance committees, which are responsible for supervising and guiding the execution of compliance matters in their respective areas, including:

- Marketing Compliance Committee: Supervises the compliance of the Company's marketing and sales activities, ensuring that advertising, promotion, and customer relationship management comply with Company policies and laws and regulations, reviews compliance reports on marketing activities, assesses potential risks, and proposes improvement suggestions;
- Information Security and Privacy Protection Committee: Responsible for formulating and supervising the Company's compliance policies in the areas of information security and privacy protection, ensuring that data processing, storage, and transmission comply with relevant legal requirements, regularly reviewing data privacy risk reports, and responding to and handling information security incidents in a timely manner. During the reporting period, the Committee confirmed that the Company's data privacy protection measures were fully implemented, and no information leakage incidents were identified.

- Quality and Compliance Management Committee: Responsible for overseeing the company's product quality and compliance management, ensuring that all products meet industry standards and regulatory requirements, and conducting pre-review of the compliance of new products to ensure that all regulatory requirements are met before products are launched. During the reporting period, no non-compliance with quality standards occurred.
- Anti-Corruption and Data Compliance Group: Responsible for reviewing the company's internal and external data transactions and financial records to ensure that there are no violations of ABAC policies or other compliance requirements, and for conducting in-depth supervision and review of compliance in relevant areas through regular meetings. During the reporting period, the company did not identify any bribery or corruption.

In addition, the relevant meetings implement archiving and document management mechanisms including but not limited to the following: reviewing the minutes of the previous meeting, reviewing the latest compliance reports, assessing newly identified risks, discussing and approving relevant policy changes, and formulating improvement measures. The decisions and recommendations of each committee are formally recorded after each meeting and submitted to the Legal & Compliance Department and senior management for further review and implementation.

Third line of defense: Internal Audit Department. As the company's third line of defense, the Internal Audit Department is independent of business departments, the Legal & Compliance Department, and the Financial Control Department, and focuses on evaluating the overall effectiveness of the company's compliance management system. The Internal Audit Department conducts an independent and comprehensive review of the company's business activities annually, with special attention to high-risk areas such as bribery, corruption, conflicts of interest, and improper marketing practices. Audit activities, while covering the company's internal business processes, have been extended to interactions with external partners, such as the compliance status of suppliers and distributors. Audit results are reported directly to the Board of Directors and provide key decision-making support for the company's senior management. Through audit results, the company can identify potential compliance gaps, take corrective actions, and continuously optimize and improve its compliance management system.

During the reporting period, the Internal Audit Department completed comprehensive reviews of the company's major business areas and conducted compliance assessments of key external partners. The audit reports showed that all audited businesses and partners complied with the company's compliance policies and legal requirements, and no significant violations were found. In addition, internal audit also cooperates with external audit firms to conduct regular independent reviews, ensuring that United Imaging Healthcare's compliance management system not only meets the company's internal standards but also reaches international best practices and legal requirements.

The company also expects all business partners (including customers, suppliers, agents, and distributors) to uphold high business ethics and work together with United Imaging Healthcare to foster an honest and compliant business environment.

2. Business Ethics Training

United Imaging Healthcare is always committed to strengthening the construction of a compliance culture and deepening business ethics-related education and training. The training content comprehensively covers the requirements of systems and policies such as the *Code of Business Conduct*, *Anti-Bribery and Anti-Corruption Policy*, *Responsible Sales and Marketing Policy* , *Conflicts of Interest Policy*, *Trade Secrets Management Policy*, *Internal Investigation Policy*, and *Whistleblower Protection Policy*. A multi-channel, diversified, and multi-level comprehensive training system has been established, with annual business ethics compliance training for all employees (including regular employees, interns, part-time employees, outsourced employees, and dispatched workers), aiming to strengthen the business ethics and compliance awareness of all employees. Through a combination of online and offline methods, and utilizing various formats such as slides, video teaching, and case discussions, the company ensures that all employees can participate in training in the most suitable way. To further consolidate the training effect, the company has also established a strict assessment mechanism to evaluate and provide feedback on employees' learning outcomes.

United Imaging Healthcare is always committed to strengthening the construction of a compliance culture and deepening business ethics-related education and training. The training content comprehensively covers the requirements of systems and policies, including the *Code of Business Conduct*, *Anti-Bribery and Anti-Corruption Policy*, *Responsible Sales and Marketing Policy*, *Conflicts of Interest Policy*, *Trade Secret Management Policy*, *Internal Investigation Policy*, and *Whistleblower Protection Policy*. A multi-channel, diversified, and multi-level comprehensive training system has been established, with annual business ethics compliance training for all employees (including regular employees, interns, part-time employees, outsourced employees, and dispatched workers), aiming to strengthen the business ethics and compliance awareness of all employees. Through a combination of online and offline methods, the company utilizes various formats such as slides, video teaching, and case discussions to ensure that all employees can participate in training in the most suitable way. To further consolidate the training effect, the company has also established a strict assessment mechanism to evaluate and provide feedback on employees' learning outcomes.

(1) General Business Ethics Training: The content systematically covers key modules such as interpretation of laws and regulations, interpretation of internal compliance policies, code of business conduct, promotion and responsible marketing, anti-bribery and anti-corruption, anti-fraud, conflicts of interest, trade secrets and privacy protection, as well as violation handling mechanisms and whistleblower protection, ensuring that trainees form a unified, clear, and actionable understanding of business ethics standards.

During the reporting period, the company released this year's business ethics compliance training to all employees. The training methods included a combination of online and offline training, with video training materials published in both Chinese and English on the internal learning platform, requiring all employees to complete the training.

To strengthen data compliance awareness among all employees, the company, combining data regulations

with business ethics, launched a Data Compliance Micro-Course, requiring all employees to comply with data protection regulations and the company's data protection and compliance policies, and to actively cooperate with the company's various governance measures in data protection. Furthermore, business ethics compliance training was conducted for all marketing employees, focusing on core compliance areas such as business ethics and code of conduct, anti-bribery and anti-corruption, anti-fraud, and conflicts of interest. To strengthen the compliance awareness of marketing employees, targeted training for key positions was subsequently carried out continuously to further enhance the compliance awareness of marketing employees.

During the reporting period, the training coverage rate reached 100%, with cumulative participation exceeding 12,000 person-times. At the same time, various compliance courses remain open for subsequent new employees to continue participating in training, ensuring that all employees can fully understand the company's business ethics standards and compliance systems and policy content.

(2) Specialized Training for Key Positions: In the first half of 2026, United Imaging Healthcare focused on important compliance areas and key position groups, carrying out multi-level, differentiated business ethics compliance special training. Among these, the company further conducted special compliance training for all marketing personnel, systematically covering core topics such as interpretation of laws and regulations, promotion of internal compliance policies, business ethics and code of conduct, anti-corruption and anti-bribery, conflicts of interest, warnings of violation cases, and accountability mechanisms, based on the business ethics and compliance risk scenarios involved in marketing activities, to comprehensively strengthen the business ethics and compliance awareness of marketing personnel. At the same time, focusing on the compliance field of bidding and tendering, and in conjunction with the *Interpretation (II) of the Supreme People's Court and the Supreme People's Procuratorate on Several Issues Concerning the Application of Law in Handling Criminal Cases of Corruption and Bribery*, special compliance training sessions covering all marketing personnel were conducted, including bidding and tendering compliance training and compliance training under the background of the new judicial interpretation, ensuring that marketing personnel have a comprehensive and in-depth understanding of relevant legal provisions and compliance standards. In the first half of 2026, the aforementioned special business ethics compliance training for all marketing personnel and new employees achieved 100% coverage of all marketing personnel.

The company conducted professional and targeted training for key positions such as the marketing department and market department, covering not only basic business ethics content but also, combined with industry characteristics and departmental functions, deeply exploring how to effectively prevent corruption and fraud risks in specific business scenarios such as market promotion, advertising, and customer relationship management, and guiding employees to master the ability to make compliant decisions in high-risk environments through case analysis and simulated scenario exercises. In marketing activities, the training detailed how to follow company policies for business etiquette, customer reception, and the organization of marketing activities, avoiding legal and reputational risks caused by improper behavior; the professional training for the market department focused on the compliance of advertising

content, the authenticity of product promotion, and transparency in communication with customers and partners.

Meanwhile, during the reporting period, the Company carried out business ethics and compliance training for all sales and marketing personnel, combining online and offline methods, covering all sales and marketing personnel. The training content focused on business ethics and codes of conduct, anti-bribery and anti-corruption, responsible marketing and market promotion, conflicts of interest, and protection of trade secrets. The Company conducts special compliance training for newly hired sales and marketing personnel every quarter to ensure that new employees promptly understand the Company's compliance requirements, and requires all sales and marketing personnel to sign compliance confirmation letters to clearly understand the business ethics and compliance standards for performing their duties. At the same time, the Company provides supplementary learning resources for marketing managers with management functions, carrying out special legal compliance training to help managers further deepen their understanding of the legal and compliance aspects of business conduct and performance management.

Relying on the combination of general training and professional training, United Imaging Healthcare continuously optimizes a multi-level and diversified training system, ensuring that employees at every level and in every department can obtain training content suitable for their job requirements, effectively promoting all employees' awareness of the importance of business ethics compliance, and further strengthening their ability to execute compliance requirements in business operations. In the second half of the year, United Imaging Healthcare will continue to conduct business ethics training, dynamically updating training content based on laws, regulatory policies, and business development needs, ensuring that the company's compliance governance capabilities for all employees remain at the industry-leading level.

In the future, the company will continue to deepen business ethics and compliance management, strengthen compliance awareness building for all employees, further optimize and expand the multi-level training system, and increase training and supervision of partners to establish a more transparent and fair cooperation mechanism.

3. Business Ethics Audit

To proactively manage compliance risks and deeply integrate business ethics standards into the company's core operations, United Imaging Healthcare has strategically deployed a risk-oriented dynamic audit system. The core of this system lies in a continuously evolving risk assessment mechanism, which forms comprehensive risk insights through systematic integration and analysis of relevant laws and regulations, operational data, and historical audit records, providing a decision-making basis for the strategic allocation of audit resources, enabling the company to precisely focus on high-risk areas that have a significant impact on corporate value, such as anti-bribery, anti-fraud, and conflicts of interest.

(1) Business Ethics Standards Audit Management: As an independent functional department, the Internal Audit Department is fully responsible for the construction and continuous optimization of United Imaging Healthcare's business ethics and compliance management system, reporting directly to the Audit Committee to ensure the independence and authority of the supervisory function. The Internal Audit

Department has established a systematic compliance risk assessment procedure to regularly identify, rank, and monitor the business ethics risks faced by each business segment of United Imaging Healthcare, with a focus on key areas such as anti-bribery, anti-fraud, network and data security protection, privacy and information security protection, and conflicts of interest.

To standardize audit standards, the Internal Audit Department has formulated and implemented the *Internal Audit System* and 21 supporting practical guidelines, providing clear operational basis and evaluation criteria for the compliance management of each business unit. Among them, the *Internal Audit Practice Guide - Business Ethics Standards Audit* further clarifies the company's audit scope and operational procedures in the field of business ethics compliance, ensuring compliance in key areas such as anti-corruption, anti-fraud, employee conduct management, and responsible marketing. Before conducting audits, the Internal Audit Department comprehensively collects laws and regulations, institutional documents, operational data, and historical audit records through a systematic risk assessment process, conducts a preliminary assessment of business compliance, and formulates audit plans covering the global operational network based on this. After audit findings are identified, a closed-loop management mechanism of "rectification notice - rectification within a time limit - follow-up verification" is adopted to ensure that all compliance deficiencies are effectively corrected.

(2) "Three-Year Coverage" Plan and Audit Matters for Business Ethics Audits: Regarding the "Three-Year Coverage" plan for business ethics audits, the Audit Department of United Imaging Healthcare formulates detailed annual audit plans and implements institutional rotation arrangements to ensure coverage of all operating institutions within every three years. The audit scope covers all domestic and overseas employees and management, holding subsidiaries and their subordinate branches at all levels, and core third-party business partners (distributors, suppliers, and service providers, etc.), continuously strengthening the effectiveness of business ethics supervision. The overall rotation arrangement for the "Three-Year Coverage" of business ethics audits is: the first year targets the headquarters, the second year targets domestic subsidiaries, and the third year targets overseas subsidiaries; at the same time, more frequent reviews are conducted on high-risk areas to respond to market changes and new compliance challenges. The 2026 internal audit plan has included key audits of emerging markets and high-risk areas to dynamically respond to the ever-changing business environment.

United Imaging Healthcare's business ethics audits cover key areas such as anti-corruption, anti-fraud, employee conduct management, and responsible marketing. Based on risk assessment results, the Audit Department focuses on reviewing high-risk key areas related to business ethics. The company has provided detailed provisions for various audit matters through the *Internal Audit Practice Guide - Business Ethics Standards Audit*:

- Anti-corruption audit: Assess bribery risks by analyzing historical cases, Transparency International's Corruption Perceptions Index, and other data, and formulate annual audit plans for high-risk areas. Based on comprehensive risk ratings, the company selects specific subsidiaries and business areas for audit each year and sets a three-year rotation plan to ensure comprehensive coverage of all operating institutions and business departments globally;

- Anti-fraud audit: Focuses on checking internal fraud risks, including fabricated reimbursements, inflated expenses, forged contracts, and other behaviors. The company has established complete procedures to ensure that all financial operations and contract executions comply with legal and company policy requirements;
- Employee conduct management: The audit covers employee conduct standards, with special attention to conflict of interest management and the implementation of confidentiality agreements for employees in key positions;
- Responsible marketing audit: Reviews the marketing activities of the company and its agents to ensure that their content meets responsible marketing requirements and eliminates misleading or false advertising; the concurrently released *Internal Audit Practice Guide - Responsible Marketing Audit* clarifies the responsibilities of each functional organization and systematically guides responsible marketing audits and key matters of concern.

(3) Business Ethics Audit Procedures and Mechanisms: In terms of audit procedures and mechanisms, United Imaging Healthcare dynamically identifies and focuses on audit areas based on risk assessment results. The audit procedure begins with a comprehensive assessment of potential risks, testing the effectiveness of control measures through methods such as "compliance testing." The Audit Department regularly works closely with various business departments and functional departments such as the Legal Compliance Department and the Financial Control Department to ensure that all policies and procedures are fully implemented. Audit reports are submitted directly to the Audit Committee, and corresponding rectification plans are formulated based on the audit results, ensuring the company's compliance with ethical standards and continuous improvement. In addition, the Audit Department has set up a dedicated reporting mailbox at internalaudit@united-imaging.com to enable all employees and relevant parties to anonymously report potential violations, further strengthening the company's internal supervision mechanism. Specific audit procedures include:

- Preliminary preparation and risk assessment: Following the risk-oriented principle, collect relevant laws and regulations, institutional processes, and historical audit records, conduct a rigorous preliminary assessment of the compliance of business activities, and formulate a detailed audit plan covering the global operational network. The plan takes achieving comprehensive coverage within three years as a strategic goal, ensuring that the audit scope seamlessly extends to all employees, organizations, and third-party partners at home and abroad;
- Audit execution: Based on risk assessment results, the Audit Department focuses on high-risk areas, including in-depth audits of key areas such as anti-bribery, anti-fraud, conflicts of interest, and responsible marketing. The audit process includes detailed examination of relevant documents, financial records, contracts, and transaction processes;
- Preliminary audit results and verification: After executing the audit, the Audit Department verifies the preliminary audit results with the audited department, ensuring that all identified issues are fully explained and resolved through on-site interviews and document verification;

- Audit report and rectification tracking: After the verification phase is completed, the Audit Department prepares a detailed audit report listing the identified issues and recommendations. The report is submitted to the Audit Committee for review, and rectification measures are formulated based on the audit results. The Audit Department will continue to track the rectification progress to ensure that all issues are effectively resolved.

(4) Progress of Business Ethics Audit Work: In the first half of 2026, the Internal Audit Department of United Imaging Healthcare carried out compliance audit work in an orderly manner according to the annual audit plan. The audit scope covered domestic operating institutions and overseas branches in Singapore, Malaysia, and other regions, focusing on key areas such as conflict of interest management, information security and data privacy protection, anti-bribery and anti-corruption compliance, reasonableness of logistics expenses, after-sales spare parts management, and financing guarantee business risks. As of June 30, 2026, the Company has completed over 10 audit projects in total. For the issues identified in the audits, rectification notices have been issued to the relevant responsible units, and these issues have been included in the Company's audit rectification tracking ledger, with rectification verification required within a specified timeframe.

Project	H1 2026 Status
Number of Completed Audit Projects	Over 10 projects
Audit Coverage of Operating Entities	All domestic operating entities and overseas branches including Singapore, Malaysia, and others
Key Audit Areas	Conflict of interest management, information security and data privacy protection, anti-bribery and anti-corruption compliance, reasonableness of logistics costs, after-sales spare parts management, and financing guarantee business risks
Issue Rectification Mechanism	Rectification notices were issued for all issues and included in the Company's audit rectification tracking ledger, with rectification verification required within a specified timeframe
H2 Plan	Expand audit scope to more operating entities based on the annual audit plan and risk ranking

Based on the annual audit plan and risk ranking, the Internal Audit Department will expand the audit scope to more operating entities in H2. The Company will continue to apply the risk-oriented audit methodology, conducting systematic reviews of key business processes in the aforementioned regions, and through a full-cycle management mechanism of "identifying issues - urging rectification - verifying closure," build a solid compliance defense for the Company's robust global business development.

(5) Outlook and Planning: United Imaging Healthcare will continue to practice the risk-oriented internal audit strategy of "prevention and governance," further strengthening internal control and compliance management. For internal control issues and deficiencies identified during audits, the Audit Department will promptly propose improvement recommendations to relevant management and follow up on the implementation of rectifications. Looking ahead, the Company's internal audit work will continue to adhere to a risk-oriented approach, continuously enhancing the depth and breadth of business ethics internal audits, introducing more advanced audit techniques and tools, further strengthening risk identification and monitoring in key business areas, and ensuring the continuous optimization and improvement of the internal control system; at the same time, it will strengthen the professional competence of the audit team, enhancing the team's audit capabilities and acumen through systematic training and practice, to cope with the complex and ever-changing market environment and regulatory requirements, and to safeguard the Company's sustainable development.

Section IV Share Changes and Shareholder Information

I Share Capital Changes

i.Share Change Schedule

1. Share Change Schedule

During the reporting period, the total number of ordinary shares and the share capital structure of the Company did not change.

2. Explanation of Share Changes

□ Applicable√ Not applicable

3. Impact of share changes occurring between the end of the reporting period and the disclosure date of the semi-annual report on financial indicators such as earnings per share and net assets per share (if any)

□ Applicable√ Not applicable

4. Other content deemed necessary by the Company or required to be disclosed by securities regulatory authorities

□ Applicable√ Not applicable

ii.Changes in Restricted Shares

□ Applicable√ Not applicable

II Shareholder Information

i.Total number of shareholders:

Total number of ordinary shareholders as of the end of the reporting period (households)	40,380
Total number of preferred shareholders with restored voting rights as of the end of the reporting period (households)	/
Total number of shareholders holding shares with special voting rights as of the end of the reporting period (households)	/

Number of depositary receipt holders

□ Applicable√ Not applicable

ii. Shareholding table of the top ten shareholders and the top ten shareholders of unrestricted shares as of the end of the reporting period

Situation where the top ten shareholders hold shares through both ordinary securities accounts and securities company client credit transaction guarantee securities accounts

√ Applicable□ Not applicable

Shanghai Yiduan holds 20,520,776 shares through ordinary securities accounts and 4,470,392 shares through investor credit securities accounts.

Unit: shares

Shareholding of the top ten shareholders (excluding shares lent through securities lending)								
Shareholder Name (Full Name)	Increase/Decrease during the reporting period	Number of shares held at period end	Proportion (%)	Number of shares held with selling restrictions	Number of restricted shares including shares lent through securities lending	Pledge, marking, or freezing status		Shareholder Nature
						Shares Status	Quantity	
United Imaging Healthcare Technology Group Co., Ltd.	-	167,550,968	20.33	-	-	None	-	Domestic non-state-owned legal person
Shanghai Lianhe Investment Co., Ltd.	-	134,959,614	16.38	-	-	None	-	State-owned legal person
Shanghai Yingsheng Investment Partnership (Limited Partnership)	-	60,204,628	7.30	-	-	None	-	Other

Shanghai Yiduan Investment Co., Ltd.	-	24,991,168	3.03	-	-	None	-	Domestic non-state-owned legal person
Shanghai Zhongke Daofu Investment Partnership (Limited Partnership)	-	24,306,858	2.95	-	-	None	-	Other
Yan Quanliang	-	19,371,789	2.35	-	-	None	-	Domestic natural person
HKSCC Nominees Limited	195,186	17,747,146	2.15	-	-	None	-	Unknown
Shanghai Beiyuan Investment Partnership (Limited Partnership)	-	16,900,961	2.05	-	-	None	-	Other
Bank of China Limited - HuaBao CSI Medical Exchange Traded Open-End Index Securities Investment Fund	1,615,050	16,820,779	2.04	-	-	None	-	Unknown
Ningbo Meishan Bonded Port Area Yingkang Investment Management Partnership (Limited Partnership)	-	12,411,182	1.51	-	-	None	-	Other

Ningbo Meishan Free Trade Port Area Yingjian Investment Management Partnership (Limited Partnership)	-	12,411,182	1.51	-	-	None	-	Other

Shareholding of the top ten shareholders with unrestricted shares (excluding shares lent out through refinancing)			
Shareholder Name	Number of Unrestricted Tradable Shares Held	Share Type and Quantity	
		Type	Quantity
United Imaging Healthcare Technology Group Co., Ltd.	167,550,968	RMB ordinary shares	167,550,968
Shanghai Lianhe Investment Co., Ltd.	134,959,614	RMB ordinary shares	134,959,614
Shanghai Yingsheng Investment Partnership (Limited Partnership)	60,204,628	RMB ordinary shares	60,204,628
Shanghai Yiduan Investment Co., Ltd.	24,991,168	RMB ordinary shares	24,991,168
Shanghai Zhongke Daofu Investment Partnership (Limited Partnership)	24,306,858	RMB ordinary shares	24,306,858
Yan Quanliang	19,371,789	RMB ordinary shares	19,371,789
HKSCC Nominees Limited	17,747,146	RMB ordinary shares	17,747,146
Shanghai Beiyuan Investment Partnership (Limited Partnership)	16,900,961	RMB ordinary shares	16,900,961
Bank of China Limited - HuaBao CSI Medical Exchange Traded Open-End Index Securities Investment Fund	16,820,779	RMB ordinary shares	16,820,779
Ningbo Meishan Free Trade Port Area Yingkang Investment Management Partnership (Limited Partnership)	12,411,182	RMB ordinary shares	12,411,182
Ningbo Meishan Free Trade Port Area Yingjian Investment Management Partnership (Limited Partnership)	12,411,182	RMB ordinary shares	12,411,182

Explanation of the buyback special account among the top ten shareholders	Not applicable
Explanation of the above shareholders' delegated voting rights, entrusted voting rights, and waiver of voting rights	Not applicable
Explanation of the above shareholders' affiliated relationships or concerted actions	1. United Imaging Group and Shanghai Yingsheng are enterprises controlled by Xue Min, the actual controller of the Company. 2. Zhongke Daofu and Shanghai Beiyuan are both private investment funds managed by Shanghai Daofu Yuantong Equity Investment Management Co., Ltd. as the private fund manager. 3. Ningbo Yingkang and Ningbo Yingjian are both employee shareholding platforms of the Company, and their executive partners are both Zhang Qiang. 4. Except for the above, the Company has not received any declaration from other shareholders regarding the existence of affiliations or concerted action agreements, and it is unknown whether there are affiliations or concerted action relationships among other shareholders.
Explanation of preferred shareholders with restored voting rights and their shareholding amounts	Not applicable

Note: Among shareholders with unrestricted shares, Ningbo Yingkang and Ningbo Yingjian are tied for tenth place.

Share lending through the securities refinancing business by shareholders holding 5% or more, the top ten shareholders, and the top ten holders of unrestricted circulating shares

□ Applicable√ Not applicable

Changes from the previous period for the top ten shareholders and the top ten holders of unrestricted circulating shares due to securities refinancing lending/return

□ Applicable√ Not applicable

Shareholding amounts and restricted sale conditions of the top ten shareholders with restricted shares

□ Applicable√ Not applicable

Table of the top ten domestic depositary receipt holders of the company as of the end of the reporting period

□ Applicable√ Not applicable

Share lending through the securities refinancing business by depositary receipt holders holding 5% or more, the top ten depositary receipt holders, and the top ten holders of unrestricted depositary receipts

□ Applicable√ Not applicable

Changes from the previous period for the top ten depositary receipt holders and the top ten holders of unrestricted depositary receipts due to securities refinancing lending/return

□ Applicable√ Not applicable

Holding amounts and restricted sale conditions of the top ten holders of restricted depositary receipts

□ Applicable√ Not applicable

iii. Table of the top ten shareholders by voting rights as of the end of the reporting period

□ Applicable√ Not applicable

iv. Strategic investors or general legal persons becoming top ten shareholders through placement of new shares/depositary receipts

□ Applicable√ Not applicable

III Information on directors, senior management, and core technical personnel

i. Changes in shareholdings of current directors, senior management, and core technical personnel and those who resigned during the reporting period

□ Applicable√ Not applicable

Other explanations

√ Applicable□ Not applicable

The company's directors, senior management, and core technical personnel hold shares in the company through Ningbo Yingju, Ningbo Yingli, Ningbo Yingjian, Ningbo Yingkang, and Shanghai Yingdong (collectively, the "Employee Shareholding Platforms"). During the reporting period, the Employee Shareholding Platforms did not reduce their holdings.

The company's senior management, core technical personnel, and other core employees participated in the strategic placement at the time of the company's IPO through CITIC Securities United Imaging Healthcare Employee STAR Market Strategic Placement No. 1 Collective Asset Management Plan, CITIC Securities United Imaging Healthcare Employee STAR Market Strategic Placement No. 2 Collective Asset Management Plan (hereinafter referred to as the "United Imaging Healthcare No. 2 Employee Asset Management Plan", which was allocated 3,695,573 shares and held 816,410 shares at the end of the reporting period), CITIC Securities United Imaging Healthcare Employee STAR Market Strategic Placement No. 3 Collective Asset Management Plan, and CITIC Securities United Imaging Healthcare Employee STAR Market Strategic Placement No. 4 Collective Asset Management Plan. As of the end of the reporting period, the changes in indirect shareholdings of senior management and core technical personnel are as follows:

Name	Position	Indirect shareholding at the beginning of the period	Indirect shareholding at the end of the period	Reason for change
Miao Hong	Senior Vice President	Directly holds 6,000,079.09 units of the United Imaging Healthcare No. 2 Employee Management Plan	Directly holds 6,000,079.09 units of the United Imaging Healthcare No. 2 Employee Management Plan	/
Lv Yunlei	Vice President	Directly holds 8,490,171.56 units of the United	Directly holds 8,490,171.56 units of the United	/

		Imaging Healthcare No. 2 Employee Management Plan	Imaging Healthcare No. 2 Employee Management Plan	
Wang Chao	Core technical personnel	Directly holds 14,069,996.25 units of the United Imaging Healthcare No. 2 Employee Management Plan	Directly holds 14,069,996.25 units of the United Imaging Healthcare No. 2 Employee Management Plan	/

ii. Equity incentives granted to directors, senior management, and core technical personnel during the reporting period

1. Stock options

□ Applicable√ Not applicable

2. Type I restricted shares

□ Applicable√ Not applicable

3. Type II restricted shares

□ Applicable√ Not applicable

iii. Other explanations

□ Applicable√ Not applicable

IV Changes in controlling shareholders or actual controllers

□ Applicable√ Not applicable

V Implementation and changes of depositary receipt arrangements during the reporting period

□ Applicable√ Not applicable

VI Special voting rights shares

□ Applicable√ Not applicable

VII Preferred shares

□ Applicable√ Not applicable

Section V Financial Report

I Financial Statements

Consolidated Balance Sheet

June 30, 2026

Prepared by: Shanghai United Imaging Healthcare Co., Ltd.

Unit: RMB

Item	Notes	June 30, 2026	December 31, 2025
Current Assets:			
Cash and Cash Equivalents	VII (1)	7,232,226,619.15	5,502,937,108.96
Reserve for Settlement		-	-
Lending Funds		-	-
Financial Assets at Fair Value Through Profit or Loss	VII (2)	1,717,054,366.96	4,926,542,409.75
Derivative Financial Assets	VII (3)	-	-
Notes Receivable	VII (4)	163,116,314.71	91,603,965.94
Accounts Receivable	VII (5)	5,866,601,509.12	5,590,248,672.01
Financing Receivables		-	-
Prepayments	VII (8)	357,725,329.92	264,137,851.08
Insurance Premiums Receivable		-	-
Reinsurance Receivables		-	-
Reserve for Reinsurance Contracts		-	-
Other Receivables	VII (9)	222,600,328.99	160,381,814.73

Including: Interest Receivable		-	-
Dividends Receivable		-	-
Financial Assets Purchased Under Resale Agreements		-	-
Inventories	VII (10)	7,238,105,817.88	5,728,954,000.61
Including: Data Resources		-	-
Contract Assets	VII (6)	44,706,049.59	39,544,383.52
Assets Held for Sale		-	-
Non-current Assets Due Within One Year	VII (12)	234,921,941.68	325,604,781.54
Other Current Assets	VII (13)	441,425,746.00	243,037,673.10
Total Current Assets		23,518,484,024.00	22,872,992,661.24
Non-current Assets:			
Loans and Advances to Customers		-	-
Debt Investments		-	-
Other Debt Investments		-	-
Long-term Receivables	VII (16)	129,440,072.29	175,204,564.76
Long-term Equity Investments	VII (17)	185,773,353.57	189,899,425.70
Other equity instrument investments		-	-
Other non-current financial assets	VII (19)	130,880,900.00	130,880,900.00
Investment property		-	-
Fixed assets	VII (21)	3,635,624,469.38	3,228,066,733.05
Construction in progress	VII (22)	3,002,589,736.41	2,868,572,615.90
Productive biological assets		-	-

Oil and gas assets		-	-
Right-of-use assets	VII (25)	247,890,198.82	265,003,292.18
Intangible assets	VII (26)	1,963,012,074.32	1,512,812,075.51
Including: data resources		-	-
Development expenditure		352,053,258.70	429,588,646.46
Including: data resources		-	-
Goodwill	VII (27)	22,104,603.13	22,104,603.13
Long-term deferred expenses	VII (28)	54,561,905.27	58,610,076.19
Deferred tax assets	VII (29)	543,471,336.20	474,663,559.66
Other non-current assets	VII (30)	649,613,383.28	556,180,212.23
Total non-current assets		10,917,015,291.37	9,911,586,704.77
Total assets		34,435,499,315.37	32,784,579,366.01
Current liabilities:			
Short-term borrowings	VII (32)	1,524,607,874.56	944,721,233.21
Borrowings from central bank		-	-
Borrowed funds		-	-
Financial liabilities at fair value through profit or loss		-	-
Derivative financial liabilities		-	-
Notes payable	VII (35)	659,285,502.57	420,141,402.99
Accounts payable	VII (36)	3,248,099,946.18	2,349,170,643.63
Advances from customers		-	-
Contract liabilities	VII (38)	2,653,544,222.92	2,975,154,056.73

Securities sold under repurchase agreements		-	-
Deposits from customers and interbank deposits		-	-
Securities trading agency funds		-	-
Securities underwriting agency funds		-	-
Employee compensation payable	VII (39)	447,230,093.91	806,276,577.83
Taxes and surcharges payable	VII (40)	644,872,932.44	639,996,649.60
Other payables	VII (41)	868,119,269.16	898,235,871.92
Including: Interest payable		-	-
Dividends payable		147,604,296.96	-
Handling charges and commissions payable		-	-
Reinsurance premiums payable		-	-
Liabilities held for sale		-	-
Non-current liabilities due within one year	VII (43)	59,262,688.85	58,753,856.21
Other current liabilities	VII (44)	156,762,265.93	187,384,320.84
Total current liabilities		10,261,784,796.52	9,279,834,612.96
Non-current liabilities:			
Insurance contract reserves		-	-
Long-term borrowings		-	-
Bonds payable		-	-
Including: Preferred shares		-	-
Perpetual bonds		-	-
Lease liabilities	VII (47)	231,836,673.83	252,568,441.01
Long-term payables		-	-

Long-term employee compensation payable	VII (49)	-	-
Provisions	VII (50)	2,684,708.30	2,721,872.01
Deferred income	VII (51)	475,371,919.25	475,087,466.20
Deferred tax liabilities	VII (29)	10,783,829.70	10,358,896.33
Other non-current liabilities	VII (52)	1,432,035,944.68	1,202,627,471.57
Total non-current liabilities		2,152,713,075.76	1,943,364,147.12
Total liabilities		12,414,497,872.28	11,223,198,760.08
Owners' equity (or shareholders' equity):			
Paid-in capital (or share capital)	VII (53)	824,157,988.00	824,157,988.00
Other equity instruments		-	-
Including: Preferred shares		-	-
Perpetual bonds		-	-
Capital reserve	VII (55)	14,031,199,158.32	13,957,021,962.83
Less: Treasury shares	VII (56)	733,148,424.63	449,839,312.68
Other comprehensive income	VII (57)	-136,641,451.86	-52,269,467.74
Special reserve		-	-
Surplus reserve	VII (59)	412,078,994.00	412,078,994.00
General risk reserve		-	-
Retained earnings	VII (60)	7,630,108,520.71	6,880,716,865.53
Total equity attributable to owners of the parent company (or shareholders' equity)		22,027,754,784.54	21,571,867,029.94
Non-controlling interests		-6,753,341.45	-10,486,424.01
Total owners' equity (or shareholders' equity)		22,021,001,443.09	21,561,380,605.93

Total liabilities and owners' equity (or shareholders' equity)		34,435,499,315.37	32,784,579,366.01

Company head: Zhang Qiang Head of Accounting: Wang Jianbao Head of Accounting Department: Zhang Hui

Consolidated Income Statement

January-June 2026

Unit: Yuan Currency: RMB

Item	Notes	First half of 2026	First half of 2025
I. Total operating revenue		7,051,579,098.09	6,015,901,402.16
Of which: Operating revenue	VII (61)	7,051,579,098.09	6,015,901,402.16
Interest income		-	-
Earned premiums		-	-
Fee and commission income		-	-
II. Total operating costs		6,227,312,283.55	5,075,101,040.91
Of which: Operating costs	VII (61)	3,724,610,123.40	3,132,664,301.76
Interest expense		-	-
Fee and commission expense		-	-
Surrender benefits		-	-
Net claims paid		-	-
Net amount of insurance contract reserves withdrawn		-	-
Policy dividend expense		-	-
Reinsurance expenses		-	-

Taxes and surcharges	VII (62)	39,206,135.92	30,107,015.65
Selling expenses	VII (63)	1,045,327,479.93	938,304,878.27
Administrative expenses	VII (64)	311,122,220.11	257,182,484.27
Research and development expenses	VII (65)	1,010,648,325.79	766,458,924.01
Financial expenses	VII (66)	96,397,998.40	-49,616,563.05
Of which: Interest expenses		15,531,596.08	5,292,016.92
Interest income		-42,416,993.91	-44,496,516.79
Add: Other income	VII (67)	295,497,431.44	215,480,112.85
Investment income (losses are indicated by "-")	VII (68)	39,186,065.57	39,841,032.04
Of which: Investment income from associates and joint ventures		-4,126,072.13	-1,073,833.88
Gains on derecognition of financial assets measured at amortized cost (losses are "-")		-	-
Exchange gains (losses are "-")		-	-
Net investment hedge gains (losses are "-")		-	-
Gains on changes in fair value (losses are "-")	VII (70)	-7,013,914.79	-45,441,421.76
Credit impairment losses (losses are "-")	VII (71)	-105,755,741.64	-72,911,342.79
Asset impairment losses (losses are "-")	VII (72)	5,974,359.14	-197,713.08
Gains on disposal of assets (losses are "-")	VII (73)	813.00	-640,729.77
III. Operating profit (losses are "-")		1,052,155,827.26	1,076,930,298.74
Add: Non-operating income	VII (74)	1,143,762.00	2,148,497.13
Less: Non-operating expenses	VII (75)	20,258,428.39	6,106,665.13
IV. Total profit (total losses are "-")		1,033,041,160.87	1,072,972,130.74

Less: Income tax expenses	VII (76)	144,012,126.17	85,076,398.44
V. Net profit (net losses are "-")		889,029,034.70	987,895,732.30
(I) Classified by operating continuity			
1. Net profit from continuing operations (net losses are "-")		889,029,034.70	987,895,732.30
2. Net profit from discontinued operations (net losses are "-")		-	-
(II) Classified by ownership			
1. Net profit attributable to shareholders of the parent company (net losses are "-")		896,995,952.14	998,018,064.12
2. Profit or loss attributable to minority shareholders (net loss is filled in with "-" sign)		-7,966,917.44	-10,122,331.82
VI. Net amount of other comprehensive income after tax		-84,371,984.12	-3,315,448.42
(I) Net amount of other comprehensive income after tax attributable to owners of the parent company		-84,371,984.12	-3,315,448.42
1. Other comprehensive income that cannot be reclassified to profit or loss		-	-
(1) Changes in remeasurement of defined benefit plans		-	-
(2) Other comprehensive income under the equity method that cannot be reclassified to profit or loss		-	-
(3) Changes in fair value of other equity instrument investments		-	-
(4) Changes in fair value of the enterprise's own credit risk		-	-

2. Other comprehensive income to be reclassified to profit or loss		-84,371,984.12	-3,315,448.42
(1) Other comprehensive income under the equity method that can be reclassified to profit or loss		-	-
(2) Changes in fair value of other debt investments		-	-
(3) Amount of financial assets reclassified into other comprehensive income		-	-
(4) Credit impairment allowance for other debt investments		-	-
(5) Cash flow hedge reserve		-	-
(6) Exchange differences on translation of foreign currency financial statements		-84,371,984.12	-3,315,448.42
(7) Others		-	-
(II) Net amount of other comprehensive income after tax attributable to minority shareholders		-	-
VII. Total comprehensive income		804,657,050.58	984,580,283.88
(I) Total comprehensive income attributable to owners of the parent company		812,623,968.02	994,702,615.70
(II) Total comprehensive income attributable to minority shareholders		-7,966,917.44	-10,122,331.82
VIII. Earnings per share:			
(I) Basic earnings per share (yuan/share)		1.10	1.21
(II) Diluted earnings per share (yuan/share)		1.10	1.21

If a business combination under common control occurred in the current period, the net profit realized by the acquired party before the combination is: 0 yuan, and the net profit realized by the acquired party in the previous period is: 0 yuan.

Person in charge of the company: Zhang Qiang Person in charge of accounting: Wang Jianbao Person in charge of accounting institution: Zhang Hui

Consolidated Cash Flow Statement

January-June 2026

Unit: Yuan Currency: RMB

Item	Notes	First half of 2026	First half of 2025
I. Cash flows from operating activities:			
Cash received from sales of goods and rendering of services		7,276,949,606.78	6,178,837,680.41
Net increase in customer deposits and deposits from banks and other financial institutions		-	-
Net increase in borrowings from the central bank		-	-
Net increase in funds borrowed from other financial institutions		-	-
Cash received from original insurance contract premiums		-	-
Net cash received from reinsurance business		-	-
Net increase in policyholder deposits and investment funds		-	-
Cash received from interest, fees, and commissions		-	-
Net increase in borrowed funds		-	-
Net increase in repurchase business funds		-	-

Net cash received from securities trading on behalf of clients		-	-
Tax refunds received		280,473,003.11	324,863,010.51
Other cash received related to operating activities	VII (78)	168,420,694.92	158,711,457.91
Subtotal of cash inflows from operating activities		7,725,843,304.81	6,662,412,148.83
Cash paid for goods purchased and services received		4,445,958,372.60	3,873,800,637.00
Net increase in customer loans and advances		-	-
Net increase in deposits with the central bank and interbank deposits		-	-
Cash paid for original insurance contract claims		-	-
Net increase in funds lent out		-	-
Cash paid for interest, fees, and commissions		-	-
Cash paid for policy dividends		-	-
Cash paid to and on behalf of employees		1,988,045,059.32	1,637,468,936.03
Taxes and surcharges paid		670,839,426.02	425,196,601.60
Other cash paid related to operating activities	VII (78)	863,020,548.36	677,186,174.43
Subtotal of cash outflows from operating activities		7,967,863,406.30	6,613,652,349.06
Net cash flows from operating activities		-242,020,101.49	48,759,799.77
II. Cash flows from investing activities:			
Cash received from the recovery of investments		21,907,857,628.00	20,191,246,227.11
Cash received from investment income		55,966,353.89	44,402,082.08

Net cash received from the disposal of fixed assets, intangible assets, and other long-term assets		9,000.00	65,400.00
Net cash received from the disposal of subsidiaries and other business units		-	-
Cash received from other investing activities	VII (78)	-	-
Subtotal of cash inflows from investing activities		21,963,832,981.89	20,235,713,709.19
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets		1,444,852,905.80	1,077,380,818.06
Cash paid for investments		19,267,496,532.10	18,675,232,199.99
Net increase in pledged loans		-	-
Net cash paid for acquisition of subsidiaries and other business units		-	-
Cash paid for other investing activities	VII (78)	-	-
Subtotal of cash outflows from investing activities		20,712,349,437.90	19,752,613,018.05
Net cash flows from investing activities		1,251,483,543.99	483,100,691.14
III. Cash flows from financing activities:			
Cash received from capital contributions		11,700,000.00	-
Of which: cash received from minority shareholders' capital contributions to subsidiaries		11,700,000.00	-
Cash received from borrowings		1,146,194,373.81	71,749,911.33
Cash received from other financing activities	VII (78)	-	-
Subtotal of cash inflows from financing activities		1,157,894,373.81	71,749,911.33

Cash paid for debt repayments		565,652,492.91	552,984,320.94
Cash paid for dividends, profits or interest expenses		8,328,131.69	127,366.72
Of: Dividends and profits paid by subsidiaries to minority shareholders		-	-
Cash paid for other financing activities	VII (78)	324,078,094.62	40,391,520.69
Subtotal of cash outflows from financing activities		898,058,719.22	593,503,208.35
Net cash flows from financing activities		259,835,654.59	-521,753,297.02
IV. Effect of exchange rate changes on cash and cash equivalents		-67,205,677.71	-717,683.65
V. Net increase in cash and cash equivalents		1,202,093,419.38	9,389,510.24
Add: Beginning balance of cash and cash equivalents		5,310,299,085.16	5,867,855,094.11
VI. Ending balance of cash and cash equivalents		6,512,392,504.54	5,877,244,604.35

Company head: Zhang Qiang Head of Accounting: Wang Jianbao Head of Accounting Department: Zhang Hui